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Abstract 
Introduction  
Oral mucositis is an inflammatory and frequently ulcerative side effect of cancer 
therapy, which has been identified by patients as the most debilitating side effect of 
their treatment. Mucositis is a dose limiting toxicity which exerts a substantial clinical 
and economic impact and negatively affects patient quality of life. The patient 
experience of mucositis is under-reported in the literature. To date, no interventions 
have been identified that have proven successful in the prevention of mucositis for 
patients receiving all types of therapy. Vitamin E has shown conflicting results in 
clinical trials. This thesis combines appraisal of the literature and empirical research, 
and uses lessons learned from previous studies together with the results of a feasibility 
study to identify a best practice model for future trials. 
 
Methods  
The Cochrane risk of bias (ROB) instrument was used to assess the ROB in the studies 
included in the Cochrane prevention review. A sensitivity analysis was conducted after 
studies assessed at unclear or high risk of overall bias were excluded. A systematic 
review of assessment instruments was conducted which identified 50 instruments. 
Consideration of the appropriateness of these instruments for the use in a clinical trial 
for the prevention of mucositis was based on the practicality, comparability, and 
reproducibility, and the impact of these instruments on patients. Three of these 
instruments were chosen for use in a clinical trial of adults undergoing stem cell 
transplant. Finally, a feasibility study was designed, developed and conducted which 
investigated vitamin E for the prevention of mucositis in patients undergoing 
conditioning for bone marrow transplantation. Through lessons learned from previous 
studies, consultations with medical professional, the MHRA, ethics committee and 
suppliers, a protocol was developed for a double blind RCT. The process of gaining 
MHRA and ethical approval, and the repackaging of intervention and placebo products 
to meet MA-IMP requirements are described.   
 
Results  
130 articles were assessed for risk of bias. Only ten studies were assessed as being at 
low overall risk of bias. Blinding of outcome assessors and adequate allocation 
concealment were identified to be important considerations in the planning of future 
studies. Although only nine patients were recruited into the feasibility study, a number 
of issues affecting the design and conduct of future trials were identified. Recruitment in 
particular was identified to be problematic. Strategies for overcoming this problem in 
future trials were discussed. The methods of blinding and allocation concealment 
employed were found to be feasible for use in future trials. Expected adverse events 
patients undergoing stem cell transplantation were also reported.  
 
Conclusion  
Further studies are required to investigate interventions for the prevention of mucositis. 
It is of upmost importance that these trials are rigorous in both their methodology and 
subsequent reporting in order to elicit the maximum benefit for patients taking part in 
clinical trials, and future patients undergoing therapy for cancer.  
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Chapter 1 Introduction 
 
1.1 What is cancer? 
Cancer is a class of disease in which cells multiply uncontrollably, giving rise to 
tumours. These tumours may be benign or malignant. Benign cells are not cancerous 
because they do not spread to other sites in the body, while malignant cells have the 
ability to spread, leading to the destruction of the surrounding tissue. These cells can 
also proliferate to other parts of the body through the blood or lymphatic system, in a 
process called metastasis (Macmillan, 2010a). There are over 200 types of cancer, of 
which approximately 85% are carcinomas: cancers of the epithelium. Among the most 
common of these type of cancers are carcinomas of the breast, lung, prostate and bowel 
(Macmillan, 2010a). In contrast, leukaemia and lymphoma, cancers of the blood and 
lymph glades, account for approximately 6.5% of all types of the disease; while 
sarcomas, cancers of the bone, muscle and fatty tissue, account for approximately 1% 
(Macmillan, 2010a). The remaining 7.5% of cancer incidence is comprised of a variety 
of rarer cancers, including brain tumours and multiple myeloma.  
 
Haematological malignancies are cancers affecting the lymph nodes, blood and bone 
and include leukaemia, lymphoma and multiple myeloma (Lichtman, 2008). The 
proliferation and infiltration of leukaemia cells into tissue disturbs cell and metabolic 
function, and results in anaemia, neutropenia, thrombocytopenia, haemorrhage and 
infection (Bratt-Wyton, 2000). There are two types of leukaemia: chronic and acute. 
Acute diseases are characterised by their sudden onset. The most common types of 
acute leukaemia are acute myeloid leukaemia (AML) and acute lymphoblastic 
leukaemia (ALL) (Bratt-Wyton, 2000). ALL is most prevalent in children aged between 
two and seven years old, although adults over 40 years old are also commonly affected 
(Bratt-Wyton, 2000). In contrast to these acute diseases, chronic leukaemias are slower 
to develop. Chronic myeloid leukaemia (CML) and chronic lymphoblastic leukaemia 
(CLL) are common types of this disease (Bratt-Wyton, 2000).  
 
Lymphoma cells infiltrate tissue, bone marrow and organs, leading to the destruction of 
healthy tissue. Although the typical site of involvement is the lymph nodes, tissue 
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without nodes can also be affected. Lymphomas can be separated into two distinct 
types: Hodgkin’s disease (HD) and non-Hodgkin’s Lymphoma (NHL). NHL can be 
additionally separated into low-grade and high-grade lymphoma (Grundy, 2000). Low 
grade disease is slow growing and asymptomatic, and as a consequence, patients are not 
generally diagnosed until their disease is at a late, and incurable, stage.  Untreated high 
grade disease is rapidly terminal. However, tumours can be responsive to chemotherapy, 
if caught early enough (Grundy, 2000). In contrast the incidence of disease-free survival 
with NHL can be as high as 85% in patients with stage one and two disease (Grundy, 
2000).  
 
Multiple myeloma (MM) is an incurable malignancy characterised by uncontrolled 
plasma cell growth, resulting in the infiltration of plasma cells into bone and the 
development of osteolytic lesions. The excessive secretion of abnormal 
immunoglobulins is a characteristic of this disease, however, a rare non-secretory form 
of the disease does also exist (Dowling, 2000). Patients with MM commonly suffer 
renal failure as a consequence of hyperviscosity syndrome, an abnormal viscosity of the 
plasma, or hypercalcaemia, which is caused by the release of calcium into the blood due 
to bone destruction. Spinal cord compression may also be a consequence of myeloma 
(Dowling, 2000). Despite treatment, patients inevitably relapse with myeloma. 
Although new drug regimes have increased the number of patients achieving a complete 
or very good remission, relapse after first line therapy can be expected within two or 
three years of diagnosis (Kumar, 2010).  
 
1.2 Treatment for cancer 
Treatment for cancer usually involves chemotherapy, radiotherapy, hormone therapy, 
biological therapy, or surgery, either as a single therapy or in combination (Davies and 
Epstein, 2010). Transplantation with stem cells, or bone marrow, is another method of 
treatment, which is commonly used in haematology patients (Blazar et al., 2006).  
 
 
   
19 
 
1.2.1 Chemotherapy 
Chemotherapy can be administered, either singularly or in combination, with the 
intention of cure, for the prolongation of life, or for palliation (Peterson and Lalla, 2010) 
The synthesis and function of deoxyribonucleic acid (DNA) is altered by the 
administration of chemotherapy drugs (Bratt-Wyton, 2000), which can be given either 
intravenously, orally or by injection, in cycles, often over a number of months. 
Chemotherapy may be separated into four distinct types: alkylating agents, anti-tumour 
antibiotics, plant alkaloids and anti-metabolites (Thomson, 2000). Alkylating agents 
form molecular bonds with DNA, causing cross-breaking, substitution or strand 
breaking reactions, which bring about cell death (Skeel, 2006). Alkylating agents also 
prevent the formation of ribonucleic acid (RNA) (Thomson, 2000). Melphalan and 
cyclophosphamide are alkylating chemotherapies commonly used in the treatment of 
myeloma (Dowling, 2000). Anti-tumour antibiotics, which include doxorubicin and 
bleomycin, are produced from species of fungus (Thomson, 2000). These drugs affect 
the synthesis and functioning of DNA and RNA (Skeel, 2006). Anti-metabolite 
chemotherapies interfere with the synthesis of purine and pyrimidine (Thomson, 2000), 
and, after they have been incorporated into metabolic pathways, transmit false messages 
which prevent the synthesis of DNA and RNA (Ingwersen, 2001). Methotrexate is an 
anti-metabolite chemotherapy used in the treatment of a range of different cancers, 
including ALL (Bratt-Wyton, 2000). Plant alkaloids are cell cycle specific drugs which 
interrupt metaphase by crystallizing the microtubular proteins (Ingwersen, 2001, 
Thomson, 2000). Vinblastine and etoposide are common plant alkaloids (Ingwersen, 
2001).  
 
1.2.2 Radiotherapy and TBI 
Radiotherapy uses ionising radiation to eliminate tumour cells (Spreadborough and 
Read, 2000), and can be given externally, whereby daily fractions of radiotherapy are 
directed towards the tumour; or internally, either through the application of radioactive 
material into the tumour (brachytherapy), or through radioisotope treatment whereby the 
treatment is drunk or injected into the body (Macmillan, 2010a). The amount of 
radiotherapy given is measured in gray (GY); in patients with head and neck cancer, this 
therapy generally administered on an outpatient basis, with the patient attending daily 
weekday appointments during the six week therapy cycle. The administration of high 
dose radiotherapy to the entire body is termed total body irradiation (TBI) 
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(Spreadborough and Read, 2000). As TBI can penetrate the central nervous system, 
unlike chemotherapy, it is employed in conjunction with chemotherapy in patients 
undergoing transplantation (Spreadborough and Read, 2000).  
 
1.2.3 Transplantation 
Haematopoietic stem cell transplantation, a term which is often used interchangeably 
with bone marrow transplantation (and hereafter abbreviated as BMT), involves the 
administration of stem cells to patients who have been pre-treated with high-dose 
chemotherapy or a combination of chemotherapy and TBI. In this process cancer 
therapy is used to destroy the patient’s bone marrow and the patient is then ‘rescued’ 
using stem cells. These stem cells are either previously harvested from the patient after 
the administration of growth factors to boost the amount of stem cells circulating in the 
blood, or harvested in the same manner from another individual who has been identified 
as a ‘match’ to the patient. The administration of the patient’s own stem cells is termed 
autologous transplant, while the use of donated cells is called allogeneic transplant 
(Outhwaite, 2000). Previous to the use of stem cells, bone marrow was harvested from 
patients during a surgical procedure and used in a similar manner to stem cells 
transplant. Bone marrow harvesting may still be employed when a patient has trouble 
producing enough stem cells to harvest, or alternatively when the donor chooses to 
donate bone marrow rather than stem cells. Some patients may receive a mixed 
transplant of both bone marrow and stem cells due to problems collecting enough stem 
cells. BMT is an inpatient procedure, in which patients are hospitalised for up to four 
weeks.  
 
The administration of chemotherapy, with or without TBI, before transplantation is 
termed conditioning. This procedure lasts approximately a week in allogeneic transplant 
patients and one or two days for patients receiving an autologous transplant. The term 
‘day 0’ is used to denote the day a patient receives their transplant (Outhwaite, 2000). 
The days before transplantation, during which the patient receives myeloablative 
treatment, are denoted with a minus sign (day-3, day-2, day-1 etc.) and the days 
immediately after transplantation being designated a plus sign (day+1, day+2, day+3 
etc.). Due to the risk of infection, all BMT patients are barrier nursed in private rooms 
during hospitalisation and medical staff and visitors undergo infection control 
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procedures, which include hand washing and the donning of protective clothing before 
entering the room. 
 
1.3 Side effects of cancer treatment 
Advances in the cancer treatments have led to increased patient survival though the use 
of new, highly toxic regimes.  However the administration of these new treatments have 
also increased the incidence of toxicities, or side effects, associated with their use (Jones 
et al., 2006). The nature and scale of these side effects are diverse, and may not be 
experienced by all patients undergoing therapy. Common side effects include 
myelosuppression which increases the patient’s risk of infection, alopecia, nausea and 
vomiting, gastrointestinal mucositis, oral complications, fatigue, reproduction issues 
and damage to major organs in the body, such as the heart. Oral complications include 
oral infection, salivary gland dysfunction, hyposalivation, haemorrhage, compromised 
wound healing, taste disturbances, osteonecrosis, necrosis and fibrosis of the soft 
tissues, possible induction of  secondary malignancy and oral mucositis (OM) (Davies 
and Epstein, 2010).  
 
Figure 1: Clinical Presentation of Oral Mucositis 
(Scully 2006. Permission granted) 
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Mucositis is an inflammatory and frequently ulcerative side effect of cancer treatment, 
which has been identified by patients as the most debilitating aspect of their treatment 
(Bellm et al., 2000, Stiff, 2001). The incidence of this condition varies depending on the 
treatment administered and individual patient characteristics. Incidences as high as 
100% have been reported in patients receiving radiotherapy for head and neck cancers 
(Peterson et al., 2009b). OM can be extremely painful for the patient and can have a 
significant impact on their quality of life by limiting their ability to eat, drink, talk, 
swallow and sleep. Although patients are generally prescribed opiates for pain control, 
break-through pain is not uncommon, and the reliance on opiates can introduce 
additional problems for the patient, due to their sedative effect. OM therefore constitutes 
a clinically relevant problem, as patients with severe mucositis often require breaks in 
planned courses of treatment to allow the oral cavity to recover; such breaks can 
negatively impact tumour control and therefore the patient’s overall chance of survival 
(Rosenthal, 2007). Ulceration also offers a gateway for opportunistic infection, which 
when combined with nadirs in the white cell count of the patient, can elicit devastating 
effects (Peterson and Lalla, 2010). Unplanned admissions and extended hospital stays, 
together with the need for nutritional support and opiates, exert a significant economic 
impact. As such, the discovery of an intervention which could either prevent or reduce 
the severity of OM would have a hugely beneficial impact, not only clinically and 
economically, but also most importantly for the patient’s quality of life.  
 
A number of interventions have been investigated for the prevention of mucositis, with 
mixed results. A recent update of the Cochrane review of interventions for the 
prevention of mucositis included 130 trials of 43 separate agents (Worthington et al., 
2010). However, to date, no intervention has been found to be beneficial for the 
prevention of mucositis across all treatment modalities. Many of these trials are small 
and poorly reported. Additional trials are required to confirm these results. Some 
interventions that have been excluded from the Cochrane review are relatively safe and 
economical and merit further evaluation. One such intervention is vitamin E. Vitamin E 
has been previously evaluated in randomised controlled trials (RCTs), the ‘gold 
standard’ for assessing the effectiveness of interventions, in the prevention of mucositis 
in patients undergoing chemotherapy (Sung et al., 2007) and radiotherapy (Ferreira et 
al., 2004) with conflicting results. Further RCTs would be required to confirm the 
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effectiveness of vitamin E for the prevention of mucositis. However, before a large 
scale study of any intervention is conducted, it is advisable to conduct a feasibility study 
to thoroughly explore the pragmatic aspects of the research project (Easterbrook and 
Matthews, 1992).   
 
1.4 Overview of this thesis 
This thesis combines appraisal of the literature and empirical research, and uses lessons 
learned from previous studies together with the results of a feasibility study to identify a 
best practice model for future trials. Figure 2 displays the conceptual diagram for the 
thesis. 
Feasibility
Study
Practical 
Considerations
Systematic Review 
of Oral Assessment 
Instruments
Study Design
Risk of Bias
Literature Review
 
Figure 2: Thesis diagram 
 
Chapter two reviews the literature surrounding mucositis. Sonis’ five phase hypothesis 
for development of mucositis is explained and treatment and patient related factors 
which may affect the OM incidence or severity are discussed. Such factors are 
important as the identification of high risk patients allows for better treatment planning 
and patient education, and the early employment of interventions to treatment pain and 
associated oral symptoms. The clinical impact of mucositis is then explored: as the 
development of mucositis increases a patients susceptibility to infection, increases a 
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patients’ length of hospital stay (Sonis et al., 2001, Vera-Llonch et al., 2007a, Vera-
Llonch et al., 2007b) and requirement for opiate pain control, and in severe cases may 
necessitate breaks in treatment to allow for the oral surface to recover. Such treatment 
breaks may affect the success of treatment (Blijlevens et al., 2009, Epstein and 
Schubert, 2004, Scully et al., 2006). Consequently therefore, mucositis also exerts a 
significant economic impact, although the actual costs described may not translate from 
an American health care model to a British model. Lastly the impact of mucositis on the 
patient is discussed.  
 
Interventions previously trialled for the prevention of mucositis are discussed in chapter 
three. This chapter provides a brief outline of the use of RCTs and systematic reviews 
and then discusses the latest update of the Cochrane review of interventions for the 
prevention of mucositis (Worthington et al., 2010). Three interventions were identified 
in this update that were beneficial for the prevention of mucositis at all three levels of 
interest: cryotherapy in patients receiving chemotherapy, honey in patients receiving 
radiotherapy, and Keratinocyte GF in a range of different treatments. However, no 
interventions were found to be beneficial for all treatments, and further research is 
needed. One drawback of the prevention review is that only studies which provide data 
in the correct formats can be included, which leads to the exclusion of studies providing 
data in formats other than the number of patients experiencing each grade of mucositis. 
Although text only inclusions have been included in the latest update of the review in an 
attempt to address this issue, this has not prevented whole interventions from being 
excluded from the review due to the manner in which data were presented or due to the 
oral assessment instrument employed. One such intervention is vitamin E. The 
remainder of chapter three discusses the conflicting results of studies which have 
examined vitamin E for either the prevention or treatment of mucositis.  
 
Chapter four is an empirical piece of research which assesses the risk of bias (ROB) of 
the studies included in the Cochrane review for the prevention of mucositis 
(Worthington et al., 2010). A bias is a systematic error in results, which can operate in 
either direction, leading to an over or underestimation of the effect of the intervention 
under investigation. All 130 studies included in the latest prevention review were 
assessed for ROB using the Cochrane ROB instrument. Outcome assessor blinding and 
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adequate allocation concealment were chosen as the key domains of interest, and a 
sensitivity analysis was performed in which all studies at high or unclear ROB for these 
domains were excluded from the prevention review and the results reanalysed. Overall 
ROB was also determined, and the results of the sensitivity analysis discussed.  
 
Chapter five considers how information from studies identified by the Cochrane 
prevention review can be used to inform future trials. Recruitment rates were calculated 
for the 80 studies which provided dates for the start and end of recruitment. Two mean 
averages were then determined: an overall average and an average for studies conducted 
on single sites. Next, all 130 studies were examined to determine which other outcomes 
were reported by the authors. Nineteen categories of outcomes were identified. 
However, there was little consistency in what studies were reported. Adverse events 
were the most frequently identified outcome, but were reported by only 47% of the 
studies assessed for ROB. Patient quality of life was the least frequently reported 
outcome. The timing of oral assessment was also explored, which again showed little 
consistency, with a variety of timings employed from daily, twice weekly, weekly, and 
monthly. Three studies only assessed the oral cavity a total of twice (Li et al., 2006, 
Pfeiffer et al., 1990, Sorensen et al., 2008). The final section of this chapter examines 
the pitfalls and problems identified by previous studies. These ranged from recruitment 
problems and slow accrual of patients into the study, to drug dispensing errors, and 
difficulty in obtaining the intervention or placebo products used in the study. The use of 
a feasibility study to identify potential problems is then discussed.  
 
Chapter six presents a systematic review of oral assessment instruments for use in 
adults, which was conducted in order to select instruments for use in a feasibility study. 
The results of a systematic search for the update of the Children’s Cancer and 
Leukaemia Group (CCLG) mouth care guidelines (UKCCLG-PONF, 2006) and a 
subsequent linked publication which aimed to identify oral assessment instruments for 
use in children (Gibson et al., 2010), were used to determine suitable oral assessment 
instruments for use in adults. A total of 391 papers were identified in the literature 
search. Fifty oral assessment instruments were included in the review, of which only 10 
had been validated. This chapter goes on to describe instruments in detail and then 
discuss their various merits and issues before selecting three instruments for use in a 
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future trial. The instruments chosen were the daily index of mucositis (DIM) (Tardieu et 
al., 1996), the oral mucositis daily questionnaire (OMDQ) (Stiff et al., 2006), and the 
World Health Organisation (WHO) instrument (World Health Organization (WHO), 
1979).  
 
The feasibility trial protocol is presented in chapter 7. This chapter details the 
development of the feasibility study and describes the process of finding a supplier for 
the intervention and placebo products and the need for the repackaging of these 
products to meet manufacturer’s authorisation for investigation medicinal products 
(MA-IMP) requirements. The MRC frameworks for complex interventions are 
presented and the use of a phase three design is justified. The inclusion and exclusion 
criteria are discussed, along with reasons for these decisions. A discussion of the ethical 
issues applicable to this trial is also included in this chapter along with diagrams which 
detail the patient experience during allogeneic and autologous transplant.  
 
The results of the feasibility study are discussed in chapter eight. The first part of this 
chapter describes feasibility issues identified during the trial. The discussion of 
Clinician interest and the available patient population is probably one of the most 
important aspects of this section, as the recruitment of patients into the feasibility study 
was severely affected by a lack of access to patients and by the dynamics of the staff on 
the ward. A lack of consistency in the standard oral care given to patients is highlighted. 
The feasibility of the recruitment, consent, randomisation and blinding procedures are 
also detailed in this section. The second part of this chapter details the results of the 
study. However, as only nine patients were recruited into the study, the focus of this 
section is not on the statistical difference between the study arms but rather on the 
results of individual patients. The oral mucositis outcomes are discussed first and a 
difference between the DIM and WHO oral assessment instruments was identified. The 
data produced using the pain scales, nutritional screening instruments, and the adverse 
events recorded during the study are then reported. 
 
Chapter nine presents the discussion which considers the findings of the feasibility 
study together with the findings of the other chapters in this thesis. Barriers to 
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recruitment of patients and the need for Clinician input into trial design are important 
topics discussed in this chapter, as these issues adversely affected the success of 
recruitment in the feasibility study. The feasibility of the method of allocation 
concealment and outcome assessor blinding employed in this study are considered and 
the importance of the use of these domains in future trials, in particular those in which 
patient blinding is unfeasible, are discussed. The time required for adverse event 
reporting and the problem of ensuring accurate reporting of adverse events after patients 
have been discharged are also talked about in detail. Finally recommendations for future 
trials are made. The conclusion of this thesis is presented in Chapter ten. 
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Chapter 2 Literature Review 
2.1 Introduction  
This chapter provides the background to the thesis. The first section begins by focusing 
on OM development, and then subsequently on the amelioration and exacerbation of 
this condition by various patient and treatment factors, before finally considering the 
greater impact of mucositis on patients and resources. The second section of the 
literature review focuses on interventions for the prevention of mucositis.  
 
2.2 Incidence and development of mucositis 
The incidence of OM varies depending on the type of treatment the patient receives. 
Mucositis has been reported in between 40% and 79% of patients receiving standard 
chemotherapy (Cascinu et al., 1994, Nottage et al., 2003, Okuno et al., 1999, Ramirez-
Amador et al., 2010) and between 60% and 100% of patients with head and neck cancer 
receiving radiotherapy (Cengiz et al., 1999, Makkonen et al., 1994, Trotti et al., 2003). 
In patients undergoing bone marrow or stem cell transplants the incidence is much 
higher, with between 76% and 100% of patients developing some degree of mucositis 
(Blazar et al., 2006, Castagna et al., 2001, Lilleby et al., 2006, McGuire et al., 1993, 
Salvador, 2005, Spielberger et al., 2004, Vera-Llonch et al., 2007a, Wardley et al., 
2000), and between 66% and 76% of patients developing severe mucositis (Bolwell et 
al., 2002, Wardley et al., 2000, Woo et al., 1993).  
 
The direct mucotoxic effects of chemotherapy usually starts to be seen at four or five 
days post therapy with the reddening of the mucosa, a process called erythema (Scully 
et al., 2006). Ulceration starts to develop between seven and 11 days after chemotherapy 
(Ramirez-Amador et al., 2010, Scully et al., 2006, Woo et al., 1993). In the absence of 
infection, OM generally begins to resolve between days 14 and 17 (Scully et al., 2003, 
Woo et al., 1993). The development of mucositis varies depending on the type of 
treatment received. Mucositis induced by chemotherapy commonly takes place on the 
non-keratinized mucosal surfaces of the mouth, including the soft palate, buccal 
mucosa, floor of the mouth and tongue (Scully et al., 2003). Surfaces with higher levels 
of keratinization have a greater resistance to trauma (Schubert, 1993), and therefore 
erythema and ulcers usually appear on the gingivae (gums) later in mucositis 
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development. In a longitudinal study of 59 patients undergoing BMT, Woo and 
colleagues found that 96% of observed oral lesions were located on non-keratinized 
surfaces, with the buccal mucosa, floor of the mouth and the ventrolateral tongue being 
the sites most frequently involved (Woo et al., 1993). Ulceration of the hard palate is 
rare in patients receiving chemotherapy, and in the bone marrow transplant patient may 
be attributed to herpes simplex virus (HSV) (Scully et al., 2006) or graft-versus-host 
disease, a side effect of the transplant process (Woo et al., 1993). 
 
Unlike mucositis induced by chemotherapy, radiation-induced mucosal damage in head 
and neck patients can take place anywhere within the radiation field, affecting both the 
keratinized and non-keratinized surfaces (Scully et al., 2003), with the most common 
areas of involvement being the lateral and ventral aspects of the tongue, the buccal 
mucosa and the soft palate (Treister and Sonis, 2007). Pain and erythema are generally 
the first signs of radiation mucositis which tend to begin at doses of around 10 GY, 
typically at the end of the first week of treatment (Treister and Sonis, 2007). Mucositis 
commonly becomes ulcerative at doses of 30 GY (Scully et al., 2003), and a 
pseudomembrane, a fibrous layer on the surface of the mucous membrane, may 
develop. In the absence of infection, spontaneous healing normally starts approximately 
two weeks after the completion of treatment (Treister and Sonis, 2007). In contrast to 
chemotherapy-induced mucositis, which has a relatively short duration, it is common 
for patients receiving radiotherapy for head and neck cancers to suffer from ulcerative 
mucositis which persists for up to four weeks following treatment completion (Sonis, 
2009).  
 
2.3 Models of mucositis 
Until relatively recently, the principal theory of mucositis development was that 
chemotherapy or radiotherapy caused the indiscriminate destruction of stem cells 
located in the basal epithelium of the oral cavity, inhibiting cell turnover and resulting 
in ulceration (Barasch and Peterson, 2003, Logan et al., 2007, Sonis, 2009). However in 
1998, Sonis put forward a new hypothesis for mucositis development which proposed a 
more complex sequence of events (Sonis, 1998). This model initially involved four 
phases: the inflammatory-vascular phase, the epithelial phase, the ulcerative phase and 
the healing phase (Sonis, 1998). In 2004, the model was expanded to incorporate a fifth 
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phase. The model currently comprises: the initiation phase, the upregulation and 
message generation phase, the signal amplification phase, the ulceration phase and the 
healing phase (Sonis, 2009) (Figure 3). 
 
 
Figure 3: The Five Phase Model of Mucositis 
(Sonis 2009. Permission granted) 
 
During the initiation phase, chemotherapy or radiotherapy-induced DNA strand 
breakage results in clonogenic death of cells in the basal epithelium (Sonis, 2009).  
Direct mucosal damage also results from the generation of reactive oxygen species 
(ROS) (Logan et al., 2007, Sonis, 2004). In the second phase of Sonis’ model DNA 
stand breakages and lipid peroxidation trigger the production of transcription factors, 
including the tumour protein p53 and nuclear factor-κB (NF-κβ), through transduction 
pathways. NF-κβ has an important role in the body’s inflammatory response, eliciting 
both pro-inflammatory and anti-inflammatory processes depending on at which point 
the pathway is stimulated (Logan et al., 2007). NF-κβ is responsible for the upregulation 
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of approximately 200 genes including: pro-inflammatory cytokines (tumour necrosis 
factor (TNF)), interleukin-6 (IL-6) and interleukin-β (IL-β), cell adhesion molecules, 
immunoreceptors, acute phase proteins, cell surface receptors and stress response genes. 
Such genes affect mucosal integrity by inducing cell death, tissue damage and apoptosis 
(Logan et al., 2007). Radiation and chemotherapy also target fibroblasts within the 
submucosa during this phase, through the activation of matrix metalloproteinase 3 
(MMP3) by cyclooxygenase-2 (COX-2) (Logan et al., 2007). MMP3 breaks down the 
basement membrane of the epithelium, and helps destructive signal promotion (Sonis, 
2004). 
 
Sonis’s third stage is the ‘signal amplification phase.’ This stage involves both direct 
damage to cells, and the continuation and amplification of the proinflammatory 
cytokine initiated processes (Cawley and Benson, 2005), through positive or negative 
feedback loops (Sonis, 2009). For example, TNF production leads to an increase in 
production of NF-κβ, which in turn leads to the increased production of TNF (Sonis, 
2009). TNF is a pleiotropic protein which has a role in the inflammatory immune 
response (Logan et al., 2007). TNF instigates cell death by disrupting cytotoxic 
inflammation, blood flow, and immune response regulation (Rieger, 2001). Many of 
these mechanisms occur simultaneously. Sonis recently used the metaphor of airline 
flight maps to explain the inter-related mechanisms at action during this phase, and how 
busy hubs (major cities) and outlying nodes can get overwhelmed when busy. This 
deadlock prevents intermittent resolution of the inflammatory cascade, and results in the 
fourth phase: ‘ulceration’(Sonis, 2009). 
 
The ‘ulceration phase’ takes place between days ten and 15 post-treatment. This stage 
shows the most overt clinical signs of mucositis, with the presence of deep ulcers, and 
on occasions a pseudomembrane (Cawley and Benson, 2005). The breakdown in 
mucosal integrity introduces avenues for the entry of bacteria, and this can result in the 
development of sepsis (Sonis, 2004). Data from animal models shows that during the 
transition between intact mucosa and ulceration, the number of mucosal bacteria 
increases over 300 times (Sonis, 2009). The penetration of the submucosa by products 
of these colonizing bacteria, together with the penetration of cell wall products such as 
lipopolysaccharides and cell wall antigens (Sonis, 2009), promote further damage, by 
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initiating the production of additional cytokines (Logan et al., 2007, Sonis, 2004). This 
is especially damaging in the neutropenic patient, as sepsis or bacteraemia may result if 
bacteria invades the submucosa (Sonis, 2009) 
 
The fifth and final stage of this model is the ‘healing phase’ (Sonis, 2004). This is the 
least understood phase in the model (Logan et al., 2007). During this phase the 
epithelial cells that surround the ulcer proliferate into the wound, and start to form 
layers. This process is stimulated by extracellular matrix signalling  from the submucosa 
(Sonis, 2009). Crucially, cells located below the mucosal surface remain damaged, 
never fully returning to their previous condition, increasing the risk of future trauma 
(Cawley and Benson, 2005).  
 
2.4 Factors affecting mucositis development 
The identification of factors which increase a patient’s risk of developing mucositis is 
beneficial for use in both clinical practice and research. Patients most at risk of 
developing severe mucositis can be identified before treatment and early interventions 
employed. Such factors can also be used to stratify patients in clinical trials in order to 
balance the treatment arms, and such factors can be controlled for in post hoc analyses. 
Various studies have attempted to identify the factors affecting mucositis development.  
Fourteen of these studies have used multivariate analysis. This method of statistical 
analysis allows the identification of the contribution of individual risk factors in the 
development of an outcome, in this case oral mucositis, and eliminates the influence of 
confounding variables (Katz, 2003). The studies using this method of analysis are 
shown in Table 1. The studies identified were conducted in three different populations. 
The majority of studies identified factors affecting mucositis development in patients 
undergoing autologous or allogeneic transplantation (Blijlevens et al., 2008, Bolwell et 
al., 2002, Grazziutti et al., 2006, Mattsson et al., 2006, Ohbayashi et al., 2008, Robien et 
al., 2004, Salvador., 2005, Vokurka et al., 2009, Wardley et al., 2000). Three studies 
were performed in chemotherapy patients (Cheng et al., 2008, McCarthy et al., 1998, 
Schwab et al., 2008), and only one study was identified in radiotherapy patients (Elting 
et al, 2007). Twenty-six factors affecting mucositis severity were identified. These can 
be separated into treatment related and patient related factors, and will be used to inform 
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the backbone of the next section of this review. Where relevant, studies not employing 
multivariate analyses will be used as secondary levels of evidence.  
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Table 1: Studies Using Multivariate Analysis to Identify Factors Affecting Mucositis Development or Intensity 
Author Patient Characteristics 
Condition and 
treatment Chemotherapy Risk factors included in analysis Results Comment 
Chemotherapy 
Cheng et al, 
2008 
 
82 Paediatric 
patients 
 
Chemotherapy 
patients. 
 
Vincristine, 
etoposide, 
doxorubicin, 
Daunorubicin, 
methotrexate, 
cytarabine, 
melphalan, 
cyclophosphamide.  
Gender, pre chemotherapy 
weight, height and BMI, pre-
existing dental problems, nadir 
neutrophil count, peak AST/ALT, 
peak creatinine, peak nausea and 
vomiting, use of cytokines, use of 
multi-vitamins, 
Lower body weight (P=0.0013) 
Lower value of log nadir neutrophil 
count (P=0.0025)  
Higher value of peak creatinine 
(P=0.025). 
 
McCarthy et 
al, 1998  
63 patients 
34M/ 29F 
Chemotherapy 
patients 
 
5-Flurouracil  Gender, diagnosis of diabetes, 
age, use of prostheses, education, 
BSA, smoking status, 
consumption of alcohol, use of 
prescription drugs, salivary flow 
rate, plaque index, use of 
medication for xerostomia, 
presence of xerostomia, patient 
reports of oral problems at 
baseline, 
performance status, cytotoxic 
regimen, chemotherapy by 
continuous infusion, 
baseline neutrophil count, 
baseline white cell count and 
presence of herpes simplex virus 
antibody 
Xerostomia at baseline (OR=10.0, 
P=0.04) 
Baseline neutrophil count below 4000 
cells /mm3 (OR=3.9, P=0.0355) 
Prospective 
study 
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Author Patient Characteristics 
Condition and 
treatment Chemotherapy Risk factors included in analysis Results Comment 
Schwab et 
al, 2008 
683 patients  
383M/300F 
Chemotherapy 
 
5-Flurouracil Gender, creatine levels, genotypes 
(DPYD, TYMS, MTHFR), 
diarrhoea, leucopoenia, use of 
folinic acid, mode of 
chemotherapy administration.  
Female gender (OR, 2.37; 95% CI, 
1.32 to 4.26, P=0.0036) 
DPYD*2A allele (OR, 58; 95% CI 
1.71 to 19.4, P=0.013) 
 
Studied 
treatment 
related toxicities 
associated with 
5-FU. Not only 
mucositis. 
Transplantation 
Blijlevens et 
al, 2008 
 
197 patients 
113M/ 84F 
Autologous 
transplant 
 
Melphalan 
200mg/m2, or 
carmustine 
300mg/m2, 
etoposide 
800mg/m2, 
cytarabine 800 to 
1600mg/m2 or 
melphalan 
140mg/m2 
Age, BSA, weight, height,  
performance status, chemotherapy 
type and dose. 
 
Determinants of severe OM 
incidence: 
Melphalan dose per kg body weight 
(MM patients) (P<0.001),  
Carmustine dose per kilogram of 
body weight (NHL patients) 
(P<0.001),  
ECOG performance status (P=0.013) 
 
Determinants of severe OM duration: 
Melphalan dose in MM patients 
(P=0.009) 
Carmustine dose in NHL patients 
(P=0.006) 
Multi-site study 
(25 centres in 13 
EU countries).  
Prospective 
study. 
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Author Patient Characteristics 
Condition and 
treatment Chemotherapy Risk factors included in analysis Results Comment 
Bolwell et 
al, 2002 
 
79 patients, 
56M/23F 
Autologous stem 
cell transplant 
patients 
 
Busulfan, 
cyclophosphamide 
and etoposide or 
busulfan and 
cyclophosphamide. 
Two patients 
received other 
regimes 
Gender, age, actual body weight, 
ratio of actual body weight to 
ideal body weight, chemotherapy 
courses, conditioning regimen, 
mobilization regimen, diagnosis, 
prior radiation. 
Prior radiation therapy (P=0.001),  
Diagnosis of NHL (P=0.007), 
Mobilisation with etoposide 
(P=0.034) 
Diagnosis was 
significant in 
univariate 
analysis but did 
not reach 
significance in 
multivariate 
analysis. 
Prospective 
study 
Grazziutti et 
al, 2006 
 
381 consecutive 
patients  
235M/146F 
Autologous 
transplant 
Melphalan  Age, race, weight, BSA, BMI, 
liver and renal function, 
melphalan dose, serum albumin, 
gender. 
Severe Mucositis predictors: 
High serum creatinine (OR=1.581; 
95% CI: 1.080-2.313, P=0.018) 
Higher Melphalan dose per 
kg/bodyweight (OR=1.595; 95% CI: 
1.065-2.389; P=0.023) 
Higher alkaline 
phosphatise also 
identified in 
univariate 
analysis  
Mattsson et 
al, 1991 
 
205 consecutive 
allogeneic BMT 
patients, 
127M/78F 
Allogeneic patients Cyclophosphamide 
or 
cyclophosphamide 
with TBI. 
Age, gender, conditioning with 
TBI, GVHD prophylaxis, 
prolonged aplastic period, number 
of HLA matches, bone marrow 
dose <3x108, herpes simplex 
virus,  septicaemia, 
Bone marrow dose <3x108 cells/kg 
(P<0.0001),  
prolonged aplastic period (WBC 
count <0.2x109 cells/l) for more than 
14 days (P<0.005),  
HSV-seropositive recipients 
(P<0.01),  
Conditioning with TBI (P<0.02), 
Age and GVHD 
prophylaxis 
with 
methotrexate 
were significant 
in univariate 
analysis  
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Author Patient Characteristics 
Condition and 
treatment Chemotherapy Risk factors included in analysis Results Comment 
Ohbayashi 
et al, 2008 
 
96 patients 
 
Allogeneic 
transplant 
Cyclophosphamide 
/ TBI, 
busulfan / 
cyclophosphamide 
Recovery of WBC count, age, 
date of transplant, oral health 
care, conditioning regime, source 
of donor (related/unrelated), use 
of oral cryotherapy, diagnosis, 
gender, type of graft, number of 
HLA mismatches, incidence of 
severe GVHD, risk (high / low) 
Conditioning regime (P=0.003) 
Oral health care (P=0.024) 
Conditioning 
regime, age, 
donor source, 
oral health care 
and date of 
transplant all 
significant in 
univariate 
analysis. 
Robien et al, 
2004 
 
133 patients Allogeneic stem 
cell transplant 
patients 
 
Cyclophosphamide 
/TBI or 
busulfan / 
cyclophosphamide 
Gender, race, age, weight, height, 
BMI, BSA, treatment with 
interferon-alfa, smoking history, 
conditioning regimen, relationship 
of donor, source of stem cells, 
compatibility of patient with 
donor, incidence of graft versus 
host disease, date of transplant, 
use of growth factors and 
ganciclovir, length of time 
between diagnosis and transplant, 
hydroxyurea, use of cytarabine 
and busulfan, use of methotrexate, 
use of multi-vitamins,   
Conditioning regimes including TBI 
(P<0.01) 
BMI>25 (P<0.01) 
MTHFR 677TT Genotype (P=0.01) 
Pretransplant multivitamin 
supplementation (P=0.04) 
Current smoking (P=0.04) 
Smoking result 
based on only 4 
patients.  
Salvador  
2005  
140 patients  
84M/54F 
Autologous stem 
cell transplant 
patients 
Melphalan, or 
etoposide and 
melphalan. 
Age, gender, diagnosis, cytotoxic 
regimen, serum creatinine level, 
BMI, level of prevention, 
Peak creatine (P=0.0436) 
Chemotherapy protocol (P=0.0042) 
Diagnosis (P=0.0042) 
Level of prevention (P=0.0181) 
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Author Patient Characteristics 
Condition and 
treatment Chemotherapy Risk factors included in analysis Results Comment 
Vokurka et 
al, 2006  
148 patients 
BMT, 94M/54F 
Autologous stem 
cell transplant 
patients  
BEAM or 
melphalan 
chemotherapy  
BMI, cytotoxic regime, 
mouthwash solution, number of 
cells in the graft, age, gender, 
Female gender 
Melphalan administration 
Short report. No 
figures given for 
multivariate 
analysis.  
Vokurka et 
al, 2009 
 
101 patients 
53M / 48F 
Allogeneic stem 
cell transplant 
patients 
 
Busulfan and 
cyclophosphamide  
fludarabine and 
Melphalan  
Age, cytotoxic regimen, gender, 
BMI, number of HLA  matches, 
type of graft, number of cells in 
the graft, methotrexate dose, 
creatinine clearance, history of 
mucositis, diabetes, use of oral 
prosthesis, use of filgrastim, time 
since last chemotherapy 
administration, bilirubin levels,  
Melphalan dose per kg of bodyweight 
(P=0.0083) 
Melphalan dose (per kg bodyweight) 
also a predictor of severe mucositis 
(P=0.0086) 
Female gender 
was significant 
in a univariate 
analysis. 
Wardley et 
al, 2000  
429 patients 
270M/159F 
 
Mixed autologous 
and allogeneic 
transplant patients 
 
Cyclophosphamide 
and Busulfan, 
Cyclophosphamide 
and TBI, 
Carmustine, 
Cyclophosphamide, 
etoposide and 
carmustine, 
Melphalan, 
Melphalan and TBI.  
Cytotoxic regimen, type of cells, 
use of growth factors, age, 
gender,  
Conditioning regime (P<0.00005) Myeloablative 
regime, 
haematopoietic 
progenitor 
source, use of 
myeloid growth 
factors, and age 
were all 
significant in a 
univariate 
analysis. 
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Author Patient Characteristics 
Condition and 
treatment Chemotherapy Risk factors included in analysis Results Comment 
Radiotherapy 
Elting et al, 
2007  
204 patients 
159M/45F 
Head and Neck 
patients 
Mean RT Dose 
(Grays)=67 
63 patients received 
altered 
fractionation. 
Age, gender, diabetes, use of 
chemotherapy,  use of intensity-
modulated radiotherapy, use of 
altered fractionation, type of 
cancer, oral health 
Determinants of OM (all grades) 
duration: 
Chemotherapy use (P<0.001) 
Oral cavity or oropharynx primary 
(P<0.001) 
Determinants of severe OM (grades 
3/4) duration: 
Oral cavity or oropharynx primary 
(P<0.001) 
Altered fractionation schedules 
(P=0.04) 
Risk of grade 3 or 4 mucositis 
duration 
Oral cavity or oropharynx primary 
(OR, 9.4 95%CI 47.1-21.8, P<0.001) 
Diabetes (OR, 6.6 95% CI 1.3-34.1, 
P=0.02 
Altered fractionation schedules 
(P=0.002) 
 
AOR=Adjusted Odds Ratio, AST=aspartate aminotransferase, ALT=alanine aminotransferase, BEAM=Bischloroethyl nitrosourea etoposide ara-c melphalan, BMI=Body 
mass index, BSA=Body surface area, CI= Confidence Intervals, EU= European Union,  F=Female, GVHD=Graft versus host disease, HLA=Human leukocyte antigen, 
KG=Kilogram, M=male,  MEL=Melphalan, OR=Odds Ratio RT=Radiotherapy, TBI=Total body irradiation,  WBC= White blood cell,  
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2.4.1 Therapy related factors 
2.4.1.1 Chemotherapy regimes 
Wardley and colleagues (2000) identified conditioning regimens as the only factor 
affecting mucositis development using a multivariate analysis. In this study melphalan, 
an alkylating chemotherapy, was associated with the greatest incidences of mucositis in 
an analysis of 429 patients receiving a variety of chemotherapy regimens while 
undergoing transplantation (Wardley et al., 2000). Melphalan administration was also 
identified as a risk factor by Vokurka and others (2006), who studied 148 patients 
receiving chemotherapy with either melphalan or a combination of carmustine, 
etoposide, cytarabine and melphalan chemotherapy (BEAM) (Vokurka et al., 2006).  
 
Three studies identified melphalan dose per kilogram (kg) of bodyweight as a 
determinant of severe mucositis (Blijlevens et al., 2008, Grazziutti et al., 2006, Vokurka 
et al., 2009). Melphalan dose is normally calculated based on the patient’s body surface 
area. This can result in a wide variation in the actual dose a patient receives (Grazziutti 
et al., 2006), and as a consequence lighter patients may receive a higher dose of 
chemotherapy than necessary. Blijlevens and others have hypothesised that the 
difference between  the body surface area dose and the per kilogram dose may explain 
why low body weight and female gender have been identified as risk factors for OM 
development, as these patients tend to receive high doses of chemotherapy per kilogram 
of their body weight (Blijlevens et al., 2008). The identification of high peak creatinine 
levels as a risk factor for mucositis development by two studies (Cheng et al., 2008, 
Salvador, 2005) is notable as melphalan administration is associated with an increased 
risk of nephrotoxicity. It therefore appears that this decrease in kidney function may 
result in a delay in the elimination of chemotherapy agents, and therefore an increase in 
mucosal damage.  
 
Other chemotherapy drugs that have been suggested to exhibit higher incidences of 
mucotoxicity include 5-fluorouracil (5-FU), cisplatin, etoposide, methotrexate, taxanes 
(docetaxel and paclitaxel), melphalan, cytarabine, vinblastine and doxorubicin 
(Ramirez-Amador et al., 2010, Robien et al., 2004, Scully et al., 2003). In addition to 
exhibiting direct mucosal effects, etoposide and methotrexate are cell cycle specific 
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drugs which are excreted in the saliva, which possibly explains the increased 
mucotoxicity associated with these drugs (Avritscher et al., 2004, Pico et al., 1998). In 
addition to the type of chemotherapy administered, the method of administration may 
affect mucositis severity. Damon et al (2004), conducted an RCT comparing the levels 
of toxicity in patients receiving etoposide as a bolus infusion compared to those 
receiving the drug by continuous infusion, and reported that the continuous infusion 
group experienced significantly more mucositis than patients in the bolus group (Damon 
et al., 2004). 
 
2.4.1.2 Radiotherapy regimes 
Only one study identified employed a multivariate analysis to identify risk factors for 
mucositis development in radiotherapy patients (Elting et al., 2007). The use of 
concomitant chemotherapy was identified as a determinant of mucositis development in 
this study; whereas, the use of altered fractionation schedules were identified as a 
determinant of severe mucositis (grades three and four). Primary site of cancer in the 
oral cavity or oropharynx were identified as a determinant in both categories (Elting et 
al., 2007). The suggestion that patients with cancer of the oral cavity or oropharynx may 
experience more mucositis and mucositis of a greater severity is logical given that the 
oral cavity of these patients will receive large doses of radiotherapy directly to the 
mucosa.  
 
The use of altered fractionation: (the use of hyperfractionated regimes in which the dose 
a patient receives during each radiotherapy schedule is reduced but the number of 
sessions is increased) or the use of concomitant boost (the introduction of extra 
radiotherapy sessions per day at the same dosage), increases the risk of mucositis 
because the total dose of radiotherapy a patient receives may be increased and the 
timescale of the therapy reduced. Elting and colleagues’ (2007), findings are supported 
by the results of the continuous hyperfractionated accelerated radiotherapy (CHART) 
trial which compared hyperfractionated to conventional radiotherapy in 918 patients 
with head and neck cancer. and reported that patients receiving hyperfractionated 
regimes experienced mucositis of higher incidence and longer duration (Bentzen et al., 
2001). However, the authors also report that resolution of confluent mucositis was 
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quicker in the patients receiving hyperfractionated therapy, which is a notable result 
(Bentzen et al., 2001).  
 
2.4.1.3 Combinations of chemotherapy and radiotherapy 
Patients undergoing BMT may also receive TBI. There is currently no consensus in the 
published data on the mucotoxicity of chemotherapy regimens when combined with 
TBI (Avritscher et al., 2004). Mattsson and colleagues (1991), prospectively studied 
205 allogeneic BMT patients. Patients were treated with either cyclophosphamide or a 
combination of cyclophosphamide and TBI. Unfortunately, the authors are vague about 
the number of patients who received each protocol. Mucosal lesions developed in 148 
patients, 138 of whom had received TBI. In a multivariate analysis, treatment with TBI 
was identified as a risk factor for lesion development (P<0.02). These findings are 
supported by the work of Zerbe and colleagues (1992), who conducted a retrospective 
chart analysis of 20 patients who had undergone transplantation over a two year period. 
Nine of these patients received busulfan, etoposide and cyclophosphamide conditioning. 
Another nine patients received TBI with etoposide and cyclophosphamide. The final 2 
patients received other protocols (Zerbe et al., 1992). There was a trend towards an 
earlier onset of mucositis in patients treated with TBI in this study. However, this 
difference was not statistically significant. Patients treated with TBI also experienced a 
higher average daily mucositis score, measured using the oral assessment guide (OAG), 
during the first week of treatment. Significant differences were found between the 
groups at day 0 (P=0.0192), day+2 (P=0.033) and day+4(P=0.033). However, no 
significant differences between the groups were found either overall, or for the first 
week data (Zerbe et al., 1992).  
 
Conversely, Woo and colleagues (1993), reported a similar incidence of ulcerative 
mucositis in nine patients receiving a busulfan and cyclophosphamide (77.8%) 
compared to 24 patients who received cyclophosphamide and TBI (79.2%) in their 
longitudinal study. The mean score of mucositis in the patients treated with busulfan 
was slightly higher, with a score of 2.4, compared with the score of 2.0 in the patients 
receiving TBI (Woo et al., 1993). These results are supported by data from the 
prospective study conducted by Wardley (2000), where patients treated with melphalan 
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experienced mucositis of a greater severity than patients receiving TBI (Wardley et al., 
2000).  
 
It is notable that patients receiving a combination of cyclophosphamide etoposide and 
carmustine or melphalan experienced both a higher incidence and a greater mean 
severity of ulcerative mucositis than patients treated with TBI. While the potential for 
the use of TBI to increase mucositis severity is supported by head and neck cancer 
patients receiving concurrent chemoradiotherapy experiencing more severe mucositis 
than with radiotherapy alone (Trotti et al., 2003); the potential for TBI to result in either 
mucositis of greater intensity or earlier onset has not yet been demonstrated  
 
2.4.2 Patient related factors 
2.4.2.1 Previous history of mucositis  
Previous occurrences of mucositis have been suggested as a factor in mucositis 
development (Kostler et al., 2001), due to damage sustained previously by cells below 
the mucosal surface making the patient more susceptible to subsequent bouts of 
mucositis (Cawley and Benson, 2005). However, this was not identified as a factor in 
mucositis development in any of the studies shown in Table 1, although it should be 
noted that only one study included a history of mucositis as a potential risk factor 
(Vokurka et al., 2009).  
 
2.4.2.2 Age 
The impact of age on the incidence and severity of mucositis is a contentious issue. It 
has been suggested that due to increased rates of cell division in this group, younger 
patients may be at a greater risk of mucositis (Pico et al., 1998, Sonis et al., 1978). 
Conversely, it has also been argued that due to a reduction in renal function associated 
with the aging process, older populations may be more at risk (McCarthy et al., 1998), 
due to reduced renal function increasing the toxicity of antineoplastic medications by 
altering their pharmacokinetic and pharmacodynamic effects (Avritscher et al., 2004). It 
is notable that while age was analysed as a potential risk factor by 12 studies, and was 
identified in the univariate analyses of three studies shown in Table 1 (Mattsson et al., 
1991, Ohbayashi et al., 2008, Wardley et al., 2000), it was not identified in any of the 
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multivariate analyses, suggesting that age may not be an independent risk factor for 
mucositis development and may instead be associated with some other factor, such as 
type of disease or conditioning regime.      
 
2.4.2.3 Smoking 
Smoking was identified as a risk factor for mucositis development in only one study 
(Robien et al., 2004) shown in Table 1. However, this result is based on an extremely 
small subsample of only four patients. Conversely, smoking was not identified as a risk 
factor by McCarthy and colleagues (1998), the only other study which analysed this 
potential risk factor. Smoking cigarettes has been reported to significantly reduce the 
incidence of severe mucositis in patients in a study by Kazemian (2009), which 
investigated benzydamine for the prevention of mucositis. This analysis was again 
based on a small subset of 20 patients, and the results of this study do not appear to be 
supported elsewhere in the literature. More research into this area is warranted.  
 
2.4.3 Summary of patient and treatment related factors 
Table 1 shows the results of studies which have employed multivariate analyses in an 
attempt to identify treatment and patient related factors which may affect the 
development and severity of mucositis. There appears to be little consistency in the 
results of these studies, with only TBI and melphalan dose per kilogram of bodyweight 
being identified as possible factors by more than one study. More research is needed in 
this area is the prediction of at risk patients is to become a real possibility. However, 
stratification by whether or not a patient receives TBI should be considered in clinical 
trials conducted in patients undergoing transplantation. If such trials include both 
patients receiving high dose and low dose melphalan chemotherapy, then stratification 
by melphalan dose may be advisable.  
 
2.5 Impact of mucositis 
The impact of mucositis is threefold: its economic and clinical effects may be more 
obvious, but the impact of severe mucositis on the patient experience should not be 
overlooked. The next section of this literature review will discuss the impact of 
mucositis on each of these areas in detail.  
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2.5.1 Clinical impact of mucositis 
2.5.1.1 Treatment breaks 
Mucositis is a dose limiting toxicity (Peterson and Cariello, 2004) as severe mucositis 
can necessitate dose modifications or breaks in treatment to allow the patient to recover, 
which may adversely affect the outcome of treatment (Blijlevens et al., 2009, Epstein 
and Schubert, 2004, Scully et al., 2006). Indeed, very severe mucositis may force the 
complete cessation of treatment (Blijlevens et al., 2009).  
 
2.5.1.2 Length of hospital stay 
Several studies have reported that patients with severe mucositis require longer periods 
of hospitalisation compared to patients with mild or no mucositis (Sonis et al., 2001, 
Vera-Llonch et al., 2007a, Vera-Llonch et al., 2007b). Vera-Llonch and colleagues 
reported a five day difference in length of hospital stay between patients with severe 
mucositis and those with no mucositis (P<0.001) in a retrospective analysis of patients 
undergoing autologous transplantation (Vera-Llonch et al., 2007b). When allogeneic 
patients were studied using the same methods, length of hospital stay was longer still, 
with patients suffering from severe mucositis requiring a mean of 14 extra days in 
hospital compared to patients without oral symptoms (P<0.0001) (Vera-Llonch et al., 
2007a). Two authors have used the oral mucositis assessment scale (OMAS) instrument 
to explore the clinical impact of mucositis (Bolwell et al., 2002, Sonis et al., 2001). 
Sonis and colleagues (2001), conducted a retrospective study of a mixed sample of 92 
autologous and allogeneic patients undergoing stem cell transplantation and reported 
that a one-point increase in peak OMAS score was associated with an extra 2.6 days in 
hospital (P<0.01) (Sonis et al., 2001). While Bolwell and others (2002), prospectively 
studied 79 patients undergoing autologous transplantation using a modified version of 
the OMAS instrument, and reported that patients with a score of greater than one 
experienced a hospital stay six days longer than patients with a score of less than one 
(P<0.001) (Bolwell et al., 2002). 
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2.5.1.3 Pain 
“Pain is a clinically significant component of mucositis and an important factor on 
decreased quality of life among cancer patients” (Elting et al., 2003:1538) 
 
Mucositis-induced pain is generally acute in nature and follows the pattern of mucositis 
development and resolution, reaching a peak approximately seven or eight days post-
therapy and generally resolving by day 21 (McGuire et al., 1998). It is generally 
reported as being mild to moderate in intensity (Epstein and Schubert, 2004, McGuire et 
al., 1998). Like mucositis incidence, oral pain due to cancer treatment does not affect 
every patient in the same way. A small minority of patients will not experience oral pain 
at all. However, certain types of treatment are associated with higher incidence of pain 
due to mucositis than others. The incidence of oral pain is virtually 100% in the head 
and neck population (Alvarado et al., 2002, Epstein and Schubert, 2004). In the BMT 
population, reported occurrences of pain range between 47% and 86% (McGuire et al., 
1993, Fall-Dickson et al., 2008). Among the general chemotherapy population, figures 
range between 40% and 70%, reflecting the incidences of mucositis in these populations 
(Alvarado et al., 2002). It has been suggested that the true incidence of mucositis related 
pain may be higher than that currently recognised in the literature (Epstein and 
Schubert, 2004), due to the under-reporting of the symptom by patients, or the under-
recording or under-treatment of the condition by medical staff.   
 
Head and neck cancer is commonly treated with surgery, radiotherapy or chemotherapy, 
or a combination thereof. Each of these treatment modalities is associated with pain 
(Epstein and Schubert, 2004). Surgery can result in acute pain, which may become 
chronic due to scarring or other musculoskeletal syndromes. Radiation can also cause 
acute pain, which continues to persist long after treatment has abated, and can cause 
long-lasting discomfort and sensitivity to the mucosa. The use of chemotherapy in 
conjunction with radiotherapy can intensify the level of mucosal damage, increasing the 
amount of pain experienced by the patient (Epstein and Schubert, 2004). Research has 
shown that pain control in this patient population is generally poor (Wong, 2006). 
Patients can therefore experience long-lasting pain due to treatment, which can have a 
significant impact both on clinical resources and patient quality of life.  
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Patients receiving the same types of treatment may not be expected to experience the 
same amount of pain, or interpret their pain in the same way. Indeed some patients have 
reported believing that their pain was a positive thing, as this meant that the treatment 
was working (Borbasi et al., 2002). A patient’s perceived level of pain is multifactorial 
and is influenced by a number of physiologic, sensory, affective, cognitive, behavioural 
and sociocultural dimensions (Epstein and Schubert, 2004, McGuire et al., 1998). The 
physiological dimension of pain encompasses the cause of the pain, in this case 
mucositis, the duration and physical aspects of the pain (the ulceration and 
inflammation), and the temporal pattern of the pain: whether the pain is intermittent or 
chronic in nature (McGuire et al., 1998). The sensory dimension concerns what the pain 
feels like for the patient: its location and intensity (McGuire et al., 1998). The patient’s 
emotional response to the pain, including, but not limited to, anxiety, depression and 
mood disturbances describes the affective dimension of pain (McGuire et al., 1998). 
The cognitive dimension refers to the patient’s thoughts about the pain, the meanings 
attributed to the pain by the patient and any coping strategies employed. The patients 
attitudes in relation to pain, and the relief of pain, are also included in the cognitive 
dimension in this model (McGuire et al., 1998). The behavioural dimension of the pain 
model pertains to the patient’s observable behaviours. Such behaviours can either be 
those attempting to alleviate pain, such as the use of painkillers, or alternatively, 
behaviours that indicate the presence of pain, such as grimacing (McGuire et al., 1998). 
The final dimension of pain is the sociocultural dimension of pain. This dimension 
covers the profusion of ethnic, spiritual, social, cultural, and demographic factors that 
influence a person’s perception of pain and their response to this stimulus (McGuire et 
al., 1998). The patient’s experience of pain is therefore very complex and is comprised 
of a number of inter-related factors, which affect both how the patient perceives their 
pain and how they deal with this pain. However, despite oral pain being identified as the 
most important symptom to be measured in clinical trials by both patients and 
Clinicians (Cella 2003), only 36% of the studies included in the 2010 update of the 
Cochrane review of interventions for the prevention of mucositis reported some type of 
pain measurement (Worthington et al., 2010).  
 
2.5.1.4 Infection 
Infection is possibly the most important complication of cancer treatment (Blijlevens et 
al., 2009, Brown and Wingard, 2004). The invasion of infective organisms into the 
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ulcerated mucosa also act to drive and amplify the fourth stage of the Sonis mucositis 
model (Sonis, 2009), through the production of positive feedback loops (Scully et al., 
2006). Under normal conditions, the mucosal surface of the oral cavity acts as a barrier 
to prevent the passage of pathogens into the body. The shedding of the surface layer of 
the mucosa additionally acts to reduce the number of organisms colonising the oral 
cavity (Brown and Wingard, 2004). However, mucositis ulceration damages the 
integrity of this barrier and this allows the invasion of infecting organisms. Cancer 
patients who are suffering from neutropenia, the absence of neutrophils due to 
treatment, are considered most at risk of developing an infection. Patients undergoing 
transplantation, who commonly experience a prolonged period of neutropenia, have 
been shown to be three times more likely to develop streptococcal bacteraemia than 
patients without ulceration (Ruescher et al., 1998). The first, and sometimes only, sign 
of infection in neutropenic patients is generally a fever (Blijlevens et al., 2009). The 
occurrence of fever during neutropenia, a condition termed febrile neutropenia, is life 
threatening, and left untreated may result in the death of the patient due to sepsis 
(Blijlevens et al., 2009). 
 
In their study validating the OMAS instrument, Sonis and others identified that a one 
point increase in peak OMAS score was associated with one additional day of fever, and 
just over twice the risk of significant infection (P<0.01 for both) (Sonis et al 2001). 
Prevention and treatment of infection has, through the need for increased use of 
prophylactic antibiotics and extra procedures and tests, a significant clinical impact. 
Such a clinical impact also has economic implications and can cause distress to the 
patient and their families.  
 
2.5.2 Economic impact of mucositis 
In addition to its clinically relevant impact, mucositis also exhibits a significant 
economic cost. More hospital admissions, and longer hospital stays, together with the 
administration of drugs to alleviate pain and fight infection, and interventions to prevent 
and treat the condition, result in higher costs for treating patients with, compared to 
patients without, mucositis. Various authors have attempted to quantify this economic 
impact, using a variety of methods. All these studies were conducted in the United 
States of America (USA), and therefore all figures given are in United States dollars ($).  
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Sonis and colleagues (2001), conducted an analysis of the economic impact of mucositis 
in BMT using data collected from 92 patients during the validation of the OMAS 
instrument. The authors obtained hospital charges for the 70 patients in the study based 
within the USA and calculated that a one-point increase in peak OMAS score was 
associated with additional hospital charges totalling $25,405 (Sonis et al., 2001). The 
authors also calculated that hospital charges were $43,000 higher, during the 100 days 
post-transplant, for patients who developed ulcerative mucositis compared with those 
who did not (Sonis et al., 2001).  
 
In 2003, Elting and colleagues conducted a retrospective analysis of a cohort of 599 
patients with solid cancers undergoing chemotherapy. The primary objective of this 
study was to study bleeding outcomes in these patients, and therefore the sample was 
comprised entirely of patients with neutropenia or thrombocytopenia. Hospital costs for 
this study were based on a daily fixed fee of $1000 per day, a figure derived from mean 
U.S medicare payments (Elting et al., 2003). The authors report that the occurrence of 
mucositis increased the cost of hospitalisation per cycle of chemotherapy by 62%, from 
$3893 per cycle in patients without mucositis to $6277 per cycle in patients with the 
condition (Elting et al., 2003). While the costs of mucositis in BMT patients reported by 
Sonis and colleagues (2001), were much higher than those reported by Elting and others 
(2003), the authors conclude that the number of patients treated with solid tumours is far 
greater than those receiving BMT, and therefore in aggregate, the costs associated with 
mucositis in this group may be greater than those associated with transplantation (Elting 
et al., 2003).  
 
In 2007, Elting and colleagues published the results of a retrospective chart analysis of 
204 head and neck patients who received treatment at the M.D. Anderson Cancer Centre 
during 2002, and calculated costs using data from the hospital’s accounting system in 
2002 and inflated to 2006 prices using the Consumer Price Index for Medical Care. The 
authors report that increased resource utilization due to mucositis  resulted in costs 
escalating by $1700 in patients with mild mucositis (grades 1 and 2) and by $3600 in 
patients with severe ulcerative mucositis (grades 3 and 4) (Elting et al., 2007). The costs 
reported in this study varied considerably when subsamples of patients receiving 
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different types of treatment were analysed. In patients receiving radiotherapy only, the 
mean cost of treatment in patients without mucositis (after adjustment for patient and 
disease factors) was $14,646 (95% CI, $11,801 to $18,178) compared to $20,624 (95% 
CI, $19,227-$22,122) in patients with mucositis (P=0.006) (Elting et al., 2007). 
However, in patients receiving a combination of radiotherapy and chemotherapy, the 
difference in costs in patients suffering from mucositis compared to those without 
mucositis was not significant (P=0.35) (Elting et al., 2007).  
 
All of the economic analyses of the costs associated with mucositis detailed in this 
literature review were conducted retrospectively. There are significant organisational 
challenges associated with attempting to conduct such analyses prospectively, which 
explains why no such study has been identified. However, this retrospective nature of 
data collection is problematic, as mucositis incidence may be underestimated, especially 
mild forms of the condition, which may bias the results of the study (Elting et al., 2003). 
Retrospective analyses are also at the mercy of the quality of oral assessment used at a 
centre. Peterman and colleagues (2001), conducted a retrospective chart analyses of 45 
patients with head and neck cancer and reported that severe mucositis was associated 
with significantly higher costs for outpatient nutrition (P=0.03) and prescription 
medications (P=0.0005). However, the authors concluded that variability in the use of a 
single method of oral assessment by different assessors, and the failure of assessors to 
employ a single grading system may have introduced unmeasured error into the results 
(Peterman et al., 2001). The results of this study are therefore highly questionable.   
 
To date, no attempt has been made to quantify the economic impact of mucositis in 
British patients. The structure of healthcare in the United States, with its methods of 
direct billing, lends itself to such economic evaluations, and it would be difficult to 
replicate such studies using the British publicly funded healthcare model. Likewise, care 
should be used when applying these American-generated costs in Britain, due to the 
differences in our health systems. However, even without such direct figures it can be 
concluded that mucositis has a significant economic impact.   
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2.5.3 Impact of mucositis on the patient experience 
Patients’ reports of mucositis can be separated into two groups: those collected 
quantitatively using questionnaires; and those made during qualitative interviews. To 
date, four qualitative studies have been conducted to study mucositis from the patient’s 
perspective.  
 
Borbasi and colleagues, (2002) qualitatively interviewed six patients undergoing 
autologous transplantation. The four male and two female patients, aged between 38 and 
63 years old, were interviewed weekly during hospitalisation for four weeks and then at 
eight weeks and 12 weeks post transplant. In total, 19 out of a planned 36 interviews 
were conducted. Although it was anticipated that interviews would last between 45 
minutes and one hour, some interviews were shorter, and three patients refused to be 
interviewed when their mucositis was at its most severe (Borbasi et al., 2002). Three 
patients died during data collection, and an unspecified number of patients had to be 
interviewed over the telephone post-discharge, due to problems keeping hospital 
appointments, indicating how difficult it is to conduct research in this area. Patients 
were asked to relate their symptom experience of mucositis at various stages of the 
transplant process to an interviewer and to keep a record of thoughts and feelings in a 
diary. Unfortunately, such diaries were underutilised, probably due to the severity of 
illness experienced by this group (Borbasi et al., 2002).  
 
Using a phenomenological analysis, the authors identified three phases of the transplant 
process: the preparatory, peak and persisting phases; and five key themes: ‘the presence 
of nurses’, ‘therapeutic interventions’, ‘manifestations of mucositis’, ‘the distress of 
eating (and not eating)’ and ‘whether the treatment was worthwhile’ (Borbasi et al., 
2002, p1051). Although the patients encountered different severities of mucositis, all 
experienced some symptoms, with patients describing ‘tingling’ and mild sore throat at 
the onset of mucositis. As mucositis increased in severity, taste changes and difficulty 
with chewing and swallowing, loss of appetite, xerostomia and pain were reported. All 
patients experienced periods of low mood due to their symptoms, with some describing 
feelings of social isolation due to the discomfort associated with the condition (Borbasi 
et al., 2002). In addition to reporting an increase in feelings of anxiety at mealtimes, due 
to problems swallowing, patients also reported frustration that their symptoms made the 
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prospect of eating unappealing. Patients also reported periods where they were unable to 
eat, which they found distressing as they associated the ability to eat with recovery 
(Borbasi, 2002).  
 
Two patients continued to experience mucositis symptoms post-discharge. One patient 
reported swallowing problems at five weeks post-treatment. These problems continued 
to persist and were still negatively impacting his quality of life 11 weeks after 
transplantation. Another patient reported the use of artificial saliva at six weeks post-
transplant, and stated that her eating and drinking related were worse at this time than 
they had been during treatment (Borbasi et al., 2002).  
 
Although the authors experienced many problems collecting data, the results of this 
study are important as they suggest that in addition to causing pain and problems eating, 
severe mucositis can increase patients’ feelings of anxiety, distress and social isolation, 
impairing their quality of life. Interestingly, the authors comment that, although patients 
believed that they had been prepared for mucositis symptoms, in reality they were 
actually only prepared for the physical manifestations of mucositis, and not the 
psychological aspects of the condition (Borbasi et al., 2002). How exactly therefore, do 
we prepare patients for the psychological onslaught of mucositis? Unfortunately this 
question has not been addressed in the literature to date.  
 
To date, the Borbasi and colleagues study is the only prospective qualitative study 
conducted to explore patient reports of mucositis. The problems conducting interviews 
with patients while mucositis was at its peak, and the level of attrition experienced, 
illustrate the problems of conducting research in the transplant population. Three 
retrospective qualitative studies have been published. All of these studies will be 
susceptible to recall bias. Cheng (2009) conducted the only qualitative study to date 
exploring reports of mucositis in children. This phenomenological study aimed to 
describe the lived experiences of mucositis. Semi-structured interviews were conducted 
with 22 paediatric patients who had experienced ulcerative mucositis within six months 
of interview and their parents. The mean age of children taking part in this study was 
12.1 years old; the youngest patient recruited was six, and the oldest was 19 years old 
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(Cheng, 2009). Twelve of the children recruited were male. Nine patients had a 
diagnosis of acute lymphoblastic leukaemia, seven had osteosarcoma and four patients 
suffered from lymphoma. The diagnosis of the remaining two patients was unspecified 
(Cheng, 2009). The vast majority of the parents recruited were female (91%). One male 
parent and one grandmother also took part in the interviews (Cheng, 2009). The 
interviews conducted with children lasted between 20 and 30 minutes, although the 
author states that the youngest children often took part in shorter interviews.  
 
Like Borbasi and colleagues, Cheng (2009) identified five themes: ‘symptoms 
experienced’, ‘negative emotional outcomes’, ‘the dilemma of eating (or not eating)’, 
‘challenges in oral care’ and ‘healthcare needs’ (Cheng, 2009, p831), and fourteen 
categories: ‘consequences of pain’, ‘location of ulceration’, ‘control of pain’, ‘distress 
of children’, ‘emotional tension’, ‘distress of parents’, ‘eating is fundamental to life’, 
‘poor nutritional status’ and ‘weight loss’, ‘importance of oral care’, ‘pressure to do 
mouthcare’, ‘children’s co-operation’, ‘education needs’, ‘psychological preparation’ 
and ‘compassionate care’(Cheng, 2009, p831).  
 
The patients interviewed by Cheng experienced a great deal of pain, which was present 
despite the administration of opioids. This pain was described as the worst aspect of oral 
mucositis by the children. Oral mucositis led to social isolation for some patients as they 
were unable to speak due to their symptoms (Cheng, 2009). When interviewed, parents 
specified the need for better education about mucositis, in order to make them better 
prepared to deal with the condition psychologically (Cheng, 2009). Both patients and 
parents felt that they were underprepared for the severity of mucositis and its associated 
symptoms, and suggested a need for psychological support, and organised displacement 
activities for patients, to help both groups deal with the situation (Cheng, 2009).  
 
Cheng found that eating, or the lack of it, caused distress to both patients and their 
carers (Cheng, 2009). Like the patients interviewed by Borbasi and others, the parents 
interviewed by Cheng equated eating with recovery and survival, and experienced 
conflicting emotions encouraging their child to eat because of the suffering that eating 
caused (Cheng, 2009). Both patients and carers also described mouth care as a source of 
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conflict and distress, as while children were aware of the importance of a clean mouth, 
the unpleasantness of the mouthwashes and the pain and discomfort involved in this 
process, led to oral care being neglected unless the child was encouraged or ‘forced’ by 
a parent (Cheng, 2009). Unfortunately, a major criticism of Cheng’s results is that the 
author does not state how old the patient is in the quotes provided, and does not discuss 
if there were any potential differences in the symptoms reported in different age-groups 
of children.  
 
Bellm and colleagues (2000) conducted qualitative interviews with patients who had 
undergone transplantation within the previous 18 months at marketing research facilities 
in five cities in America. Patients were recruited through support groups, physician and 
patient referral, and adverts placed in newspapers. All patients received honoraria of an 
unspecified nature for taking part in the study. Of the 38 patients recruited, ten were 
male and 28 were female. The mean age of subjects was 46.9 years old (Bellm et al., 
2000). When asked to recall the most debilitating aspect of their treatment, 42% of 
patients stated that mouth sores were the most incapacitating. The next most frequent 
side effect recalled by patients was nausea and vomiting (13%). Of the patients 
reporting mouth sores as a side effect of treatment, 23 patients reported difficulties in 
eating, 21 reported a restriction in swallowing, 17 patients reported difficulties drinking 
and eight problems with talking (Bellm et al., 2000).  
 
The authors state that these interviews were ‘in depth’ however, according to the 
interview key, the entire interview only lasted approximately 50 minutes, with 17-20 
minutes of this time being taken up with product testing of three oral mucositis 
products. After time for introductions and questions about the transplant experience, it is 
surmised that this leaves approximately ten minutes for oral mucositis questions. It is 
therefore doubtful if the interviews where of a long enough duration to be considered to 
be ‘in depth’.  
 
The results of the Bellm and colleagues study are also at risk of recall bias, as while the 
authors intended to recruit patients who had undergone transplant in the previous 18 
months, only 60% of the sample met this criteria, with another 24% of patients having 
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had a transplant between 18 and 24 months before interview and the remaining 16% 
having had a transplant between three and six years before interview (Bellm et al., 
2000). Furthermore, the authors used a qualitative methodology to collect data and then 
chose to describe their finding quantitatively. While this method provides some 
interesting mucositis statistics, it seems that the chance to produce a richer narrative 
about the patient experience of mucositis has been missed. 
 
Rose-Ped and colleagues (2000) conducted a similar study with patients undergoing 
radiotherapy for head and neck cancers in 2002. The patients were recruited and 
interviewed using the same methods as Bellm and colleagues (Bellm et al., 2000). A 
total of 33 patients were recruited, of which 61% were male. The mean age of patients 
recruited into the study was 56.4 years old (Rose-Ped et al., 2002). To be eligible to take 
part in this study, patients originally had to have completed radiotherapy between 
January 1997 and October 1998; however, patients who completed radiotherapy before 
1997 were also included due to problems with recruitment, with five patients who 
received radiotherapy during or before 1995 being included in the sample, making the 
possibility of recall bias a possibility once again. The interviews were longer than in the 
previous study, with patient dialogues lasting approximately 45 minutes.  
 
When asked to describe the most troubling side effects they experienced during 
treatment, patients reported sore throat (20%), mouth sores and pain (18%), and 
xerostomia (14%) most frequently. Eighty-eight percent of the patients interviewed 
reported that mucositis impaired their ability to eat and drink, resulting in weight losses 
in 83% of patients which ranged from 12 pounds (5.44kg) to 79 pounds (35kg). 
Patients’ reports of time to mucositis development and resolution varied considerably, 
with mucositis developing on average within 2.5 weeks after the start of radiotherapy, 
with a range of one to eight weeks. Time taken to resolution ranged from two to 24 
weeks, with a mean time to resolution of 8.7 weeks (Rose-Ped et al., 2002). Ninety 
percent of patients reported taste changes, with 54% of patients reporting that they 
experienced a complete loss of taste (Rose-Ped et al., 2002). Unfortunately, once again 
the authors miss the opportunity to provide a rich narrative of the mucositis experience, 
instead favouring the quantitative reporting of findings.  
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Stiff (2001) reports the results of a ‘retrospective survey’ of 41 patients who underwent 
BMT at his institution, 30 of whom received autologous transplantation. Of the patients 
interviewed, 50% reported mucositis as the most debilitating side effect associated with 
their treatment, followed by nausea and vomiting (29%), diarrhoea (8%) and rash (3%) 
(Stiff, 2001). These data seem to support the figures reported in the Bellm and 
colleagues study (Bellm et al., 2000), with the slight disparity between the reports 
probably due to Bellm and colleagues asking patients specifically about mouth sores 
while Stiff appears to have asked about mucositis.  
 
Using the Loyola BMT toxicity scale, Stiff reports that 29% of patients rated their 
mucositis as ‘ten out of ten’ (worst possible), compared to 12% of the sample reporting 
‘five out of ten’. The average reported level was nine (Stiff, 2001). No patients reported 
severity of mucositis below level five. One very interesting element of this retrospective 
survey is that mucositis was more severe than expected in 84% of patients surveyed 
(Stiff, 2001). In addition, 65% of patients interviewed reported that they received no 
interventions to control their symptoms, or alternatively, that when such interventions 
were used, they were inadequate, resulting in only a 50% improvement in symptoms 
(Stiff, 2001). Of the patients reporting mucositis as the worst toxicity they experienced 
during transplantation, 65% (n=13) of patients reported that they were still experiencing 
residual symptoms when contacted to take part in the survey, while 50% of patients 
(n=7) experiencing reporting that they were experiencing xerostomia (Stiff, 2001). 
These residual symptoms reported by Stiff support data collected during quantitative 
interview by Borbasi and colleagues (Borbasi et al., 2002), and suggest that patients 
continue to suffer from oral complications long after the visual signs of mucositis 
(ulceration) have resolved.  
 
While the results reported by Stiff (2001), are very interesting and appear to support the 
work of others, this report is not without criticism. These data were not published 
independently, and instead included as part of a much larger review of mucositis during 
stem cell transplantation. As this was only a short report, only basic patient 
characteristics are given, which do not extend to the age, gender or disease status of the 
patients surveyed, nor anything but the most basic details of the method of interviewing 
them. The author states that 25 patients had undergone transplantation in excess of a 
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year prior to completing the survey, while 11 patients had been transplanted during the 
six months before the survey (Stiff, 2001). Presumably, therefore the five outstanding 
patients had received a transplant between six months and a year prior to the survey. 
Unfortunately, when discussing the patients still reporting latent oral effects at the time 
of survey, the author does not state when these patients were transplanted, which limits 
the usefulness of this information, as it is not possible to determine how long patients 
were continuing to experience oral symptoms post-transplantation.  
 
Patient reporting of mucositis is an under-researched area. While there are hundreds of 
studies of interventions for the prevention, treatment and management of mucositis, the 
literature surrounding the patient experience of mucositis is scarce. To date, only four 
qualitative studies have interviewed patients about their experiences of mucositis, and 
only one of these studies has been conducted prospectively. Many of the patients 
interviewed described pain as the worst symptom of mucositis (Cheng, 2009), however, 
of the 89 studies included in the 2007 update of the Cochrane review of interventions 
for mucositis  prevention, only 26 studies directly measured patient reports of pain, or 
collected data on use of analgesia as a proxy measure of pain levels (Worthington et al., 
2007). In addition, only three studies measured patient ability to eat or drink 
(Worthington et al., 2007), suggesting that the focus of research is the physical signs of 
mucositis (ulceration) rather than the symptoms that patients report as most the 
distressing elements of the condition. Patients from a number of studies describe their 
mucositis as being worse than they had previously expected, and that some of these 
symptoms continued to impact their quality of life after the ulceration had resolved. It is 
clear from the small amount of data available that patients and their families have a 
number of unmet needs that are still to be addressed.  
 
2.6 Conclusion  
Oral mucositis is a distressing treatment-related toxicity which exerts both a clinical and 
economic impact and negatively affects patient quality of life. Incidences of mucositis 
as high as 75 to 100% have been reported in bone marrow transplant patients. Severe 
mucositis extends the length of hospital stay, increases a patient’s susceptibility to 
infection and demand for opiate pain relief and can necessitate breaks in treatment, 
which in turn can adversely affect treatment outcome. Patient experiences of mucositis 
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are underreported in the literature. Significant gains could be made if such a disease 
could be prevented, especially within high risk patient groups such as patients 
undergoing transplantation. The ability to effectively prevent mucositis would arguably 
be more advantageous than the capability to treat the condition, as effective prevention 
would be of economic and clinical benefit, and positively impact patient quality of life. 
Based on the need for interventions to prevent oral mucositis in patients with cancer 
undergoing therapy established by this literature review, the next chapter will consider 
published reports of interventions trialled for the prevention of mucositis.  
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Chapter 3 Prevention of Mucositis 
 
3.1 Introduction 
The prevention of oral mucositis has been identified as being advantageous in the 
previous chapter. This chapter will focus on the use systematic reviews to detail the 
results of interventions previously trialled for the prevention of mucositis.  
 
3.2 Randomised Controlled Trials  
A variety of different interventions have been studied for the prevention of oral 
mucositis. A large number of these studies have been conducted as randomised 
controlled trials (RCTs). In an RCT, participants are randomized to either the 
experimental arm, in which they are to receive the intervention under investigation, or 
the control arm, where they receive a placebo, no treatment or an alternative treatment. 
At the end of the study these groups are compared and the pre-specified outcomes 
measured to determine if the intervention is better than the other treatment or control 
(Jadad 1998). RCTs have been called the ‘gold standard’ method of conducting research 
that assesses the effectiveness of interventions, however this moniker is a matter of 
debate (Grossman and Mackenzie, 2005).  
 
As the results of large numbers of RCTs are published each year, it is difficult for an 
individual, such a Clinician, researcher or patient, to read each one of these reports and 
decide on their own if a particular intervention is effective for a condition or disease 
overall. Therefore the results of RCTs are often discussed in reviews. The combination 
of study results can strengthen the evidence for the effectiveness, or ineffectiveness, of a 
particular intervention, or alternatively show that it is ineffective.  
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Figure 4: Hierarchy of Study Evidence  
(adapted from Mantzoukas, 2008) 
 
There are two broad types of reviews: traditional literature reviews and systematic 
reviews. Traditional reviews have been described as haphazard and biased, often 
reflecting the opinion of the review’s authors (Mulrow, 1987). Systematic reviews, 
however, aim to provide a more objective, comprehensive overview of the research 
literature in order to obtain a reliable summary that may assist in the clinical decision 
making process. Systematic reviews follow explicit, well-documented, scientific 
methodology in order to reduce both systematic errors (biases) and random errors (those 
occurring by chance). The combining of studies within a systematic review may include 
a meta-analysis, providing a more powerful estimate of effect, although this is not 
always appropriate. Meta-analysis is the statistical pooling of data from two or more 
studies (although it is sometimes used to refer to the whole review process). Systematic 
reviews of RCTs occupy the top tier of the hierarchy of study evidence pyramid shown 
in Figure 4.  
 
3.3 Systematic Reviews 
General reviews of the literature provide an overview of the subject, usually in the form 
of a description, with little critical analysis (Bowling, 2002). These studies do not 
generally supply information about how a literature search was conducted, how the 
information was chosen for inclusion or how decisions were made about the exclusion 
of some of the literature. Selection bias is therefore a potential problem with these 
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reviews, as the author may have purposely chosen not to include a study because the 
data contradicts the previous work or author opinion. Systematic reviews avoid these 
issues by having an explicit search strategy and inclusion criteria before any literature 
searching takes place. An assessment of trial quality is also usually conducted. In a 
meta-analysis, the data from trials identified in a search may be pooled and analysed to 
produce a single result from the aggregated data (Bowling, 2002). This pooling of data 
controls for sample size and site specific effects and strengthens the power to detect true 
effects (Bowling, 2002). The Cochrane Collaboration is an independent organisation 
which produces a vast array of systematic reviews and meta-analyses on a variety of 
topics. The Collaboration was founded in 1993 with the aim of providing accurate 
information about the effects of healthcare interventions to the world.  
 
3.4 Cochrane review for the prevention of mucositis in patients receiving treatment 
for cancer 
A systematic review of interventions for the prevention of oral mucositis was first 
published by the Cochrane Collaboration in 2000 and has been constantly updated 
(Clarkson et al., 2000, Clarkson et al., 2003, Worthington and Clarkson, 2002, 
Worthington et al., 2006, Worthington et al., 2007). The latest update of the review is 
due to be published in December 2010. The Cochrane prevention review only includes 
studies which provide mucositis data on a zero to four point scale, such as the WHO or 
CTCAE instruments (Cancer Therapy Evaluation Program, 2009, World Health 
Organization (WHO), 1979). These data are dichotomised as follows: any mucositis, 
moderate plus severe mucositis, and severe mucositis (Worthington et al., 2007). In the 
2007 update of the review, 277 studies were eligible but only 89 studies were included. 
The majority of the 188 excluded studies were ineligible because data were not in the 
correct format with mucositis data presented in the form of number of days with 
mucositis or as an area under the curve analysis. The 2010 update of the review, 379 
studies were eligible for inclusion into the review, of which 248 were excluded for a 
variety of reasons. One-hundred-and-thirty studies were included, of which 13 were text 
only inclusions. In total 43 interventions were included in the review: acyclovir, 
allopurinol mouth rinse, amifostine, antibiotic pastille or paste, benzydamine, beta 
carotene, chamomile, chewing gum, Chinese herbs (two different types), chlorhexidine, 
clarithromycin, cryotherapy, dental stent, epidermal growth factor, glutamine, 
granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-
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stimulating factor (GM-CSF), histamine gel, honey, hydrolytic enzymes (two different 
types), indigowood root, intestinal trefoil factor, iseganan, keratinocyte growth factor 
(GF), laser, oral care, pentoxifylline, pilocarpine, polaprezinc, povidone-iodine, 
prednisone, propantheline anticholinergic, prostaglandin, morning versus evening 
administration of radiotherapy, shenqi-fanghou, superoxide dismutase (SOD), 
sucralfate, traumeel S, yangyin-humo decoction and zinc sulphate. However, only 18 of 
these interventions were included in the meta-analysis, as the remaining interventions 
either provided data from only one study (and were therefore included in the single 
studies table), or presented data for more than one study, but in different dichotomies. In 
addition, hydrolytic enzymes and Chinese herbs were separated into single studies and 
placed in the single studies table because the included studies had significantly different 
drug compositions, which prohibited pooling of these data.   
 
3.4.1 Mugard and Caphosol  
Two interventions were notable in their absence from the review: Mugard and Caphosol 
(a calcium phosphate rinse) are both oral rinses currently vigorously promoted for the 
prevention and treatment of mucositis in the United Kingdom. However, the evidence 
for the efficacy of either intervention is scant. To date, no prospective trials of Mugard 
have been published, and all manufacturer claims of efficacy are based on the results of 
studies employing a historical control group, data from one of which are discussed on 
their website but with no academic references provided (Access Pharmaceuticals INC, 
2009). There are concerns about the underreporting of mucositis in such datasets, 
especially those in which mucositis incidence is not the main focus of investigation, and 
instead is recorded as an adverse event, which may be the case in trials which 
investigated the efficacy of a particular cancer treatment (Sonis, 2010). Although one 
randomised double blind study of Caphosol has been conducted, this study was 
excluded from the prevention review due to confounding as, in addition to Caphosol 
rinse, the intervention group received fluoride oral dental trays, while the control group 
received saline trays (Papas et al., 2003). The two other studies referenced by the 
manufacturer in its publicity material employ historical control groups. This lack of 
proven efficacy is concerning, as the manufacturers of Caphosol, Eusa Pharma, 
currently run a patient information website called “mouths made good” which in 
addition to providing general mucositis information, heavily advertises the product. 
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Well designed and conducted, prospective, double blind RCTs are required to test the 
claims made by the manufacturer regarding the potential for mucositis prevention with 
these products.  
 
In the Cochrane prevention review, nine interventions were found to be beneficial for 
the prevention of mucositis in comparison to either a control or placebo in at least one 
dichotomy: aloe vera, amifostine, antibiotic pastille or paste, cryotherapy, glutamine, 
honey, keratinocyte growth factor (keratinocyte GF) and laser. However, only three 
interventions, cryotherapy, honey, and keratinocyte GF, were found to be statistically 
significantly better for the prevention of mucositis at all three dichotomies of interest 
(any versus none, moderate plus severe versus any and none, and severe versus 
moderate plus severe, any and none). This is a notable result, as cryotherapy and honey 
are ‘low-tech’ and relatively cheap interventions; while in comparison keratinocyte GF 
is expensive. 
 
3.4.2 Keratinocyte GF 
Keratinocyte GF, otherwise known as Kepivance (palifermin) or Repifermin, is a 
fibroblast growth factor which stimulates cell proliferation and differentiation resulting 
in epithelial tissue thickening (Blazar et al., 2006, Brizel et al., 2008). This increase in 
cell proliferation counteracts the destruction of the mucosal layer during the 
administration of cancer therapy. Data from six trials were entered into the prevention 
review meta-analysis: two studies were conducted in patients receiving chemotherapy 
for colorectal cancers (Meropol et al., 2003, Rosen et al., 2006), one study was 
conducted in patients receiving chemoradiotherapy for head and neck cancer (Brizel et 
al., 2008). The remaining three studies were conducted in patients undergoing stem cell 
transplantation: two were conducted in autologous patients receiving either 
chemotherapy and TBI or a mix of regimes (Freytes et al., 2004, Spielberger et al., 
2004), and one was in patients receiving allogeneic transplantation (Blazar et al., 2006). 
Five of the six studies employed a form of growth factor named Kepivance (Palifermin) 
(Blazar et al., 2006, Brizel et al., 2008, Meropol et al., 2003, Rosen et al., 2006, 
Spielberger et al., 2004). The remaining study used Repifermin compared to placebo in 
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a phase one/two trial design (Freytes et al., 2004). In total, 598 patients were studied in 
the six studies.   
 
Keratinocyte GF was found to be beneficial for the prevention of OM at all three levels 
of interest. However, a considerable amount of heterogeneity was identified in meta-
analyses for the prevention of any mucositis (Chi2=10.11, df=1 (P=0.001), I2=90%) and 
moderate plus severe mucositis (Chi2= 32.92, df= 5 (P<0.0001), I2=85%). After 
exploration, this heterogeneity was hypothesised to be a result of the large amount of 
variation in the dose and scheduling of Keratinocyte GF, and differences between the 
patient groups in terms of cancer type and method of treatment (Worthington et al., 
2010). This heterogeneity could indicate that keratinocyte is beneficial for mucositis 
prevention across a broad range of treatment and patient factors. This intervention 
however is not without its drawbacks. It is very expensive, costing £544.24 per vial 
(Anonymous, 2010); and as the typical regimen for transplantation involves three doses 
of keratinocyte GF before conditioning therapy and three days after the administration 
of stem cells (Spielberger et al., 2004), the total cost per patient for a course of 
treatment is £3265.44 (Anonymous, 2010), which may prohibit its use in certain 
countries, especially those in which a patient’s level of health insurance cover may 
affect treatment choices. Palifermin is a Keratinocyte GF which has also been 
associated with a number of adverse events. Very common events, which represent 
more than 10% of all events include: taste alterations, thickening of the lining of the 
mouth and discolouration of the oral cavity, peripheral oedema, rash, pruritus, joint 
pain, erythema and fever (European Medicines Agency, 2010).   
 
As well as the expense and number of adverse events associated with Keratinocyte GF, 
concerns have been raised about the suitability of the use of growth factors in children, 
as the long term safety of the drug and its potential impact on secondary malignancies is 
not known (Electronic Medicines Compendium, 2010). The safety profile of this drug 
when used concomitantly with therapy for non-haematological malignancies is also 
unproven (Electronic Medicines Compendium, 2010). In addition, the Medicines and 
Healthcare products Regulatory Agency (MHRA) recently restricted the use of 
Kepivance to only autologous patients undergoing conditioning with both chemotherapy 
and TBI (MHRA, 2010). This change was due to the results of a, to date unpublished, 
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double blind RCT conducted in patients with multiple myeloma undergoing autologous 
transplantation, which showed no therapeutic benefit in the reduction of severe 
mucositis duration or frequency in favour of palifermin, and suggested that patients 
treated with palifermin experienced more serious adverse events and treatment related 
adverse events than patients in the placebo group. These results changed the risk-benefit 
analysis for the use of the drug to such an extent that the MHRA and the European 
Medicines Agency have both issued updates to Healthcare professionals warning 
against its use in autologous patients receiving therapy with chemotherapy alone 
(MHRA, 2010). Whilst Keratinocyte GF appears to be beneficial in the prevention of 
mucositis, its expense, association with adverse events and the restrictions on its use, 
mean that keratinocyte GF is not a suitable agent for the prevention of mucositis in most 
patient populations.  
 
3.4.3 Cryotherapy 
Cryotherapy, the application of crushed ice or ice pops during chemotherapy, was 
another intervention found to be beneficial at all dichotomies of interest. Six studies 
provided data for this intervention, one of which was a text only inclusion as the data 
were not in the correct format for inclusion into the meta-analysis. This study was a 
parallel group study of 18 patients undergoing conditioning for allogeneic BMT 
(Svanberg et al., 2007). Of the remaining five studies, three were conducted in patients 
receiving chemotherapy with 5-fluorouracil (5-FU) in combination with other drugs 
(Cascinu et al., 1994, Mahood et al., 1991, Rocke et al., 1993), while the remaining two 
studies were conducted in patients undergoing stem cell transplantation (Gori et al., 
2007, Lilleby et al., 2006). None of these studies employed any form of patient or 
outcome assessor blinding. In total data from 527 patients were included in the meta-
analysis. Once again statistically significant heterogeneity was identified for the 
outcome any mucositis (chi square 14.77, df=4, P=0.005, I2=73%), moderate plus 
severe mucositis (chi square = 19.02, df=4, P=0.0008, I2=79%), and severe (chi square 
14.31, df=4, P=0.006, I2=72%). Cryotherapy is hypothesised to prevent mucositis 
through a decrease in blood flow to the oral cavity as a consequence of vasoconstriction, 
leading to the mucosal receiving less exposure to chemotherapy (Lilleby et al., 2006). 
This intervention is therefore potentially most beneficial in chemotherapy drugs which 
have short-half lives, such as 5-FU. However, it is currently unclear if cryotherapy may 
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be of benefit either in the prevention of mucositis induced by radiotherapy or in the 
prevention of mucositis induced by chemotherapy drugs with longer half lives.  
 
3.4.4 Honey 
Honey was the final intervention which was found to be beneficial at all three 
dichotomies of interest. Data from three studies were entered into the meta-analysis, two 
of these studies were conducted in patients receiving radiotherapy for head and neck 
cancer (Biswal, 2003, Rashad et al., 2008), while the remaining study was performed in 
patients receiving radiotherapy for head and neck cancers (Motallebnejad et al., 2008). 
In total data from 120 patients were entered into the meta-analysis, as all studies each 
recruited 40 patients. Only one study employed outcome assessor blinding 
(Motallebnejad et al., 2008). The application of honey is hypothesised to speed up 
wound healing through epithelisation (Biswal, 2003). Honey also has antimicrobial 
properties (Rashad et al., 2008). Patients in these studies were asked to move the honey 
around their mouth in order to coat the mucosa, before swallowing it. However, this 
may be difficult for patients suffering from xerostomia (absence of saliva), or trismus 
(constriction of the mouth), both of which are common side effects of radiotherapy.  
 
The submitted update of the Cochrane prevention review, to be published in November 
2010, has highlighted three potential interventions for the prevention of mucositis. 
However, none of these interventions have been found to be universally beneficial for 
the prevention of mucositis for all types of cancer therapy, and all three interventions 
have potential drawbacks either in terms of the intervention itself, or the available 
evidence. The cost of a course of therapy and the scale of the side effects associated 
with its use are disadvantages of keratinocyte GF application. The lack of outcome 
assessor blinding in all cryotherapy trials, and all but one of the honey studies, and the 
small numbers of patients entered into the honey studies are also matters of concern. 
Whilst the 2010 version of the prevention review has made gains in the synthesis of 
information about interventions that are, and are not, beneficial for the prevention of 
mucositis, a ‘golden bullet’ intervention to solve the problem has still not been 
identified. Further clinical trials are therefore crucial.  
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3.5 Potential weakness of the review 
The exclusion of studies employing multi-component instruments is arguably the 
greatest weakness of the Cochrane prevention review, as the variety of different 
mucositis assessment instruments available results in large numbers of studies being 
excluded. However, it would be very difficult, if not impossible, to find a method of 
including data from all available studies, due to the number of ways that data are 
presented. Therefore, the inclusion of studies that present data that can be dichotomised 
in the manner above currently constitutes the best method of producing meaningful 
results. In an attempt to counter this weakness, the text from a number of studies which 
included data which were not in the correct format, but which employed an 
appropriately subjective assessment instrument were included in the 2010 update of the 
review as additional information. However, this has not prevented whole interventions 
from being excluded from the analysis. One such intervention is vitamin E. Two studies 
have been conducted investigating vitamin E in the prevention of vitamin E (Sung et al., 
2007, Ferreira et al., 2004). One of these studies was excluded because the data 
presented were in the wrong format (Ferreira et al., 2004), while the other was an ‘n-of-
1 study’ (Sung et al., 2007), in which each patient served as their own control, a method 
of analysis which cannot be presently incorporated into the meta-analysis. Neither of 
these interventions could be included as text only inclusions in the review due to one of 
these studies presenting data in the form of weeks of mucositis and the other study 
employing data in a format which were not compatible with other studies.  
 
3.6 Justification for the choice of vitamin E as the intervention for the feasibility 
study 
The Cochrane prevention review was used as the basis for deciding on an appropriate 
intervention. A list of interventions which had either been identified as requiring more 
research; or which had been excluded from the review due to data being in an 
inappropriate format, was drawn up by the author, who then considered the possibility 
of running a small non-commercial feasibility trial using these interventions, with a 
limited budget and within a three year timescale. It was apparent that a number of 
interventions were not appropriate as these were produced under licence by 
pharmaceutical companies, which were unlikely to allow a novice researcher the use of 
their product for a clinical trial. Honey was briefly considered as a possible intervention, 
however, as a similar trial was being conducted at the proposed study site this was 
discounted as a possible intervention. After careful consideration vitamin E was 
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eventually chosen because: 1) while it appeared beneficial for the treatment of 
mucositis, there was conflicting information on whether this intervention was beneficial 
for the prevention of mucositis; 2) previous trials had been assessed as being at unclear 
risk of bias and there was a need for a well-designed, conducted and reported trial using 
this intervention, 3) it was easy obtainable and relatively cheap, which meant that such a 
trial could be conducted using a small budget and 4) vitamin E had been previously 
studied in patients undergoing both chemotherapy without any identified effect on 
chemotherapy efficacy.   
 
3.7 Vitamin E 
Vitamin E is a fat soluble vitamin that exhibits anti-oxidant and anti-inflammatory 
effects, preventing the peroxidation of the polyunsaturated lipids in membranes (Olson, 
2000). The predominant source of the vitamin in the diet are oils derived from plant 
products (Zingg, 2007). D-α-tocopherol (RRR-alpha-tocopherol) is the most active form 
of the vitamin (Gonzalez, 1990). Other forms of alpha-tocopherol are shown in Table 2.  
Table 2: Forms of Alpha Tocopherol. 
 International units (iu)/ mg Relative activity 
D-alpha-tocopherol 1.49 1.00 
D-alpha tocopherol acetate 1.36 0.91 
Dl-alpha-tocopherol  1.10 0.74 
Dl-alpha-tocopherol acetate 1.00 0.67 
(Adapted from Bender, 2005) 
 
3.7.1 Vitamin E for the prevention of mucositis 
Ferreira and colleagues (2004) studied vitamin E in the prevention of radiation-induced 
mucositis in patients with head and neck cancers. In this study 45 patients were 
randomised to receive vitamin E, 800mg (as 400mg twice a day), or control, 500mg/mL 
of evening primrose oil. Immediately before radiation therapy, patients were asked to 
dissolve the capsule in saliva and rinsed their mouth with the solution for five minutes, 
before swallowing. The procedure was repeated between eight and 12 hours later for the 
second dose of vitamin E or placebo. Patients were followed from the beginning to the 
end of their radiation treatment. A difference in the number of mucositis events 
observed was reported, with the intervention group experiencing 17 fewer events than 
the control group (p=0.038). The authors also reported a significant difference in pain 
scores for patients in the intervention group (p=0.0001) (Ferreira et al., 2004).  
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Sung and colleagues (2007) performed a series of double blind N-of-1 trials using 
vitamin E for the prophylaxis of chemotherapy-induced oral mucositis in paediatric 
chemotherapy patients. The authors enrolled 16 patients, with median age of 12.7 years, 
scheduled to receive doxorubicin chemotherapy. Ten of the children in this study were 
male (Sung et al., 2007), and nine had a diagnosis of Ewing’s Sarcoma, three had a 
diagnosis of large cell lymphoma, three had a diagnosis of osteosarcoma and one patient 
relapsed embryonal rhabdomyosarcoma. Forty-five post chemotherapy cycles were 
randomised with patients allocated to receive either 800mg of vitamin E or a corn oil 
placebo. Vitamin E was administered diluted in corn oil, and the patients were asked to 
expectorate the solution after rinsing. Six patients failed to complete the study, three of 
whom withdrew due to premature discontinuation of doxorubicin. The authors report 
that patients receiving vitamin E experienced a lower mean mucositis score per cycle of 
chemotherapy than patients in the placebo group (0.2 in the vitamin E arm compared to 
0.3 in the placebo arm). However, this difference was not found to be statistically 
significant (Sung et al., 2007).   
 
3.7.2 Vitamin E for the treatment of mucositis 
Two studies have also shown positive effects in the treatment of oral mucositis. 
Wadleigh and colleagues (1992) conducted the first trial of vitamin E in the treatment of 
chemotherapy-induced mucositis. In this single blind study, patients were randomised to 
receive either a topical application of vitamin E, or a placebo, consisting of a mixture of 
coconut and soyabean oil. These were administered upon the appearance of oral lesions, 
in a dose of 800mg (as 400mg twice a day). In total, 18 patients were randomised to 
take part in the study, 11 of these patients were being treated for head and neck cancer, 
five for oesophageal cancer, one patient for acute myelogenous leukaemia and one for 
hepatoma. In patients randomised to the intervention group, 66% experienced resolution 
of mucosal symptoms within four days, while, 88% of the control group did not 
experience resolution of symptoms during the study period (p=0.025) (Wadleigh et al., 
1992). The results reported are impressive; however, the methodology suffers from a 
small sample size (n=18), and a short follow-up of five days.  
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El-Housseiny and colleagues (2007) also studied paediatric cancer patients. The authors 
recruited 80 patients with chemotherapy-induced oral mucositis and randomized them to 
receive either 100mg of topical vitamin E or 100mg systemic vitamin E twice daily. No 
control group was employed. Both groups were followed for five days. 63 patients 
completed the follow-up period and were included in the final analysis. At the end of 
the trial, in the group of patients who received vitamin E topically 24 patients (80%) 
experienced fully resolution of their symptoms, two patients (6.7%) had world health 
organisation (WHO) grade one mucositis, two patients (6.7%) had WHO grade two 
mucositis and one patient had grade four mucositis (3.3%). There was a statistically 
significant difference in mucositis scores at the end of the trial compared with baseline 
for the topical group (P=<0.001). In the systemic group, zero patients experienced full 
resolution of symptoms, 11 patients (33.3%) had grade 1 mucositis, nine patients 
(27.3%) had grade 2, nine patients (27.3%) had grade 3, and four patients (12.1%) 
experienced grade 4 mucositis. There was no statistically significant difference between 
mucositis scores at the end of the trial and at baseline for patients treated systemically 
with vitamin E (P=0.317) (El-Housseiny et al., 2007).   
 
3.7.3 Proposed mechanism of action of vitamin E 
A notable omission from the literature concerning vitamin E for the prevention or 
treatment of mucositis is a proposed mechanism of action. In fact it could be argued that 
the mechanism of action of interventions for the prevention of mucositis is a much 
under-researched area. While Sung and colleagues did state that vitamin E may act to 
prevent mucositis through its function as an antioxidant (Sung et al., 2007), they failed 
to develop this point further. As vitamin E is a phenolic antioxidant, which through the 
donation of hydrogen makes free radicals un-reactive (Olson, 2000), it could be 
hypothesised that the administration of vitamin E to patients receiving chemotherapy 
could act to reduce the action of the reactive oxygen species produced during the 
initiation phase of the five-phase model of mucositis (Sonis, 2009). This would 
therefore limit the damage of the signalling and amplification phase of this model, 
which would result in a decrease the eventual damage to the oral mucosa. In addition, as 
vitamin E has anti-inflammatory effects and a role in the regulation of cell proliferation 
and intracellular signalling, it could be hypothesised that vitamin E could have both role 
outside its antioxidant function (Olson, 2000). The proposed mechanism of action of 
vitamin E in the prevention of mucositis requires much more research. 
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3.8 Conclusion 
A number of interventions have been identified in this chapter which have been trialled 
for the prevention of OM. None of these interventions have been found to be universally 
beneficial for the prevention of mucositis across different groups of patients. One of the 
interventions considered was vitamin E. Vitamin E (D-alpha-tocopherol), is cheap, 
easily obtainable and high doses have not been associated with adverse consistent 
adverse events. Given its potentially positive effects in the treatment of mucositis, it was 
deemed appropriate to conduct a non-commercial single site feasibility study to 
investigate this intervention for the prevention of mucositis.  
 
Before designing a study which aims to explore the feasibility of conducting a future 
trial with vitamin E for the prevention of mucositis, there are a number of 
methodological issues that need to be considered: 
• How potential biases may affect the quality and interpretation of study results 
and how these potential biases may be avoided when designing a trial 
• What we can learn from reports of previous studies to avoid making the same 
mistakes, and how the results of previous studies can inform the design of future 
trials 
• What oral assessment instruments are available for use in a clinical trial 
 
The next chapter of this thesis looks at the risk of bias in the studies included in the 
2010 Cochrane mucositis prevention review and how the exclusion of studies 
considered to be at high or unclear ROB reflects the results of the review.  
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Chapter 4 Risk of Bias in RCTs included in the Cochrane Review of 
interventions for the prevention of oral mucositis in patients 
undergoing treatment for cancer 
 
4.1 Introduction  
Biases can affect the quality and interpretation of the results. A key aspect of 
developing a study protocol is a clear understanding of potential biases. Hence this 
chapter will identify potential biases through the utilisation of the Cochrane ROB 
instrument and will highlight the areas of methodological development in a study which 
require further attention.  
 
4.2 Aim:  
To explore the ‘Risk of Bias’ in studies included in the Cochrane review for the 
prevention of mucositis and to determine how risk of bias affects the results of the 
review using a sensitivity analysis.  
 
4.3 What is bias? 
A bias is a systematic error in results, which can operate in either direction, leading to 
an over or underestimation of the effect of the intervention under investigation.  
 
4.4 Types of bias in clinical trials  
Table 3 shows the different sources of bias that may be important in clinical trials. The 
magnitude of these biases can vary.  
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Table 3: Sources of Bias in Clinical Trials 
Type of bias Domain Description 
Selection bias Randomisation, 
Allocation 
concealment 
“systematic differences between 
baseline characteristics of the groups 
that are compared” 
Performance 
bias 
Blinding “systematic differences between 
groups in the care that is provided, or 
in exposure to factors other than the 
interventions of interest” 
Detection bias Blinding “systematic differences between 
groups in how outcomes are 
determined” 
Attrition bias Incomplete 
outcome reporting 
“systematic differences between 
groups in withdrawals from a study” 
Reporting 
bias 
Selective outcome 
reporting 
“systematic differences between 
reported and unreported findings” 
Cochrane Handbook Chapter on ROB (Higgins and Altman, 2009,  8.4a) 
 
The Cochrane Risk of Bias (ROB) instrument assesses the risk of bias in a study across 
the following eight domains: sequence generation, allocation concealment, blinding of 
carers, patients and outcome assessors, incomplete outcome data, selective reporting 
and other.  
 
Random allocation between experimental and control groups is used to give all 
participants an equal chance of being allocated to either group. It is an attempt to reduce 
confounding, by ensuring that the groups are well matched for certain variables, for 
example age or gender. The process of randomisation also minimises selection bias by 
ensuring that neither trial staff nor the participants themselves are able to predict to 
which group they will be allocated (Hackshaw, 2009). The method used to randomly 
allocate participants can be as simple and ‘low-tech’ as the toss of a coin or the drawing 
of cards, alternatively, computer randomisation may be favoured in large scale studies, 
where repeated coin tosses are impractical. Any method of randomisation employed is 
suitable as long as it has a random component (Higgins and Altman, 2009). Unsuitable 
methods of sequence generation include allocation based on day of the week, or patient 
or file number, or date of birth. These methods are additionally unsuitable because it is 
impossible to conceal the allocation schedule, resulting in foreknowledge of which 
group a particular participant will be allocated to (Higgins and Altman, 2009).  
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Adequate randomisation can be undermined by the non-protection of the generated 
sequence. Adequate allocation concealment prevents the researcher admitting the 
patients into the trial having foreknowledge of upcoming allocations (Schulz et al., 
2002). Inadequate concealment may lead to selective enrolment, with a researcher 
delaying the allocation of a certain participant until the appropriate allocation slot 
(Higgins and Altman, 2009). The most desirable method of allocation concealment is 
probably central allocation by a third party such as a hospital pharmacy. Another 
method that can be employed is the use of opaque sealed envelopes to conceal the 
randomisation sequence. However, such a method can be easily abused, if the envelopes 
are held up to the light, or an envelope is returned to the pile if the initial allocation is 
not favoured by the researcher. Sequential numbering of envelopes to ensure that 
patients are allocated in sequence and only opening the envelope after it has been 
irreversibly allocated to the patient are methods that should be employed in order to 
reduce the susceptibility of this method to abuse (Higgins and Altman, 2009). The use 
of drugs containers of identical appearance which are sequentially numbered are another 
possible method of allocation concealment. In this instance drugs are packed before 
randomisation, often by an external site, and dispensed to the patients in sequence, 
therefore reducing selection bias. However, such methods of allocation concealment are 
only appropriate if the randomisation master list is also concealed. It is pointless to go to 
the trouble of putting mechanisms in place to protect the allocation sequence, with the 
use of envelopes or sequentially numbered containers of drugs, and then fail to protect 
the master list by making it easy for staff to access it. The use of external companies, or 
pharmacies to generate the randomisation list and then protect it, is a way of getting 
around this issue. Unsuitable methods of concealment include the posting of the 
randomisation sequence on a notice board, or the circulation of the sequence between 
the trial staff by email.  
 
It is easy to mix up allocation concealment with blinding. Allocation concealment 
protects the generated sequence until the assignment has been made, whereas blinding 
protects the sequence after the assignment has been assigned (Schulz et al., 2002). It is 
also always possible to achieve allocation concealment regardless of the intervention 
(Schulz et al., 2002); however, blinding cannot be implemented in some trials due to the 
nature of the intervention under investigation (Higgins and Altman, 2009). Blinding is a 
procedure in whereby the participants, study staff and outcome assessors involved in a 
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trial are kept oblivious of an allocation after randomisation has taken place (Higgins and 
Altman, 2009). A lack of patient blinding can influence the assessment of outcome 
(detection bias) (Juni et al., 2001), either by a lack of expectation in patients in the 
control arm, or by the potential for a psychological effect arising from participants 
knowing that they are receiving a new treatment (Schulz et al., 2002). A lack of blinding 
in outcome assessors may also increase detection bias. If the assessor believed that the 
new intervention was superior they may, either subconsciously or otherwise, be more 
generous in their assessments. Blinding in mucositis studies is therefore very important, 
as these studies may record patient reports of pain or employ subjective methods of 
mucositis assessment. The employment of blinding also aims to reduces performance 
bias: the preferential provision of additional treatment interventions to one arm (Schulz 
et al., 2002). In mucositis trials, an unblinded Clinician may, either consciously or 
otherwise, administer additional pain relief to patients randomised to receive placebo in 
a study where the analgesic properties of an intervention are being studied. Similarly, if 
a patient knew they were receiving the intervention of interest, they may subconsciously 
not ask for additional pain relief when they need it.  
 
The exclusion of randomised patients from data analysis can result in attrition bias 
(Gurusamy et al., 2009). Attrition from a study can occur for a variety of reasons. The 
most obvious is that the patient chooses to withdraw from the study, or was withdrawn 
due an adverse event. A patient may also fail to attend an outpatient appointment, or to 
return completed questionnaires or journals. Human error may also result in attrition if a 
member of staff forgets to complete a relevant form, or loses a completed questionnaire 
(Higgins and Altman, 2009). Another common reason for attrition is that a patient is 
subsequently deemed ineligible; due to a change in the planned course of treatment or 
medication they are to receive (Higgins and Altman, 2009).  
 
Selective outcome reporting is another potential source of bias. This is defined as the 
selection and reporting of significant results from a sub-section of the available data, in 
addition to the selective withholding of non-significant studies (Higgins and Altman, 
2009). Selective outcome reporting may become apparent when the authors have a 
range of different time points to choose from, or when there are severe different ways to 
analyse the data. Mucositis data can be presented in a variety of different ways. 
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Maximum scores, subset analyses, scores at set time points or area under the curve 
analyses can all be used to report the results of a study, and the ‘cherry picking’ of 
significant analyses together with non reporting of non-significant analyses may bias the 
study results, and any subsequent meta-analyses. In cross-over studies selective 
reporting may also be an issue in publications which only report the first period results. 
Such differences between intervention and control arm may be significant during the 
first period but not overall, and the reporting of the results in this manner may result in 
the intervention being mistakenly regarded as efficacious. The authors of the Cochrane 
handbook suggested that the protocols of included studies should be compared to the 
resulting publication to determine whether the pre-specified primary and secondary 
outcomes in the protocol are included in the resulting publication (Higgins and Altman, 
2009). However, protocols are rarely available. Therefore, it is the view of the Cochrane 
Oral Health group that the publication of mucositis grades for all patients included in 
the analysis is sufficient for an answer of ‘yes’ for this criterion.  
 
The last assessment in the risk of bias tool is ‘other’, a catch-all section of any other 
threats of validity (shown in Table 4). Early stopping is a threat to internal validity. 
Extreme intervention effects are more likely in studies that have stopped early (Higgins 
and Altman, 2009). However, such results are not shown in studies that are terminated 
early due to other issues, such as problems with recruitment or side effects, and these 
factors are therefore not judged to be at risk of bias. Baseline imbalances in items 
correlated to the outcome of interest also cause bias in the effect estimate of an 
intervention (Higgins and Altman, 2009). For example, in a mucositis study, if more 
patients receiving a particularly mucotoxic drug, such as methotrexate, were randomised 
to the placebo group, any potential benefit in the prevention of mucositis shown in the 
intervention group may be a result of bias. Such imbalances may indicate problems with 
randomisation (Higgins and Altman, 2009). 
 
Unfortunately, scientific fraud is another potential threat to the internal validity of a 
study. Recently, Chinese studies have been an area of concern, as reviews have reported 
that Chinese herbal medicine studies reported in Chinese have shown considerably 
larger effect sizes than those reported in English (Shang et al., 2007), and that some 
Chinese medicine trials have not employed an adequate placebo comparator (Qi et al., 
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2008). However, most concerning of all is the suggestion that some Chinese herbal 
medicine and western medicine studies conducted in China, which claim to be RCTs, 
are not actually ‘true’ RCTs at all, and that the term “randomised” had been misused by 
the authors (Wu et al., 2009b). As it is near impossible to distinguish between legitimate 
RCTs and these fraudulent studies The Cochrane Oral Health group feels it has no 
option but to classify all studies conducted in China at high ROB in the ‘other’ category.  
 
Table 4: Other Potential Threats to Validity 
Other potential threat to validity 
Early stopping 
Baseline imbalance  
Blocked randomization in unblinded trials 
Selective reporting  
Interim results 
Fraud 
Deviation from the study protocol 
Administration prior to randomisation of an 
intervention that could increase or reduce the 
effect of the subsequent randomized products 
Administration of an intervention or a co-
intervention considered to be inappropriate 
Inappropriate influence of funders 
Contamination 
Amended from the Cochrane Handbook (Higgins and Altman, 2009) 
 
4.5 Methods: 
The full texts of all new and previously included studies in the Cochrane prevention 
review (Worthington et al., 2010) were assessed by the researcher (GB) for risk of bias 
(ROB) in eight categories (adequate sequence generation, allocation concealment, 
blinding of carers, patients and outcome assessors, income outcome data, free of 
selective bias and other) using the assessment rules shown Table 5. This work was 
undertaken as part of an update of the review. 
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Table 5: Assessment Rules 
Sequence 
generation 
Yes 
• “Reference to a random number table”. 
• “Use of a computer number generation” 
• “Tossing coins” 
• “Shuffling envelopes” 
• “Minimization” 
No • “Allocation based on birth date” 
• “Allocation based on physician judgement” 
• “Allocation based on hospital number or some other rule” 
Unclear • “Insufficient information to make a judgement of either ‘yes’ or 
‘no’” 
Allocation 
concealment 
Yes 
• “Central method of allocation” 
• “Drug containers of identical appearance which are sequentially 
numbered” 
• “Opaque sequentially numbered envelopes” 
No • “Use of an open allocation list” 
• “Assignment envelopes without appropriate safeguards” 
• “Alternation or rotation” 
Unclear • “Insufficient information to make a judgement of either ‘yes’ or 
‘no’” 
Blinding 
Yes 
• “Blinding of participants and key personnel. Unlikely that this 
blinding could have been broken” 
• “Participants or key study personnel are unblinded and the non 
blinding of others was unlikely to introduce bias” 
No 
• “No or incomplete blinding. Outcome of interest is likely to be 
influenced by a lack of blinding” 
• “Blinding described. However, it is likely that blinding could be 
broken”. 
Unclear • “Insufficient information to make a judgement of either ‘yes’ or 
‘no” 
Incomplete 
outcome 
data 
Yes 
• “No missing outcome data” 
• “Missing outcome data balanced across arms. Both groups have 
similar reasons for missing data.” 
• “Dichotomous outcomes: The proportion of missing data are 
insufficient to have a clinically meaningful impact on the 
intervention effect estimate.” 
No 
• “Imbalance between arms for missing data or withdrawals.” 
• “Dichotomous outcomes: The proportion of missing data are 
enough to have a clinically meaningful impact on the intervention 
effect estimate.” 
Unclear • “Insufficient information to make a judgement of either ‘yes’ or 
‘no” 
Selective 
outcome 
reporting 
Yes 
• “Study protocol is available and when compared with the 
publication, all outcomes of interest have been reported in the 
manner which was pre-specified” 
• “Study protocol is not available, however it is clear that all 
expected outcomes are reported (mucositis incidence by grade)” 
No 
• “One or more reported outcome measures have been reported 
incompletely and therefore cannot be entered into the meta-
analysis.” 
• “One or more reported primary outcomes were not pre-specified.” 
Unclear • “Insufficient information to make a judgement of either ‘yes’ or 
‘no’” 
Assessment rules amended from the Cochrane Handbook (Higgins and Altman, 2009, 8.5.c). 
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After the initial assessment for ROB, GB then divided the articles between members of 
the Cochrane Oral mouth-care group (AMG, HW, JC, SF, TW) for second assessment. 
Initial and secondary assessments were compared and in the event of differences of 
opinion a dialogue was established between the researchers. Unresolved differences 
were taken to a third party. In order to determine the impact of the ROB on the results 
of the prevention review a sensitivity analysis was conducted with only the studies 
judged to be at low risk of bias for allocation concealment and blinding of outcome 
assessors. Outcome assessor blinding was selected as a key domain because a lack of 
blinding has been reported to significantly influence effect size: Juni and colleagues 
reported that open outcome assessment influenced effects size by 35% (95% CI 1% to 
57%) (P=0.046) in a meta-analysis which compared the use of low weight heparin to 
standard heparin for the prevention of post-operative thrombosis (Juni et al., 1999). 
Allocation concealment was chosen as a key domain because effect sizes have been 
found to be exaggerated in studies with subjective outcomes (Wood et al., 2008). As the 
assessment of mucositis is subjective, this was considered an appropriate key domain.  
 
Sensitivity analyses were first conducted for each domain independently in order to 
explore the effect of each of the key domains on the results of the prevention review. It 
was considered that this would provide a greater understanding of the impact of 
adequate allocation concealment and outcome assessor blinding on the results of the 
review and might help explain the results of the overall ROB sensitivity analysis. The 
full version of the Cochrane prevention review used fixed effects measures for meta-
analyses which include less than four studies and random effects measures for meta-
analyses with more than four studies. The sensitivity analyses were therefore conducted 
using these rules.   
 
There are a number of methods for presenting the overall risk of bias. This can be done 
for each study, for each intervention and for the results of the review overall. The 
Cochrane handbook suggested defining the ROB for each study based on ROB 
assessments from key domains. Adequate allocation concealment and outcome assessor 
blinding were identified as key domains for assessing overall ROB prior to conducting 
the sensitivity analysis. Overall ROB was determined for each study in the review using 
the grading rules shown in Table 6.  
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Table 6: Overall Risk of Bias Criteria 
 
 
 
 
Amended from the Cochrane Handbook (Higgins and Altman, 2009,  8.7a) 
 
4.6 Results: 
The risk of bias was assessed for the 130 studies (43 interventions) included in the 2010 
update of the review (Worthington et al., 2010). The brief results of these assessments 
are shown in Table 7.  
Low Low ROB (judgement of yes) for both the allocation concealment 
and outcome assessor blinding domains 
Unclear Judgement of unclear for either allocation or outcome assessor 
blinding domains 
High High ROB (judgement of no) for either allocation concealment or 
outcome assessor domains 
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Table 7: Risk of Bias Results 
Author Intervention 
Adequate 
sequence 
generation 
Allocation 
Concealment 
Blinding Incomplete 
outcome 
data 
addressed 
Free of 
selective 
bias 
Free of 
other bias 
Overall 
risk of 
bias Carer Patient 
Outcome 
assessor 
Bubley, 1989 Acyclovir Yes Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Abbasi Nazari, 
1989 Allopurinol Unclear Unclear Unclear Yes Yes Unclear Unclear No Unclear 
Dozono, 2007 Allopurinol Unclear Unclear No No No Yes Yes No High 
Loprinzi, 1990 Allopurinol Unclear Unclear Unclear Yes Yes Yes Yes No Unclear 
Panahi, 2010 Allopurinol Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear 
Puataweepong, 
2009 Aloe Vera Unclear Unclear Unclear Yes Yes Yes Yes No Unclear 
Su et al, 2004 Aloe Vera Yes Unclear Unclear Yes Yes Unclear Unclear Yes Unclear 
Antonadou,  
2002 Amifostine Unclear Unclear No No No Yes Yes Yes High 
Bourhis, 2000 Amifostine Unclear Yes No No No Yes Unclear Unclear High 
Brizel, 2000 Amifostine Yes Yes No No No Yes Unclear Yes High 
Buentzel, 2006 Amifostine Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear 
Buntzel, 1998 Amifostine Unclear Unclear No No No Yes Yes No High 
Haddad, 2009 Amifostine Yes Yes No No No Yes Unclear Yes High 
Hartmann,2001 Amifostine Unclear Unclear No No No Yes Unclear Yes High 
Koukourakis, 
2000 Amifostine Yes No No No No Unclear Unclear Yes High 
Spencer, 2005 Amifostine Unclear Unclear No No No Yes Unclear Yes High 
Vacha 2003 Amifostine Unclear Unclear No No No Yes Unclear Yes High 
Veerasarn, 2006 Amifostine Unclear Unclear No No No Unclear Unclear Yes High 
El-Sayed, 2002 Antibiotic pastille or paste Unclear Unclear Unclear Yes Yes Yes Yes No Unclear 
Stokman, 2003 Antibiotic pastille or paste Yes Yes Yes Yes Yes Yes Unclear Yes Low 
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Author Intervention 
Adequate 
sequence 
generation 
Allocation 
Concealment 
 Blinding  Incomplete 
outcome 
data 
addressed 
Free of 
selective 
bias 
Free of 
other 
bias 
Overall 
risk of 
bias Carer Patient Outcome assessor 
Symonds, 1996 Antibiotic pastille or paste Unclear Unclear Yes Yes Yes No Unclear Yes Unclear 
Wijers, 2001 Antibiotic pastille or paste Unclear Unclear Unclear Yes Yes Unclear Yes Yes Unclear 
Epstein 1989 Benzydamine Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Epstein 2001 Benzydamine Unclear Unclear Unclear Unclear Unclear Yes Unclear Yes Unclear 
Kazemian, 2009 Benzydamine Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Prada, 1987 Benzydamine Unclear Unclear Unclear Yes Yes Unclear Unclear No Unclear 
Mills, 1988 Beta-carotene Unclear Unclear No No No Yes Yes Yes High 
Fidler, 1996 Chamomile Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear 
Gandemer, 2007 Chewing gum Yes Yes No No No Yes Unclear Yes High 
Huang, 2003 Chinese 
medicine Yes No No No Unclear Yes Yes No High 
Wang, 2002 Chinese 
medicine Unclear Unclear No No Unclear Yes Unclear No Unclear 
Dodd, 1996 Chlorhexidine Unclear Unclear Yes Yes Yes Yes Unclear Yes Unclear 
Ferretti, 1988 Chlorhexidine Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Foote, 1994 Chlorhexidine Unclear Yes Yes Yes Yes Yes Yes Yes Low 
McGaw, 1985 Chlorhexidine Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Pitten, 2003  Chlorhexidine Yes Yes Yes Yes Yes Yes Unclear No Low 
Sorensen, 2008 Chlorhexidine Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear 
Spijkervet,  
1989 Chlorhexidine Unclear Unclear Unclear Yes Yes Yes Unclear Yes 
Unclear 
Wahlin, 1989 Chlorhexidine Unclear Unclear No No No Unclear Unclear No High 
Yuen, 2001 Clarithromycin Yes Unclear No No No Yes Unclear Yes High 
Cascinu, 1994 Cryotherapy Unclear Unclear No No No Yes Yes Yes High 
Gori, 2007 Cryotherapy Unclear Unclear No No No Yes Yes Yes High 
Lilleby, 2006 Cryotherapy Unclear Unclear No No No Yes Yes Yes High 
Mahood, 1991 Cryotherapy Unclear Unclear No No Unclear Yes Yes Yes Unclear 
Rocke, 1993 Cryotherapy Unclear Unclear No No No Yes Yes Yes High 
Svanberg, 2007 Cryotherapy Unclear Unclear No No No Yes Unclear Yes High 
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Author Intervention 
Adequate 
sequence 
generation 
Allocation 
Concealment 
 Blinding  Incomplete 
outcome 
data 
addressed 
Free of 
selective 
bias 
Free of 
other 
bias 
Overall 
risk of 
bias Carer Patient 
Outcome 
assessor 
Qin 2007 Dental stent Unclear Unclear Unclear Unclear Unclear Yes Yes No Unclear 
Wu, 2009 Epidermal growth factor Unclear Unclear No No No Yes Unclear Yes High 
Crawford, 1999 G-CSF Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Katano, 1995 G-CSF Unclear Unclear No No No Yes Unclear Yes High 
Schneider, 1999 G-CSF Unclear Yes Yes Yes Yes Yes Unclear No Low 
Su, 2006 G-CSF Yes Yes Yes Yes Yes Yes Yes Yes Low 
Anderson, 1998 Glutamine Unclear Unclear Yes Yes Yes Unclear Unclear Yes Unclear 
Cerchietti, 2006 Glutamine Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Choi, 2007 Glutamine Yes Unclear No No No Yes Yes Yes High 
Coghlin- 
Dickson, 2000 Glutamine Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
He, 2008 Glutamine Unclear Unclear Unclear Unclear Unclear Yes Unclear No Unclear 
Huang, 2000 Glutamine Unclear Unclear Unclear Yes No Yes Yes Yes High 
Jebb, 1994 Glutamine Unclear Unclear Unclear Yes Yes Unclear Yes Yes Unclear 
Li, 2006 Glutamine Unclear Unclear Unclear Unclear Unclear Yes Unclear Yes Unclear 
Okuno, 1999 Glutamine Unclear Unclear Yes Yes Yes Yes Yes No Unclear 
Sornsuvit, 2008 Glutamine Unclear Unclear Unclear Unclear Unclear Yes Unclear Yes Unclear 
Cartee, 1995 GM-CSF Yes Yes Yes Yes Yes Yes Unclear Yes Low 
Chi 1995 GM-CSF Unclear Unclear Unclear No No Yes Unclear Yes High 
Dazzi, 2003 GM-CSF Unclear Yes Yes Yes Yes Yes Unclear Yes Low 
Ifrah, 1999 GM-CSF Unclear Unclear Unclear Yes Yes Yes Unclear No Unclear 
Makkonen,  
2000 GM-CSF Yes Yes No No No Yes Unclear Yes 
High 
McAleese, 2006 GM-CSF Unclear Unclear Unclear No Yes Yes Yes Yes Unclear 
Nemumaitis,  
1995 GM-CSF Unclear Unclear Yes Yes Yes Yes Unclear No 
Unclear 
Saarilahti, 2002 GM-CSF Yes Yes Yes Yes Yes Yes Unclear Yes Low 
Van der Lelie, 
2001 GM-CSF Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Elad, 2006 Histamine Gel Unclear Unclear Yes Yes Yes Unclear Unclear Yes Unclear 
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Author Intervention 
Adequate 
sequence 
generation 
Allocation 
Concealment 
 Blinding  Incomplete 
outcome 
data 
addressed 
Free of 
selective 
bias 
Free of 
other 
bias 
Overall 
risk of 
bias Carer Patient 
Outcome 
assessor 
Biswal, 2003 Honey Yes Unclear No No No Yes Unclear Yes High 
Motallebnejad 
2008  Honey Unclear Unclear Unclear No Yes Yes Unclear Yes Unclear 
Rashad, 1984 Honey Unclear Unclear No No No Yes Yes Yes High 
Dorr, 2007 Hydrolytic 
enzymes Yes Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Gujral, 2001 Hydrolytic 
enzymes Unclear Unclear No No No Yes Yes Yes High 
Kaul, 1999 Hydrolytic 
enzymes Unclear Unclear No No No No Unclear Yes High 
You, 2009  Indigowood root Unclear Unclear Unclear Unclear Unclear Yes Yes No Unclear 
Peterson, 2009 Intestinal trefoil factor Unclear Unclear Yes Yes Yes Yes Yes Yes Unclear 
Giles, 2004 Iseganan Unclear Unclear Unclear Yes Yes No Unclear Yes Unclear 
Trotti, 2004 Iseganan Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Blazar, 2006 Keratinocyte GF Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear 
Brizel, 2008 Keratinocyte GF Unclear Unclear Unclear Yes Yes Unclear Unclear No Unclear 
Freytes, 2004 Keratinocyte GF Unclear Unclear Unclear Yes Yes Yes Unclear Unclear Unclear 
Meropol, 2003 Keratinocyte GF Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Rosen, 2006 Keratinocyte GF Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear 
Spielberger,  
2004 Keratinocyte GF Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear 
Antunes, 2007 Laser Unclear Unclear Yes Yes No Yes Yes Yes High 
Arun-Maiya, 2006 Laser Yes Unclear No No Yes Yes Yes Unclear Unclear 
Bensadoun,  
1999 Laser Yes Unclear Yes Yes Yes Yes Unclear Unclear Unclear 
Chor, 2009 Laser Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Cruz, 2007 Laser Unclear Unclear No No Yes Yes Yes Yes Unclear 
Schubert, 2007 Laser Unclear Unclear Unclear Yes Yes Yes Unclear No Unclear 
Borowski, 1994 Oral care Unclear Yes No No No Yes Unclear Yes High 
Shieh, 1997 Oral care Yes Unclear No No No Yes Unclear No High 
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Author Intervention 
Adequate 
sequence 
generation 
Allocation 
Concealment 
 Blinding  Incomplete 
outcome 
data 
addressed 
Free of 
selective 
bias 
Free of 
other 
bias 
Overall 
risk of 
bias Carer Patient 
Outcome 
assessor 
Attal, 1993 Pentoxifylline Yes Yes No No Unclear Yes Unclear Yes Unclear 
Lockhart, 2005 Pilocarpine Yes Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Scarantino,  
2006 Pilocarpine Unclear Unclear Unclear Yes Yes Yes Unclear Unclear Unclear 
Watanabe, 2010 Polaprezinc Unclear Unclear No No No Yes Yes No High 
Madan 2008 Povidone-iodine Unclear Yes Yes Yes Yes Yes Unclear Yes Low 
Rahn, 1997 Povidone-iodine Unclear Unclear No No No Unclear Yes Unclear High 
Vokurka, 2005 Povidone-iodine Unclear Unclear Unclear Unclear Unclear Yes Yes Yes Unclear 
Leborgne, 1998 Prednisone Unclear Unclear Unclear Yes Yes Yes Yes No Unclear 
Ahmed, 1993 Propantheline Unclear Unclear Unclear Unclear Unclear Unclear Unclear Yes Unclear 
Duenas- 
Gonzalez, 1996 Prostaglandin Unclear Unclear Unclear Yes Yes Yes Unclear No Unclear 
Hanson,1995 Prostaglandin Unclear Unclear Yes Yes Yes Yes Unclear No Unclear 
Labar, 1993 Prostaglandin Yes Unclear Unclear Yes Yes Unclear Unclear Yes Unclear 
Pillsbury, 1986 Prostaglandin Unclear Unclear Unclear Yes Yes Unclear Unclear Yes Unclear 
Veness, 2006 Prostaglandin Yes Unclear Unclear Yes Yes Yes Yes Yes Unclear 
Bjarnason, 2009
Radiation: 
morning v 
evening 
Yes Unclear No No No Yes Unclear Yes High 
Goyal, 2009 
Radiation: 
morning v 
evening 
Unclear Unclear No No Yes No Yes Yes Unclear 
Hu, 2005 Shenqi-Fanghou Unclear Unclear No No Unclear Yes Yes No Unclear 
Tu 1998 SOD Unclear Unclear Unclear Yes Yes Yes Unclear No Unclear 
Carter, 1999 Sucralfate Unclear Unclear Unclear Yes Yes Yes Unclear No Unclear 
Castagna, 2001 Sucralfate Unclear Unclear Unclear Yes Yes Yes Unclear Yes Unclear 
Cengiz, 1999 Sucralfate Unclear Unclear Unclear Yes Yes Yes Yes Yes Unclear 
Epstein and  
Wong, 1994 Sucralfate Unclear Unclear Unclear Yes Yes Yes Yes No Unclear 
Evensen, 2001 Sucralfate Unclear Unclear Unclear Yes Yes Yes Yes No Unclear 
Franzen, 1995 Sucralfate Unclear Unclear Unclear Yes Yes Unclear Unclear Yes Unclear 
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Author Intervention 
Adequate 
sequence 
generation 
Allocation 
Concealment 
 Blinding  Incomplete 
outcome 
data 
addressed 
Free of 
selective 
bias 
Free of 
other 
bias 
Overall 
risk of 
bias Carer Patient 
Outcome 
assessor 
Lievens, 1998 Sucralfate Unclear Unclear Unclear Yes Yes Unclear Unclear Yes Unclear 
Makkonen, 1994 Sucralfate Unclear Unclear Unclear Yes Yes Yes Yes No Unclear 
Nottage, 2003 Sucralfate Unclear Unclear Unclear Yes Yes Yes Unclear Unclear Unclear 
Pfeiffer, 1990 Sucralfate Unclear Unclear Unclear Yes Yes No Unclear No Unclear 
Scherlacher,  
1990 Sucralfate Unclear Unclear Unclear Unclear Unclear Unclear Unclear No Unclear 
Shenep, 1988 Sucralfate Unclear Yes Yes Yes Yes Yes Unclear Yes Low 
Oberbaum, 2001 Traumeel S Unclear Unclear Unclear Yes Yes Yes Unclear No Unclear 
Dai, 2009 
Yangygin-
Humo 
decoctalion 
Unclear Unclear No No No Yes Yes No High 
Ertekin, 2004 Zinc sulphate Unclear Unclear Unclear Unclear Unclear Yes Yes Yes Unclear 
Lin, 2006 Zinc sulphate Yes Unclear Unclear Yes Unclear Yes Unclear Yes Unclear 
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4.6.1 Results by domain 
4.6.1.1Adequate sequence generation 
Twenty-six studies (20%) were deemed to have adequate sequence generation, and 
therefore were classified as being at low risk of bias for this domain. Twelve of these 
studies employed computer-based sequence generation; while, four studies employed 
minimization, an often complex process in which treatment arms are balanced for a 
number of pre-specified criteria. Four studies did not provide enough information 
about the randomisation process; however it was the opinion of the assessors that the 
setting of these trials made adequate randomisation likely. These studies were 
conducted at the Dana Faber cancer institute (Haddad et al., 2009), the Memorial 
Sloan Kettering Cancer Centre (Su et al., 2004), the Duke Centre (Cartee et al., 1995) 
and the Finnish cancer registry (Makkonen et al., 2000). One study used biased coin 
randomisation (Su et al., 2004). Of the remaining five studies, three used a table of 
random numbers (Huang et al., 2003, Koukourakis et al., 2000, Pitten et al., 2003), 
and two studies provided limited information but made reference to appropriate 
literature concerning randomisation (Brizel et al., 2000, Shieh et al., 1997). Those 
studies considered to use an inappropriate method of randomisation were removed 
from the publication as per the exclusion criteria; therefore no studies were given a 
decision of no for this category. The remaining 104 studies (80%) were judged as 
‘unclear’. The majority of these unclear studies gave no more information than that 
they were ‘randomised’. Four studies stated that they employed the “closed 
envelope” method of randomisation. However, no information was provided about 
whether these envelopes were shuffled prior to the patient being randomised. They 
were therefore classified as “unclear”.  
 
4.6.1.2 Adequate allocation concealment 
Seventeen studies (13%) employed adequate methods of allocation concealment and 
were therefore classified as being at low risk of bias. Central randomisation was 
mentioned in 15 studies, with seven studies employing pharmacy controlled 
randomisation, six studies communicating by telephone, and one study by fax 
(Gandemer et al., 2007). Two studies employed drug containers which were identical 
in appearance and sequentially numbered (Foote et al., 1994, Madan et al., 2008). 
Two studies (1.5%) used open number tables without concealment and were 
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therefore deemed to be a high risk of bias (Huang et al., 2003, Koukourakis et al., 
2000). The remaining 111 studies (85%) were classified as unclear.  
 
4.6.1.3 Blinding 
Blinding was assessed for three different groups: patients, carers and outcome 
assessors. Nineteen studies (15%) were deemed to be at low risk of bias for carer 
blinding. Forty-four studies (34%) were classified as being at high risk of bias. Sixty-
seven (51%) studies were classified as ‘unclear’. Seventy-five studies (58%) were 
deemed to be at low risk of bias for patient blinding. Ten studies (7.7%) were 
classified as unclear. Of these studies, four were deemed unclear as they employed 
the use of a placebo control, and therefore blinding could not be discounted, while 
three studies were assessed for ROB from a data collection sheet provided by a 
translator without any additional information. Of the remaining three ‘unclear’ 
studies, one study which compared povidone-iodine to saline was described as 
‘blind’ to patients, however, this was considered by the assessors to be an 
inappropriate control as presumably the iodine solution would differ in colour from 
the saline (Vokurka et al., 2005). Another, which investigated zinc in head and neck 
patients receiving a mix of radiotherapy and chemoradiotherapy (Ertekin et al., 
2004), was classified as unclear for two reasons: firstly, because the study authors 
described the need for a double blind study in the introduction, and then failed to 
provide any information about blinding in the remainder of the text, and secondly, 
because the authors used empty capsules as the control, and the assessors were 
concerned that this would be noticeable to the patients. The remaining trial (Ahmed 
et al., 1993) only stated that “trial drugs were administered blind” (Ahmed et al., 
1993, 131), without any additional information. Forty-five studies (35%) were 
classified as being at high risk of bias for patient blinding. The majority of these 
were studies which employed no blinding, however one study was described by its 
authors as double blind, but then went on to state that a patient withdrew from the 
study because they were not allocated the intervention of interest (Wu et al., 2009a). 
The assessors were concerned that this suggested a failure in the blinding of patients 
in this study, and therefore decided to characterise the study at high risk of bias for 
all three blinding categories.  
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Seventy-seven studies (59%) were deemed to describe the method of outcome assessor 
blinding adequately and were considered to be at low risk of bias. Sixteen studies (12%) 
were classified as unclear and 37 studies (29%) were given a decision of ‘no’ and were 
therefore considered to be at high risk of blinding in this category. In a sub-analysis of 
those studies providing blinding information, only 19 studies (24.6%) gave specific 
information regarding the blinding of an outcome assessor. The remaining 58 (75%) 
studies were only described as “double blind” by the authors.  
 
4.6.1.4 Incomplete outcome data addressed 
One hundred and seven studies (82%) were considered to be at low risk of bias for this 
category. Eighteen studies (14%) were given a decision of unclear and five (3.8%) were 
considered to be at high risk of bias. These five studies experienced a high rate of drop-
out and the authors did not provide an adequate explanation of why data from these 
patients were excluded.  
 
4.6.1.5 Free of selective reporting 
Forty eight (37%) studies were deemed to be free of selective reporting for mucositis 
grade, which was determined prior to assessment as the outcome of interest for this 
category. These studies were therefore deemed to be at a low risk of bias. The 
remaining eighty-two studies were classified as unclear. These studies tended to only 
provide sub-sets of data for severe mucositis (grade>2) rather than all the information of 
interest. No studies were given a decision of ‘no’, and consequently classified at high 
risk of bias, as studies which did not provide mucositis information for at least one of 
the dichotomies of interest could not be included in the review.  
 
4.6.1.6 Free of other bias 
Thirty-six studies (28%) were deemed to be at high risk of bias in the final “other” 
category. A baseline imbalance was reported by 11 studies. Three studies reported 
gender imbalances (Abbasi Nazari et al., 2007, Makkonen et al., 1994, Puataweepong et 
al., 2009), while four studies reported age imbalances (Bensadoun et al., 1999, Ifrah et 
al., 1999, Makkonen et al., 1994). Two or more baseline imbalances were reported by 
four studies (Bensadoun et al., 1999, Ifrah et al., 1999, Makkonen et al., 1994, 
 90 
 
Puataweepong et al., 2009). Puataweepong and colleagues (2009), reported baseline 
imbalances in both patient gender (P=0.03) and previous surgery (P=0.04). Meanwhile, 
in the Ifrah study (1999), patients randomised to receive GM-CSF in the intervention 
arm of the study, were older (P=0.04) and more likely to have the Philadelphia 
chromosomal rearrangement (P=0.026). Baseline imbalances in age and gender were 
reported by Makkonen and colleagues (Makkonen et al., 1994). Bensadoun and 
colleagues (1999), reported imbalances in the number of patients receiving 
supplementary application of laser to the neck, which was hypothesised to exert a 
distant beneficial effect. In this study patients in the intervention group also tended to be 
older. However, no P values were presented by the authors for this imbalance 
(Bensadoun et al., 1999). Risk of bias was assessed for eight studies from a data 
collection form completed by a translator. Loprinzi and colleagues (1990), initially 
aimed to recruit 120 patients into their allopurinol study, however, the power calculation 
was re-run after 77 patients and as the results were found to favour the intervention, the 
study was terminated and the data published. In the Duenas-Gonzalez and colleagues 
study (1996), an interim analysis conducted in the 16 patients recruited into the study 
showed a significant difference in favour of the placebo, and the authors therefore 
decided to cease recruitment. Epstein and Wong (1994), also report the results of an 
interim analysis, in this case a trial of 33 patients which compared sucralfate to placebo. 
This trial was terminated after an interim analysis suggested that the impact of 
sucralfate on mucositis prevention was minimal (Epstein and Wong, 1994).   
 
4.6.2 Sensitivity analysis based on individual ROB domains: 
4.6.2.1 Allocation concealment 
If studies lacking adequate allocation concealment are excluded from the review, the 
results are notably altered. Firstly, such exclusions removed 114 studies (87%), and 33 
interventions (77%), from the results of the publication. Perhaps more importantly, eight 
of these excluded interventions were previously found to be statistically significant in 
the results of the meta-analysis update (Worthington et al., 2010). Of the remaining 17 
studies, three were interventions either comprised of only one study (Attal et al., 1993, 
Gandemer et al., 2007), or which only had data from one study available at each 
dichotomy (Borowski et al., 1994). In addition, one intervention, povidone-iodine, 
cannot be discussed in the sensitivity analysis as the only study assessed to be at low 
ROB for allocation concealment was a text only inclusion (Madan et al., 2008). The 
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results of these studies which were reported in the single studies or text only tables of 
the review, rather than as a meta-analysis, do not change, and will therefore not be 
discussed.  
 
Table 8 details the results of the sensitivity analysis compared to the results of the 
review. Interventions which became statistically beneficial after the removal of studies 
assessed to be at high or unclear ROB are highlighted in green. Interventions which 
moved from significant to non-significant are highlighted in yellow. 
 
Table 8 : Impact of the Removal of Studies Judged to be at High or Unclear ROB for 
Allocation Concealment on Results1 
Intervention Dichotomies Analysis including all 
studies 
P  
value 
Analysis excluding 
studies at high or 
unclear ROB 
P 
value 
N (RR (95% CI) N (RR (95% CI) 
Amifostine Any 
mucositis 
3 0.95 (0.91, 0.99) 0.007 0 - - 
Moderate to 
severe 
6 0.78 (0.62, 0.98) 0.03 1 1.03 (0.83, 1.28) 0.80 
Severe 9 0.68 (0.45, 1.03) 0.07 1 1.76 (1.01, 3.07) 0.05 
Antibiotic 
pastille / paste 
Any 
mucositis 
3 0.92 (0.85, 0.99) 0.03 0 - - 
Moderate to 
severe 
2 0.92 (0.78, 1.08) 0.32 0 - - 
Severe 3 0.87 (0.71, 1.07) 0.19 1 0.87 (0.70, 1.10) 0.24 
Chlorhexidine Any 
mucositis 
4 0.76 (0.47, 1.24) 0.27 1 1.04 (0.93, 1.15) 0.50 
Moderate to 
severe 
3 0.93 (0.72, 1.21) 0.58 2 1.42 (1.05, 1.93) 0.02 
Severe 4 0.82 (0.54, 1.23) 0.33 1 1.01 (0.62, 1.64) 0.97 
GCSF Any 
mucositis 
4 0.77 (0.48, 1.23) 0.27 2 1.04 (0.83, 1.32) 0.79 
Severe 2 0.36 (0.15, 0.86) 0.02 2 0.36 (0.15, 0.86) 0.02 
GM-CSF Any 
mucositis 
2 0.93 (0.84, 1.04) 0.21 1 0.91 (0.80, 1.04) 0.16 
Moderate to 
severe 
2 0.89 (0.76, 1.05) 0.17 0 - - 
Severe 6 0.73 (0.39, 1.40) 0.35 2 1.02 (0.52, 1.99) 0.96 
Sucralfate Any 
mucositis 
4 1.03 (0.96, 1.11) 0.42 0 - - 
Moderate to 
severe 
5 0.83 (0.59, 1.18) 0.30 1 0.94 (0.67, 1.33) 0.75 
Severe 8 0.74 (0.54, 1.01) 0.06 1 0.33 (0.10, 1.07) 0.06 
                                                     
1
 Interventions which became statistical beneficial after the removal of studies assessed to be at high or 
unclear ROB are highlighted in green. Interventions which moved from significant to non-significant are 
highlighted in yellow. 
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4.6.2.1.1 Amifostine 
 
 
Figure 5: Amifostine ‘Moderate Plus Severe’ Mucositis Dichotomy After Exclusion of 
Studies Assessed to be at Unclear or High ROB for Allocation Concealment 
 
In the review update, amifostine was found to significantly prevent mucositis compared 
to placebo or no treatment in the ‘any’ and ‘moderate to severe dichotomies’. However, 
all three studies included in the amifostine ‘any mucositis’ dichotomy in the review 
were assessed as being at high ROB, and therefore this dichotomy was excluded from 
the sensitivity analysis. The exclusion of studies assessed at high ROB in the moderate 
to severe dichotomy changed the risk ratio from 0.78 (95% confidence intervals (CI) 
0.62, 0.98) to 1.03 (95% CI 0.83, 1.28) (Figure 5). The exclusion of the studies assessed 
at high ROB for allocation concealment from the ‘severe’ mucositis dichotomy changed 
the result to significantly favour the control group  and changes the risk ratio from 0.68 
(0.45, 1.03) to 1.76 (1.01, 3.07) (P=0.05) (Figure 6).  
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Figure 6: Amifostine ‘Severe Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Allocation Concealment 
 
4.6.2.1.2 Antibiotic pastille or paste 
 
 
Figure 7: Antibiotic Pastille or Paste ‘Severe Mucositis’ Dichotomy After Exclusion of 
Studies Assessed to be at Unclear or High ROB for Allocation Concealment 
 
Four studies were included in the prevention review comparing an antibiotic pastille or 
paste to either a placebo or no-treatment and this intervention was found to be 
significant in the “any mucositis” dichotomy compared to either a control or no 
treatment. When the ROB assessments are incorporated (Figure 7), data were only 
available for the severe mucositis dichotomy and no statistically significant differences 
were found.  
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4.6.2.1.3 Chlorhexidine 
 
 
Figure 8: Chlorhexidine ‘Any Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Allocation Concealment 
 
Limiting the meta-analysis to include only studies assessed as being at low risk of bias 
for allocation concealment removed four studies from the sensitivity analysis. 
Consequently, this changed the risk ratio from 0.76 (95% confidence intervals (CI) 0.47, 
1.24) to 1.04 (95% CI 0.93, 1.15) for the prevention of ‘any’ mucositis (Figure 8).  
 
 
Figure 9: Chlorhexidine ‘Moderate to Severe Mucositis’ Dichotomy After Exclusion of 
Studies Assessed to be at Unclear or High ROB for Allocation Concealment 
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Figure 10: Chlorhexidine ‘Severe Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Allocation Concealment 
 
The removal of studies without adequate allocation concealment significantly altered 
the risk ratio in favour of the control in the moderate mucositis dichotomy, from 0.93 
(95% CI 0.72, 1.21) to 1.42 (95% CI 1.05, 1.93) (Figure 9). The risk ratio for the 
prevention of severe mucositis are also altered from 0.82 (95% CI 0.54, 1.23) to 1.01 
(95% CI 0.62, 1.64) (Figure 10).  
 
4.6.2.1.4 G-CSF 
 
 
Figure 11: G-CSF ‘Any Mucositis’ Dichotomy After Exclusion of Studies Assessed to 
be at Unclear or High ROB for Allocation Concealment 
 
Four studies included in the full version of the prevention review compared the use of 
G-CSF to no treatment, and data were provided by more than one study for two 
dichotomies: any mucositis and severe mucositis. Two of these studies were judged to 
be at low ROB for allocation concealment (Schneider et al., 1999, Su et al., 2006). The 
exclusion of the high and unclear ROB studies altered the risk ratio for the prevention of 
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‘any’ mucositis from 0.77 (95% CI 0.48, 1.23) to 1.02 (95% CI 0.86, 1.24) (Figure 11). 
Data were only provided for one study in the ‘moderate to severe’ dichotomy, and two 
studies in the ‘severe mucositis’ dichotomy, and as all these studies were assessed to be 
at low ROB for allocation concealment the result of these meta-analysis were 
unchanged.   
 
4.6.2.1.5 GM-CSF 
 
 
Figure 12: GM-CSF ‘Any Mucositis’ Dichotomy After Exclusion of Studies Assessed 
to be at Unclear or High ROB for Allocation Concealment 
 
Of the seven studies included in the original prevention review analysis for GM-CSF, 
one compared GM-CSF to sucralfate (Saarilahti, 2002) and was included in the single 
studies table. Of the remaining studies, three were judged to be at low ROB for 
allocation concealment. The exclusion of the other studies marginally altered the risk 
ratio for the ‘any mucositis’ dichotomy from 0.93 (95% CI 0.84, 1.04) to 0.91 (95% CI 
0.80, 1.04) (Figure 12). No studies providing data in the moderate to severe dichotomy 
were assessed to be at low risk of bias, and this dichotomy was therefore removed from 
the sensitivity analysis. The risk ratio for the prevention of severe mucositis was altered 
from 0.73 (95% CI 0.39, 1.40) to 1.00 (95% CI 0.60, 1.67) (Figure 13).  
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 Figure 13: GM-CSF ‘Severe Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Allocation Concealment
 
4.6.2.1.6 Sucralfate 
 
Figure 14: Sucralfate ‘Moderate to Severe mucositis’ Dichotomy After Exclusion of 
Studies Assessed to be at Unclear or High ROB for Allocation Concealment
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Figure 15: Sucralfate ‘Severe Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Allocation Concealment2 
 
4.6.2.2 Outcome assessor blinding 
Studies deemed to be at high or unclear risk of bias for outcome assessor blinding were 
removed from the analyses, leaving 26 interventions, comprising 77 studies, in the 
meta-analysis. Seven of these interventions (Acyclovir, Chamomile, Histamine gel, 
Intestinal Trefoil factor, Prednisone, SOD, Traumeel S.) were comprised of only one 
study and were therefore unchanged. The results from the meta-analysis of laser versus 
povidone were also unchanged (Arun Maiya et al., 2006). The results of an additional 
eight interventions (Aloe vera, Antibiotic pastille or paste, Benzydamine, Iseganan, 
Keratinocyte growth factor, Prostaglandin and Pilocarpine) were unchanged due to all 
included studies being assessed at low risk of bias for outcome assessment. Another 
intervention, povidone-iodine, cannot be discussed in the sensitivity analysis as the only 
study assessed to be at low ROB for outcome assessor blinding was a text only 
inclusion (Madan et al., 2008). Finally, one intervention, hydrolytic enzymes, was not 
included in the sensitivity analysis as the substantial level of heterogeneity identified in 
the prevention review meta-analysis prevented the pooling of data for this intervention. 
Table 9 details the results of the sensitivity analysis compared to the results of the 
review. 
 
 
 
                                                     
2
 Generic inverse variance method used as Pfeiffer 1990 study was a cross-over trial 
Study or Subgroup
Carter 1999
Castagna 2001
Cengiz 1999
Evensen 2001
Nottage 2003
Pfeiffer 1990
Scherlacher 1990
Shenep 1988
Total (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.85 (P = 0.06)
log[Risk Ratio]
-0.1625
-0.47
-2.12
0.122
-0.1555
-0.1748
-1.5187
-1.11
SE
0.22
0.263
1.48
0.12
0.401
0.2
0.572
0.6
Weight
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
0.0%
100.0%
100.0%
IV, Fixed, 95% CI
0.85 [0.55, 1.31]
0.63 [0.37, 1.05]
0.12 [0.01, 2.18]
1.13 [0.89, 1.43]
0.86 [0.39, 1.88]
0.84 [0.57, 1.24]
0.22 [0.07, 0.67]
0.33 [0.10, 1.07]
0.33 [0.10, 1.07]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.02 0.1 1 10 50
Favours sucralfate Favours control
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Table 9: Impact of the Removal of Studies Judged to be at High or Unclear ROB for 
Outcome Assessor Blinding on Results. 
Intervention Dichotomies 
Analysis including all 
studies P Value 
Analysis excluding 
studies at high or 
unclear ROB 
P 
Value 
N RR (95% CI) N RR (95% CI) 
Allopurinol 
Any 
mucositis 4 0.77 (0.50, 1.19) 0.24 3 0.93 (0.73, 1.20) 0.59 
Moderate to 
3severe 
2 0.66 (0.50, 0.86) 0.002 2 0.66 (0.50, 0.86) 0.002 
Severe 2 0.81 (0.63, 1.04) 0.09 2 0.81 (0.63, 1.04) 0.09 
Amifostine 
Any 
mucositis 3 0.95 (0.91, 0.99) 0.007 0 -  
Moderate to 
severe 
6 0.78 (0.62, 0.98) 0.03 1 1.03 (0.83, 1.28) 0.80 
Severe 9 0.68 (0.45, 1.03) 0.07 1 1.76 (1.01, 3.07) 0.05 
Antibiotic 
pastille / paste 
Any 
mucositis 3 0.92 (0.85, 0.99) 0.03 3 0.92 (0.85, 0.99) 0.03 
Moderate to 
severe 
2 0.92 (0.78, 1.08) 0.32 2 0.92 (0.78, 1.08) 0.32 
Severe 3 0.87 (0.71, 1.07) 0.19 3 0.87 (0.71, 1.07) 0.19 
Chlorhexidine 
Any 
mucositis 4 0.76 (0.47, 1.24) 0.27 4 0.76 (0.47, 1.24) 0.27 
Moderate to 
severe 
3 0.93 (0.72, 1.21) 0.58 3 0.93 (0.72, 1.21) 0.58 
Severe 4 0.82 (0.54, 1.23) 0.33 3 0.78 (0.44, 1.38) 0.39 
G-CSF 
Any 
mucositis 4 0.77 (0.48, 1.23) 0.27 3 0.87 (0.56, 1.35) 0.53 
Severe 2 0.36 (0.15, 0.86) 0.02 2 0.36 (0.15, 0.86) 0.02 
Glutamine 
Any 
mucositis 6 0.77 (0.56, 1.05) 0.10 3 0.85 (0.57, 1.26) 0.42 
Moderate to 
severe 
6 0.87 (0.69, 1.10) 0.25 3 0.89 (0.68, 1.16) 0.38 
Severe 8 0.52 (0.29, 0.93) 0.03 4 0.57 (0.23, 1.38) 0.21 
Honey 
Any 
mucositis 3 0.70 (0.56, 0.88) 0.002 1 0.37 (0.21, 0.65) 0.0006 
Moderate to 
severe 
2 0.48 (0.31, 0.74) 0.0009 0 - - 
Severe 2 0.26 (0.13, 0.52) 0.0002 0 - - 
Laser 
Any 
mucositis 3 0.91 (0.71, 1.17) 0.47 2 0.97 (0.63, 1.48) 0.87 
Moderate to 
severe 
2 0.64 (0.38, 1.08) 0.10 1 1.66 (0.52, 5.28) 0.39 
Severe 2 0.20 (0.06, 0.62) 0.006 1 0.74 (0.13, 4.10) 0.73 
Radiotherapy 
(am v pm) 
Severe 2 1.07 (0.85, 1.36) 0.56 2 0.59 (0.24, 1.43) 0.24 
                                                     
3
 Interventions which became statistical beneficial after the removal of studies assessed to be at high or 
unclear ROB are highlighted in green. Interventions which moved from significant to non-significant are 
highlighted in yellow. 
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4.6.2.2.1 Allopurinol 
 
Figure 16: Allopurinol ‘Any Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Outcome Assessor Blinding4 
 
Three of the four studies included in the allopurinol meta-analyses were described as 
being double blind and were therefore assessed to be at low risk of bias. The exclusion 
of the Dozono and colleagues study (1989), altered the risk ratio for the prevention of 
mild mucositis from 0.77 (95% CI 0.50, 1.19) to 0.93 (95% CI 0.75, 1.14) (Figure 16). 
As all studies in these analyses were assessed to be at low ROB, the moderate and 
severe dichotomies remained unchanged.  
                                                     
4
 Generic inverse variance method used as Dozono 1989 and Loprinzi 1990 studies were cross-over trials 
Study or Subgroup
Abbasi-Nazari 2007
Dozono 1989
Loprinzi 1990
Panahi 2009
Total (95% CI)
Heterogeneity: Chi² = 2.38, df = 2 (P = 0.30); I² = 16%
Test for overall effect: Z = 0.70 (P = 0.48)
log[Risk Ratio]
-0.14
-1.2518
0.167
-0.46
SE
0.13
0.463
0.205
0.45
Weight
67.3%
0.0%
27.1%
5.6%
100.0%
IV, Fixed, 95% CI
0.87 [0.67, 1.12]
0.29 [0.12, 0.71]
1.18 [0.79, 1.77]
0.63 [0.26, 1.52]
0.93 [0.75, 1.14]
Risk Ratio Risk Ratio
IV, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours allopurinol Favours control
Intervention Dichotomies 
Analysis including all 
studies P 
Value 
Analysis excluding 
studies at high or 
unclear ROB 
P 
Value 
N RR (95% CI) N RR (95% CI)  
Sucralfate 
Any 
mucositis 4 1.03 (0.96, 1.11) 0.42 4 1.03 (0.96, 1.11) 0.42 
Moderate to 
severe 
5 0.94 (0.67, 1.33) 0.75 5 0.94 (0.67, 1.33) 0.75 
Severe 8 0.74 (0.54, 1.01) 0.06 7 0.83 (0.64, 1.08) 0.17 
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4.6.2.2.2 Amifostine 
 
Figure 17: Amifostine: ‘Moderate to Severe mucositis’ Dichotomy After Exclusion of 
Studies Assessed to be at Unclear or High ROB for Outcome Assessor Blinding 
 
Only one of the 11 studies included in the amifostine analysis was assessed as being at 
low ROB for outcome assessment. None of the studies included in the ‘any’ mucositis 
dichotomy employed outcome assessor blinding, and this category was therefore 
removed from the sensitivity analysis. The removal of the other inclusions, altered the 
risk ratio from 0.78 (95% CI 0.62, 0.98) to 1.03 (95% CI 0.83, 1.28) in the prevention of 
moderate mucositis dichotomy (Figure 17) and from 0.68 (95% CI 0.45, 1.03) to 1.76 
(95% CI 1.01, 3.07) for the prevention of severe mucositis (Figure 18). In this latter 
analysis, the results were changed to significantly favour the control (P=0.05).  
 
 
Figure 18: Amifostine ‘Severe Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Outcome Assessor Blinding 
Study or Subgroup
Antonadou 2002
Brizel 2000
Buentzel 2006
Koukourakis 2000
Spencer 2005
Veerasarn 2006
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.25 (P = 0.80)
Events
19
116
47
12
19
4
47
Total
22
148
65
60
43
32
65
Events
23
130
45
38
32
14
45
Total
23
153
64
70
47
30
64
Weight
0.0%
0.0%
100.0%
0.0%
0.0%
0.0%
100.0%
M-H, Fixed, 95% CI
0.87 [0.72, 1.04]
0.92 [0.83, 1.03]
1.03 [0.83, 1.28]
0.37 [0.21, 0.64]
0.65 [0.44, 0.96]
0.27 [0.10, 0.72]
1.03 [0.83, 1.28]
Amifostine Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours amifostine Favours control
Study or Subgroup
Antonadou 2002
Bourhis 2000
Brizel 2000
Buentzel 2006
Buntzel 1998
Haddad 2009
Hartmann 2001
Koukourakis 2000
Spencer 2005
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.99 (P = 0.05)
Events
5
11
52
25
0
22
5
1
5
25
Total
22
12
148
65
14
29
20
60
43
65
Events
18
11
60
14
12
20
10
15
15
14
Total
23
12
153
64
14
29
20
70
47
64
Weight
0.0%
0.0%
0.0%
100.0%
0.0%
0.0%
0.0%
0.0%
0.0%
100.0%
M-H, Fixed, 95% CI
0.29 [0.13, 0.65]
1.00 [0.79, 1.27]
0.90 [0.67, 1.20]
1.76 [1.01, 3.07]
0.04 [0.00, 0.62]
1.10 [0.80, 1.51]
0.50 [0.21, 1.20]
0.08 [0.01, 0.57]
0.36 [0.14, 0.92]
1.76 [1.01, 3.07]
Amifostine Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours amifostine Favours control
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4.6.2.2.3 Chlorhexidine 
 
 
Figure 19: Chlorhexidine ‘Severe Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Outcome Assessor Blinding 
 
Seven of the eight studies included in the chlorhexidine meta-analyses were deemed to 
be at low ROB for outcome assessor blinding. The removal of the Wahlin study (1989), 
which did not employ blinding, significantly altered the risk ratio for the severe 
mucositis analysis from 0.82 (95% CI 0.54, 1.23) to 0.73 (95% CI 0.53, 0.99) (P=0.04) 
(Figure 19). The results for mild and moderate mucositis were unchanged as all studies 
in these dichotomies were assessed at low ROB for outcome assessor blinding.  
 
4.6.2.2.4 G-CSF 
 
 
Figure 20: G-CSF ‘Any Mucositis’ Dichotomy After Exclusion of Studies Assessed to 
be at Unclear or High ROB for Outcome Assessor Blinding 
 
Study or Subgroup
Foote 1994
Sorensen 2008
Spijkervet 1989
Wahlin 1989
Total (95% CI)
Total events
Heterogeneity: Chi² = 7.78, df = 2 (P = 0.02); I² = 74%
Test for overall effect: Z = 2.03 (P = 0.04)
Events
14
9
12
8
35
Total
25
70
15
14
110
Events
15
21
12
9
48
Total
27
64
15
14
106
Weight
29.8%
45.4%
24.8%
0.0%
100.0%
M-H, Fixed, 95% CI
1.01 [0.62, 1.64]
0.39 [0.19, 0.79]
1.00 [0.70, 1.43]
0.89 [0.49, 1.62]
0.73 [0.53, 0.99]
Chlorhexidine Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours chlorhexidine Favours control
Study or Subgroup
Crawford 1999
Katano 1995
Schneider 1999
Su 2006
Total (95% CI)
Total events
Heterogeneity: Chi² = 14.23, df = 2 (P = 0.0008); I² = 86%
Test for overall effect: Z = 2.43 (P = 0.02)
Events
26
2
8
17
51
Total
93
7
8
19
120
Events
48
7
6
18
72
Total
102
7
6
21
129
Weight
65.2%
0.0%
10.4%
24.4%
100.0%
M-H, Fixed, 95% CI
0.59 [0.40, 0.87]
0.33 [0.12, 0.95]
1.00 [0.77, 1.30]
1.04 [0.83, 1.32]
0.75 [0.59, 0.94]
G-CSF Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.2 0.5 1 2 5
Favours G-CSF Favours control
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Three of the studies included in the G-CSF analyses were assessed as being at low ROB 
for outcome assessor blinding. The exclusion of the Katano study (1995), which 
employed no blinding, altered the risk ratio to significantly favour G-CSF for the 
prevention of ‘any’ mucositis: from 0.77 (95% CI 0.48, 1.23) to 0.75 (95% 0.59, 0.94) 
(P=0.02) (Figure 20). The results of the moderate and severe mucositis analyses 
remained the same.  
 
4.6.2.2.5 Glutamine 
 
 
Figure 21: Glutamine ‘Any Mucositis’ Dichotomy After Exclusion of Studies Assessed 
to be at Unclear or High ROB for Outcome Assessor Blinding5 
 
Five of the ten studies included in the glutamine analysis were assessed as being at low 
ROB for outcome assessment. The removal studies which did not employ blinding 
altered the risk ratio from 0.77 (95% CI 0.56, 1.05) to 0.94 (95% CI 0.77, 1.15) for the 
‘any mucositis’ dichotomy (Figure 21); from 0.87 (95% CI 0.69, 1.10) to 0.89 (95% CI 
0.69, 1.16) in the ‘moderate to severe’ dichotomy (Figure 22) and from 0.52 (95% CI 
0.29, 0.93) to 0.57 (0.23, 1.38) in the severe mucositis dichotomy (Figure 23).  
                                                     
5
 Generic inverse variance method used as Anderson 1998 and Jebb 1994 studies were cross-over trials 
Study or Subgroup
7.1.1 Oral suspension/supplementation
Anderson 1998
Choi 2007 (1)
Jebb 1994 (2)
Li 2006
Okuno 1999
Subtotal (95% CI)
Heterogeneity: Chi² = 5.05, df = 2 (P = 0.08); I² = 60%
Test for overall effect: Z = 0.60 (P = 0.55)
7.1.2 IV supplementation
Sornsuvit 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable
log[Risk Ratio]
-0.478
-1.11
-0.201
-0.05
0.077
-1.11
SE
0.22
0.38
0.38
0.14
0.12
1.06
Weight
21.3%
0.0%
7.1%
0.0%
71.6%
100.0%
0.0%
IV, Fixed, 95% CI
0.62 [0.40, 0.95]
0.33 [0.16, 0.69]
0.82 [0.39, 1.72]
0.95 [0.72, 1.25]
1.08 [0.85, 1.37]
0.94 [0.77, 1.15]
0.33 [0.04, 2.63]
Not estimable
Risk Ratio
(1) control = 'best supportive care'
(2) 15g/day
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours glutamine Favours placebo
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Figure 22: Glutamine ‘Moderate to Severe mucositis’ Dichotomy After Exclusion of 
Studies Assessed to be at Unclear or High ROB for Outcome Assessor Blinding6 
 
 
Figure 23: Glutamine ‘Severe Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Outcome Assessor Blinding7 
                                                     
6
 Generic inverse variance method used as Jebb 1994 study was a cross-over trial 
7
 Generic inverse variance method used as Anderson 1998 and Jebb 1994 studies were cross-over trials 
Study or Subgroup
7.2.1 Oral suspension/supplementation
Choi 2007 (1)
Dickson 2000
Huang 2000 (2)
Jebb 1994 (3)
Okuno 1999
Subtotal (95% CI)
Heterogeneity: Chi² = 2.33, df = 2 (P = 0.31); I² = 14%
Test for overall effect: Z = 0.97 (P = 0.33)
7.2.2 IV supplementation
Sornsuvit 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable
log[Risk Ratio]
-1.24
0.058
-0.02
-0.3567
-0.0202
-1.11
SE
0.66
0.2
0.18
0.2
0.27
1.06
Weight
0.0%
39.2%
0.0%
39.2%
21.5%
100.0%
0.0%
IV, Fixed, 95% CI
0.29 [0.08, 1.06]
1.06 [0.72, 1.57]
0.98 [0.69, 1.39]
0.70 [0.47, 1.04]
0.98 [0.58, 1.66]
0.89 [0.69, 1.13]
0.33 [0.04, 2.63]
Not estimable
Risk Ratio
(1) control = 'best supportive care'
(2) swish & expectorate oral suspension
(3) 15g/day
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours glutamine Favours placebo
Study or Subgroup
7.3.1 Oral suspension/supplementation
Anderson 1998
Huang 2000
Jebb 1994 (1)
Li 2006
Okuno 1999
Subtotal (95% CI)
Heterogeneity: Chi² = 6.76, df = 2 (P = 0.03); I² = 70%
Test for overall effect: Z = 0.29 (P = 0.77)
7.3.2 IV supplementation
Cerchietti 2006
He 2008
Sornsuvit 2008
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 2.27 (P = 0.02)
log[Risk Ratio]
-1.109
-2.12
0.2231
-0.29
-0.198
-1.542
-1.17
-1.61
SE
0.46
1.35
0.23
0.39
0.65
0.68
0.67
1.5
Weight
18.2%
0.0%
72.7%
0.0%
9.1%
100.0%
100.0%
0.0%
0.0%
100.0%
IV, Fixed, 95% CI
0.33 [0.13, 0.81]
0.12 [0.01, 1.69]
1.25 [0.80, 1.96]
0.75 [0.35, 1.61]
0.82 [0.23, 2.93]
0.94 [0.64, 1.39]
0.21 [0.06, 0.81]
0.31 [0.08, 1.15]
0.20 [0.01, 3.78]
0.21 [0.06, 0.81]
Risk Ratio
(1) 15g/day crossover design
Risk Ratio
IV, Fixed, 95% CI
0.01 0.1 1 10 100
Favours glutamine Favours placebo
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4.6.2.2.6 Honey 
 
 
Figure 24: Honey ‘Any Mucositis’ Dichotomy After Exclusion of Studies Assessed to 
be at Unclear or High ROB for Outcome Assessor Blinding 
 
Of the three studies entered into the analysis which investigated honey for the 
prevention of mucositis, one was assessed as being at low risk of bias for outcome 
assessor blinding (Motallebnejad et al., 2008). This intervention had been previously 
found to be beneficial in the prevention of all dichotomies for mucositis, albeit with 
high levels of heterogeneity in data in the ‘any’ or ‘moderate plus severe mucositis’ 
dichotomies. The removal of studies assessed at high ROB for outcome assessor 
blinding removed the moderate to severe and severe dichotomies, and altered the risk 
ratio for ‘any mucositis’ from 0.70 (95% CI 0.56, 0.88) to 0.37 (95% CI 0.21, 0.65) 
(Figure 24).  
 
4.6.2.2.7 Laser  
 
 
Figure 25: Laser ‘Any Mucositis’ Dichotomy After Exclusion of Studies Assessed to be 
at Unclear or High ROB for Outcome Assessor Blinding 
 
Study or Subgroup
Biswal 2003
Motallebnejad 2008
Rashad 2008
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 3.41 (P = 0.0006)
Events
13
7
17
7
Total
20
20
20
20
Events
13
20
20
20
Total
20
20
20
20
Weight
0.0%
100.0%
0.0%
100.0%
M-H, Fixed, 95% CI
1.00 [0.63, 1.58]
0.37 [0.21, 0.65]
0.85 [0.70, 1.05]
0.37 [0.21, 0.65]
Honey Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours Honey Favours control
Study or Subgroup
Antunes 2007
Chor 2009
Cruz 2007
Total (95% CI)
Total events
Heterogeneity: Chi² = 2.44, df = 1 (P = 0.12); I² = 59%
Test for overall effect: Z = 0.16 (P = 0.87)
Events
16
8
13
21
Total
19
17
28
45
Events
19
12
11
23
Total
19
17
31
48
Weight
0.0%
53.5%
46.5%
100.0%
M-H, Fixed, 95% CI
0.85 [0.68, 1.05]
0.67 [0.37, 1.20]
1.31 [0.70, 2.43]
0.97 [0.63, 1.48]
Laser Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
Favours laser Favours control
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Five studies of the six studies investigating the use of laser in the prevention of 
mucositis were assessed to be at low ROB for outcome assessor blinding; however, two 
of these studies were text only inclusions, which could not be included in the sensitivity 
analysis (Bensadoun et al., 1999, Schubert et al., 2007) and the other study compared 
laser application to povidone-iodine and is therefore unchanged (Arun Maiya et al., 
2006). The exclusion of the unblinded Antunes and colleagues study (2007), altered the 
risk ratio from 0.91 (95% 0.71, 1.17) to 0.97 (95% CI 0.63 to 1.48) for the prevention of 
‘any’ mucositis (Figure 25), from 0.64 (95% CI 0.38, 1.08) to 1.66 (95% CI 0.52, 5.28) 
in the prevention of ‘moderate to severe’ mucositis (Figure 26) and from 0.20 (95% CI 
0.06, 0.62) to 0.74 (95% CI 0.13, 4.10) in the prevention of ‘severe’ mucositis category 
(Figure 27).  
 
 
Figure 26: Laser ‘Moderate to Severe Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Outcome Assessor Blinding 
 
 
Figure 27: Laser ‘Severe Mucositis’ Dichotomy After Exclusion of Studies Assessed to 
be at Unclear or High ROB for Outcome Assessor Blinding 
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Cruz 2007
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
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7
6
6
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28
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17
4
4
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Weight
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M-H, Fixed, 95% CI
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1.66 [0.52, 5.28]
Laser Control Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
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Study or Subgroup
Antunes 2007
Cruz 2007
Total (95% CI)
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Heterogeneity: Not applicable
Test for overall effect: Z = 0.35 (P = 0.73)
Events
1
2
2
Total
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3
3
Total
19
31
31
Weight
0.0%
100.0%
100.0%
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4.6.2.2.8 Radiotherapy am versus pm 
 
 
Figure 28: Radiotherapy Morning versus Afternoon ‘Severe Mucositis’ Dichotomy 
After Exclusion of Studies Assessed to be at Unclear or High ROB for Outcome 
Assessor Blinding 
 
Blinding of outcome assessor was employed in only one of the two studies included in 
the morning versus evening radiation meta-analysis (Goyal et al., 2009). The exclusion 
of the unblinded Bjarnason and colleagues study (2009), altered the risk ratio from 1.07 
(95% 0.85, 1.36) to 0.59 (95% CI 0.24 to 1.43) for the prevention of ‘severe’ mucositis 
(Figure 28).   
 
4.6.2.2.8 Sucralfate 
 
 
Figure 29: Sucralfate ‘Severe Mucositis’ Dichotomy After Exclusion of Studies 
Assessed to be at Unclear or High ROB for Outcome Assessor Blinding8 
 
                                                     
8
 Generic inverse variance method used as Pfeiffer 1990 study was a cross-over trial 
Study or Subgroup
Biarnason 2009
Goyal 2009
Total (95% CI)
Total events
Heterogeneity: Not applicable
Test for overall effect: Z = 1.17 (P = 0.24)
Events
63
7
7
Total
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88
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Events
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12
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Weight
0.0%
100.0%
100.0%
M-H, Fixed, 95% CI
1.18 [0.93, 1.49]
0.59 [0.24, 1.43]
0.59 [0.24, 1.43]
Radiotherapy AM Radiotherapy PM Risk Ratio Risk Ratio
M-H, Fixed, 95% CI
0.1 0.2 0.5 1 2 5 10
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Study or Subgroup
Carter 1999
Castagna 2001
Cengiz 1999
Evensen 2001
Nottage 2003
Pfeiffer 1990
Scherlacher 1990
Shenep 1988
Total (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 10.28, df = 6 (P = 0.11); I² = 42%
Test for overall effect: Z = 1.38 (P = 0.17)
log[Risk Ratio]
-0.1625
-0.47
-2.12
0.122
-0.1555
-0.1748
-1.5187
-1.11
SE
0.22
0.263
1.48
0.12
0.401
0.2
0.572
0.6
Weight
19.2%
15.7%
0.8%
30.1%
8.7%
21.1%
0.0%
4.4%
100.0%
IV, Random, 95% CI
0.85 [0.55, 1.31]
0.63 [0.37, 1.05]
0.12 [0.01, 2.18]
1.13 [0.89, 1.43]
0.86 [0.39, 1.88]
0.84 [0.57, 1.24]
0.22 [0.07, 0.67]
0.33 [0.10, 1.07]
0.83 [0.64, 1.08]
Risk Ratio Risk Ratio
IV, Random, 95% CI
0.02 0.1 1 10 50
Favours sucralfate Favours control
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Eleven of the 12 studies included in the sucralfate analyses were assessed to be at low 
risk of bias; however, two of these studies were text only inclusions which could not be 
included in the sensitivity analysis (Epstein and Wong, 1994, Lievens et al., 1998). The 
removal of the Scherlacher study (1990), altered the risk ratio for severe mucositis from 
0.74 (95% CI 0.54, 1.01) to 0.83 (95% CI 0.64, 1.08) (Figure 29). The generic inverse 
variance method was used for this analysis as the Pfeiffer and colleagues study (1990), 
was a cross-over trial. As the Scherlacher study (1990), only provided data for the 
severe dichotomy, the other results remained unchanged.  
 
4.6.2.3 Overall ROB 
Ten studies were assessed at low ROB overall (8%); 82 (63%) were described as 
unclear; and the remaining 38 studies (29%) were defined as being at high ROB. Two of 
the studies assessed to be at low risk of bias could not be entered into the sensitivity 
analysis because they were either a text only inclusion (Madan et al., 2008) or were 
presented in the single studies table in the main version of the review (Saarilahti, 2002). 
Therefore the results of eight studies are presented in Table 10. After the exclusion of 
studies assessed to be at high or unclear ROB, only one intervention, G-CSF, was found 
to be statistically beneficial for the prevention of severe mucositis. In addition, the 
results of the moderate to severe dichotomy for chlorhexidine were changed to 
significantly favour the control group.  
 
Table 10: Impact of the Removal of Studies Judged to be at High or Unclear Overall 
ROB910 
Intervention Dichotomies 
Analysis including all 
studies P Value 
Analysis excluding 
studies at high or 
unclear ROB 
P 
Value 
N RR (95% CI) N RR (95% CI) 
Allopurinol 
Any 
mucositis 4 0.77 (0.50, 1.19) 0.24 0 - - 
Moderate to 
severe 
2 0.66 (0.50, 0.86) 0.002 0 - - 
Severe 2 0.81 (0.63, 1.04) 0.09 0 - - 
Aloe Vera Severe 2 0.74 (0.58, 0.96) 0.02 0 - - 
                                                     
9
 Interventions which became statistical beneficial after the removal of studies assessed to be at high or 
unclear ROB are highlighted in green. Interventions which do not change and remain significant are 
highlighted in yellow. 
10
 Studies found to be statistically beneficial for the prevention of mucositis in the updated full prevention 
review are highlighted in blue 
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Intervention Dichotomies 
Analysis including all 
studies P Value 
Analysis excluding 
studies at high or 
unclear ROB 
P 
Value 
N RR (95% CI) N RR (95% CI) 
Amifostine 
Any 
mucositis 3 0.95 (0.91, 0.99) 0.007 0 - - 
Moderate to 
severe 
6 0.78 (0.62, 0.98) 0.03 0 - - 
Severe 9 0.68 (0.45, 1.03) 0.07 0 - - 
Antibiotic 
pastille / paste 
Any 
mucositis 3 0.92 (0.85, 0.99) 0.03 0 - - 
Moderate to 
severe 
2 0.92 (0.78, 1.08) 0.32 0 - - 
Severe 3 0.87 (0.71, 1.07) 0.19 1 0.87 (0.70, 1.10) 0.24 
Chlorhexidine 
Any 
mucositis 4 0.76 (0.47, 1.24) 0.27 1 1.04 (0.93, 1.15) 0.50 
Moderate to 
severe 
3 0.93 (0.72, 1.21) 0.58 2 1.42 (1.05, 1.93) 0.02 
Severe 4 0.82 (0.54, 1.23) 0.33 1 1.01 (0.62, 1.64) 0.97 
Cryotherapy 
Any 
mucositis 5 0.74 (0.57, 0.95) 0.02 0 - - 
Moderate to 
severe 
5 0.53 (0.31, 0.91) 0.02 0 - - 
Severe 5 0.36 (0.17, 0.77) 0.008 0 - - 
G-CSF 
Any 
mucositis 4 0.77 (0.48, 1.23) 0.27 2 1.03 (0.86, 1.24) 0.74 
Severe 2 0.36 (0.15, 0.86) 0.02 2 0.36 (0.15, 0.86) 0.02 
Glutamine 
Any 
mucositis 6 0.77 (0.56, 1.05) 0.10 0 - - 
Moderate to 
severe 
6 0.87 (0.69, 1.10) 0.25 0 - - 
Severe 8 0.52 (0.29, 0.93) 0.03 0 - - 
GM-CSF Any 
mucositis 2 0.93 (0.84, 1.04) 0.21 1 0.91 (0.80, 1.04) 0.16 
Moderate to 
severe 
2 0.89 (0.76, 1.05) 0.17 0 - - 
Severe 6 0.73 (0.51, 1.04) 0.08 2 1.00 (0.60, 1.67) 0.99 
Honey 
Any 
mucositis 3 0.70 (0.56, 0.88) 0.002 0 - - 
Moderate to 
severe 
2 0.48 (0.31, 0.74) 0.0009 0 - - 
Severe 2 0.26 (0.13, 0.52) 0.0002 0 - - 
Keratinocyte 
GF 
Any 
mucositis 2 0.82 (0.71, 0.94) 0.005 0 - - 
Moderate to 
severe 
6 0.80 (0.68, 0.94) 0.006 0 - - 
Severe 5 0.75 (0.62, 0.89) 0.001 0 - - 
Laser 
Any 
mucositis 3 0.91 (0.71, 1.17) 0.47 0 - - 
Moderate to 
severe 
2 0.64 (0.38, 1.08) 0.10 0 - - 
Severe 2 0.20 (0.06, 0.62) 0.006 0 - - 
Pilocarpine 
Any 
mucositis 2 1.05 (1.00, 1.10) 0.06 0 - - 
Moderate to 
severe 
2 1.05 (0.94, 1.16) 0.41 0 - - 
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Intervention Dichotomies 
Analysis including all 
studies P Value 
Analysis excluding 
studies at high or 
unclear ROB 
P 
Value 
N RR (95% CI) N RR (95% CI) 
Povidone -
Iodine 
Any 
mucositis 2 0.90 (0.76, 1.08) 0.27 0 - - 
Moderate to 
severe 
2 0.82 (0.62, 1.10) 0.18 0 - - 
Severe 2 0.65 (0.40, 1.06) 0.08 0 - - 
Prostaglandin 
Any 
mucositis 3 1.03 (0.94, 1.12) 0.57 0 - - 
Severe 3 1.01 (0.77, 1.33) 0.93 0 - - 
Radiotherapy 
(am v pm) 
Severe 2 1.07 (0.85, 1.36) 0.56 0 - - 
Sucralfate 
Any 
mucositis 4 1.03 (0.96, 1.11) 0.42 0 - - 
Moderate to 
severe 
5 0.94 (0.67, 1.33) 0.75 1 0.94 (0.67, 1.33) 0.75 
Severe 8 0.74 (0.54, 1.01) 0.06 1 0.33 (0.10, 1.07) 0.06 
 
4.7 Discussion 
In Cochrane reviews, ROB assessments play an important part in how the results of 
studies are interpreted. As review authors can choose to exclude studies at high risk of 
bias overall, it may be beneficial for authors planning future studies to think about the 
risk of bias in their study design if they are aiming for inclusion in a Cochrane meta-
analysis.  
 
The results of studies assessed as being at high ROB should be interpreted with caution. 
Honey and Cryotherapy were found to be significantly beneficial for the prevention of 
mucositis at all levels of interest in the full review (Worthington et al., 2010). However, 
none of the cryotherapy studies employed adequate blinding; four were conducted with 
no blinding, while Mahood and colleagues stated that staff assessing mucositis were 
often unaware of allocations (Mahood et al., 1991), and was therefore classified as 
‘unclear’. In addition, two of the three honey studies employed no blinding, while 
Motallebnejad used a single blind design in which the outcome assessor was blind 
(Motallebnejad et al., 2008). Clearly both of these interventions suffer from 
methodological issues which impact the ROB assessments. It is obviously impossible to 
blind patients and research staff to whether a patient receives ice chips or not. However, 
it should possible with careful planning to blind an outcome assessor, especially if 
patients are being treated as outpatients. Even in small studies, a member of the research 
team who is not tasked with the daily care of the patients is usually able to fulfil this 
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role. This has been done successfully in four out of the five laser studies in the review 
and in one of the two morning versus evening radiation trials, even though the blinding 
of patients and other personnel was impossible (Arun Maiya et al., 2006, Bjarnason et 
al., 2009, Cruz et al., 2007).  
 
Adequate allocation concealment should also be possible to achieve. Staff planning to 
conduct clinical trials in hospital settings commonly have access to a clinical trials unit, 
which should be able to arrange such central allocation by telephone or fax. If such a 
service is unavailable, there is still the possibility that the allocation can be concealed 
using envelopes or drug containers of identical appearance, or through the use of 
pharmacy controlled randomisation.  
 
In addition to study design, the manner in which studies are written up is also important, 
as a well-conducted trial with a poorly written paper may be misclassified as being at 
high or unclear ROB (Nuesch et al., 2009). It is possible that some ROB assessments 
may change if authors were contacted and asked specific questions about the design and 
execution of their study. However, attempting to do this in a manner that does not lead 
or prompt a certain answer is difficult to achieve, as this may introduce other forms of 
bias into the results. While the manner in which a trial is written up for publication 
remains important, it is clear that future studies should be designed with ROB in mind.  
 
At present the results of the sensitivity analysis for overall ROB does not appear in the 
Cochrane prevention review, which may be an oversight. Although, overall risk of bias 
decisions were discussed alongside each intervention in the results of the review, it is 
possible that the inclusion of the overall risk of bias sensitivity analysis might provide 
additional useful information to clinicians. Table 10 shows that the exclusion of studies 
assessed for unclear or high risk of overall bias changed the results of the moderate to 
severe dichotomy for chlorhexidine to significantly favour placebo. As chlorhexidine is 
an intervention which is commonly used in the prevention of oral mucositis (Glenny et 
al., 2004), despite a lack of benefit being identified in previous updates of the Cochrane 
prevention review (Worthington et al., 2007), the publication of these findings may help 
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to alter current clinical practice. The incorporation of such sensitivity analyses should 
therefore be considered for inclusion in the next update of the review.  
 
The Cochrane method of assessing ROB is a useful method of assessing potential biases 
in a study, however, these assessments are not without issue. As with any method of 
assessment, decisions can be subjective and be influenced by the experience of a 
researcher. The Cochrane handbook (Higgins and Altman, 2009) provides some 
examples of studies at high, unclear or low risk of bias in each category, however, the 
researcher found a number of studies which did not clearly fit within any of the criteria. 
The practice of conducting ROB assessments in duplicate with other members of the 
Oral Health Group proved invaluable in these circumstances and should be adopted in 
other reviews. Authors of future reviews need to carefully consider their motives for 
conducting a sensitivity analysis of their reviews prior to their use, and in addition pre-
specify which criteria they consider to be ‘key domains’, to prevent such analyses 
becoming a fishing expedition.  
 
4.8 Conclusion 
In this chapter studies included in the Cochrane review of interventions for the 
prevention of mucositis were assessed for ROB (Worthington et al., 2010). The 
assessment of bias in this manner is important in order to avoid exaggerating the effect 
estimate of a particular intervention (Nuesch et al., 2009). After consideration of the 
impact of potential biases the interpretation of study results, the following will be built 
into the feasibility design: 
• A central method of allocation, the hospital pharmacy, will be used to dispatch the 
intervention and placebo products, therefore ensuring adequate allocation 
concealment 
• Drugs containers which are identical in appearance and sequentially numbered, will 
also be used to ensure adequate allocation concealment 
• Blinding of outcome assessor will be attempted to ensure that mucositis 
assessments, together will all other data collection, will be conducted without the 
knowledge of allocations. 
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 Chapter 5: What can we learn from previous studies?  
 
5.1 Introduction 
In this chapter the conclusions of the Cochrane review (Worthington et al., 2010) will 
be analysed to determine what information they can provide to help researchers 
planning future studies. In addition, some of the studies excluded from the Cochrane 
review will also be discussed.  
 
5.2 Aim 
To review the studies included in the Cochrane review update to determine: 
• what the expected rate of recruitment is for future trials 
• what other outcomes were reported 
• the timing of oral assessment that were used  
• the problems and pitfalls that were experienced 
 
5.3 Methods  
Studies included in the Cochrane review update were examined to determine if they 
provided any relevant information. Studies providing dates for recruitment were 
included in the analysis. If exact dates were not given, data were inputted using the first 
day of the month for start of recruitment and the last possible day in the month for the 
end of recruitment. Mean averages were then calculated to provide the average number 
of patients recruited per week overall. A sub-set analysis was then conducted for single 
site studies.  
 
5.4 Results 
5.4.1 Recruitment  
80 of the 130 studies (61.5%) assessed provided enough information to calculate 
recruitment rates in patient per week. The total number of patients recruited by these 
studies was 6812. The average number of patients recruited per week was 1.13. The 
highest recruitment rate recorded in a study was 7.66 patients per week. This was a 
multi-site study of iseganan in the prevention of mucositis in head and neck cancer 
patients undergoing a mix of therapies (Trotti et al., 2004). The lowest recruitment rate 
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recorded meanwhile was 0.153 patients per week, in a study investigating glutamine in 
patients with solid tumour undergoing chemotherapy (Anderson et al., 1998). As 
expected, the majority of studies reporting high rates of recruitment were multi-site 
studies; if such studies were excluded, and the averages recalculated for only the single 
site studies, the mean average rate of recruitment was reduced to 0.79 patients per week. 
 
5.4.2 Other outcomes 
One hundred of the 130 studies assessed mucositis as the primary outcome measure. 
Twenty-four studies assessed mucositis as a secondary outcome, while in seven studies 
it was unclear whether mucositis was the primary outcome measure. Figure 30 shows 
the frequency of the other reported outcome measures and illustrates that there was little 
consistency in which other outcomes were reported by the assessed studies. It is 
important to recognise that these outcome measures are what the authors choose to 
report, and there may have been other outcomes of interest which have not been 
reported in the publications assessed. However, it is impossible to estimate the scale of 
any omission without access to the original trial protocols.  
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Figure 30: Frequency of Outcome Measures Other Than Mucositis to be Included in the 
Cochrane Review Update 
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Adverse events were the most frequently reported outcome measure and were reported 
by 62 studies (47.6%). Blood changes were reported by 50 studies (38%), while patient 
reports of pain and use of analgesics were reported by 47 studies (36%). Patient weight 
loss or gain was the fourth most frequently reported outcome, and was detailed in 42 
publications (32%). Dysphagia was reported by 35 studies (27%) and systemic infection 
or the use of antibiotics by 34 (26%). Oral hygiene, occurrence of febrile episodes, 
occurrence of death or overall health, xerostomia, cancer reoccurrence, patients 
difficulties in eating or drinking, calorific intake, the cost of the intervention and length 
of hospital stay were all outcome measures reported in less than 21% of the studies 
assessed for ROB. Patient quality of life was the least frequently reported intervention 
(5%).   
 
5.4.3 Oral assessment 
Seventeen studies (13%) provided no information regarding the frequency of 
assessment, seven of these were translated studies, and this may represent an oversight 
on the data extraction sheet provided to the translators. Forty seven (35.9%) studies 
assessed mucositis weekly, 16 (12%) twice weekly and 24 (18%) daily. Three studies 
(2%) assessed the oral cavity trice weekly, while two studies (1.5%) assessed the oral 
cavity every two days (Lockhart et al., 2005, Oberbaum et al., 2001). Three studies only 
assessed the oral cavity twice: in one of these studies assessments were carried out at 
baseline and day ten (Pfeiffer et al., 1990), in another assessments were conducted at 
baseline and day 12 (Li et al., 2006), while the third study gave no more information 
(Sorensen et al., 2008). Three studies assessed the oral cavity three times during data 
collection (Cruz et al., 2007, Panahi et al., 2010, Pitten et al., 2003). Two studies 
assessed the oral cavity four times, both these studies were keratinocyte GF studies, and 
both assessed patients on day one, four, eight and 15 (Meropol et al., 2003, Rosen et al., 
2006). Two studies employed monthly assessments (Dodd et al., 1996b, Jebb et al., 
1994). Five studies (3.8%) stated that they used ‘historical methods’ to assess mucositis 
when the patient was seen in clinic some weeks after treatment. However, as no 
additional information is given for these studies, it is difficult to know what is meant by 
this statement. It is possible that the authors conducted a review of the patient notes. 
The remaining seven studies employed variable timescales for assessment. For example, 
Cartee and colleagues (1995) assessed the oral cavity daily between days one and five, 
then daily from day eight until ten and then on days 15 and 22. Unfortunately, the 
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authors give no rationale for the use of such timings. The high number of studies 
employing weekly assessment may be misleading, as a subset analysis revealed that 43 
(91%) of these studies were trials involving head and neck patients undergoing 
radiotherapy and, or chemoradiotherapy. These patients tend to be treated on an 
outpatient basis, and are seen in clinic once a week, which may explain the high 
numbers of studies employing weekly oral assessment.  
 
5.4.4 Problems and pitfalls 
Of the 130 studies assessed 12 (9%) studies gave information about the problems they 
experienced during data collection. Two studies reported more than one problem 
(Nottage et al., 2003, Veness et al., 2006). Six studies reported problems in recruiting 
patients into the study (Dorr et al., 2007, Gandemer et al., 2007, McAleese et al., 2006, 
Su et al., 2004, Su et al., 2006, Veness et al., 2006). While two studies stopped early 
because of issues with either the intervention or placebo products: Veness and 
colleagues (2006), reported a difficulty in obtaining study medications in later parts of 
the trial, despite this trial being sponsored, and the products supplied, by a 
pharmaceutical company; meanwhile Nottage and colleagues (2003), had to cease 
recruitment when the expiry date of the placebo was reached. One study ceased 
recruitment after a change in standard radiotherapy regimes on the unit and the type of 
radiotherapy used in the study became redundant (Haddad et al., 2009).  
 
Two studies reported drug dispensing errors (Anderson et al., 1998, Trotti et al., 2004). 
In addition, one study was excluded from the prevention review because of a drug 
dispensing error (Giles et al., 2003). In the Giles and colleagues study, a drug 
dispensing error affected 102 patients. These patients were allocated at least one bottle 
of either intervention or placebo against their randomised assignment. Unfortunately, as 
the drugs were dispensed every five days, the longer a patient remained on the study, 
the greater the chances that they were affected by this error. Twenty-seven patients were 
potentially affected by a problem with a voice activated randomization procedure in the 
Trotti and colleagues (2004) study. These patients were therefore excluded from the 
analysis. 
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5.5: Discussion 
This chapter has assessed the literature included in the Cochrane prevention review to 
determine what information they provide, which could be used to inform future trials. A 
number of issues have been identified. These will now be discussed.  
 
5.5.1 Feasibility study 
Two studies assessed experienced problems during randomisation (Anderson et al., 
1998, Trotti et al., 2004). Another study, excluded from the review, reported a 
pharmacy dispensing error which affected 32% of all patients recruited into the study 
(Giles et al., 2003). All three of these issues were due to technology failure. It is 
possible that such issue could have identified if a rigorous feasibility study had been 
conducted prior to the commencement of data collection. Any technology, pharmacy 
release procedures, recruitment policies or methods of assessment due to be employed 
in a trial should be trialled in a feasibility study and the results analysed before the main 
trail is conducted (Easterbrook and Matthews, 1992). In this way, costly mistakes, such 
as those experienced in the Giles and colleagues study could be avoided if one element 
of the study is found not to work.  
 
5.5.2 Recruitment  
Recruitment problems were explicitly mentioned by six studies assessed for ROB. 
However, it could be surmised from the long recruitment periods and the low number of 
patients recruited that some other studies also experienced problems, but that these 
authors choose not to discuss these issues in their publications. McAleese and 
colleagues (2006), for example, recruited 29 patients in 165 weeks, while Anderson and 
colleagues (1998) recruited 24 patients in 156 weeks. Neither article mentions problems 
with recruitment. A wide variation in recruitment rates was identified within the 
literature, with rates of recruitment being much higher in multi-site studies. However, in 
such multi-site studies research nurses are generally tasked with data collection and 
recruitment of patients, and as these staff typically work on more than one study at a 
time, it is possible that recruitment for one particular project may take preference over 
another. Gandemer and colleagues (2007), stated that nursing staff found it difficult to 
devote time to the study. However, it is possible that such barriers to recruitment, at 
least in terms of researchers, could be reduced if a member of staff was employed to 
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work purely on the study, and take responsibility for conducting all recruitment and data 
collection. Based on the studies included in the Cochrane review, future multi-site 
studies can expect to recruit approximately 1.13 patients per week. Single site studies 
can expect to recruit approximately 0.79 patients a week.  
 
Recruitment into clinical trials is an acknowledged problem in the literature (Gul and 
Ali, 2010, Toerien et al., 2009). Under recruitment of patients into a trial reduces 
statistical power and can lead to type II errors, false negatives, if a study fails to recruit 
the number of patients demanded by the sample size calculation (Gul and Ali, 2010, 
Oude Rengerink et al., 2010). Slow recruitment into studies also has economic 
consequences for the trial, as the recruitment period may have to be extended in order to 
reach targets, which may have considerable consequences in terms of staff and resource 
utilisation (Gul and Ali, 2010). Many different barriers to patients taking part in 
research have been identified, which include: a dislike or distrust of the research 
process, a preference for one intervention in the trial over another, a dislike of the 
prospect of randomisation or the possibility of being randomised to a placebo arm, and a 
concern about the possibility of adverse events (Mills et al., 2006, Oude Rengerink et 
al., 2010). Unfortunately, attempts to address some of these barriers by educating 
patients about the research process have not been found to significantly increase rates of 
patient consent (Du et al., 2008, Ellis et al., 2002). The use of a pilot or feasibility study 
can help identify problems recruiting patients to take part in a study prior to a costlier 
larger study being conducted.  
 
5.5.3Timing of oral assessments 
No consistency was identified regarding the timings of oral assessments in the studies 
assessed for ROB. Weekly assessments were employed most frequently; however, this 
result may be confounded by the number of these studies which were conducted in 
radiotherapy patients, who would commonly be seen for weekly outpatients’ 
appointments. The number of studies which employed historical methods of assessment 
is concerning as mucositis has been found to be under documented in chart reviews 
(Dodd et al., 1996a). There is a danger that important oral changes may be missed if 
oral assessments are conducted too infrequently, however, conversely conducting such 
assessments too frequently increases the burden on both patients and researchers (Eilers 
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and Epstein, 2004). The task therefore is to conduct oral assessments frequently enough 
to detect important changes, but not too frequently as to bother patients. Research has 
suggested that oral cavity changes can be identified within four hours of the initiation of 
stressors, in the absence of interventions which act to counteract such a stressor 
(DeWalt and Haines, 1969). Clearly, conducting oral assessments every four hours is 
not practical. However, daily assessments of the oral cavity may be feasible. 
 
5.5.4 Adverse event reporting 
Fewer than 50% of the articles assessed for ROB reported adverse events. This is a 
concerning oversight, as this is crucial information when developing future trials of any 
intervention, and is used to inform risk-benefit analyses. Few studies provided 
information about how this adverse event reporting was conducted, or provided 
information regarding how long patients were followed-up after receiving their last dose 
of intervention or placebo. In those studies which did provide this information, patients 
were routinely followed up for between 28 and 30 days after their last dose. A length of 
follow-up of 30 days after a patient receives their last dose of intervention or placebo 
therefore appears to be appropriate for use in future studies.  
 
5.6 Conclusion 
This chapter has assessed studies included in the Cochrane prevention review 
(Worthington et al., 2010) to determine what information they provide which could be 
used to inform a future trial. Expected recruitment rates were calculated from papers 
providing the necessary information. A lack of consistency was identified in the other 
outcomes reported by these studies. Adverse events were the most frequently reported 
outcome; however these were reported by only 62 studies (47.6%), a concerning result 
which should be addressed in future trials. Patient quality of life was the least frequently 
reported outcome, this supports one of the conclusions in the literature review of this 
thesis, which stated that patient reports of mucositis were an under-reported area of 
research. A variety of timings of oral assessment were identified, three studies only 
assessed the oral cavity twice, which is not appropriate for use in future trials because of 
the possibility that important changes may be missed. Twelve of the assessed studies 
reported problems during data collection, which ranged from early stopping due to 
issues with the intervention or placebo products, to recruitment problems. Three studies 
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reported drug dispensing errors, which may have been identified prior to starting data 
collection had a feasibility study been conducted. The next chapter of this thesis will 
identify appropriate oral assessments for use in a feasibility trial. 
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Chapter 6 A Systematic Review of Oral Assessment Instruments for 
Use in Adults 
 
6.1 Rationale 
Oral assessment is crucial to accurately monitor and document the severity and 
progression of mucositis. Accurate assessment using a valid, reliable and sensitive tool, 
which is easy for the researcher to use, and does not fatigue or increase patient pain is 
important for both research and clinical settings (Tomlinson et al., 2007). In the clinical 
setting, regular monitoring of the oral cavity facilitates the employment of interventions 
for OM treatment and the alleviation of associated symptoms. Within the context of a 
RCT, accurate oral assessment using a valid, reliable and sensitive tool, which is easy 
for the researcher to use, and does not fatigue or increase patient pain, is vital for the 
comparison of intervention and control groups. To identify the various methods of oral 
assessment currently available in the literature, and to determine the most appropriate 
instrument available for use in children, the Children’s Cancer and Leukaemia Group 
(CCLG) mouth care group conducted a search of the literature in 2004, and published a 
systematic review of instruments as part of their mouthcare guidelines in 2006 
(UKCCLG-PONF, 2006). The CCLG mouth care group is a multidisciplinary group of 
experts in the fields of paediatric oncology, evidence based practice and oral care. The 
primary aim of this group is the development of oral care guidelines for children and 
young people undergoing therapy for cancer (UKCCLG-PONF, 2006).  In early 2008, 
before the update of the mouthcare guidelines, the literature search was repeated by the 
author, and the review updated. This systematic review was also reproduced as a linked 
publication, which was co-authored by the author (Gibson et al., 2010). The results of 
the 2008 literature search were used by the author to conduct a separate systematic 
review to determine the most suitable oral assessment instruments for use in a clinical 
trial of adults with haematological cancers undergoing stem cell transplantation. This 
systematic review is presented in the remainder of this chapter.  
 
6.2 Objectives 
To identify oral assessment instruments previously used for the assessment of oral 
mucositis in adults in order to select suitable instruments for use in a trial involving 
patients undergoing stem cell transplantation. 
 122 
 
 
6.3 Method 
6.3.1 Eligibility criteria 
Articles describing an oral assessment instrument for use in adult patients with cancer 
receiving treatment, or any study describing either an adaptation of an existing oral 
assessment instrument, or the validation of an existing instrument.  
 
6.3.2 Information sources and search  
In March 2008, the search strategy previously employed when developing the oral care 
guidelines (UKCCLG-PONF, 2006) was re-run on the following electronic databases: 
MEDLINE (OVID BIOMED 1980- March 2008), EMBASE (OVID BIOMED1980- 
March 2008), The Cochrane Library (Issue 2, 2008) and CINAHL (OVID 
BIOMED1980- March 2008). Briefly, this search strategy was comprised of a root 
search of terms including ‘neoplasm’, ‘radiotherapy’, ‘chemotherapy’ and ‘bone 
marrow transplantation’ and then an oral assessment specific search, which included 
terms such as ‘oral ulcer’, ‘stomatitis’ and ‘severity of illness index’. A copy of the 
complete search strategy can be found in Appendix 2.  
 
6.3.3 Study selection and data collection process 
 6.3.3.1 Screening, identification of eligible publications and data extraction used 
for the CCLG guideline update and linked publication 
The titles and abstracts of the 2008 search results were first screened by the author and 
then distributed to another member of the group for duplicate screening. After 
potentially eligible studies had been identified, the full papers were acquired by the 
author who then distributed them between paired members of the CCLG mouth care 
group for extraction in duplicate. Data extraction comprised two distinct phases: the 
first phase was the extraction of the components of each assessment instrument and the 
completion of a table showing the frequency of items used to score the oral cavity; the 
second phase was to determine whether any validity/reliability information was 
provided in the paper, and if this was present, to assess these studies using an adaptation 
of the diagnostic studies checklist (Scottish Intercollegiate Guidelines Network (SIGN), 
2002). Disagreements between paired members were taken to a third party.  
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6.3.3.2 Screening, identification of eligible publications and data extraction used 
for this review 
The author then re-read the articles and extracted each of the instruments into the 
formats shown in Table 11 and Table 12. Articles not meeting the inclusion criteria for 
the adult review were excluded.  
 
6.3.4 Synthesis of results 
Data pooling was narrative in both the CCLG guidelines and linked publication and in 
this review.  
 
6.4 Results 
6.4.1 Study selection 
A total of 391 articles were identified during the repeat of the search. Three-hundred 
and twenty-three of these publications were excluded because either the participants or 
instrument didn’t fulfil the inclusion criteria. The additional 37 publications previously 
included in the review were also removed. This left 31 potentially eligible publications 
studies, which was reduced to 28 studies after the removal of a quality of life scale and 
two duplicate assessment instruments. Fifty-four assessment instruments were identified 
for inclusion in the CCLG guidelines and linked publication (Gibson et al., 2010). 
However, four of these instruments were designed, or amended, for use in children 
(Chen et al., 2004, Gandemer et al., 2007, Gibson et al., 2006, Sung et al., 2006), and as 
these did not meet the inclusion criteria for this review, these articles were therefore 
excluded. Therefore 50 oral assessment instruments were identified for inclusion in this 
review. Figure 31 shows the flow of information through the different phases of the 
systematic review. 
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Figure 31: Flow of information through the different phases of the systematic review 
(adapted from Gibson et al., 2010, permission granted) 
 
6.4.2 Study characteristics 
As suggested by Parulekar and colleagues (1998), these 50 oral assessment instruments 
can be separated into two groups depending on how they grade the oral cavity 
(Parulekar et al., 1998). Twenty-one of these instruments identified in the search were 
“simple scales” which assign symptoms a score collectively using a scale of four or five 
grades. The remaining 29 scales were “multi-component” scales, which assign a 
numerical grade to individual oral symptoms (Table 11). Information about inter-rater 
or intra-rater reliability and validity testing were provided by 12 instruments, 11 of these 
were multi-component instruments (Dibble, 1996, Donnelly, 1992, Eilers et al., 1988, 
Kushner et al., 2008, McGuire et al., 2002, Olson et al., 2004, Potting et al., 2006, Sonis 
et al., 1999, Spijkervet et al., 1989a, Stiff et al., 2006, Tardieu et al., 1996), and one of 
which was a simple scale (Anonymous, 1991).  
 
Seven of these instruments were validated in patients undergoing autologous or 
allogeneic transplantation (Donnelly, 1992, Eilers et al., 1988, Kushner et al., 2008, 
McGuire et al., 2002, Potting et al., 2006, Stiff et al., 2006, Tardieu et al., 1996). Two 
were validated in radiotherapy patients (Dibble, 1996, Spijkervet et al., 1989a). One in a 
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mixed group of patients receiving radiotherapy or chemoradiotherapy (Olson et al., 
2004). One instrument was validated in chemotherapy patients (Anonymous, 1991), and 
one in both chemotherapy and radiotherapy patients (Sonis et al., 1999). The number of 
patients assessed during validation ranged from 10 (Dibble, 1996) to 212 (Stiff et al., 
2006).  
 
Ten of the instruments shown in Table 11 and Table 12 were modifications of previous 
instruments (Aquino et al., 2005, Bolwell et al., 2002, Dudjak, 1987, Ferretti et al., 
1988, Hickey et al., 1982, Kushner et al., 2008, McGuire et al., 2002, Olson et al., 2004, 
Trotti et al., 2000), however, only two of these instruments were re-validated after 
modifications were made (McGuire et al., 2002, Olson et al., 2004).  
 
Of the 21 simple instruments presented in Table 11, six graded mucositis on a scale 
from zero to three (Anonymous, 1991, Carl and Emrich, 1991, Ferretti et al., 1988, 
Hickey et al., 1982, Lindquist et al., 1978, Tanner et al., 1981), 12 used a grading scale 
numbered between zero and four (Byfield et al., 1985, Chapko et al., 1991, Cox, 1995, 
Damon et al., 2004, Pitten et al., 2003, Seto et al., 1985, Turhal et al., 2000, Trotti et al., 
2000, Van der Schueren et al., 1983, World Health Organization (WHO), 1979), and the 
remaining three instruments employed a zero to five grading scale (Cancer Therapy 
Evaluation Program, 2003, Cancer Therapy Evaluation Program, 2009). In all three of 
these scales, grade five is simply stated as “death”. Five simple scales graded mucositis 
based on size of confluence or ulceration (Carl and Emrich, 1991, Damon et al., 2004, 
Ferretti et al., 1988, Trotti et al., 2000, Van der Schueren et al., 1983). However, two of 
these instruments only used size as a descriptor in the later grades of the instrument and 
employed other descriptors in the earlier grades (Damon et al., 2004, Van der Schueren 
et al., 1983).   
 
The 29 multi-component instruments shown in Table 12 varied considerably in their 
size and complexity. The instrument with the greatest number of categories was the Oral 
Mucositis Index (OMI), which was comprised of 34 items. This instrument was later 
modified, and the number of items reduced to 20, by McGuire and colleagues (2002). 
However, this 20-item OMI still had the second greatest number of categories of all the 
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instruments included in Table 12. This instrument was the only one to include a set of 
complex grading instructions for use when determining a grade. The multi-component 
instrument with the least number of categories was Lievens’ oral assessment instrument, 
which was comprised of two categories: dysphagia and mucositis (Lievens et al., 1998).  
 
Twenty-one of the multi-component instruments shown in Table 12 employed a 
combined final score. The remaining eight instruments either provided a score for each 
category or the authors gave insufficient information about whether, or not, a total score 
was generated when using the scale. Three of the instruments in Table 12 required 
calculations which were more complex than simple addition or subtraction to determine 
a final score: Spijkervet and colleagues (1989a), present an instrument for mucositis 
assessment that grades eight sites in the oral cavity for the presence of mucositis 
(erythema and ulceration) and the size of these areas. To determine a mucositis grade 
using this instrument, the degree of mucositis at each of the eight sites was first 
calculated, and then the scores of the eight sites summed. The final score was calculated 
by dividing the sum of the sites with mucositis by the number of sites assessed to 
produce a mean score for the oral cavity (Spijkervet et al., 1989a). The authors provided 
a summary of this calculation in an equation. The OMAS instrument (Sonis et al., 
1999), assessed nine sites of the oral cavity for presence of erythema using a 3-point 
scale, and size of ulceration, using a four point scale. A total score was generated for 
this instrument by summing the scores for ulceration and erythema for each site, and 
then by determining an overall mean score for all nine sites. Bolwell and colleagues 
(2002) presented a modified OMAS scale which assessed eight sites of the oral cavity. 
Ulceration was scored either zero (not present) or one (present) and erythema was 
scored between zero and one (0=none, 0.5=mild to moderate, 1=severe). The total score 
for this instrument was calculated by summing the ulceration and erythema scores and 
dividing these scores by the number of evaluable sites, before summing the average 
ulceration and erythema scores.  
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Figure 32: Frequency of Items Used to Score the Oral Cavity  
 
Figure 32 shows the frequency of the various items used to grade mucositis in the 
instruments shown in Table 11 and Table 12. There seems to be little consistency in 
which items are commonly included in assessment tools. Not surprisingly, the mucous 
membrane was the most frequently included in assessment instruments, with 44 
instruments (88.8%) including this category. Pain was the second most frequent item, 
used by 29 instruments (58%). Only 24 (48%) of the assessment instruments identified 
measured a patient’s ability to swallow or level of dysphagia, and the tongue was only 
scored by 22 instruments (44%). Teeth were included in 9 instruments (18%) and the 
ability of the patient to perform self-care in only two (4%).  
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Table 11: Simple Scales 
Name Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Other information 
Byfield et al, 198511 N/A 
“Minimal dysphagia, thinning 
but no overt break in mucosal 
integrity” 
“Significant dysphasia, 
semi soft foods only, focal 
mucosal vesicles or 
denuded patches” 
“ Fluids only tolerated by 
mouth, obvious large 
confluent patches of 
mucosal denudation” 
“Parenteral fluids only, 
severe confluent mucosal 
denudation with bleeding” 
Part of a much greater 
tool, which also 
includes CNS, lower 
GI, upper GI, and 
haematological 
scoring systems.” 
Carl et al, 199112 
“No clinically noticeable 
changes” 
(Mild) 
 
“Colour changes (erythema), 
no surface ulceration, mild 
discomfort” 
(Moderate) 
 
“Surface ulcerations in 
islands <1 cm, moderate 
discomfort, able to eat” 
(Severe) 
“Confluent areas of 
ulceration, tongue, palate, 
floor of the mouth, buccal 
mucosa; able to eat with 
great difficulty only” 
N/A  
CALGB (Turhal et al, 
2000)13 “None” 
“Painless ulcers, erythema 
and mild soreness” 
“Painful erythema, edema, 
or ulcers, but can eat” 
“Painful erythema, edema, 
or ulcers, and cannot eat” 
“Requires parenteral or 
enteral support” - 
Chapko et al, 198914 “None” “Mild” “Moderate” “Severe” “Life threatening” - 
CTC AE v2 (Radiation)15, 
Trotti et al, 2000 “None” “Erythema of the mucosa” 
“Patchy 
pseudomembranous 
reaction (patches generally 
<1.5 cm in diameter and 
non-contiguous)” 
“Confluent 
pseudomembranous 
reaction (contiguous 
patches generally >1.5cm 
in diameter)” 
“Necrosis or deep 
ulceration; may include 
bleeding not induced by 
minor trauma or abrasion” 
Update of Cox et al 
1995. 
 
  
                                                     
11
 Byfield et al, 1985, p792 
12
 Carl et al, 1999, p366 
13
 Turhal et al, 2000, p56 
14
 Chapko et al, 1989, p181 
15
 Trotti et al, 2000, p30 
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Name Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Other information 
CTC AE v216 
(Chemotherapy), Trotti et 
al, 2000 
“None” 
“Painless ulcers, erythema, or 
mild soreness in the absence 
of lesions” 
“Painful erythema, edema 
or ulcers but can swallow” 
“Painful erythema, edema, 
or ulcers preventing 
swallowing or requiring 
hydration or parenteral (or 
enteral) nutritional 
support” 
“Severe ulceration 
requiring prophylactic 
intubation or resulting in 
documented aspiration 
pneumonia”. 
Update of Cox et al 
1995. 
CTC AE 
version 3 
CTC AE v.317 
(clinical exam) 
“None” “Erythema of the mucosa” “Patchy ulcerations or Pseudomembranes” 
“Confluent ulcerations or 
pseudomembranes; 
bleeding with minor 
trauma” 
“Tissue necrosis 
significant spontaneous 
bleeding; life-threatening 
consequences” 
Grade 5= “death” 
CTC AE v.318 
(functional / 
symptomatic) 
“None” “Minimal symptoms, 
normal diet” 
“Upper aerodigestive tract 
sites: Symptomatic but 
can eat and swallow 
modified diet.” 
“Upper aerodigestive tract 
sites: Symptomatic and 
unable to adequately 
aliment or hydrate orally.” 
“Symptoms associated 
with life-threatening 
consequences” 
Grade 5= “death” 
CTC AE v.419 “None” 
“Asymptomatic or mild 
symptoms; intervention not 
indicated” 
“Moderate pain; not 
interfering 
with oral intake; modified 
diet 
indicated” 
“Severe pain; interfering 
with 
oral intake” 
“Life-threatening 
consequences; urgent 
intervention indicated” 
Grade 5=  “death” 
Damon et al, 200420 “None” “Erythema” “Pain requiring continuous 
narcotics or preventing 
eating” 
“Ulceration>25% oral 
surface” 
“Airway compromise 
requiring intubation”  
  
                                                     
16
 Trotti et al, 2000, p31 
17
 CTC AE, 2003, p24 
18
 CTC AE, 2003, p24 
19
 CTC AE, 2009, p46 
20
 Damon et al, 2004, p470 
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Name Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Other information 
Ferretti et al, 198821 “None” 
“Mild: Mucosal redness with 
one or two small ulcerations 
(<1 cm) and minimal 
discomfort” 
“Moderate: Mucosal 
ulcerations with one or 
two large ulcerations 
(>1cm), substantial 
discomfort but patient able 
to eat” 
“Severe: Multiple mucosal 
ulcerations with severe 
discomfort; patient unable 
to eat” 
N/A 
Assessment tool 
modified from 
Lindquist (1978) and 
Tanner (1981). 
Hickey et al, 198222 “No Stomatitis” 
“Whiteish gingival area 
observed, or patient mentions 
slight burning sensation or 
pain in the oral cavity” 
“Moderate erythema and 
ulcerations or white 
patches present; patients 
complains of pain, but can 
eat, drink or swallow” 
“Severe erythema and 
ulceration or white patches 
present; patient complains 
of severe pain and cannot 
eat, drink or swallow” 
N/A 
Lindquist/ Hickey 
scoring tools used 
interchangeably in 
many studies. 
Modification of 
Lindquist (1978) to 
include swallow. 
Lindquist et al, 197823 “No stomatitis” 
“Erythema observable and / 
or patient mentions slight 
burning sensation in oral 
cavity” 
“Erythema and ulceration 
or white patches present 
upon clinical examination. 
Patient complains of intra-
oral pain but is able to eat” 
“Erythema and ulceration 
or white patches present. 
Patient complains of 
severe intra-oral pain and 
is unable to eat” 
N/A 
Lindquist/ Hickey 
scoring tools used 
interchangeably in 
many studies. 
NIH CTC, 199324 “None” “Painless ulcers, erythema or 
mild soreness” 
“Painful erythema, 
oedema, or ulcers, can eat” 
“Painful erythema, 
oedema, or ulcers, cannot 
eat” 
“Require parenteral or 
enteral support”  
Pitten et al 200325 “No signs / symptoms” 
“Reddening, incipient 
erosions, minimal 
discomfort” 
“Reddening, erosions, 
small ulcerations, 
substantial discomfort: 
patient unable to eat” 
“Erosions, ulcerations, 
severe discomfort: Patient 
can drink only” 
“Severe ulcerations: 
patient needs parenteral 
nutrition” 
 
  
                                                     
21
 Ferretti et al, 1988, p485 
22
 Hickey et al, 1982, p190 
23
 Lindquist et al, 1978, p 313 
24
 NIH CTC, 1993 
25
 Pitten et al, 2003, p285 
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Name Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Other information 
RTOG/ EORTC, 
(Acute radiation morbidity) 
Cox et al, 199526 
“No change over 
baseline” 
“Injection/may experience 
mild pain not requiring 
analgesic” 
“Patchy mucositis that 
may produce an 
inflammatory 
serosanguinous discharge/ 
may experience moderate 
pain requiring analgesia” 
“Confluent fibrinous 
mucositis/ may include 
severe pain requiring 
narcotic” 
“Ulceration, haemorrhage 
or necrosis”  
Seto et al, 198527 - “Localized erythema only, 
with no pain” 
“Generalized erythema 
without pain or localized 
erythema or ulcers with 
mild pain” 
“Multiple ulcers or 
generalized erythema with 
moderate pain” 
“Generalized erythema or 
ulcers with moderate to 
severe pain” 
 
Tanner et al, 198128 “None” “Mucosal redness with 
minimal discomfort” 
“Mucosal redness with 
some mucosal ulceration 
and substantial 
discomfort” 
“Mucosal redness, 
extensive areas of 
ulceration, much 
discomfort and dysphasia, 
necessitating delay of 
radiotherapy / sometimes 
of chemotherapy” 
N/A  
Van der Schueren et al, 
198329 “No changes” “Slight erythema” “Pronounced erythema” “Spotted mucositis” 
“Confluent mucositis 
(patches larger than 0.5cm 
in diameter).” 
 
  
                                                     
26
 Cox et al, 1995, p1344 
27
 Seto et al, 1985, p494 
28
 Tanner et al, 1981, p768 
29
 Van der Schueren et al, 1983, p200 
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Name Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Other information 
WCCNR, Anon 199130 
“The mouth appears 
healthy. The colour is 
normal pink. There are no 
lesions. There is no 
bleeding. The mucosa is 
moist. There is no edema 
or infection present. 
There are no oral 
limitations to eating or 
drinking. The patient 
experiences no oral 
discomfort.” 
“The mouth has evidence of 
slightly increased redness in 
one or more areas. There are 
1 to 4 lesions somewhere in 
the oral cavity. The mucosa 
may appear to be thinning in 
several areas. There is no 
bleeding or infection present. 
The mucosa is moist. There is 
mild edema in one to several 
areas. The patient tends to 
avoid harsh, hot, or spicy 
foods because the mouth is 
sensitive to such irritation. 
The patient experiences mild 
discomfort that may be 
described as burning 
sensation.” 
“There is moderate 
increase in redness 
throughout most of the 
mucosal surfaces. There 
are more than 4 lesions 
somewhere in oral cavity, 
but they still discretely 
separate and not 
coalescing with adjacent 
lesions. The mucosa tends 
to bleed upon probing or 
manipulating. The mucosa 
appears slightly drier than 
normal. The saliva may be 
slightly thicker than 
normal. Most areas are 
moderately edematous. 
There may be evidence 
suggesting that infections 
present in the mouth 
manifested by white or 
yellow patches. The 
patient is unable to eat 
except for very bland soft 
foods, but is able to drink 
liquids that are not hot, 
spicy or acidic. The patient 
experiences moderate 
continual pain and requires 
intermittent analgesics.” 
“The oral mucosa is 
severely red throughout all 
of the oral cavity. There 
are multiple confluent 
ulcers which may be to the 
point of total denudation 
of the oral cavity. Bleeding 
is occurring spontaneously 
without any particular 
stimulation. There is 
marked xerostomia. 
Edema is severe 
throughout the entire 
mouth. There are white, 
yellow, or purulent patches 
present in the mouth 
suggesting infection. The 
patient is unable to eat or 
drink or even to swallow 
own saliva. With 
persuasion, the patient 
may be able to swallow 
oral medications. The 
patient has severe constant 
pain constant pain 
requiring systemic 
analgesia.” 
-  
WHO31 
Anon, 1979 “None” “Soreness and erythema” 
“Ulcers, erythema. Patient 
can swallow solid diet” 
“Ulcers, extensive 
erythema. Patient cannot 
swallow solid diet” 
“Mucositis to the extent 
that alimentation is not 
possible" 
 
 
                                                     
30
 Anon, 1991, p10-11 
31
 WHO, 1979 
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Table 12: Multi-Component Instruments 
Author Components included Additional information 
Aquino et al, 
2005 
8 items scored from 0 to 2: lips, tongue, hard 
and soft palate, buccal and labial mucosa, 
gingival, teeth, patient assessment of pain, 
saliva production. 
Compound score 
Modified Walsh Instrument 
Beck et al, 1979  16 items scored from 1 to 4: lips (texture, 
colour, moisture), tongue (texture, colour, 
moisture), mucous membranes (colour, 
moisture), gingivae (colour, moisture), teeth 
(shine, debris, dentures) saliva, voice, ability 
to swallow. Included patient perceptions of 
oral cavity.  
Compound score 
Bentzen et al, 
2001 
4 items scored: mucositis distribution, pain on 
swallowing and requirement for analgesics all 
scored from 0 to 3. Dysphagia scored from 0 
to 5.  
Grade 1 not used when 
scoring mucositis 
distribution. Skin grading 
also included in instrument. 
Bolwell et al, 
2002 
8 sites scored 0 to 1 for ulceration and 
erythema: labial mucosa (maxillary, 
mandibular), buccal mucosa (right, left), 
lateral and ventral tongue (right, left), floor of 
the mouth and lingual frenum, soft palate and 
fauces 
Compound score generated 
from sum of average 
ulceration score and 
average erythema score. 
Adaptation of OMAS 
(Sonis et al, 1999) 
Bruya et al, 
1975 
13 items scored from 1 to 3: 5 items assess 
physical status (level of consciousness, 
breathing, nutritional habits, ability to chew 
and ability to self-care) 12 items assess oral 
cavity: lips (texture, colour, moisture) tongue 
(texture, colour, moisture), mucous membrane, 
gingival tissue, saliva, teeth, taste, voice 
 
Dibble et al, 
1996 
(MacDibbs) 
4 items scored from 0 to 3: pain, dryness, 
eating, talking, taste, saliva production, 
swallow, number of ulcers, presence of 
vesicles, red areas or white patches, size of 
largest ulcer in mm.  
Also included potassium 
hydroxide smear and herpes 
simplex culture. 
Compound score. 
Donnelly et al, 
1992 
5 items scored from 0 to 3: lesions, erythema, 
oral oedema, pain, dysphagia. 
Compound score 
Dudjak et al, 
1987 
8 items scored from 1 to 4: lips, mucous 
membranes, palate and oropharynx, gingivae, 
saliva, swallow, diet, taste and ability to self-
care.  
Adaption of Beck  
(1979) 
Compound score 
Eilers et al, 
1988 
(OAG) 
8 items scored from 1 to 3: voice, swallow, 
lips, tongue, saliva, mucous membrane, 
gingivae and teeth. 
Compound score 
Harris et al, 
2006 
Pain assessed in 5 locations from 0 to 10. 
Ability to swallow, eat and talk graded “able”, 
“with difficulty” or unable. Visual assessment 
(colour, presence of ulcers, white or red areas 
and dryness).  
Pain tool 
Stomach, gut and anus also 
included in tool. 
Kolbinson et al, 
1988 
8 sites scored: lips, mucosa (labial, buccal), 
palate (hard, soft), tongue (dorsal, ventral and 
floor of the mouth), gingivae. Atrophy, 
erythema, vascularity, ulceration, bleeding, 
and salivary viscosity assessed for each site 
and graded from 0 to 3. 
Compound score 
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Author Components included Additional information 
Kushner et al, 
2008 
9 sites scored using 10mm VAS for erythema 
and ulceration: upper/lower lip, right/ left 
inner cheek, floor of mouth, right/ left ventral 
and lateral tongue, soft palate and fauces, and 
hard palate. VAS also used for total erythema 
and total ulceration. 
Modified OMAS score. 
Compound score 
Kushner et al, 
2008 
(PROMS) 
10 Visual analogue scales (VAS). Patients 
asked to indicate level of mouth pain, 
difficulty speaking  and level of speech 
restriction due to mouth sores, difficulty eating 
hard and soft foods, restriction in eating due to  
mouth sores, difficulty and restriction in 
drinking due to mouth sores, difficulty 
swallowing due to mouth sores and change in 
taste.  
Patient generated 
instrument 
Lievens et al, 
1998 
2 items scored: mucositis (size of spotting) 
and dysphagia. Mucositis graded 0-6, 
dysphagia 0-4. 
 
Maciejewski et 
al, 1996 
7 items scored: mucositis type, ulceration, 
dysphagia all graded from 0 to 4. Mucositis 
area, oedema, bleeding and odynophagia 
graded from 0 to 3.  
Compound score 
McGuire et al, 
1993 
9 sites scored: Mucosa (labial, right buccal, 
left buccal), tongue, soft palate, floor of the 
mouth, hard palate, gingivae and lips. Severity 
of erythema scored from 0-3, extent of 
ulceration/ erythema scored from 0-4. Pain 
also assessed. 
 
McGuire et al, 
2002 (OMI) 
20 items scored 1-3: mucosa (labial, buccal), 
tongue (dorsal, lateral and ventral surfaces), 
floor of mouth and soft palate graded for 
atrophy, erythema, edema and size of 
ulceration and pseudomembrane (cm). 
Compound score 
Authors provide a complex 
list of grading rules. 
Modified OMI score. 
Öhrn et al, 2001 10 items assessed using VAS: pain, mouth 
dryness, ability to talk, salivary viscosity, 
dysphagia, ability to perform oral hygiene, 
alterations in taste, condition of the lips and 
gingivae and whether the patient feels that 
they have a clean mouth. 
Patient reported measures. 
Olson et al, 
2004 
3 items scored from 0 to 3: lesions, erythema 
and bleeding 
Compound score 
Modified WCCNR grading 
scale. Instrument grades 
signs not areas. 
Passos et al, 
1966 
8 items scored from 1 to 3: saliva, tongue, 
palates, membranes and gums, teeth, odour, 
lips and nares 
Compound score 
Potting et al, 
2006 
6 items scored from 0 to 3: erythema, oedema, 
lesions, pain, dryness, viscosity. Lips, uvula 
and tonsillar crypts, and oral mucosa of the 
gingival palate examined for the 6 items 
scored. 
Instrument grades signs not 
areas. 
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Author Components included Additional information 
Raether et al, 
1989 
Percentage of ulceration accessed for 7 sites: 
mucosa (buccal and labial, alveolar mucosa) 
gingival, hard palate, soft palate and 
oropharynx, floor of the mouth and ventral 
surface of tongue, and dorsal surface of the 
tongue. 
Compound score 
Schubert et al, 
1992 (OMI) 
34 items scored from 0 to 3: atrophy and 
pseudomembrane assessed at 11 sites each: 
lips (upper lower), labial mucosa (upper and 
lower), buccal mucosa (right and left) tongue 
(dorsal, lateral and ventral tongue), soft palate 
and floor of the mouth. Erythema not assessed 
in soft palate. Edema assessed for buccal 
mucosa (right and left) 
Compound  score 
Sonis et al, 
1999 (OMAS) 
9 sites graded from 0 to 3 for ulceration/ 
pseudomembrane and 0 to 2 for erythema: lips 
(upper and lower), cheeks (right and left) 
ventral and lateral tongue (right and left), floor 
of the mouth, soft palate and fauces and hard 
palate. 
Compound score 
Spijkervet, 
1989 
8 sites graded: buccal mucosa (left and right), 
hard and soft palate, dorsum and border of the 
tongue (left and right), floor of the mouth. 
Each site graded from 0 to 4(no mucositis to 
ulceration), length of erythema/ ulceration also 
graded from 1 to 4. 
Compound score. Complex 
calculations required. 
Stiff et al, 2006 
(OMDQ) 
6 questions incorporating 8 items : diarrhoea, 
mouth and throat soreness, swallow, drinking, 
eating, talking, sleeping, overall health 
Patient reported instrument 
Tardieu et al, 
1996 (DIM) 
8 categories incorporating 16 items: lips, 
gingival, mucosa, tongue all scored from 0 to 
3 for aspect, colour and dryness (12 items), 
swallow, saliva, talking and pain, scored 0-3 
(4 items).  
Compound score 
Van Drimmelen 
and Rollins, 
1969 
7 categories incorporating 8 items scored from 
1 to 3: palates (moisture, debris), tongue 
(coating, moisture),  membranes (moisture, 
debris), gingivae, teeth, lips (moisture, general 
condition) odour 
Compound score 
Walsh et al, 
1990 
10 items: voice, swallow, lips, tongue, buccal 
mucosa, hard and soft, palate, gingival, saliva 
production and teeth all scored, from 0 to 2. 
Patient self assessment scored 0 to 3.  
Compound score 
Weisdorf et al, 
1989 
7 sites scored 0 to 3: tongue, gingivae, hard 
palate, mucosa (buccal, alveolar), floor of the 
mouth, soft palate. Percentage area of mucosal 
ulceration also recorded. 
Compound score 
DIM=Daily index of mucositis, OAG=Oral assessment guide, OMAS=Oral mucositis assessment scale, 
OMDQ=Oral mucositis daily questionnaire, OMI=Oral mucositis index, PROMS=Patient reported oral 
mucositis scale,  
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6.5 Discussion 
This review identified 50 instruments previously used for the assessment of oral 
mucositis in adults. The attributes and problems with these instruments identified will 
now be discussed.  
 
6.5.1 Simple scales 
Simple scales are generally quick and easy to use making them perfect to use in busy 
outpatients’ clinics. However, one of the tools shown in Table 11 was simplistic to the 
point of being facile. The Chapko and colleagues (1991), instrument graded mucositis 
on a scale from zero to four: “mild”, “moderate”, “severe’ and “life threatening”, with 
no additional descriptors. Exactly what constitutes “life-threatening” mucositis is not 
clear, and no information was provided about the actual component of mucositis being 
scored. The severity of pain and nausea were also assessed using the same five point 
scale, which may explain the terminology used. The use of such a tool in either clinical 
practice or a clinical trial would necessitate extensive training of personnel to define 
such differences, and even if this was achieved, it is likely that distinctions between 
moderate and severe would depend on assessor experience of severe mucositis.  
 
Simple scales have been criticised because the criteria used in these instruments may be 
open to interpretation (Potting et al., 2006). Twelve of the instruments presented in 
Table 11 assessed the oral cavity using a zero to four scale. The researchers developing 
the Western Consortium for Cancer Nursing (WCCNR) instrument hypothesised that 
distinction between grades two and three is difficult in simple scales, and leads to poor 
inter-observer reliability (Anonymous, 1991). However, the authors then undermined 
their argument by putting forward a scale with only three grades, which, while possibly 
addressing the inter-observer reliability issue, had the potential to hide the true extent of 
the problem by classifying both moderate-to-severe and severe cases of mucositis as a 
grade 3, therefore removing the potential to define between them. Such a distinction 
may be clinically relevant.  
  
The World Health Organisation (WHO) and Radiation Therapy Oncology Group 
(RTOG) instruments have frequently been used to assess mucositis in clinical trials 
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(Quinn et al., 2008, Sonis et al., 2004, Worthington et al., 2007). Both instruments 
assessed pain, erythema and ulceration using a scale of zero to four. However, the WHO 
also included the patient’s ability to swallow solid food and ability to drink liquids 
(World Health Organization (WHO), 1979). Neither of these instruments have been 
validated. However, Quinn noted that the WHO instrument is based on expert opinion 
and has been used for nearly 30 years (Quinn et al., 2008).  
 
6.5.2 Multi-component instruments 
Multi-component scales provide an abundance of information about changes occurring 
in the oral cavity. They are therefore an excellent resource for use in clinical trials. 
However, while these instruments provide useful information about the condition of the 
oral cavity, many of these instruments requires extensive and sustained examination of 
the oral cavity, and it is likely that the patient will have to keep their mouth open for an 
extensive period of time during assessment, or alternatively, repeatedly open and close 
their mouth, which could be distressing for a patient who was in a great deal of pain, 
and completely impractical in a patient suffering from any of the symptoms clustered 
with OM, such as nausea or vomiting (McGuire et al., 1998).  
 
In twenty-one of the multi-component instruments shown in Table 12, a total score was 
generated by combining the sub-scores in each category. This score can be achieved 
through a number of means and this therefore may result in the clinical meaning of the 
score becoming altered or in an important change being missed because it is masked by 
other changes (Olson et al., 2004). An improvement in the appearance of the mucous 
membrane in a patient screened repeatedly using the Oral Assessment Guide (OAG), for 
example, may be masked by an increase in the level of plaque on the patient’s teeth, 
leading to the decrease in mucous membrane score being hidden by an increase in the 
score of the teeth category, and therefore no overall change in score. The OAG has 
additionally been criticised because this instrument graded categories that are not 
specific to mucositis. Therefore a patient with another condition, for example hepatic 
lesions, had the potential to score highly on this tool without actually suffering from 
oral mucositis (Dibble, 1996). 
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Three multi-component assessments instruments identified in Table 12 require more 
complex mathematics than simple addition or subtraction to assign a grade, which 
precludes the use of these instruments in everyday clinical practice, and may increase 
both researcher burden and increase the risk of miscalculations in research. It is also 
difficult to imagine these instrument being routinely used in clinical trials, due to the 
amount of training that research staff would require before accurate data collection 
could be ensured. In addition, the use of Spijkervet and colleagues scale is made 
difficult by the amount of continual observation required to accurately measure the oral 
cavity, and the use of a 2cm gauge to assess the size of ulceration. This is likely to be 
uncomfortable and fatiguing for the patient, especially if a researcher had never 
previously used this instrument.  
 
In addition to the Spijkervet instrument, a number of other scales employed the use of 
measurement devices to assess the oral cavity. Five simple scales grade ulceration based 
on size (Carl and Emrich, 1991, Damon et al., 2004, Ferretti et al., 1988, Trotti et al., 
2000, Van der Schueren et al., 1983). A ruler or gauge would have to be used with these 
instruments. The MacDibbs instrument, a multi-variable scale, employed the use of a 
periodontal probe to measure depth of ulceration (Dibble, 1996). The authors did not 
give any information about whether the use of the instrument caused pain or discomfort 
to the patient, in fact, no literature at all was identified that detailed the suitability of the 
assessment process to the patient. The recent European group for Bone Marrow 
Transplant (EBMT) guidelines on the assessment of OM in adults stated that excessive 
touching of the injured mucosa could result in worsening of the damage, and therefore 
such examinations should be short and precise (Quinn et al., 2008). It is possible that 
the use of such a periodontal probe, especially by a researcher new to its use, could 
result in greater irritation of the oral cavity and patient distress. For this reason, the 
EMBT guidelines recommended that the Oral Mucositis Index (OMI) and MacDibbs 
instruments (Dibble, 1996, McGuire et al., 2002, Schubert et al., 1992) should only be 
used after all other alternatives have been considered and discounted (Quinn et al., 
2008).  
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6.5.3 Objective versus subjective and functional items 
In addition to separating instruments into simple and multi-component scales (Parulekar 
et al., 1998), they can also be separated into instruments containing objective items, 
those containing subjective or functional items, or a combination of two or more 
(Tomlinson, 2008). The inclusion of subjective items in oral assessment instruments is a 
contentious issue. Sonis and others (2004), argued that mucositis damage should be 
scored objectively and separately from assessment of functional (ability to eat or drink) 
and subjective (pain) variables, as functional items, such as the ability to eat, may not be 
related to mucositis. The authors pointed out that a number of instruments included the 
use of parenteral nutrition as an indicator of severe mucositis (National Institute of 
Health, 1993, Turhal et al., 2000). Some hospitals have policies of automatically placing 
transplant patients on parenteral nutrition, or alternatively prescribing such support due 
to intestinal toxicity, when the patient is still able to eat and drink. In such instances, the 
use of these instruments would result in overestimation of mucositis severity (Sonis et 
al., 2004). However, two of the instruments shown in Table 11 use the requirement for 
parenteral nutrition in addition to other criteria such as ‘severe ulceration’(Byfield et al., 
1985, Pitten et al., 2003). The use of such instruments would probably not result in 
over-estimation of severity as other criteria for assessment exist. The choice of 
instrument for mucositis assessment should take into account hospital policy, therefore 
reducing the possibility that other factors could result in overestimation of mucositis 
severity. In addition, training of staff to recognise if the use of nutritional support, or the 
patient’s reluctance to eat or drink, was due to mucositis, or some other factor, and 
grade accordingly would also help in this area.  
 
The authors of the EMBT guidelines (Quinn et al., 2008) disagreed with the opinion of 
Sonis and Colleagues (2004), stating that assessment should be conducted using an 
instrument that can measure the physical, functional and subjective changes of the oral 
cavity, and that if such a tool is not available, a combination of instruments should be 
employed (Quinn, 2008). The authors did however note that assessment of functional 
symptoms should be conducted prior to any assessment of the oral cavity (Quinn et al., 
2008). Tardieu and colleagues (1996), presented an instrument that allowed the 
examiner to assess the oral cavity using a combination of subjective and objective or 
purely objective criteria (Tardieu et al., 1996). The Tardieu and colleagues daily index 
of mucositis (DIM) instrument included 12 objective items and four subjective 
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categories: pain, swallow, dryness of the oral cavity and talking. This instrument was 
designed so that subjective categories could be removed if warranted (Tardieu et al., 
1996).  
 
6.5.4 Pain 
The inclusion of pain assessment in 29 of the instruments shown in Table 11 and Table 
12 is notable, as pain measurement in oral assessment instruments is controversial 
(Tomlinson et al., 2008). Jaroneski (2006), argued that as pain is a distressing 
component of mucositis reported by patients, the use of a pain scale is essential in 
assessment (Jaroneski, 2006). Conversely, it has also been argued that the use of 
analgesia may result in the underscoring of this pain (Sonis et al., 2001, Tomlinson et 
al., 2008). Pain assessments included in the instruments identified in this review can be 
separated into two groups: those which grade pain as mild, to severe, and those which 
assign a grade to pain based on the requirement for different grades of analgesics. The 
DIM instrument developed by Tardieu and colleagues (1996), does the latter, grading 
pain assessment on a scale from zero to four, and incorporating the requirements for 
minor analgesics (such as paracetemol) and major analgesics (morphine) (Tardieu et al., 
1996). The under-reporting of pain due to the use of analgesia would not be a concern 
with the use of this instrument, as it employed the use of analgesia as a proxy for pain 
when assessing this category.   
 
The EBMT guidelines stated that patient reports of pain should be included in oral 
assessments, and recommended the use of a visual analogue scale (VAS) to record such 
information (Quinn et al., 2008). Two recently developed instruments reported entirely 
patient reported symptoms, including pain, using VAS. Both these instruments were 
developed for patients undergoing bone marrow transplantation (Kushner et al., 2008, 
Stiff et al., 2006). Stiff and colleagues (2006), produced the oral mucositis daily 
questionnaire (OMDQ) for patients undergoing autologous transplantation (Stiff et al., 
2006). This instrument was comprised of six questions, and asked patients to score their 
overall health, the amount of mouth and throat soreness that they have experienced in 
the previous 24 hours, how much this soreness had affected their ability to perform 
activities (swallowing, talking, eating, drinking, talking), how they would rate this 
soreness, how much diarrhoea they had experienced during the same timeframe, and 
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how they would rate this diarrhoea (Stiff et al., 2006). The Kushner instrument was 
developed for use in allogeneic transplantation. This instrument is slightly longer than 
the Stiff and colleagues instrument, and asked the patients to complete 12 VAS about 
their level of mouth pain, whether they had any difficulty speaking due to ulceration, 
difficulty eating hard and soft food, their level of restriction in eating, their difficulty 
drinking due to ulceration, any level of restriction in drinking, if they had difficulty 
swallowing and any change in taste (Kushner et al., 2008). Both these instruments have 
been validated by the authors at the point of development.  
 
6.5.5 Modifications of previous instruments 
Ten of the instruments shown in Table 11 and Table 12 are modifications or updates of 
previous instruments. The recently updated National Cancer Institute instrument (NCI 
CTC version 4) assessed mucositis using patient reports of pain and the patient’s ability 
to eat and drink to assign a grade. Pain was defined as moderate if it did not interfere 
with oral intake, and severe if it did (Cancer Therapy Evaluation Program, 2009). 
Previous versions of this scale also included the assessment of ulceration and erythema 
and it is not clear why the authors felt that the omission of these items was necessary.  
The removal of such items has resulted in an instrument that could be used to grade 
mucositis without requiring the patient to open their mouth. In addition, it could be 
argued that the removal of any mention of erythema or ulceration has resulted in an 
instrument that could be used to measure a number of different oral conditions, and not 
specifically mucositis. 
 
It is possible that the psychometric properties of an assessment instrument may be 
altered by the modification of its components (Eilers and Epstein, 2004). Many of the 
instruments shown in Table 11 and Table 12 have been modified without the authors 
providing a rationale for such changes and, with the exception of the revised WCCNR 
and 20-item OMI instruments (McGuire et al., 2002, Olson et al., 2004), without testing 
of the validity or reliability of the modified instrument. McGuire and colleagues 
modified the OMI that was previously developed by Schubert and colleagues (1992), 
changing the number of items assessed using this instrument from 34 to 20 items, before 
validating the new instrument. These modifications were made to make the instrument 
easier to use for non-dental health professionals (McGuire et al., 2002). However, this 
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instrument is still very complex. In addition to a set of instructions for using the 
instrument, the authors also provided a list of grading rules that incorporated a decision 
tree, which even in small text took up more than half a page of the journal article.  
 
6.5.6 Reliability and validity information 
The CCLG review of oral assessment instruments found that, of the 54 instruments 
identified in the search, only 15 of them had any form of validity or inter/ intra-rater 
reliability testing (Gibson, 2010). Of these 15 instruments, three were for use in children 
and therefore not suitable for use in a clinical trial with adults (Chen et al., 2004, Gibson 
et al., 2006, Sung et al., 2006). Table 13 shows the validity and reliability assessments 
for the 12 instruments designed for use in adults. These instruments were assessed using 
an adaptation of the diagnostic check-list (Scottish Intercollegiate Guidelines Network 
(SIGN), 2002). Eight instruments reported inter-rater reliability information: the amount 
of agreement between the scores generated by two researchers assessing the oral cavity 
independently; while only three instruments reported intra-rater reliability: the amount 
of agreement between repeated oral assessments performed by the same researcher 
(McGuire et al., 2002, Stiff et al., 2006, Tardieu et al., 1996). Five studies reported face 
validity, which was defined as whether the instrument accurately measured what it was 
designed to assess (Gibson et al., 2010). However, all instruments were felt by the 
authors to measure the condition of the oral cavity. Six instruments reported content 
validity, a measure of the comprehensiveness of the instrument, while criterion validity, 
the comparison of the instrument with another oral assessment instrument, was reported 
for six instruments. However, adequate blinding of researchers to the results of the other 
assessment scale was only employed by one study (Kushner et al., 2008). Lastly, 
construct validity, defined as the testing whether the instrument assesses what it was 
designed to, was reported by three studies (Kushner et al., 2008, McGuire et al., 2002, 
Spijkervet et al., 1989a). Only one study, the 20-item OMI (McGuire et al., 2002) 
reported content, face criterion and construct validity. However, it should be noted that 
the use of this instrument was specifically warned against, unless all alternatives had 
been discounted, by the EMBT guidelines, due the level of extensive oral examination 
required (Quinn et al., 2008) 
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Table 13: Assessment of studies, using adapted ‘Diagnostic studies’ checklist, reporting validity/reliability testing of oral assessment tools 
 
Dibble 
1996 
Donnelly  
1992 
Eilers 
1988 
Kushner 
2008 
McGuire 
 2002 
Olson 2004 Potting 
 2005 
Sonis 
1999 
Spijkervet 
1988 
Stiff  
2006 
Tardieu 
1996 
WCCNR 
1991 
PARTICIPANTS             
Was selection bias avoided? N Y Y N U U Y Y U Y Y U 
Did the study include an 
appropriate spectrum of 
participants?   
Y Y Y Y Y Y N Y Y Y Y Y 
RELIABILITY             
Inter-rater measured? Y N Y N Y Y Y Y Y N Y N 
Was the duration between 
assessments suitable so as not to 
have allowed a true change in 
oral health status?  
U - Y - Y Y Y Y Y - Y U 
Intra-rater measured? N N N N Y N N N N Y Y N 
Was the duration between 
assessments suitable so as not to 
have allowed a true change in 
oral health status?   
- - - - U - - - - Y U - 
VALIDITY             
Was face validity reported? N N N Y Y N Y Y Y N N N 
Do you feel the tool appears to 
measure the condition of the 
Y Y Y Y Y Y Y Y Y Y Y Y 
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Dibble 
1996 
Donnelly  
1992 
Eilers 
1988 
Kushner 
2008 
McGuire 
 2002 
Olson 2004 Potting 
 2005 
Sonis 
1999 
Spijkervet 
1988 
Stiff  
2006 
Tardieu 
1996 
WCCNR 
1991 
mouth? 
Was content validity reported?  Y N Y N Y N Y Y N N N Y 
Were appropriate experts 
consulted in the development of 
the tool and/or a rigorous 
evaluation of the literature? 
Y - Y - Y - Y Y - - - Y 
Does the tool address all the -
attributes of the -concept under 
investigation? 
Y - Y - Y - Y Y - - - Y 
Does the tool include any 
irrelevant items? 
N - N - N - N N - - - N 
Was criterion validity reported?  N N N Y Y Y* N N Y Y N Y 
Was the test compared with a 
valid reference standard? 
- - - Y Y Y* - - Y Y - Y 
Were the test and reference 
standards measured 
independently (blind) of each 
other? 
- - - Y U U - - U N - U 
Was the choice of patients for 
assessment by the reference 
standard independent of the 
test’s results? 
- - - Y U U - - Y - - U 
Was the reference standard 
measured before any 
- - - U U U - - U - - Y 
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Dibble 
1996 
Donnelly  
1992 
Eilers 
1988 
Kushner 
2008 
McGuire 
 2002 
Olson 2004 Potting 
 2005 
Sonis 
1999 
Spijkervet 
1988 
Stiff  
2006 
Tardieu 
1996 
WCCNR 
1991 
interventions were started with 
knowledge of test results? 
Was construct validity 
reported? 
N N N Y Y N N N Y N N N 
Do you feel there is good 
justification for the theoretical 
construct used? 
- - - Y Y - - U Y - - - 
N=No, Y=Yes, U=Unclear, *radiotherapy only,   Adapted from Gibson, 2010 (permission granted) 
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It is of concern that of the 50 assessment instruments identified in this review; only 10 
of these have been reported as validated. A number of the non-validated instruments 
shown in Table 11 and Table 12 are routinely used in both clinical research and 
practice, which is worrying considering that even basic testing, such as inter-rater 
reliability testing, has not been conducted using these instruments. It is also of concern 
that there does not appear to be a trend towards newer instruments being more likely to 
be validated than older instruments, as 7 of the validated instruments shown in Table 13 
are in excess of 10 years old. Although, it should be noted that both of the recently 
developed patient generated instruments (Kushner et al., 2008, Stiff et al., 2006) have 
both been validated.  
 
6.5.7 Choice of instruments for a RCT conducted in patients undergoing stem cell 
transplantation 
6.5.7.1 Simple scales 
It is acknowledged that the WHO instrument has not been validated, and therefore it 
could be argued that the choice of this instrument for use in the feasibility study is 
questionable. However, it was chosen because it was the most frequently employed 
instrument in the studies assessed for ROB, being used in 32 of the 133 included studies 
(24%). The use of this instrument in the feasibility study would permit comparison with 
the results of other studies and would allow the results of the feasibility study to be a 
potential inclusion in the Cochrane prevention review (Worthington et al., 2010). This is 
therefore a suitable choice of simple scale for use in the feasibility study.  
 
6.5.7.2 Multi-component instruments  
Seven of the multi-component instruments shown in Table 13 have been validated in 
patients undergoing BMT (Donnelly, 1992, Eilers et al., 1988, Kushner et al., 2008, 
McGuire et al., 2002, Potting et al., 2006, Stiff et al., 2006, Tardieu et al., 1996). It is 
therefore most appropriate to choose one of these seven instruments to use in the 
feasibility study. However, two of these instruments were identified after the ethics 
application for the trial was submitted (Kushner et al., 2008, Potting et al., 2006), 
leaving five instrument to choose from. The use of the 20-item OMI (McGuire et al., 
2002) is not recommended by the EMBT guidelines, and therefore is not an appropriate 
instrument for the feasibility study (Quinn et al., 2008). The OAG included a category 
that is not specifically related to mucositis (teeth) (Eilers et al., 1988), and since this 
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instrument could be argued to be an assessment instrument which grades the condition 
of the oral cavity, rather than mucositis, it is not an appropriate choice for the feasibility 
study. One the three remaining instruments, Donnelly (1992), has not been investigated 
for inter and intra-rater reliability, and is therefore not an appropriate choice for use in a 
clinical trial. The DIM (Tardieu et al., 1996) is an instrument which assesses both the 
objective and subjective components of mucositis and provides a large amount of 
information about the status of the oral cavity because it assigns a grade by site 
(mucosa, gingivae, lips, tongue), rather than just the overall. It is therefore a good 
choice for use in association with the WHO instrument, which provides more basic 
information. As patient reports of mucositis have been identified as under-reported in 
the literature elsewhere in this thesis, it seems appropriate to also employ the use of a 
patient generated screening instrument in the feasibility study. The OMDQ is a patient 
generated instrument which asks patients to grade level of mouth and throat soreness 
and the impact their oral symptoms have on their ability to eat, swallow, talk, drink and 
sleep (Stiff et al., 2006).  
 
6.5.8 Limitations of this review 
This review has a number of limitations. All oral assessment instruments identified in 
this review were in English. This was despite the systematic search being conducted 
without language restriction. It is extremely likely that a number of non-English oral 
assessment instruments exist, and this review should therefore be considered to only 
provide an overview of oral assessment instruments written in English. Another 
limitation of this review is that, with the exception of reliability and validity 
information, no attempt was made to assess the quality of the oral assessment 
instruments, due to a lack of consensus regarding how best to do this in these 
instruments.  
 
6.6 Conclusion 
This review has identified 50 multi-component instruments in the literature. However, 
only 12 of these instruments have been validated. Three instruments have been selected 
for use in a clinical trial: the Tardieu instrument (DIM) and the OMDQ instrument (Stiff 
et al., 2006, Tardieu et al., 1996). Both of these were developed for use in the transplant 
population. One non-validated simple scale was also identified for use: the WHO 
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instrument (World Health Organization (WHO), 1979). Copies of these three 
instruments can be found in Appendix 3. Further details of the use of these instruments 
are included in the protocol chapter, which is presented next. In addition, this protocol 
chapter will describe the use of one further assessment instrument: a nutritional 
assessment tool.  
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Chapter 7: Protocol Development and Feasibility Trial Methods 
This chapter details the process of protocol development and builds upon the results of 
previous chapters (Figure 2). The methods of the feasibility study are presented along 
with the rationale for any decisions that have been made.  
 
7.1. Study design, setting, aim, objectives and outcome measures 
7.1.1 Study design 
A prospective randomised double blind placebo control trial design was employed.  
 
7.1.1.1 Choice of a phase III design 
There are four different phases of clinical trials. Phase I trials are the first earliest phase 
of trial development (Braveman, 2010). In this phase, a new intervention is tested in 
order to identify the maximum tolerated dose which can be given of the drug before 
patients experience unacceptable adverse events (Friedman et al., 1998). A dose 
escalation design is commonly used in these trials, whereby a small dose is given to 
cohort of patients to determine toxicity, and if this is not identified then a larger dose is 
then administered. This continues until an unacceptable level of toxicity is reached and 
the study terminated. In phase II studies, the biologic effects and adverse events of the 
intervention are determined. Various designs for phase II trials have been put forward: 
Simon and colleagues (1985) suggested a design whereby patients are randomised 
between two or more treatment arms. The trial is then conducted and the response rate 
for each arm assessed and the treatment arm with the highest response rate are chosen 
for further study. This method of comparison has also been adapted to incorporate the 
use of historical control groups , which allow for arms of the study to be terminated in 
the event of adverse events (Rubinstein et al., 2005). Other designs which incorporate a 
randomised standard treatment arm or phase II/III design have also been suggested 
(Rubinstein et al., 2005).  
 
Phase III trials include a control arm and are conducted to determine the effectiveness of 
a particular intervention. These trials are conducted prospectively, and aim to obtain a 
definitive answer about whether the intervention is effective; close monitoring of side 
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effects are also a key theme of these studies (Braveman, 2010). Phase IV trials are 
commonly conducted after a drug has been marketed, and aim to study adverse events 
over a longer duration. These studies last several years and are often used to study the 
effects of an intervention in groups of patients not included in earlier studies 
(Braveman, 2010).  
 
It was decided to use a phase III design for this feasibility study for a number of 
reasons: As vitamin E was already used as a supplement, and trials have already 
identified the maximum tolerated dose and adverse events for this product, it was felt 
that the use of a phase I trial design was redundant. A phase II design was therefore 
thoroughly considered, but was eventually rejected, as neither a therapeutic dose nor a 
dose response relationship for vitamin E has been identified in the, quite extensive, 
literature on the prevention or treatment of chemotherapy side effects, including 
mucositis. The researcher was therefore concerned that a phase II study could be 
conducted which could fail to identify a therapeutic dose. A phase III design which 
employed a placebo control arm was therefore selected, in order to determine the 
effectiveness of the intervention. However, before such a study could be conducted it 
was decided to first conduct a feasibility study to explore the issues surrounding this 
design. 
 
7.1.2 Setting 
This was a single site study conducted on the haematology unit of a cancer hospital in 
the North West of England. The unit could accommodate 20 patients in private side 
rooms.  
 
7.1.3 Aim 
To assess the feasibility of conducting a trial to explore the effectiveness of d-α-
tocopherol in the prevention of oral mucositis compared to a soya bean oil placebo, over 
and above standard care, in a sample of patients undergoing conditioning for bone 
marrow transplantation. 
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7.1.4 Main objectives 
• To explore the recruitment, retention and adherence of patients in an RCT of 
patients undergoing bone marrow transplantation. 
• To explore the suitability of pharmacy release, methods of blinding and adverse 
event reporting in this setting 
• To explore the suitability of the tools used for outcome assessment (WHO, DIM, 
PG-SGA, OM-DQ). 
 
7.1.5 Secondary exploratory objectives 
• To compare the duration of ulcerative mucositis measured using the WHO 
instrument in the intervention group to those of the control group  
• To compare the highest mucositis grades measured using the WHO instrument 
• To compare the highest mean mucositis scores generated by the Daily Index of 
Mucositis (DIM) instrument 
• To compare the pattern of mucositis measured using the WHO instrument over 
time between the two groups 
• To compare the pattern of mucositis measured using the DIM instrument over 
time between the two groups 
• To compare patients' reports of oral pain between the groups 
• To compare mean nutritional screening scores between the groups 
 
7.1.6 Study outcome measures 
As this was a feasibility study, data collected in this study was used to assess the 
practicality of patient recruitment and the expected rate of recruitment for a larger study, 
the suitability of the randomisation, blinding and allocation concealment procedures, 
and the number of adverse events and protocol violations. The suitability of the data 
collection instruments was also considered. It was planned that data collected during 
this study would be used to inform sample size calculations for a larger study.  
 
7.2. Sample size 
It was planned that 60 patients (30 per group) would be recruited to take part in the 
feasibility study. This figure was chosen after considering that approximately 84 
patients underwent treatment in the Haematology unit in 2007 and that the unit was 
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substantially expanded to accommodate more patients early in 2008, and that in order to 
estimate a parameter, such as a mean or median value, 30 patients or greater are 
required (Lancaster et al., 2004). The rate of drop out for this study was estimated at 
30%. In addition, it was planned to recruit six patients to take part in the pilot. The pilot 
was planned to ensure that patients were able to follow the protocol and to check that 
the data collection sheets were adequate. 
 
7.3 Recruitment, informed consent, randomisation, allocation concealment and 
blinding 
7.3.1 Recruitment  
All patients fitting the inclusion criteria were identified using the hospital database and 
from discussions with Clinicians. All eligible patients were approached by a member of 
the medical team to ask them if they would be interested in speaking to the researcher. 
The researcher spoke to the patient about the study and gave them a patient information 
sheet to read. Patients were also informed that participation in the study was voluntary 
and that any decision not to enrol would not affect their treatment options. Patients 
choosing to enrol in the study were informed that they could remove themselves from 
the study at any time, and that this decision would not affect their standard of care.  
 
7.3.2 Recruitment of non-English speaking patients 
The recruitment of non-English speaking patients to research is an on-going difficulty in 
clinical trials (Jiwa, 1999). While it is evident that patients who fall this group should 
not be discriminated against by a policy of non-recruitment, the fact remains that 
recruitment in this area is difficult and produces additional consent issues. For the 
feasibility trial, it was planned to use the hospital translation team to help speak to 
patients who did not speak English as a first language.  
 
7.3.3 Informed consent  
The researcher returned to speak to the patient a minimum of 24 hours after the first 
approach, to ask the patients if they were willing to take part in the study and to answer 
any questions patients may have had. Those patients willing to take part in the study 
were then asked to sign the consent form. Three copies of the content form were signed: 
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the master copy was placed in the study file, one copy was retained by the patient, and 
the remaining copy was filed in the patient’s notes.  
 
7.3.4 Randomisation 
The randomisation was computer generated by an independent statistician from the 
department of Nursing, Midwifery and Social Work at the University Of Manchester. 
The pharmacy department at the hospital held a copy of the randomisation sequence. 
Additional copies of this sequence were held by the researcher’s supervisors until the 
end of the study. At baseline (the day before starting chemotherapy), prior to 
randomisation, basic demographical data were collected: age, gender, smoking status, 
diagnosis, treatment (type of transplant), and current (if any) use of supplements.  
 
7.3.5 Pharmacy release  
Once the patient had been recruited to the study they were assigned the next number in 
sequence, the pharmacy release form was signed by a doctor and the pharmacy was 
contacted and asked to dispatch the drug container with the same number. Checks by 
the hospital pharmacy prevented the containers being dispatched out of order. 
 
7.3.6 Blinding and allocation concealment  
This study was a double blind RCT. Both the patients and the outcome assessor were 
blind to the treatment allocation. The allocation sequence was concealed using pre-
packed bottles which were identical in appearance and sequentially numbered. In 
addition, the use of the hospital pharmacy to dispense the intervention and placebo 
products also ensured adequate allocation concealment.  
 
7.4 Inclusion and exclusion and withdrawal criteria  
This study recruited adults diagnosed with haematological malignancies (Lymphoma, 
Leukaemia and Multiple Myeloma) undergoing conditioning for both allogeneic and 
autologous transplantation. This population was chosen because they are at risk of 
developing severe mucositis due to the high doses of chemotherapy used for 
conditioning. The exclusion criteria consisted of patients undergoing conditioning for 
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other cancers, children, and patients who were allergic to soya or who took exception to 
gelatine, which was an ingredient in the capsules. Patients with oral mucositis at 
baseline, or those prescribed warfarin, were also excluded. As the ethics committee 
were concerned that oral mucositis may be confused with other types of ulceration, 
patients prescribed bactrim or clarithromycin antibiotics at baseline, were also added to 
exclusion criteria, as these drugs may be associated with oral ulceration.   
 
The inclusion and criteria were not checked against admissions onto the unit prior to 
starting the study, as the researcher would have required ethical and trust approval to 
access patient notes. However, the inclusion and exclusion criteria were discussed with 
two of the Consultants on the unit before the application for ethical approval was made, 
and the overall opinion was that the vast majority of patients admitted to the unit would 
meet the inclusion criteria. It should be noted that only one potential participant 
screened prior to recruitment did not meet the inclusion criteria for the study, due to 
their use of warfarin.   
 
The expansion of the unit increased the number of transplant spaces available and 
therefore subsequently the number of patients who were referred to the hospital from 
other hospitals both from within the UK, and from abroad. It was expected that 
approximately 120 patients would be treated on the unit between June 2008 and July 
2009, and after careful study of the transplant planning lists, this figure appears to have 
been correct. It was calculated by the statistician that 66 patients would be needed to be 
recruited for the study. This was based on the literature which suggested that 30 patients 
were required to estimate a parameter such as a mean (Lancaster et al., 2004). This was 
interpreted conservatively by the statistician, who decided that 30 patients would be 
required in order to calculate a mean, and another 30 would be required to estimate a 
standard deviation, and that another six would be required for the small pilot at the 
beginning of the study. It is arguable that the likelihood of recruiting 66 patients during 
the trial was over-estimated during the process of setting up the study on the unit. 
Conversely, it could also be argued had the problems with clinical staff not been 
experienced, the level of recruitment into the trial would have been great enough to at 
least allow for an adequately powered calculation of parameters.  
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A number of different steps were taken in an attempt to increase the recruitment of 
patients into the study after the issues with clinical staff were experienced. The easiest 
way to increase the numbers in the pool of available patients would have been to 
increase the number of study sites, and therefore change the study design from a single 
to a multi-site study. To determine if this was a possibility, consultants at another 
hospital were approached informally to gauge their reaction. Unfortunately, they were 
unable to help due to other trials being conducted on the unit and therefore the study 
remained a single site study. The inclusion and exclusion criteria were also reassessed 
but it was found not to be possible to widen the already relatively broad criteria.  
 
7.4.1 Inclusion criteria 
Both male and female subjects were recruited to take part in the feasibility study. The 
inclusion criteria were as follows: 
• Patients aged 18 years old or over. 
• Patients diagnosed with Multiple Myeloma, leukaemia or lymphoma 
• Patients planned to undergo conditioning for BMT transplantation 
• WHO mucositis score of 0 
• Patients not enrolled in other oral mucositis trials 
• Patients treated as inpatient 
 
7.4.2 Exclusion criteria 
The exclusion criterion consisted of the opposite of the inclusion criteria listed above 
and in addition included: 
• Patients who had a religious or dietary exception to gelatine. 
• Patients who were being prescribed warfarin. 
• Patients who had an allergy to soya lecithin.  
• Patients prescribed septrin (bactrim) at recruitment 
• Patients prescribed clarithromycin at recruitment 
• Patients prescribed any drug other than chemotherapy/radiotherapy that in the 
opinion of a Clinician might have caused mucositis.  
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7.4.3 Withdrawal criteria 
The withdrawal criteria for this study were as follows: 
• Patient withdrew their consent to take part in the study. 
• Patient suffered a suspected unexpected adverse event (SUSAR). 
• Patient lost capacity 
If a patient asked to withdraw during the study, they were given the option of stopping 
the supplementation but continuing with oral screening, pain and nutritional 
assessments. 
 
7.5 Treatment Arms 
7.5.1 Intervention group 
The intervention group was provided with capsules of natural source D-α-tocopherol in 
a dosage of 1000iu (670mg). This capsule was purchased from Healthplus (Dolphin 
House, 27 Cradle Hill Industrial Estate, Seaford. East Sussex, BN25 3JE) and was 
produced in France by Capsugel (Ploërmel, ZI de Camagnon, BP 320, 56803 Ploermel, 
Cedex, France). 
 
7.5.2 Control group 
The control group were provided with a placebo containing soya bean oil in a gelatine 
capsule. This capsule was purchased from Healthplus (Dolphin House, 27 Cradle Hill 
Industrial Estate, Seaford. East Sussex, BN25 3JE) and was produced in France by 
Capsugel (Ploërmel, ZI de Camagnon, BP 320, 56803 Ploermel, Cedex, France).  
 
7.5.3 Finding a supplier 
An extensive search was conducted for a company who could supply both vitamin E 
and a suitable placebo product. Healthplus was eventually chosen due to their close 
working relationship with Capsugel (the manufacturer of the intervention and placebo). 
Healthplus approached Capsugel on behalf of the Researcher to ask if it was possible 
for them to manufacture placebo capsules of the same size and shape as the intervention 
for use in this study. Capsugel suggested soya bean oil as a placebo as it was a relatively 
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cheap ingredient already included in the vitamin E capsules. As neither Capsugel or 
Healthplus held a manufacturer’s authorisation for investigation medicinal products 
(MA-IMP) license, an authorisation required by the MHRA for products used in clinical 
trials, the researcher arranged for the intervention and placebo capsules to be 
repackaged by Preston Pharmaceuticals under their MA-IMP licence, in sequentially 
numbered containers of identical appearance, which had the additional benefit of 
ensuring adequate allocation concealment.  
 
There has been little consistency in previous studies investigating vitamin E in patients 
receiving chemotherapy, and a variety of doses of between 600mg (600IU32) and 
2147mg (3200IU33) daily have been used (Argyriou et al., 2006a, Argyriou et al., 
2006b, Blanke et al., 2001, Legha et al., 1982, Martin-Jimenez et al., 1986, Perez et al., 
1986, Sung et al., 2007, Weitzman et al., 1980, Wood, 1985). The dosages used in these 
previous studies have been well-tolerated and no negative effects on chemotherapy 
efficacy have been identified. As Healthplus, sold vitamin E in either doses of 500iu 
(335mg) or 1000iu, a single dose of 1000iu (670mg) of D-alpha-tocopherol, was chosen 
for this study. The placebo capsules were manufactured in exactly the same way as the 
intervention using the same raw materials; however, soya bean oil was added instead of 
vitamin E.  
 
7.5.4 Justification for the dose 
The dose used in this study (670mg/1000iu) was chosen after consideration of the 
following factors: 1) that the literature on studies of similar interventions for the 
prevention of mucositis or other chemotherapy related side-effects had not conclusively 
demonstrated the appropriateness of any specific dose, and, 2) that significantly larger 
doses of vitamin E had been given to patients undergoing chemotherapy (see preceding 
paragraph) with no adverse effects reported. Healthplus was selected as the 
manufacturer of the intervention and placebo products; they were able to provide two 
different sized doses (500iu and 1000iu). Based on the factors listed above the larger 
dose of vitamin E was selected, careful consideration of the literature having identified 
no adverse effect of such a dose on chemotherapy efficacy. The adverse events 
                                                     
32
 As dl-alpha-tocopherol acetate (for more information see table 2) 
33
 As d-alpha-tocopherol (for more information see table 2) 
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associated with such a dose are inconsistent in the literature and primarily have been 
reported in case reports or letters to the editor and not in RCTs. The use of the higher 
dose was hypothesised to be more likely to have an effect, and therefore the higher dose 
was selected based on the literature not having identified any consistent adverse events 
associated with such doses in RCTs. 
 
7.5.5 Contraindications and toxicities 
The toxicity of vitamin E is very low (Bendich and Machlin, 1988, Diplock, 1995, 
Kappus and Diplock, 1992), and doses of up to 3200 IU have not been associated with 
consistent adverse events (Kappus and Diplock, 1992). The majority of reports of 
adverse events in the literature have come from letters to the editor, case reports or 
uncontrolled trials, and have not been supported by the results of RCTs (Kitagawa and 
Mino, 1989, Meydani et al., 1998, Tsai et al., 1978). Such adverse events include 
gastrointestinal cramps and diarrhoea (Anderson and Reid, 1974, Gillilan et al., 1977), 
and fatigue and muscle weakness (Cohen, 1973). In addition, patients given large doses 
of vitamin E (1200iu/day) have shown prolonged clotting times due to 
hypoprothrombinemia in vitamin K deficient individuals (Bendich and Machlin, 1988). 
However, this may only be a concern for patients on anti-coagulant therapy, such as 
warfarin, a known vitamin K antagonist (Bendich and Machlin, 1988). Therefore 
patients prescribed warfarin were included in the exclusion criteria and were not 
recruited to take part in the study. 
 
7.5.6 Vitamin E and chemotherapy 
Block and colleagues (2007), systematically reviewed the impact of antioxidant 
supplementation on chemotherapeutic efficacy. The authors concluded that none of the 
trials included in the study reported a significant decrease in chemotherapeutic efficacy 
due to antioxidant supplementation and that many of the studies included in the review 
suggested increased survival times and tumour responses and fewer toxicities in patients 
treated with antioxidants than the controls (Block et al., 2007). Another review by the 
same authors incorporating a larger number of studies was published in 2008, and 
concluded that the use of antioxidants during chemotherapy has the potential to reduce 
dose-limiting toxicities (Block et al., 2008). Differences in treatment protocols and 
tumour types prevented the pooling of data in a meta-analysis in both these studies. 
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These results are also supported by a review by Drisko and colleagues (2003), who 
suggested that instead of exhibiting a negative effect, antioxidant supplementation may 
actually be of some benefit when combined with some chemotherapy regimens (Drisko 
et al., 2003). Further research into this area is ongoing. 
 
 It should be noted that while four studies which investigated the concurrent 
administration of vitamin E were included in the reviews conducted by Block and 
colleagues, all employed doses below that used in the feasibility study. However, 
studies which have administered vitamin E in higher doses than used in the feasibility 
study were included in a review by Conklin (2000), who identified no significant 
decrease in chemotherapy efficacy as a consequence of vitamin E administration.  
However, the author did note the potential for the use of an antioxidant tripeptide of 
cysteine, glycine and glutamic acid to interfere with the action of chemotherapy 
(Conklin, 2000), which suggested that the actions of different types of antioxidants on 
chemotherapy should be considered independently, and not as a class. As there are 
many different types of antioxidants, all of which work in a number of different ways, it 
would not be appropriate to discuss the impact of antioxidant supplementation on 
chemotherapeutic efficacy in term of a class effect, as not all antioxidants have the same 
effects, tolerability or safety profile (Evans et al., 2005).  
 
7.5.7 Duration of vitamin E or placebo 
In order to determine how many vitamin E capsules to order, the number of days a 
patient was expected to suffer from mucositis had first to be calculated. As a mean time 
for mucositis development has been suggested of between four (Wingard et al., 1991) 
and six days (Zerbe et al., 1992), with a median time for resolution of ulcerative 
symptoms of between nine (Spielberger et al., 2004) and 11 (Woo et al., 1993) days. It 
was therefore envisioned that patients would receive either vitamin E or placebo for 
approximately 15 days. However, as these figures are derived from historical values, 
which may be at risk of measurement bias, this figure was doubled to allow for 
unforeseen circumstances. Therefore a 30 day supply was ordered for each patient.  
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7.5.8 Instructions to patients 
Patients were asked to take one capsule daily, place the soft gel capsule in their mouth, 
break it with their teeth, mix the resulting liquid with their saliva and swish this liquid 
around their mouths for 5 minutes before expectorating it. To maximise the time for the 
intervention to exhibit an effect, patients were asked take their capsule in the evening, 
and undergo the oral assessment the next morning. Patients were additionally asked to 
refrain from eating or drinking anything for at least 30 minutes after taking the capsule. 
Patients were asked to start taking the capsules daily on the evening before they 
received chemotherapy and continue taking the capsules until they met the exit criteria 
for the study (three continuous days with a WHO score of less than 2). Patients who 
were admitted to hospital on the day they started chemotherapy were asked to start 
taking the capsules in the evening of the same day.   
 
7.6 Data collection procedures 
7.6.1 Oral assessment 
Patients had their mucositis scored using the WHO mucositis scale, and the daily index 
of mucositis (DIM) instruments. Copies of these scales can be found in Appendix 3. 
Baseline oral assessments were conducted on the day of admission prior to 
randomisation, and then daily until resolution of ulcerative mucositis. Ulcerative 
mucositis was considered to be resolved after the condition ceased to be ulcerative, 
shown by three continuous days of a WHO score of grade one or below. Mucositis 
scoring was conducted using a halogen light source to assess the patient’s oral cavity. 
Patients were asked to point out any painful areas of their mouths to the researcher. This 
patient input was important as a previous study reported that patients are able to detect 
oral cavity changes between 1 day and 3 days earlier than Clinicians (Stiff et al., 2006).  
 
7.6.2 Pain scores 
The patient’s reports of pain were collected using the Oral Mucositis Daily 
Questionnaire (OMDQ) (Stiff et al., 2006). A copy of this instrument can be found in 
Appendix 3. This tool was comprised of six questions and recorded patients’ self reports 
of mouth and throat soreness, and diarrhoea events over the preceding 24 hours. This 
instrument also employed a skip pattern, allowing the patients to pass on questions that 
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did not apply. Baseline OMDQ assessments were conducted prior to randomisation and 
then daily until the patient met the exit criteria.  
 
7.6.3 Nutritional screening 
Patients underwent nutritional screening at baseline, prior to randomisation. This was 
repeated every seven days until the end of data collection. Patients were screened using 
the Patient Generated Subjective Global assessment (PG-SGA) instrument. This tool 
included the patient’s medical history: weight changes, functional capacity, 
gastrointestinal symptoms, and dietary intake; an assessment of metabolic stress; and a 
short physical assessment to identify muscle wasting, oedema and loss of subcutaneous 
fat (Barbosa-Silva and Barros, 2006). A total score was then calculated.  
 
Patients were asked to complete the first section of the form (patient medical history); 
however, in the event that the patient did not feel up to this task, the researcher asked 
them the relevant questions and completed this section for them. The researcher then 
calculated the patient’s metabolic demands and performed the short physical 
assessment. The concurrent validity of the PG-SGA has been previously identified in 
populations with cancer and, as expected, was found to correlate with patient weight 
loss over the preceding 6 months (Bauer et al., 2002). The PG-SGA has also been 
reported to be a moderately reliable instrument (Bauer et al., 2002). 
 
7.6.4 Researcher reflective diary 
The researcher kept a reflective diary for the duration of the trial. This diary was used to 
record any issues and problems encountered during the trial, such as recruitment. This 
diary was used to complement the study data as an additional source of information 
while planning a larger full trial.  
 
7.6.5 Definition of the end of the trial 
The trial officially ended when the last visit was conducted with the last patient in the 
study. GB was responsible for notifying the LREC, MHRA and Sponsor of the end of 
the trial.  
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7.6.6 The patient journey 
7.6.6.1 Allogeneic transplant 
 
 
 
Figure 33: The Expected Journey of a Patient Undergoing Allogeneic Transplantation 
 
Figure 33 shows the allogeneic patient experience. Patients undergoing allogeneic 
transplantation typically received seven days of conditioning before receiving their 
transplant. In addition to chemotherapy, this conditioning may also include TBI. 
Donated stem cells were administered to the patient, on their 9th day in hospital. This 
day is denoted ‘day 0’. The expected day of discharge for hospital varies depending on 
how well the patient coped with the transplantation process: whether they contracted a 
virus during hospitalisation or whether GVHD was a problem. Figure 33 also shows the 
patient experience during the feasibility study. It was planned that patients would 
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undergo baseline assessments prior to randomisation, on the day of their admission onto 
the unit. Oral (WHO, DIM) and pain assessments (OMDQ) would then be conducted 
daily and nutritional assessments weekly (PG-SGA). On the evening of the day of their 
admission into hospital, it was planned that patients would start taking the placebo or 
intervention products, and would continue to do so until they met the exit criteria for the 
study.  
 
7.6.6.2 Autologous transplant 
 
Figure 34: The Expected Journey of a Patient Undergoing Autologous Transplantation 
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Figure 34 shows the expected experience of patients undergoing autologous 
transplantation. Patients undergoing autologous transplantation typically received one 
day of conditioning, on the day after their admission to hospital. Their own harvested 
stem cells were administered on the day after conditioning, a day termed day ‘0’. The 
length of hospitalisation for autologous transplant patients was typically shorter than for 
allogeneic transplantation, but depended on how a patient coped with transplant. The 
patient experience during the feasibility study is also shown in Figure 34. Patients 
underwent baseline assessments prior to randomisation, on the day of their admission 
onto the unit. Oral (WHO, DIM) and pain assessments (OMDQ) were then be 
conducted daily and nutritional assessments weekly (PG-SGA). On the evening of the 
day of their admission into hospital, patients were asked to start taking the placebo or 
intervention products, and to continue to do so until they met the exit criteria for the 
study. 
 
7.7 Pharmacovigilance 
The recording of adverse events was an important part of the feasibility trial. Data were 
collected on all new events reported by a patient. The hospital standard operating 
procedures for the reporting of adverse events were followed, a copy of this document 
can be found in Appendix 7 (disk). As this trial was a feasibility study all adverse events 
were recorded, including all adverse events that are not considered to be urgent. The 
researcher was responsible for the safety reporting process. Data were collected on 
every new symptom experienced by the patient during the trial. Each new symptom was 
assessed using the criteria outlined in Table 14  
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Table 14: Adverse Event Reporting Definitions 
 Definition 
Adverse Event “Any untoward medical occurrence in a patient enrolled in the 
study, who has been administered a medicinal product and 
does not necessarily have a causal relationship with this 
treatment”  
Adverse Reaction 
 
“All untoward and unintended responses to an investigational 
medicinal product related to any dose administered. All 
adverse events having a reasonable causal relationship to a 
medicinal product qualify as adverse reactions”  
Unexpected Adverse Reaction “An adverse reaction, the nature, or severity of which is not 
consistent with the applicable product information” 
Serious Adverse Event or 
Serious Adverse Reaction 
(SAE or SAR) 
 
“Any untoward medical occurrence or effect that at any dose 
which  
• results in death, 
• is life threatening, 
• requires hospitalisation or prolongation of existing 
hospitalisation, 
• results in persistent or significant disability or 
incapacity” 
Suspected Serious Adverse 
Reaction  
 
“A SSAR is defined as an SAR the nature and severity of 
which is consistent with information about the IMP in question 
as presented the investigator’s brochure.” 
Suspected Unexpected 
Serious Adverse Reaction 
(SUSAR) 
“Any SAR where the nature, or severity of the reaction is not 
consistent with the applicable product information in the 
investigator’s brochure. Requires expedient reporting to the 
MHRA and Trust and ethics committee.” 
Adapted from the Hospital Standard Operating Procedures pages 5-7(see appendix 7) 
 
7.7.1 Annual Safety Reports 
The submitting of annual safety reports to the MRHA and the LREC was the 
responsibility of GB.  
 
7.8 Statistics and data analysis 
7.8.1 Plans for data analysis 
Data were inputted by the researcher and a 10% sample was then double-checked. Data 
were analyzed using the Statistical package for the social sciences (SPSS) 15.0 and 
 166 
Microsoft Excel. For the area under the curve analysis (AUC), missing data were 
generated by averaging the scores generated immediately before and after the gap. Data 
were analysed using the intention-to-treat principle (ITT). This allowed patients lost to 
follow-up, or who did not follow their randomized protocol to be analysed according to 
their randomised group. As this study was a feasibility study, the analysis was 
exploratory not hypotheses testing. It was planned that analyses would include 
confidence intervals and effect sizes in addition to point estimates, where possible. It 
was planned that the results of this feasibility study would be used to also provide 
figures that could be later used as the basis for sample size calculations for a larger 
study.  
 
7.8.1.1 Primary analysis 
The primary analysis compared AUC, for both the DIM and WHO scores, between the 
two treatment groups, based on the intention to treat principle. The Mann Whitney U 
test was used, and a 2-sided significance test was adopted with critical level of 
significance set at 0.05. This analysis was conducted by an independent statistician 
before the randomisation code was broken. The decision to use an independent 
statistician to conduct the primary analysis, and then break the randomisation code, was 
made by the researcher and her supervisors in an attempt to avoid the potential for bias. 
All other analyses were performed by the researcher.  
 
7.8.1.2 Duration of ulcerative mucositis 
The mean mucositis scores were determined for the intervention and control group for 
both of the oral assessment instruments. An area under the curve analysis was 
performed for these data to compare the two groups. 
 
7.8.1.3 Highest DIM score 
The mean daily index of mucositis scores was calculated for each of the two groups. An 
analysis was planned using the Mann-Whitney U test.  
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7.8.1.4 Highest WHO score 
The mean daily index of mucositis scores was calculated for each of the two groups. An 
analysis was planned using the Mann-Whitney U test.  
 
7.8.1.5 Nutritional screening 
The highest nutritional score was calculated. An analysis was planned to compare the 
mean nutritional score at week three and the highest nutritional score by arm using the 
Mann-Whitney U test. 
 
7.8.1.6 Pain scores 
Analysis was conducted for each question on this instrument as the OMDQ did not 
require the calculation of a compound score. An analysis was planned using the Mann-
Whitney U test. 
 
7.9 Ethical issues  
7.9.1 Confidentiality 
The confidentiality of records that could identify participants were protected, and the 
privacy and confidentiality of patients was respected in accordance with the applicable 
regulatory requirements. Each patient enrolled in the study was given a patient number. 
Patient information was anonymised before being placed on university computers. Data 
held on external devices, such as pen drives, were anonymised and encrypted. 
Information sheets containing patient information was kept in a lockable filing cabinet.  
 
7.9.2 Right to withdraw 
Patients undergoing high dose chemotherapy or radiotherapy are obviously an at risk 
patient group. They therefore require treatment with sensitivity and support. The wishes 
of any participant who did not want to follow the study protocol on a particular day 
were respected. Patients who chose to withdraw from the study were respectfully asked 
if they would allow the researcher to follow them up by continuing to undergo daily oral 
and pain assessments and weekly nutritional assessments. Patients who declined were 
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thanked for their time and reassured that their withdrawal would not affect the standard 
of care that they would receive.  
 
7.9.3 Consent 
Obtaining adequate informed consent to participate in research is an important ethical 
issue. This feasibility study followed the guidelines pertaining to consent as outlined in 
the MRC guidelines for Good Clinical Practice in Clinical Trials (Medical Research 
Council, 1998) 
 
7.9.4 Equipoise 
There was genuine clinical equipoise: uncertainty whether a treatment would be of 
benefit (Freedman, 1987), in the feasibility trial because no ‘gold standard’ for the 
prevention of oral mucositis in patients undergoing conditioning for bone marrow 
transplantation currently exists, and previous trials of vitamin E for the prevention of 
mucositis have reported conflicting results. 
 
7.10 Major conclusion 
So far in this thesis, the mucositis literature and trials investigating interventions for the 
prevention of mucositis have been discussed and vitamin E has been identified as an 
intervention worthy of further study. The risk of bias in previously published trials has 
been investigated and using a sensitivity analysis, the importance of allocation 
concealment and outcome assessor blinding have been highlighted. How such trials can 
be used to inform future studies has been analysed, and the shortage of studies reporting 
adverse events has been discussed. A systematic review of oral assessment instruments 
has been also been presented, which has informed the choice of three assessment 
instruments. As shown in Figure 2, the results from these previous chapters have been 
used to inform the development of a protocol for use in a feasibility study which 
addresses all these issues. In the next chapter of this thesis the results of the feasibility 
study will be presented.  
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Chapter 8 Results of the Feasibility Study 
 
8.1 Introduction 
This chapter of the thesis presents the results of the feasibility trial and is split into two 
parts. The first section focuses on issues identified during the trial which may affect the 
feasibility of conducting a future study. The second section discusses the results of the 
study. Before going into detail about feasibility issues or the results of the trial, it is 
useful to be reminded of the previously stated study aim. 
 
8.2 Aim  
To explore the feasibility of conducting a trial to assess the effectiveness of d-alpha-
tocopherol in the management of oral mucositis compared to a soya bean oil placebo, 
over and above standard care.  
 
8.3 Section one: Feasibility  
8.3.1 Regulatory requirements and pharmacy approval  
Table 15 shows the timeline for gaining regulatory approval. The researcher first 
approached the hospital Research and Development (R and D) department in August 
2007. At approximately the same time, the Medicines and Healthcare products 
Regulatory Agency (MHRA) was contacted to determine if the proposed trial 
necessitated MHRA approval. The MHRA application proved to be extremely time 
consuming and complex due to Healthplus not holding a manufacturers authorisation 
for an investigational medicinal product (MA-IMP). This necessitated a company with 
MA-IMP being contracted to repackage the products and for qualified person (QP) 
release. The same company (Preston Pharmaceuticals) also wrote the summary of 
product characteristics document necessitated for the MHRA application, which could 
not be supplied by Healthplus.  
 
The MHRA application was initially refused, but was later accepted after the provision 
of additional product specification and sell-by date information from Healthplus and 
discussion between one of the researcher’s supervisors and the MHRA. MHRA 
approval was granted on the 6th of June 2008 and the products were ordered from 
Healthplus the same day. The placebo was manufactured and was shipped from France 
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on 31st July 2008. Trust approval was finally received on 21st August 2008, having been 
held up by a delay in approval from the hospital pharmacy department. A further delay 
to starting the trial was caused by Preston Pharmaceuticals taking two months to 
package and release the products. The intervention and placebo products were 
eventually received by the hospital pharmacy on 6th October 2008, and the first patient 
started the trial on 28th October 2008. Table 15 shows the timeline for regulatory 
approval. From initial contact with the R and D department to the first patient starting 
the trial took 64 weeks. 
Table 15: Timeline for Regulatory Approval 
Date  Action 
August 2007 Initial approach to hospital Trust Research and 
Development unit 
MHRA consulted to ask whether MHRA 
approval was necessary 
September 2007 Preston pharmaceuticals contracted to 
repackage products and write IMPD document 
October 2007 
- 
November 2007 
- 
December 2007 
- 
January 2008 
- 
February 2008 
- 
March 2008 Submission of initial MHRA application 
Submission of Ethics application 
Submission of Trust application 
April 2008 Initial MHRA application rejected 
Resubmission of MHRA application 
May 2008 
- 
June 2008 MHRA approval granted  
July 2008 Placebo manufactured. Both placebo and 
intervention shipped to Preston 
Pharmaceuticals 
August 2008 Trust approval granted 
September 2008 
- 
October 2008 
Intervention and placebo received by hospital 
pharmacy 
First patient enrolled 
June 30th 2009 End of trial as sell-by date of intervention 
products reached 
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8.3.2 Clinician interest and available patient population  
There are four consultant Clinicians on the BMT ward at the hospital, each with a 
different disease speciality. After initial contact with one of these Clinicians (EL), the 
researcher presented the project to all four consultants and the ward staff at a lunchtime 
education seminar at the hospital. During the presentation, one consultant voiced an 
objection to the planned number of patients to be recruited, stating that efficacy could 
not be proved with such small numbers across the three different types of transplant. 
When the researcher responded stating that exploration of feasibility issues was the  
primary aim of the study, the Clinician suggested the adoption of a phase 1 study in 
which all the patients were given the intervention of interest, and further stated that 
randomization and pharmacy release were unnecessary. Following discussion between 
the researcher’s supervisors, and all four consultants, the Clinician in question refused 
to take part in the trial, denying the researcher access to his patients, which reduced the 
available patient population by approximately 33%.  
 
After further discussions, an agreement was made between the supervisors and the 
remaining three consultants in order for the trial to go ahead, that instead of the patients 
swishing the liquid in their mouths and then swallowing, patients would be asked to 
swish and then expectorate the solution. The three consultants then agreed to take part 
in the study and allow the researcher access to their patients.  
 
However, in the period running up to the recruitment of the first allogeneic patient, the 
consultant treating the autologous patients raised objections to the recruitment of 
allogeneic patients, despite confidence in the study of the consultant treating these 
patients, and stated that only his autologous patients should be recruited. This 
effectively forced the researchers and her supervisors to choose which consultant to 
work with; as two autologous patients had already started the trial, the decision was 
made to continue the study recruiting only the autologous patients. Unfortunately, these 
circumstances further limited the available patient population, as while the researcher 
was in theory working with two consultants, one of these doctors treated patients who 
were very rarely transplanted. This left the researcher recruiting only patients with 
multiple myeloma undergoing bone marrow and stem cell transplantation, a group of 
patients which comprised less than 25% of the available transplant population treated on 
the unit.  
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Attempts were made to increase pool of patients available to the researcher. The 
possibility of changing the study to incorporate a multi-site design and recruiting 
patients at a different hospital was explored, but rejected after an informal approach to 
clinicians on the relevant ward identified that this was not possible as the result of other 
trials occurring there. The inclusion criteria were also reassessed, but it was decided that 
changing them was not necessary as it was access to patients that was the problem, not a 
lack of patients who met the inclusion criteria.  
 
8.3.2.1 Impact of the change in the method of application of the intervention and 
placebo 
The change in the instructions to patients for the intervention and placebo products from 
‘swish and swallow’ to ‘swish and expectorate’ had important consequences for the 
feasibility study. Firstly, it made determining what dose of vitamin E the patients 
actually received very difficult. It would be certainly less than the 670mg that they 
would have received had the vitamin E been swallowed, but the question of how much 
less could only be answered by a trial comparing the two methodologies. Measurement 
of plasma α-tocopherol levels are the easiest method of determining vitamin E levels in 
a patient (Olson, 2000). However, these were not measured in the feasibility study for 
two reasons: 1) such measures were not part of the routine blood tests and would have 
had to be specially requested from the laboratory, at considerable economic cost; and 2) 
as there was only one researcher collecting data, who was blind to the treatment 
allocation, the identification of changes in plasma vitamin E levels would have 
undermined outcome assessor blinding.  
 
This swish and expectorate technique was also used in the Sung and colleagues trial 
(Sung et al., 2007), but the authors unfortunately do not comment on the possibility that 
the reason that no benefit of vitamin E was identified in their trial may have been due to 
the inactivity of vitamin E in the oral cavity. Neither do the authors comment on the 
decision making process that led to the products being expectorated instead of 
swallowed. As vitamin E can be absorbed through the skin (Wester, 2005), it stands to 
reason that it can also be absorbed through the oral mucosa or gingivae. However, at 
what rate this absorption takes place is unclear – the literature does not describe the rate 
of absorption in 5 minutes either through the skin, oral mucosa or gingivae – and it is 
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therefore unclear how much vitamin E could be absorbed in 5 minutes of swishing. The 
proposed mechanism of action for vitamin E in the prevention of mucositis has not been 
described, however, as previous studies asked patients to apply the intervention 
topically, by swishing before the solution was swallowed, it could be hypothesised that 
it was the local absorption of the product that is important, and not an effect on overall 
body status. It is very likely that some local absorption of the intervention took place 
during the five minutes of daily swishing undertaken by patients. However, researchers 
in future trials of vitamin E for the prevention of mucositis may like to reconsider how 
long patients receive supplementation. In the feasibility study, it was planned that 
patients would be supplemented for approximately 15 days. However, since studies 
have identified that it can take up to four weeks for plasma levels of vitamin E to 
become saturated, after supplementation with a daily dose of 900IU (Kitagawa and 
Mino, 1989), authors of future studies may like to consider a longer period of 
supplementation, if they consider that it is the whole body effect rather than any local 
effect that is the important mechanism of action for this intervention. In the same 
manner, if a whole body effect is hypothesised, patient use of supplements before 
recruitment may be important as depletion of vitamin E in adipose tissue is relatively 
slow and only takes place when plasma levels are low (Skeaff, 2007). Asking patients if 
they have previously used supplements, as was done is the feasibility study, is therefore 
advised.  
 
8.3.3 Competing clinical trials 
There were a number of clinical trials taking place on the unit during the data collection 
period. The majority of these trials compared survival outcomes in patients receiving 
different types of cancer treatments. None of these trials investigated interventions for 
the prevention or treatment of mucositis and there were therefore no competing clinical 
trials taking place during the data collection period. Two patients were enrolled in the 
myeloma X trial, a study investigating the use of a second autograft in relapsed patients 
who had previously received a stem cell transplant. However, Patient 9 withdrew from 
the myeloma X trial because he wanted to undergo another autograft and was unhappy 
with the possibility that he might be randomised to receive further chemotherapy 
treatment instead. Therefore, only one patient (Patient 6) was enrolled in another 
clinical trial at the time of entry to the vitamin E trial. This patient was allocated to the 
placebo group.  
 174 
 
8.3.4 Feasibility of methods used to identify eligible patients 
Eligible patients were identified at the weekly ward transplantation meetings, held on a 
Monday lunchtime. At this meeting the transplant co-ordinator presented patients being 
considered for transplantation over the next four to six weeks. Basic patient details 
including disease type, relevant co-morbidities, the date of the patient’s next outpatient 
appointment and the name of their treating physician were provided during this meeting. 
Additional information about relevant patients was gleaned from discussions with the 
consultant treating the patient. With this information, the researcher was able to identify 
eligible patients to approach in clinic. This method of identifying patients was not 
foolproof, as patients were frequently moved on and off the transplantation list 
according to availability of beds, resulting in some patients being admitted for 
transplantation without ever appearing on the transplantation list.   
 
8.3.5 Feasibility of Patient recruitment  
Between October 2008 and June 2009, 22 patients were assessed for eligibility to enter 
the study. Two of these patients were not approached because of translation problems. 
Both patients required the involvement of translational services during clinic 
appointments, and while the patients could have been approached to take part in the 
study in the presence of a translator, due to staffing shortages, a translator would be 
unlikely to be available when the researcher returned to take consent, or during the daily 
data collection visits. Another two patients were assessed for eligibility but were not 
approached to take part in the study on the advice of the consultant Clinician. One of 
these patients had a history of non-compliance with treatment. The other patient had had 
a previous renal transplant, and it was medical consensus that this patient would have ‘a 
difficult time’. Unfortunately, the patient in question died soon after transplantation.  
 
Eighteen patients were approached to take part in the study. One patient originally 
approached when scheduled for an autograft went on to have an allograft, under the care 
of a consultant not taking part in the study. Another patient was approached but was not 
consented due to the use of warfarin. Seven patients refused to participate after being 
approached to take part in the study. Due to ethical restrictions, basic patient data were 
not collected on patients who refused to take part in the trial, and therefore comparisons 
cannot be made between patients who did and did not consent to take part in this trial. 
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Nine patients consented to take part in the trial and were randomised. Recruitment 
stopped on June 30th 2009, when the sell-by date for the intervention was reached. The 
possibility of purchasing additional Vitamin E and extending the study was followed up 
on; however the time required for Ethics, MHRA and Trust approval for an extension to 
be granted, and to permit the production of this thesis within the University of 
Manchester’s time requirements, meant that this was not considered feasible. 
 
Figure 35 shows the Consolidated Standards of Reporting Trials (CONSORT) diagram 
showing the recruitment of patients into the study. 
 
 
Figure 35: CONSORT Diagram Showing Recruitment and Follow-up of Patients and 
Data Analysis 
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8.3.6 Feasibility of the informed consent, randomisation and pharmacy release 
procedures 
The Ethics Committee mandated that all patients should be approached in the presence 
of a medical professional. While this was achievable in the outpatients’ clinic, where 
introductions were made by the consultant Clinician or a specialist registrar, recruitment 
of patients elsewhere in the hospital was difficult to organise and often poorly executed. 
In such circumstances the researcher was introduced to the patient by a nurse, who was 
often not aware of the project and who had also not previously met the patient. This 
meant that a considerable amount of researcher time was spent arranging to be 
introduced to the patient and then waiting for this introduction to be made. In one 
instance, the researcher spent four hours on the ward waiting for a nurse to be available 
to introduce her to the patient.  
 
Of the 18 patients approached to take part in the study, 14 were approached in the 
Myeloma outpatient clinic and seven of these patients consented to take part in the 
study. Two patients were missed in the clinic and were approached when they attended 
the day ward for blood tests. Both patients consented to take part in the study and both 
were randomised to the placebo group. The final two eligible patients were approached 
on the ward after they were admitted for their autograft. Neither of these patients 
consented to take part in the study, with one patient commenting that the trial was 
something they would have been interested in taking part in, however, since arriving on 
the ward the enormity of the transplantation procedure had left them unable to 
comprehend taking part in anything else; had they heard about the trial before hand they 
would probably have been willing to consent to taking part. While it is likely that 
circumstances may dictate the need for patients to be approached after being admitted to 
the ward or in other areas of the hospital; the recruitment of patients in outpatient clinics 
where the researcher can be properly introduced to the patient and the aims of the 
project clearly laid out appears to be the best strategy in future trials.  
 
All patients recruited to the study were consented on the ward on the day of admission 
for transplant. This proved to be problematic. The majority of patients were admitted 
onto the ward late in the afternoon and the researcher found that she was competing 
with the medical staff for time with the patient. After informed consent was obtained the 
patient was assigned the next available sequential patient number and the pharmacy 
release form was completed. This form required the signature of a doctor. As senior 
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house officers rotated twice during the data collection period of this study, this signature 
sometimes took a while to achieve because a new rotation of doctors had to be informed 
about the study before a signature was requested. After the form was completed it was 
given to the ward pharmacist who delivered it to the pharmacy. Occasionally, the ward 
pharmacist would fill this prescription himself, ensuring that the capsules were being 
delivered to the ward before the researcher left for the day. If the ward pharmacist was 
busy the prescription was filled by the duty pharmacist and would therefore arrive on 
the ward with the evening drug delivery, at approximately 8pm. When drugs were 
arriving in the evening the researcher had to determine which nurse would be 
responsible for the patient, find them and ask them to give the capsules to the patient 
once they arrived on the ward. Most of the time this worked well, however, patient 7 
missed her first dose of the drug because the drugs were delivered to her room and then 
immediately placed in the locked box next to her bed.  
 
While it was possible to consent a patient, gain relevant signatures, organise pharmacy 
release and enrol the patient in the trial, on both the electronic system and in their paper 
notes, in the three or so hours between the patient being admitted on to the ward and the 
pharmacy closing for the day at 5pm, it made for an extremely busy afternoon. No two 
patients were enrolled into the study on the same day. However, as many as three 
eligible patients were admitted to the ward at the same time. In this instance, had all 
three patients consented to take part in the study, completing all the consenting and 
enrolment procedures in the time allowed would not have been feasible, resulting in 
some patients starting a day later than planned. During the design of this study it was 
envisioned that patients would receive their first dose on the day prior to receiving 
chemotherapy. It should be noted that there was no scientific basis for the recruitment of 
patients on the day of admission, however for the consistency of the results it is 
advisable that patients are recruited no later than the day on which they begin their 
chemotherapy, in order to ensure that the first dose of the intervention is administered at 
a similar stage of their treatment. 
 
8.3.7 Feasibility of adverse event reporting 
Adverse events were recorded daily and graded using the CTCAE version 3, an 
extensive whole body grading system which is commonly used to grade adverse events 
in clinical trials involving patients with cancer. Adverse events assessed as serious 
(grade 3 or above) – and were therefore considered life threatening or which could 
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result in prolonged hospitalisation – were assessed for causality (using five categories: 
not related, unlikely, possibly related, probably related, definitely related) to the study 
products by the researcher and the patient’s consultant using the hospital 
pharmacovigilance guidelines (appendix 7). This method of assessing adverse events 
was included in the study protocol and discussed with the research ethics committee 
(REC) in person at the REC meeting. 
 
Before data collection started the researcher was unsure what the common side effects 
associated with stem cell transplant would be. Therefore the decision was made to 
collect data on every adverse event experienced by the patients during the study. This 
proved to be very time consuming for the researcher, necessitating accessing three 
different sets of notes for each patient all stored in separate parts of the ward. Adverse 
event reporting was estimated to take the researcher an hour a day for each patient 
taking part in the study. As the average of days a patient was on the study was 16, this 
equated to 16 hours of adverse event reporting per patient, or 144 hours (or 18 working 
days) overall. However, while prospective adverse event reporting was extremely time 
consuming, these data can be used to inform researchers in designing a future protocol 
in this field.   
 
8.3.8 Feasibility of blinding and allocation concealment 
The randomisation sequence was concealed by the use of sequentially numbered 
containers which were identical in appearance which were released by the pharmacy 
upon receiving the completed pharmacy release form. Copies of the randomisation 
sequence were held by the researcher’s PhD supervisors, the pharmacy and the 
consultant whose patients were recruited. An initial suggestion by the consultant of 
placing a copy of the sequence in the site study file was rejected by the researcher and 
the supervisors on the grounds that this file was not secure, and could be opened by 
anybody on the ward. All data were entered and the AUC analysis conducted before the 
randomization code was broken.  
 
Both patients and the researcher were blind to the treatment allocation. Because of the 
possibility of slight colour variation between the two different types of capsules, the 
researcher organised for the departmental pharmacist to check compliance to the study 
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protocol by counting the capsules in each returned pot when the patient exited the study. 
The pharmacist then returned the pot to the pharmacy for disposal and communicated 
only the number of capsules to the researcher. As allocation concealment was 
maintained during the study, in addition to the researcher and the patient, the nursing 
staff caring for the patient were blind to whether the patient was receiving the 
intervention of interest or placebo.  
 
8.3.9 Substantial amendment 
It was originally stated in the protocol that in the event of a SUSAR patients currently 
enrolled in the study would be informed and re-consented. However, during the course 
of data collection it became clear that this would require amending. One of the patients 
who declined to take part in the study later developed pancreatitis and narrowly escaped 
an admission to CCU, which had he been enrolled in the trial would have been 
classified as a SUSAR, necessitating expedient reporting to the MHRA and the ethics 
committee. This is such an atypical complication that, had this patient been enrolled in 
the study, determining causality to the intervention or placebo would have been 
difficult, resulting in the SUSAR being erroneously classified as ‘possibly’ due to the 
intervention or placebo due to the rarity of such a side effect. Therefore, it was decided 
that in the event of a SUSAR only those events assessed as being ‘probably’ or 
‘definitely’ related to the intervention or placebo would require patients to be informed 
and re-consented. SUSARs assessed as being possibly due to the intervention or 
placebo, but could just of likely resulted from something else would not require patient 
re-consent. The application for the substantial amendment was made on 30th January 
2009. Approval from the MHRA was received on 25th March 2009. The project 
continued using the original SUSAR rules during this time and changed to the new rules 
once all approvals had been received.   
 
8.3.10 Compatibility of clinical trial with standard care 
This trial was designed to be conducted over and above standard care for mucositis. 
However, the Haematology ward did not have a formal intervention for mucositis 
prevention or treatment, and an ad hoc approach to prescribing based on Clinician 
preference had been adopted. Therefore Table 16 shows a variety of different 
interventions prescribed for the management of mucositis.  
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Table 16: Other Treatments Employed for Mucositis 
 
Intervention Placebo Total 
Cryotherapy 2 0 2 
Difflam 2 2 4 
Gelclair 0 1 1 
Saline Mouthwash 2 1 3 
Salt and Soda Mouthwash 1 0 1 
Synthetic Saliva 1 1 2 
None 1 0 1 
 
No patients were prescribed any intervention to prevent mucositis. However, one patient 
(Patient 3: intervention) had read about the benefits of cryotherapy on the internet and 
had sucked ice-pops during melphalan infusion. Another patient (patient 5: intervention) 
was given an ice-pop and a glass of iced water during melphalan infusion by a nurse 
who had read the Cochrane Review on the prevention of mucositis (Worthington et al., 
2007).    
 
8.3.11 Conclusion for section one 
The first section of this thesis chapter has focused on feasibility issues identified during 
the trial. This feasibility trial suffered from delays in ethical approval and in the 
packaging of the intervention and placebo products. Difficulties gaining access to 
potentially eligible patients together with low rates of patient recruitment resulted in 
only nine patients being recruited into the trial before the trial closed in June 2009, 
when the sell-by date for the intervention products was reached. Routine oral care was 
not standardized on the unit, which resulted in a wide range of products being 
prescribed to patients. These issues will be addressed in the discussion chapter.  
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8.4 Section two: Results 
8.4.1 Patient characteristics 
Of the nine patients recruited into the study, five patients were randomly allocated to the 
intervention arm. The remaining four patients were allocated to receive the placebo. 
Table 17 details which patients were allocated to each arm.  
 
Table 17: Randomisation of Patients to the Intervention and Placebo Arms 
Placebo Intervention 
Patient 1 Patient 2 
Patient 4 Patient 3 
Patient 6 Patient 5 
Patient 7 Patient 8 
 Patient 9 
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Table 18 displays the characteristics of the patients who consented to take part in the 
study. All patients had a diagnosis of multiple myeloma. A variety of different types of 
myeloma were represented. One patient had non-secretory multiple myeloma, a rare 
form of the disease. Five of the nine patients recruited were male (56%). The mean age 
of the patients in the intervention group was 54.40 years old (SD=5.320). The youngest 
patient recruited in the study was 46 years old, and was randomised to receive the 
intervention. This patient had received previous radiotherapy for a testicular carcinoma 
in 2000. One placebo patient had also previously received radiotherapy to his pelvis 
during earlier myeloma treatment (Patient 6). All patients received melphalan in a dose 
of 200mg/m2. As this dose is calculated based on body surface area (BSA), and the 
patients in the intervention arm were heavier, it is not surprising that the mean dose of 
melphalan received by patients in the intervention arm was higher than that received by 
patients in the placebo arm. All patients had experienced prior chemotherapy, with two 
patients, one from each arm, having had a previous autologous transplant.  
 
There was large amount of variation in the amount of stem cells patients received. The 
mean overall stem cell dose was 3.80x106/kg. The intervention group received a 
substantially lower dose of stem cells than the placebo group. Patient 6 (placebo) 
received 13.62x106/kg stem cells. This exceptionally high dose was due to an extremely 
high collection being frozen for preservation during his previous transplant. As the bag 
of cells had been frozen it was not possible to split the collection into smaller doses. If 
the cell collect of Patient 6 is excluded, the placebo group received a mean of 
3.32x106/kg, still larger than the intervention group mean of 2.12x106/kg. One patient 
(Patient 9: intervention) received a combination of stem cells and bone marrow. Three 
patients recruited into this study were ex-smokers. All three stated that they had 
previously smoked less than a packet of cigarettes a day. 
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Table 18: Baseline Characteristics 
Variable Category Intervention (n=5) (%) 
Placebo (n=4) 
(%) Total (n=9) (%) 
Gender  Male 3 2 5 
Female 2 2 4 
Age (years) Mean 54.40 54.75 54.56 
Range 46-60 52-57 46-60 
SD 5.320 2.630 4.096 
Height (cm) Mean 169.68 170.35 169.98 
Range 152-183 156-185 152-185 
SD 15.55 12.26 13.32 
Weight (kg) Mean 95.7 82.6 89.9 
Range 75.0-106.8 70.0-88.5 70.0-106.8 
SD 12.34 8.654 12.32 
BMI (kg/m2) Mean 33.46 28.80 31.39 
Range 29.9-41.6 25.1-36.4 25.1-41.6 
SD 4.6998 5.2339 5.2296 
Melphalan dose 
(mg/m2) 
Mean 420 380 402.2 
Range 360-460 360-400 360-460 
SD 40.0 23.09 38.0 
Cells (x106/kg) Mean 2.12 5.89 3.80 
Range 2.03-2.24 2.45-13.62 2.03-13.62 
SD 0.08 5.20 3.76 
Previous 
Chemotherapy 
Regimes 
CTDx6 3 (33.3) 2 (22.2) 5 (55.5) 
VADx6 1 (11.1) 0 (0) 1 (11.1) 
CTDx2/VEL DEXx2 1 (11.1) 0 (0) 1 (11.1) 
CD/CVADx3/PADx2 0 (0) 1 (11.1) 1 (11.1) 
CZDEX x4, PADx2 1 (11.1) 0 (0) 1 (11.1) 
Previous Auto 1 (11.1) 1 (11.1) 2 (22.2) 
Previous Radiotherapy 1 (11.1) 1 (11.1) 2 (22.2) 
Type of 
Multiple 
Myeloma 
Light Chain Myeloma 0 (0) 2 (22.2) 2 (22.2) 
IGG (Kappa) Myeloma 1 (11.1) 1 (11.1) 2 (22.2) 
Non-secretory 
Myeloma 
1 (11.1) 0 (0) 1 (11.1) 
Oligosecretory 
Myeloma 
2 (22.2) 0 (0) 2 (22.2) 
IGA Myeloma 1 (11.1) 1 (11.1) 2 (22.2) 
Medical History Testicular cancer 1 0 1 
Sleep Apnoea 1 0 1 
Barretts’s Oesophagus 1 0 1 
Leg Ulcer 0 1 1 
DVT 0 1 1 
Medical History 
(Cont.) 
IBS 1 0 1 
Asthma 1 0 1 
Breast cysts 0 1 1 
Gynaecological polyps 0 1 1 
Jugular thrombosis 0 1 1 
Smoking Never  3 (33.3) 3 (33.3) 6 (66.6) 
Former  2 (22.2) 1 (11.1) 3 (33.3) 
CTD= Cyclophosphamide, Thalidomide and Dexamethasone. VAD=Vincristine, Adriamycin and 
Dexamethasone. VEL DEX=Velcade, Dexamethasone.  CD= Cyclophosphamide, Dexamethasone.  
CVAD= Cyclophosphamide, Vincristine, Adriamycin and Dexamethasone. PAD= Bortezomib, Doxorubicin and 
Dexamethasone. CZDEX=Cyclophosphamide, Idarubicin and Dexamethasone.  
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Three patients did not complete the study. One patient (Patient 2: intervention) was 
withdrawn from the study at day+9 due to her urgent admission to the CCU with a chest 
infection. Two patients discontinued the intervention after 5 days of supplementation 
(Patient 8) and one day of supplementation (Patient 9) respectively. Both these patients 
were randomised to receive the intervention. Patient 8 withdrew from the study due to 
uncontrolled nausea and vomiting. Patient 9 withdrew due to rigors and flu-like 
symptoms that were due to a suspected infection in his Hickman line. These symptoms 
ceased after the line was removed. Both patients gave verbal consent for the researcher 
to continue to collect daily oral and pain, and weekly nutritional scores after they 
stopped supplementation. It was the opinion of the consultant Clinician that neither 
patient’s symptoms were due to the intervention.  
 
8.4.2 Adherence patterns 
Based on previous reports of the duration of mucositis, it was thought that patients 
would receive the intervention or placebo for approximately 15 days. This was a correct 
estimation for the patients in the placebo arm. Table 19 shows the mean, median, range 
and standard deviation (SD) of supplementation for both groups.  
 
Table 19: Days of Supplementation 
Variable Intervention Placebo Overall 
Mean (doses) 7.20 15.0 10.67 
SD 2.11 1.29 5.52 
 
The highest number of doses received was 18 (Patient 6). This patient missed three 
doses on day+1, day+12 and day+15. When this patient missed his first dose, he took 
two doses the next day (morning and evening). He was counselled not to do this again. 
The lowest number of doses received was one (Patient 9). This patient suffered from 
flu-like symptoms during administration of chemotherapy and stem cells and withdrew 
from the study. Four patients missed their first dose of the medication. Patient 7 
(placebo) missed the first dose due to a staff error (see feasibility of informed consent, 
randomisation and pharmacy release). Patient 8 (intervention) was admitted to the ward 
on the day of his melphalan infusion (day-1) due to a lack of beds. Patient 5 was 
admitted to the ward with a slight cough, his first dose was therefore omitted because 
the decision of his suitability for transplant was delayed until the following morning. 
Patient 9 (intervention) was also admitted on the day his chemotherapy was due, 
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resulting in the first dose being missed. This patient then missed his second dose due to 
the aforementioned flu-like symptoms. The patient who missed the most doses was 
patient 4 who missed seven doses. This was partially due to the patient going to sleep 
very early in the evening, and therefore being unable to take her placebo dose last thing 
in the evening. After discussion with the researcher she tried taking her capsule in the 
afternoon. However, this was not too successful as she subsequently became ill with 
febrile neutropenia and missed more doses.  
 
8.4.3 Withdrawals 
Table 20 shows patient withdrawals from the trial. Three patients withdrew from the 
study. All three of these patients were randomised to receive the intervention. Patient 2 
was admitted to the CCU on day+8 after receiving 9 days of supplementation. Patient 8 
withdrew due to uncontrolled nausea and vomiting on day+2 after receiving four doses 
of vitamin E. Patient 9 also withdrew due to flu-like symptoms and rigors which 
required oxygen supplementation. This patient had been on the study for three days but 
had only received one dose (on day 0). The mean doses for the intervention group 
shown in Table 19 do not reflect either the three patients who missed their initial dose 
or the three patients who withdrew from the study in this group.  
 
Table 20: Reasons for Withdrawals 
Reason for withdrawal Intervention Placebo 
CCU admission 1 0 
Flu-like symptoms and rigors 1 0 
Uncontrolled nausea and vomiting 1 0 
Total 3 0 
 
8.4.4 Patterns of mucositis 
Due to the low number of patients recruited to take part in this study it is unwise to 
discuss any differences between the study arms, as such differences are likely to be a 
Type II error. Therefore the focus of the next section will not be on statistical 
differences between the groups, however, the results of individual patients will be 
discussed.  
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8.4.4.1 Area under the curve 
Table 21 shows the area under the curve analysis for the two arms of the study. This 
analysis was conducted by a Statistician blinded to the randomisation key. The 
randomisation key was broken only after all data had been entered and the primary 
analysis had been conducted.  
 
Table 21: Area under the Curve Analysis for Days +1 to +15. 
 N Mean SD Test 
statistic 
df p 95% CI for 
difference 
Effect 
size 
DIMcombined         
Placebo 4 303.0 52.2 t=0.48 6 0.646 -72.1 to 107.6 d=0.34 
Intervention 4 285.3 51.6 Z=-0.58  0.686  rZ=0.20 
WHOscore         
Placebo 4 18.1 11.1 t=0.25 6 0.810 -14.2 to 17.4 d=0.18 
Intervention 4 16.5 6.6 Z=-0.15  0.886  rZ=0.05 
 
 
AUC = (x2 + x1)/2 + (x3 + x2)/2 + … + (x15 + x14)/2 
= ∑ xi – x1/2 –x15/2 
where ∑ xi is the sum over all of x1, x2, …, x15. 
 
Equation 1: Area under the Curve (AUC) 
 
The AUC was calculated using the equation shown in Equation 1. Patient 2 was 
excluded from the analysis due to the extent of the missing data for this patient. A small 
number of missing values were substituted to obtain complete values for the remaining 
8 participants using linear interpolation for missing observations before day 15 (4 
observations out of 60 for DIMcombined and 1/60 for WHOscore) or last observation 
carried forward for day 15 (one observation for each measure). As expected with such a 
small sample, Table 21 shows no significant differences between the arms for mucositis 
measured using both the DIM and WHO instruments.  
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8.4.4.2 Duration of ulcerative mucositis 
Table 22 shows the duration of ulcerative mucositis as measured using the WHO tool. 
The placebo group experienced both a higher mean and median duration of mucositis. 
This may be due in part to patient 6 suffering with ulcerative mucositis for 11 days.  
 
Table 22: Duration of Ulcerative Mucositis Measured Using the WHO Instrument 
Variable Intervention Placebo Overall 
Mean duration (days) 4.60 6.25 5.33 
SD 4.57 2.61 3.46 
Median (days) 3.00 7.00 5.00 
 
 
8.4.4.3 Highest WHO mucositis grades 
Table 23 shows the highest mucositis grades experienced by patients during the trial. 
One patient (patient 7) did not develop ulcerative mucositis, represented by a WHO 
score greater than 1. Two patients (Patients 1 and 9 respectively) developed ulcers but 
did not report problems swallowing solid food. Patient 8 was the only patient to develop 
a mucositis score of four due to a bleeding ulcer at the back of his throat that inhibited 
drinking solids and made swallowing painful. However, with adequate pain control this 
situation lasted only 24 hours. 
 
Table 23: Highest Mucositis Grades Measured Using the WHO Instrument 
Arm Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 Total 
Intervention 0 0 1 3 1 5 
Placebo 0 1 1 2 0 4 
Total 0 1 2 5 1 9 
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8.4.4.4 Mean mucositis scores measured using the DIM tool 
Table 24 displays the mean and the median Daily Index of Mucositis scores for each arm. The 
intervention group experienced a lower mean but a higher median DIM score. This group also 
had a much larger standard deviation possibly due to Patient 9 (intervention) only experiencing 
a maximum DIM score of 24 and Patient 8 (intervention) and Patient 2 (intervention) 
experiencing scores of 38 and 39 respectively.  
 
Table 24: Mean Mucositis Scores Measured Using the DIM Instrument. 
Variable Intervention Placebo Overall 
Mean score (DIM) 33.00 33.75 33.3 
SD   6.04   3.50   4.80 
Median (DIM) 35.00 33.50 35.0 
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8.4.4.5 Comparison of DIM scores to WHO scores 
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Figure 36: Comparisons of DIM Score and DIM Score Without Subjective Parameters 
With WHO Score34 
 
In order to explore the differences between the oral assessment instruments graphs 
comparing the WHO and DIM daily values were plotted for each patient (Figure 36). As 
the DIM instrument was designed to allow for the exclusion of subjective assessment 
parameters (pain, talking, saliva, swallow), an altered DIM score was also plotted 
against the WHO results for comparison. Overt differences can be seen between the oral 
assessment instruments for three patients. The WHO score for Patient 1 indicates that 
                                                     
34
 DIM assessed from zero (none) to 40 (worst possible grade), WHO score assessed from zero (no 
mucositis) to four (severe mucositis) 
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this patient was still ulcerative at discharge from hospital. However, the DIM 
instrument indicates a substantial improvement in the patient’s condition in the previous 
four days, represented by a considerable decrease in score (from 35 to 13). This pattern 
remains similar when the subjective elements of the DIM instrument are removed.  
 
The WHO score for Patient 6 suggests that the oral condition in the patient is getting 
substantially better, however, the results of the DIM instrument are still extremely high, 
and are not greatly changed by the removal of the subjective components of the 
instrument. In the graphs for Patient 7 the DIM instrument once again indicates that the 
patient’s oral problem has not resolved. The differences between the WHO and DIM 
instruments results are not explained by the removal of the subjective parameters from 
the DIM tool in any of the nine patients recruited into the trial. It is clear that the DIM 
instrument provides more information about the condition of the oral cavity than the 
WHO instrument. However, it is considered worthwhile to also utilise the WHO scale in 
a clinical trial as it permits data to be dichotomised in a meta-analysis. Currently, the 
inclusion of multi-component instruments (such as the DIM instrument) is not usually 
possible in a meta-analysis due to the complexity of dichotomising data across a variety 
of instruments which have a large variation in total scores. As such, use of the DIM 
score alone could mean the exclusion of any study from future meta-analyses. Adoption 
of the WHO scale therefore permits greater comparability with other studies, at the cost 
of relatively minimal additional researcher work, and no additional patient burden. 
 
8.4.5 Pain 
Patients were asked to complete the Oral Mucositis Daily Questionnaire (OMDQ) once 
daily during supplementation. This instrument is comprised of six questions and asks 
patients to rate their overall health (scored from one: ‘worst’, to ten: ‘perfect’, on a 
VAS), the amount of mouth and throat soreness they have experienced over the 
preceding 24 hours (scored from zero: ‘none’, to four: ‘extreme’), and the impact such 
soreness has made on their ability to swallow, drink, ear, talk and sleep (scored from 
zero: ‘none’, to four: ‘unable to do’), their overall mouth and throat soreness during the 
preceding 24 hours (scored from one: ‘none’, to ten: ‘worst’, on a VAS), the amount of 
diarrhoea they have experienced (scored from zero, none, to four, severe) and rate the 
severity of this diarrhoea (scored from one: ‘none’, to ten: ‘worst’, on a VAS). One 
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patient (Patient 2, intervention) failed to complete the questionnaire twice while 
suffering from uncontrolled nausea, vomiting and diarrhoea. All remaining patients 
completed the questionnaire every day during supplementation. The results of each 
question will now be discussed in the order in which they were asked.  
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8.4.5.1 Overall health 
 
 Placebo                   Intervention 
 
Figure 37: Patient Assessments of Overall Health Plotted Against Time35 
                                                     
35
 Score of 10 indicated best possible health, score of 0 indicated worst possible health 
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Figure 37 shows the patients’ perception of their overall health in the previous 24 hours. 
At baseline this question commonly provoked the response “I’ve got cancer”. In this 
instance the researcher tried to get the patient to focus on the previous day, and not on 
their diagnosis, unless this had been a problem within the last 24 hours.  
 
All patients experienced a decrease in their perception of overall health at some point 
during treatment. The greatest decrease from baseline in overall health reported was a 
decrease of eight on the VAS. This was seen in two patients (Patients 8 and 9 
respectively). The lowest drop in perception of overall health was reported by Patient 4 
(placebo), who reported a decrease of 3 on the VAS. Only one patient (Patient 8: 
intervention) reported a score of zero (worst possible). This was on day+1, 48 hours 
after receiving chemotherapy.  
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8.4.5.2 Mouth and throat soreness in previous 24 hours 
 
Placebo                   Intervention 
 
Figure 38: Patient Assessment of Mouth and Throat Soreness Plotted Against Time36 
                                                     
36
 A score of zero denoted no soreness, a score of four denoted extreme soreness 
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Figure 38 shows the patients’ assessment of mouth and throat soreness experienced 
during the study. All patients experienced some degree of mouth and throat pain. Patient 
9 reported a sore throat at baseline and gave it a score of one. No other patients reported 
mouth or throat pain at baseline. Patient 7 took the shortest time to report pain, 
indicating a score of one at the 2nd visit (day 0). Two patients (Patients 1 and 8) took the 
longest time to report pain, both experiencing pain for the first time at time point seven 
(day+5). Two patients reported the highest possible amount of pain on the subscale (a 
grade of four): Patient 2 reported a grade of four at visit 10, which coincided with a 
DIM score of 39 and a WHO score of three (Figure 36); Patient 8 reported grade four on 
visit 11 (day+9), which coincided with a DIM score of 37 and a WHO score of three 
(Figure 36).  
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8.4.5.3 Mouth and throat soreness limiting activities 
 
      Placebo                                                   Intervention 
 
Figure 39: Limiting Activities Scores Due to Mouth and Throat Soreness Plotted 
Against Time37 
                                                     
37
 All categories graded from 0 (no limitation) to 4 (unable to do) 
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Figure 39 shows the limiting activities scores recorded by the patients. Patients were 
asked to score how any mouth and throat soreness was limiting their ability to sleep, 
talk, eat, drink and swallow on a five point scale, with zero as ‘no limitation’ and five as 
‘unable to do’. Patient 6 (placebo) reported the greatest number of activities limited by 
mouth and throat soreness. Patient 8 (intervention) reported the highest scores for this 
limitation. Interestingly, in spite of not developing ulcerative mucositis, Patient 7 
(placebo) experienced ‘a lot’ of limitation in eating at visits nine, ten and 11, suggesting 
that it may not just be the presence of ulcers that limits a patient’s ability to eat, and the 
severe erythema may be just as prohibitive to consumption of solids.  
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8.4.5.4 Overall Mouth and Throat Pain over previous 24 hours 
 
Placebo                                                         Intervention 
 
Figure 40: Overall Mouth and Throat Pain (VAS) Plotted Against Daily Index of 
Mucositis Scores38 
                                                     
38
 Mouth and throat pain graded from 0 (no soreness) to 10 (worst possible), DIM assessed from 0 (none) 
to 40 (worst possible grade) 
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Figure 40 shows the overall mouth and throat pain, recorded on a VAS, plotted against 
the DIM scores for each patient. This figure suggests some correlation between patient 
reports of pain and the DIM tool, particularly for Patient 3. With the exception of 
Patient 1, all patients started reporting pain a few days after a rise in VAS scores. The 
highest pain scores reported by the patients was a grade of eight. This score was 
reported by three patients (Patient 3: intervention, Patient 6: placebo, Patient 8: 
placebo), and in each case was associated with a peak in DIM score.  
 
8.4.6 Nutritional scores  
Patients were assessed using the Patient Generated Subjective Global Assessment Tool 
(PG SGA) once a week during supplementation. The first section of this tool, which is 
completed by the patient, asked about weight loss. A score of between zero and four 
(10% weight loss or greater) was calculated based on the amount of weight a patient had 
lost in the previous month. If the patient had lost further weight in the last two weeks an 
additional one point was added. The maximum score for this section is five. 
 
The second section asked patients about their food intake. Patients are first asked to rate 
their food intake during the past month, with reports of eating less than normal given a 
score of one. The next section asked patients about quantities giving the following 
options: “less than a normal amount (score of one), “little solid food” (score of two), 
“only liquids” or “only nutritional supplements” (both score three), “very little of 
anything” (score of four). The final option is “only tube feedings” (score of zero). The 
maximum score for this section was five. 
 
The third section asked patients to report any symptoms they have experienced during 
the previous two weeks. The presence of nausea, constipation, taste changes, a dry 
mouth, “smells bother me”, or “other” were each given a score of one. Reports of mouth 
sores or problems swallowing were each given a score of two. The existence of 
diarrhoea, pain, vomiting or a lack of appetite were each given a score of three. 
Therefore this section was scored out of a possible 23.  
 
The fourth section asked about activities and function. Patients were given the following 
options: “normal” (score of zero), “not my normal self, but able to get up and about 
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with fairly normal activities” (score of one), “not feeling up to most things, but in bed or 
chair less than half a day” (score of two), able to do little activity and spend most of the 
day in chair or bed” (score of three), “pretty much bedridden, rarely out of bed” (score 
of three). The maximum score for this section was three. 
 
Section five provides a score for the patient’s condition. Each criteria: cancer, AIDS, 
pulmonary/cardiac cachexia, presence of an open wound/decubitus or fistula, presence 
of trauma, or age greater than 65 years old was given a score of one. The maximum 
score for this section was six. Metabolic stress was assessed in section six. Fever 
presence and duration and use of steroids were each graded from zero to three, giving a 
maximum score of nine in this section. 
 
The final section of the instrument was a physical examination. Fat stores (three sites: 
orbital fat pads, triceps skin folds and the fat overlying the lower ribs) and muscles 
(seven sites: temples, clavicles, shoulders, interosseous muscles, scapula, thigh and calf) 
were graded from zero (none) to three (severe) for the amount of deficit identified 
through visual examination and gentle palpation of the sites. Fluid status (three sites) 
was also graded from three for presence of excess fluid. An overall score for each 
section was then calculated (mean value). The maximum score for this section was 
three. A total score for this instrument was then calculated by combining the scores for 
each section. The maximum possible score using this instrument was 54; however, it is 
extremely unlikely that a patient would score this anywhere near as high. Higher total 
scores using this instrument indicate that a patient was malnourished, while low scores 
indicate that a patient was well-nourished.  
 
This instrument was chosen because it was recommended by the American Dietetic 
Association (ADD) as the standard for nutritional assessment in oncology patients. The 
researcher was concerned about the reproducibility of the assessments of fat stores, and 
muscle and fluid status prior to starting the trial. However, the PG-SGA training video 
gave good examples of mild, moderate and severe deficits in fat and muscle, which the 
researcher used to make sure she was continuing to be consistent in her assessments and 
that the results for this category were therefore reproducible between patients, and for 
the same patient over time.  
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No patient showed more than a mild deficit during the physical examination. This was 
most probably due to the relatively short time-scale that patients were assessed using the 
instrument. It could therefore be argued that while the decision to use the PG-SGA 
instrument in general, and the physical examination component in particular, in the 
feasibility study was valid, it might be better employed in studies of a longer duration.  
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Placebo                                                         Intervention 
 
 
Figure 41: Total Subjective Global Assessment Scores 39 
                                                     
39
 Low scores indicates that the patient is well-nourished, higher scores indicate malnutrition 
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Figure 41 shows the total nutritional assessment scores for each patient by assessment.  
Two patients missed an assessment: Patient 2 (intervention) was in the CCU when the 
3rd assessment was due and Patient 3 (intervention) was suffering with nausea, vomiting 
and diarrhoea when the 2nd assessment should have been completed. Nutritional scores 
decreased for only two patients between visits two and three (Patient 8 and 9, both 
intervention). The highest score achieved was 28 out of a possible 44, this was recorded 
in two patients (Patient 1: placebo, patient 2: intervention). The lowest score achieved 
was by Patient 7 (placebo), this patient did not develop ulcerative mucositis and was 
able to eat during her transplant, which may have reduced her score.  
 
8.4.6.1 Change in weight from baseline      
 
 
Figure 42: Change in weight from baseline40 
 
Figure 42 shows the change in patient weight during the study. These data were 
collected at the same time as the patient was assessed using the subjective global 
assessment instrument. Patient 8 (intervention) experienced the greatest drop in weight, 
with a loss of seven kilograms (kg), corresponding to a 7% reduction in weight. Patient 
3 (intervention) was the same weight at the first and third assessments; unfortunately 
weight data from assessment two were missing for this patient due to her inability to 
undergo nutritional assessment. 
                                                     
40
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8.4.7 Adverse events and safety 
 
Table 25: Adverse Events Experienced During the Study 
Adverse event Patient Number of Patients in each arm 
experiencing event 
1 2 3 4 5 6 7 8 9 Intervention  Placebo Total 
Blood / Bone Marrow 
White Cell Count * √ √ √ √ √ √ √ √ √ 5 4 9 
Haemoglobin * √ √ √ √ √ √ √ √ √ 5 4 9 
Platelet Count * √ √ √ √ √ √ √ √ √ 5 4 9 
Red Cell Count * √ √ √ √ √ √ √ √ √ 5 4 9 
Hematocrit * √ √ √ √ √ √ √ √ √ 5 4 9 
Mean Corpuscular 
Haemoglobin * 
√ √    √  √ √ 3 2 5 
Mean Corpuscular 
Haemoglobin 
Concentration * 
√ √ √ √ √  √ √ √ 5 3 8 
Neutrophils* √ √ √ √ √ √ √ √ √ 5 4 9 
Monocytes* √ √ √ √ √ √ √ √ √ 5 4 9 
Eosinophils* √ √ √ √ √ √ √ √ √ 5 4 9 
Basophils* √ √ √ √ √ √ √ √ √ 5 4 9 
Lymphocytes* √ √ √ √ √ √ √ √ √ 5 4 9 
Myelocytes ^      √    0 1 1 
Presence of large 
Unstained Cells 
  √   √    1 1 2 
Metabolic / Laboratory 
Adjusted Calcium* √ √ √ √ √ √ √ √ √ 5 4 9 
Alkaline Phosphatase^ √ √ √   √ √ √  3 3 6 
Albumin Low             √   √ √  √ √ 4 1 5 
 High   √       1 0 1 
Total Bilirubin^  √        1 0 1 
AST^  √      √ √ 3 0 3 
GGT^ √ √ √  √ √  √ √ 5 2 7 
Elevated LDH √ √   √ √ √ √ √ 4 3 7 
Magnesium^  √ √    √   2 1 4 
Phosphate            Low             √        1 0 1 
High √  √ √ √ √ √ √ √ 4 4 8 
Potassium Low  √    √ √ √  2 2 4 
High       √ √  1 1 2 
Proteinuria   √  √  √ √  3 1 4 
Serum 
Creatinine 
Low            √        1 0 1 
High √        √ 1 1 2 
Sodium Low   √       1 0 1 
High  √   √ √    2 1 3 
Urea √ √ √ √ √ √ √ √  4 4 8 
Gastrointestinal 
Constipation     √     1 0 1 
Dehydration  √        1 0 1 
Diarrhoea √ √ √ √ √ √ √ √ √ 5 4 9 
Nausea √ √ √ √ √ √ √ √ √ 5 4 9 
Vomiting √ √ √ √ √ √ √ √ √ 5 4 9 
Xerostomia √    √ √    1 2 3 
Pulmonary/ Upper Respiratory 
Cough  √        1 0 1 
Hiccups    √  √    1 1 2 
Wheeze  √        1 0 1 
Dermatology/ skin             
Alopecia √  √ √ √ √ √ √ √ 4 4 8 
Dry Skin         √ 1 0 1 
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Adverse event Patient Number of Patients in each arm 
experiencing event 
1 2 3 4 5 6 7 8 9 Intervention  Placebo Total 
Rash         √ 1 0 1 
Injection site reaction        √  1 0 1 
Constitutional Symptoms 
Fatigue    √ √ √ √ √ √ 3 3 6 
Fever   √    √  √ 2 1 3 
Rigors  √       √ 2 0 2 
Sweating  √        1 0 1 
Weight Loss √    √     1 1 2 
Infection 
Febrile Neutropenia √  √ √  √  √ √ 3 3 6 
Infection with grade 3 
or 4 neutrophils 
√ √  √  √    1 3 4 
Cardiac Arrhythmia 
Sinus Tachycardia  √ √ √  √  √ √ 4 2 6 
Cardiac General 
Hypertension √ √   √     2 1 3 
Hypotension  √ √ √    √ √ 4 1 5 
Coagulation 
APTT^  √     √ √  2 1 3 
Clauss Fibrogen*  √*        1 0 1 
Derived Fibrogen^ √ √ √ √  √ √ √ √ 4 4 8 
Prothrombin Time^  √  √  √ √ √  2 3 5 
Neurology             
Dizziness      √    0 1 1 
Haemorrhage/ Bleeding 
GI Bleed      √    0 1 1 
Nose   √       1 0 1 
Pain 
Pain √ √ √  √    √ 4 1 5 
Not classified             
Decrease in Globulin √ √ √ √ √ √ √ √ √ 5 4 9 
CRP √ √ √ √ √ √  √ √ 5 3 8 
Decrease in Total 
Protein 
√ √ √ √ √ √ √ √ √ 5 4 9 
APTT= Activated partial thromboplastin time, AST=Aspartate aminotransferase, CRP=C-reactive protein, GGT=Gamma-glutamyl 
transpeptidase, GI=Gastrointestinal, LDH=Lactate dehydrogenase,  
*decrease below normal limits as stated in the Common Terminology Criteria (CTC) (version 3) for adverse events  
 ^ increase above normal limits as stated in the CTC v.3 for adverse events 
 
Table 25 shows all adverse events recorded during supplementation and in the 30 days 
after the last dose. All patients experienced adverse events. Due to her chest infection 
and subsequent CCU admission, Patient 2 (intervention) experienced the greatest 
number of adverse events.  
 
Two patients in the intervention group required an extra administration of G-CSF. 
Patient 3 developed an infection after supplementation had ceased which lead to a drop 
in her neutrophil count. G-CSF was administered and the patient subsequently 
discharged. This patient was seen in an outpatients' faculty close to home ten days after 
discharge and another drop in the neutrophil count (to 1.0x106/kg) was reported.  
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However, she had started to regenerate her counts (to 1.70x106/kg) when she was seen 
in outpatients (when follow-up ceased) five days later. Patient 5 also required another 
administration of G-CSF. This patient was discharged home with a neutrophil count of 
1.40x106/kg, which had dropped to 0.80x106/kg when seen in clinic. This patient had 
lost 3.6kg in the ten days since discharge and admitted he “wasn’t really eating 
anything”. When followed up in clinic ten days later, this patient had a neutrophil count 
of 1.30x106/kg. Both patients eventually developed neutrophil counts within the normal 
range (2.00-7.50x106/kg).  
 
Three patients in the Intervention group had elevated levels of aspartate 
aminotransferase (AST), an enzyme used to monitor liver damage. However, two of 
these patients (Patient 2 and Patient 3) also had elevated levels at baseline. Patient 8 
experienced an elevation of AST at day+2, three days after receiving chemotherapy and 
starting the trial, and at day+3. AST levels then returned to the normal range before 
becoming elevated again at day+16 (14 days after the cease of supplementation) and 
day+17, and at day+33 and day +46. This patient also had elevated levels of Gamma-
glutamyl transferase (GGT), and when asked by a doctor, denied he had been drinking 
since discharge stating that he had previously been informed that his liver was very 
sensitive to paracetamol, which he had received almost daily during transplantation. 
 
8.4.8 Conclusion of section two 
The second section of this chapter has detailed the results of the feasibility study. As 
this trial recruited nine patients, the previously planned methods of analysis detailed in 
the study protocol could not be used. Therefore patterns of mucositis, pain and 
nutritional support indicators were discussed. This feasibility trial identified a difference 
between the data produced by the oral assessment instruments. The suitability of these 
assessment instruments, together with the suitability of the other methods of assessment 
will be addressed in the discussion. Furthermore, the discussion will consider the 
lessons learnt in the planning, conducting and analysis of the feasibility study. It is 
hoped that the lessons learnt through this feasibility trial will be utilised in the design of 
effective studies of interventions for the prevention of OM in the future.  
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Chapter 9 Discussion 
This chapter will bring together the various elements of the previous chapters; it will 
consider the literature on the prevention of mucositis in terms of its risk of bias and 
practical issues arising during the conduct of published RCTs. It will discuss the 
assessment of mucositis within clinical trials and the choice of appropriate 
measurements tools. It will outline how these factors were used to inform the 
development of a feasibility study and how future trials should be conducted in light of 
the findings presented.  
 
It has been well established that mucositis is a painful and distressing side effect of 
cancer treatment for patients (Borbasi et al., 2002, Cheng, 2009), which has a 
substantial clinical and economic impact, manifested through an increased need for 
opiates and other supportive therapies, longer duration of hospitalisation (Vera-Llonch 
et al., 2007a) an increased risk of infection (Ruescher et al., 1998), and in severe cases, 
dose modification or treatment breaks to allow the patient to recover (Peterson and 
Cariello, 2004). The prevention of mucositis in patients treated for cancer is an area that 
receives much attention from research groups, with 130 published trials currently 
included in the Cochrane review on this topic. Thirty three trials investigating a variety 
of interventions for the prevention of mucositis are also listed as ongoing on Current 
Controlled Trials. Given the importance of this topic and the resources that go into 
conducting these trials, it is imperative that the trials are conducted to the highest 
possible standard if they are to inform clinical practice.  
 
Gaps between research findings and interventions used in clinical practice have been 
identified in the feasibility study and in the literature, particularly in the use of 
chlorhexidine for mucositis prevention (Barker et al., 2005, Glenny et al., 2004). Such 
gaps may be a consequence of Clinicians finding it difficult to keep on top of the huge 
volume of literature in this field. The use of systematic reviews and guidelines are 
methods of closing such gaps. Systematic reviews are often used as building blocks for 
the development of guidelines and for the drawing up of recommendations. However, 
for these reviews to be of most use, they need to be based on the results of high quality 
trials. An integral part of Cochrane reviews is the assessment of trial quality. The 
recently introduced risk of bias instrument assesses the internal validity of trials 
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(Hartling et al., 2009) by assessing the risk of potential biases across eight domains: 
sequence generation, allocation concealment, blinding (carers, patients and outcome 
assessors), incomplete data reporting, selective outcome reporting and other (Higgins 
and Altman, 2009).  
 
The application of the new ROB tool to the prevention of mucositis trials have shown 
83 trials to be at unclear ROB and 38 studies to be at high ROB. It is disappointing that 
out of 130 trials included in the Cochrane review and 43 interventions studied, only nine 
interventions have been shown to be potentially beneficial, and of these only one 
intervention, antibiotic pastille or paste, is supported by trials of low risk of bias, and 
even then, this result is only for the prevention of severe mucositis, as the other domains 
of interest were excluded from the analysis. However, one drawback when using the 
ROB instrument is that only what is reported in the paper can be assessed, and therefore 
studies which were well conducted but poorly reported may be misrepresented (Nuesch 
et al., 2009).  
 
By taking a closer look at the methods used within the previously published trials, both 
in terms of ROB and practical issues, and by drawing on experience from the feasibility 
study, we can gain a realistic picture of how future trials can be conducted in a way that 
ensures the results are at low risk of bias.  
 
9.1 Regulatory requirements/ pharmacy approval 
One of the first stages in the undertaking of a clinical trial is ensuring that all regulatory 
requirements are met, including ethical, regulatory and hospital trust approvals. The 
time taken for the start-up of the feasibility trial, measured from the researcher’s first 
contact with the Hospital research and development department to the first patient 
starting the trial was 14 months: a number of delays were experienced in setting up the 
study. Before the MHRA application could be submitted an Investigational Medicinal 
Product Dossier (IMPD) had to be written by Preston Pharmaceuticals. Completion of 
this dossier required additional information to be requested from the manufacturer 
(Capsugel), through the supplier (Healthplus). This was especially difficult due to a lack 
of understanding on the part of Healthplus with regard to the Ethics and MHRA 
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application process. It is possible that many of these problems could have been avoided 
had another supplier been selected to provide the intervention and placebo products. 
Further delays were experienced in waiting for the products to be packaged and 
dispatched by Preston Pharmaceuticals. The need for QP release of trial supplies has 
been identified in the literature as a barrier to the conducting trials, as this increases trial 
costs and delays (Duley et al., 2008). Recruitment in this feasibility study ceased when 
the sell-by date for the intervention was reached on 30th June 2009. Extension of the 
recruitment period would have required a reapplication to the MHRA with a new 
IMPD, which given the delays already experienced and the length left in the 
Researchers doctorate program, was not considered to be feasible. Future studies should 
keep such issues in mind when going through the regulatory approvals process.  
 
The greatest delays experienced during this study were while waiting for NHS Trust 
approval. However, since completing this trial, the researcher has heard of anecdotal 
accounts of Trust approval for other trials conducted at the same hospital taking in 
excess of a year to be granted or declined, which suggests that the six months wait for 
this trial may have been comparatively rapid. Had the researcher and her supervisors not 
taken a chance in purchasing the intervention and placebo capsules and organising for 
them to be packaged prior to Trust approval being granted then it is likely that even 
greater delays would have been experienced in starting this trial. In addition, it is likely 
that the delays experienced during the set-up of this trial would have been considerably 
longer had it been a multi-site study. Bearing in mind that the trial in question was a 
non-commercial study, it is worth considering that this timeframe may have been 
shorter had the trial been funded by industry. Nevertheless, the 14 month timeframe 
identified in this trial may actually be relatively short compared to some studies, as 
timeframes as long as two years have been identified in the literature (Dilts et al., 2006).  
 
While the application process for Ethics and the MHRA have been combined since this 
trial gained approval, there is no reason to suppose that the approvals process has 
become more rapid since 2008, especially since the Trust approval process has 
remained the same. The Trust may therefore need to strike a better balance between 
ensuring rigorous research governance and making sure that the approvals process does 
not take so long that it discourages research. Approvals processes in excess of 14 
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months would have a significant impact on the feasibility of conducting future doctoral 
projects, and may force the abandonment of a clinical trial as a suitable thesis project. 
Macdonald and colleagues (2006), conducted a review of 114 trials which were funded 
through two united Kingdom funding bodies, and reported that 41% experienced delays 
in recruitment. The majority of the reported delays concerned staffing (22 trials), 
however delays in receiving necessary approvals, in the supply of intervention or 
placebo products and delays due to clinical arrangements are also reported (McDonald, 
2006), all of which were experienced by the feasibility study. Therefore taking into 
account the delays experienced during this study, the majority of which were due to the 
regulatory process, future studies in this area should set aside at least a year for all 
approvals to be gained.  
 
9.2 Clinician interest 
Several of the problems arising during the feasibility trial may have been avoided by 
ensuring clinical staff had input into the protocol design. This may have ensured that 
concerns raised about the trial could have been ironed out prior to the study 
commencing. It might also have given staff a sense of ownership of the trial and 
improved collaboration. However, given the dynamics of staff working on the unit at 
the time of the trial it is unlikely that all issues would have been resolved. For example, 
the recruitment of allogeneic patients may still not have been possible.  
 
Barriers to, and motivational factors for, Clinician participation in clinical trials, have 
been extensively reviewed (Fallowfield et al., 1997, Keinonen et al., 2003, Raftery et 
al., 2009, Rendell et al., 2007), however many of the issues identified are not applicable 
to small non-commercial studies, such as this feasibility study, as they focus on the use 
of Clinicians to recruit patients into either large multi-site commercially funded studies, 
or barriers to Clinicians conducting their own research. However, an interest in the 
research question has been suggested as a factor motivating Clinicians to participate in 
trials (Keinonen et al., 2003, Raftery et al., 2009). Taking into account the lack of a 
ward policy for the prevention of mucositis and the ad-hoc nature of treatment when 
oral conditions did develop, it seems reasonable to conclude that mucositis may not 
have been a research priority for the Clinicians on the ward, and that this was therefore 
a barrier to their participation in the feasibility study.  
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9.3 Identifying eligible patients 
Eligible patients were identified through the researcher’s attendance at the weekly 
transplantation meeting and subsequently through the discussion of any potential patient 
with their treating Clinician. This method worked well, but tended to fall down during 
the holidays, or in one instance, when all four consultants were attending a conference. 
During such times the transplantation meetings were cancelled and a list of patients 
circulated by email. This was initially problematic for the researcher, as it was ‘hit and 
miss’ whether she would receive such emails. Occasionally patients would also move 
up and down the transplant list depending on the availability of a bed, or the need for 
emergency admissions, which resulted in some patients being missed by the researcher 
during their outpatients’ appointment. However, the development of a good working 
relationship between the researchers and the transplantation co-ordinators as the trial 
went on, helped the researcher keep track of changes to the list and made this process 
easier. Eligible patients were approached during outpatients’ appointments in the 
presence of the treating Clinician. Patients who were missed in the outpatients’ clinic 
were approached on either the day ward or after admission to the unit in the presence of 
a member of the nursing staff. The method of identifying eligible patients employed in 
this trial proved to be feasible and could be employed in a future trial. 
 
9.4 Feasibility of patient recruitment 
The feasibility study aimed to recruit six patients for the pilot and 60 patients for the 
main feasibility study, resulting in an overall sample of 66 patients. This sample size 
was decided after discussion with a statistician, who helped the researcher interpret the 
literature concerning power calculations and advised that in order to estimate a 
parameter, such as a mean or median value, 30 patients or greater are required 
(Lancaster et al., 2004). In this case, an additional 30 patients would be required to 
estimate a standard deviation, resulting in a sample of 60 patients for the main 
feasibility study. An additional six patients were to be recruited for the pilot to check 
that patients were able to follow the protocol and that the data collection sheets were 
adequate. This study was not designed to be powered to detect differences between the 
groups for the prevention of mucositis or any other parameter. However, it was thought 
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that the results of this study would be used to inform a sample size calculation of a 
future study.  
 
Unfortunately, the problems experienced in recruiting patients to the project together 
with the low number of patients taking part in the study preclude sample size 
calculations from being conducted using data from the feasibility study. Eighty-four 
patients underwent transplantation in 2007 in the unit, and as the unit had been 
expanded to accommodate more patients it was conceivable at the time of writing the 
protocol that the pre-specified aim of recruiting 66 patients for this study was 
achievable. However, the length of time taken to achieve regulatory and Trust approval, 
together with the problems recruiting allogeneic patients into the study, resulted in a 
greatly reduced recruitment pool of patients being available to the researcher.  
 
Eighteen patients were approached to take part in the feasibility study and nine patients 
were recruited, with the remaining nine patients declining to take part in the study. 
Patient recruitment into RCTs has been reported to be a significant problem (Prescott et 
al., 1999). Jenkins and Fallowfield (2000), attempted to identify patient’s reasons for 
accepting or declining to participate in clinical trials in a study conducted in patients 
with a mix of cancer types After discussion with a Clinician about clinical trials for 
which they were eligible, patients were asked to complete a questionnaire detailing their 
satisfaction with the consultation and their reasons for accepting or declining to 
participate in the proposed trial. Of the 204 patients who completed questionnaires, 147 
(72.1%) gave consent to take part in the trial proposed by their Clinician, with altruism: 
a belief that their participation would benefit future patients with the same condition, 
being the most frequently cited reason for participation. Notably, of those declining to 
participate, 32 patients (62.7%) stated that the idea of randomisation worried them, with 
ten of these patients stating that this constituted the most important factor in their 
decision in declining to take-part (Jenkins and Fallowfield, 2000). Such an aversion to 
randomisation has also been reported by Llewellyn-Thomas and colleagues (1991), who 
reported that 58% of colorectal patients approached to participate in a study declined to 
participate, with 63% of patients who refused citing an aversion to randomization as 
their main reason (Llewellyn-Thomas et al., 1991). 
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In a sub-set analysis of the Jenkins and colleagues (2000) study, the patient acceptance 
rates of trials which included a no treatment arm were compared to those of trials with 
an active treatment in all arms of the study. In this analysis, patients were found to 
significantly favour the active treatment arms option, with 80.6% of patients responding 
favourably to the active treatment studies compared to only 60.5% of patients in the no 
treatment studies (P=0.003). This sub-set analysis also showed that placebo arms were 
associated with high levels of acceptance, with 22 of the 24 patients offered a trial 
including a placebo arm deciding to enter the trial. However, the authors point out that 
this finding might be spurious as 19 of these patients were recruited by the same 
member of staff (Jenkins and Fallowfield, 2000), and it is therefore possible that this 
affected the result. It was clear to the researcher that the random element of this study 
was not favoured by some of the eligible patients. Several patients verbally stated a 
preference for the intervention of interest; while other patients made facial expressions 
of displeasure when they were informed that they had an equal chance of being 
allocated to the placebo group. The need for patient blinding was also met with a similar 
reaction by several patients.  
 
Patients have reported that they find the idea of randomisation confusing (Featherstone 
and Donovan, 1998), and that they would rather leave treatment decisions to the 
Clinicians rather than to chance (Gotay, 1991). Research into the descriptors of 
randomization employed in patient information sheets has also found that patients 
favour some descriptors of randomisation over others (Jenkins et al., 2005). In a study 
conducted by Jenkins and colleagues (2005), seven descriptors of randomisation were 
chosen from patient information sheets, and 600 patients were asked to indicate which 
statements they disliked and which ones they preferred. The most preferred description 
of randomisation in this study was one taken from the Cancerbackup website, which has 
since merged with Macmillan cancer research. This definition stated:  
“(randomisation) ... means that a computer randomly puts patients into the 
treatment groups in the trial. Each group has a similar mix of patients of 
different ages, sex and state of health” (Macmillan, 2010b, randomisation 
1st paragraph). 
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Interestingly, this was the only one of two definitions that made no reference 
randomisation being down to chance (Jenkins et al., 2005). The most disliked descriptor 
was taken from the National Cancer Institute (NCI) website, and stated:  
“(randomisation)...is a process that assigns participants by chance, rather 
than by choice, to either the investigational group or the control group” 
(National Cancer Institute, 2010, 1st paragraph).  
Participants reported that this definition was too complicated (Jenkins et al., 2005). The 
descriptor of randomisation used in the feasibility study was taken from the NRES 
guidance documents on consent forms and patient information sheets (National 
Research Ethics Service, 2009), and is dissimilar to those assessed in the Jenkins and 
colleagues study, stating:  
“Sometimes we don't know which way of treating patients is best. To find 
out, we need to compare different treatments. We put patients into groups 
and give each group a different treatment. The results are compared to see if 
one is better. To try to make sure the groups are the same to start with, each 
patient is put into a group by chance (randomly)” (National Research Ethics 
Service, 2009, 15). 
Although it appears to offer an easy-to-understand definition of randomisation, it is 
unclear if such a descriptor has been investigated using similar methods to those of 
Jenkins and others (Jenkins et al., 2005), to gauge patient opinion. Whilst patient 
preference for randomisation descriptors is an interesting topic, it is currently unclear if 
the descriptor of randomisation used in the patient information sheet affects actual 
recruitment rates. However, it may be wise to avoid overly complex descriptors of 
randomisation, such as shown on the NCI website, in future studies.  
 
In addition to concerns about randomisation, other barriers to patient participation 
include: a concern about treatment toxicity, a fear of the potential for loss of control, a 
preference for a particular treatment and the inconvenience of being involved in the trial 
and a personal preference for a particular treatment (Ellis, 2000). Certain groups of 
patients may be more receptive to the idea of a clinical trial than others. Patients who 
are naturally altruistic may be more likely to consent to research (Bevan et al., 1993, 
Jenkins and Fallowfield, 2000). In addition, various demographic factors may also be 
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important: patients who are male, older, less educated and from lower socioeconomic 
backgrounds have been reported to be more likely to take part in clinical trials (Ellis, 
2000, Gotay, 1991, Prescott et al., 1999), while ethnic minorities tend to be 
underrepresented in clinical trials (Roberson, 1994).  
 
Recruitment problems were a persistent theme in the studies assessed for ROB in 
chapter four. Six studies assessed for ROB described randomisation problems; however, 
four of these did not detail the specific nature of the problems. One study experienced a 
high rate of refusal (McAleese et al., 2006). Gandemer and colleagues (2007), in their 
chewing gum study, stated that nurses found it difficult to devote time to patient 
assessment. This lack of support staff availability is a common problem and has been 
reported as a barrier to the recruitment of patients. Clearly, recruitment will be 
significantly hampered if support staff, usually research nurses, have a large number of 
trials for which they need to recruit patients and collect data. The need for research staff 
to have time dedicated exclusively to a trial has been highlighted in the literature 
(Prescott et al., 1999), however, this still appears to be an on-going problem. Large 
multi-site, industry-sponsored trials frequently contribute financially towards research 
nurse time, or provide a payment to the hospital for every patient recruited. However, 
this may not be an option in many small, non-commercial studies, resulting in such 
studies being overlooked. The perceived importance of the research project to a 
researcher may also influence the amount of time and effort that gets put into 
recruitment, as researchers may be motivated to expend more effort on projects they 
perceive as more novel or important (Prescott et al., 1999).  
 
Slow patient accrual is therefore an established problem in clinical trials (Cox and 
McGarry, 2003), and one which appears to be especially challenging in trials conducted 
in patients with cancer (Jenkins and Fallowfield, 2000). The use of multi-site studies 
obviously leads to higher rates of recruitment, however, conducting studies on more 
than one site may not be a possibility due to financial or staffing constraints (Gul and 
Ali, 2010). Planning for longer periods of patient recruitment may help alleviate 
recruitment problems. In addition, the use of monthly or weekly recruitment targets may 
be beneficial, as they act as a constant reminder that staff need to focus on recruitment. 
However, such targets need to be frequently reviewed to allow for the recruitment 
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strategies to be changed and new strategies adopted (Gul and Ali, 2010). In their multi-
site study which compared diet and exercise, or medication, to placebo for the 
prevention, or delay in the onset, of type II diabetes, Rubin and colleagues (2002), 
describe the use of recruitment liaisons, who were in contact, on a monthly basis, with 
each site and helped to identify and resolve recruitment issues (Rubin et al., 2002). In 
those sites requiring more assistance, a stepped process of increasing contact was used, 
which included conference calls with key members of staff to address issues. If a site 
continued to experience problems after this period of intervention, they were visited by 
a member of recruitment liaison staff for a period of intensive help (Rubin et al., 2002). 
However, despite the best efforts of staff, four sites in this study did not reach their 
recruitment goals, indicating just how difficult recruitment can be. 
 
During the feasibility study, it was stipulated by the Ethics Committee that the first 
approach of any patient meeting the inclusion criteria was to be made by a member of 
the medical staff. However, it is possible that this approach may have had an impact on 
patient recruitment, especially if the member of staff was not properly educated about 
the aim and methodology of the trial, as this could misrepresent the study to the patient, 
which could impact their decision to consent to take part in the trial (Gul and Ali, 2010). 
Prior to the start of recruitment for the feasibility study, the researcher presented the 
project to unit staff in a lunchtime seminar series. However, less than 50% of the unit 
staff were present at this meeting, which meant that the researcher had to introduce, or 
reintroduce, the study to staff on the unit before asking them to approach the patient. It 
is possible; therefore, that some of the staff who made the first approach to the patient 
did not have a full understanding of the trial. Unfortunately, as such introductions were 
often made without the researcher being present, it is not possible to know what was 
said, meaning that no connections can be drawn between whether or not the staff 
member had been educated about the study, and whether the patient consented to take 
part in the study. If future studies are asked to use a member of the medical team to 
approach patients first, then it seems sensible to implement an extensive education 
programme on the units from which patients will be recruited. Such a programme could 
include an introduction talk to RCTs in general, and then to the trial (McDonald, 2006). 
This talk should be repeated at least once, to ensure staff are able to attend. In addition, 
the trial should be advertised on the ward, with copies of the patient information sheet, 
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or an introduction to the study sheet specifically written for staff, made available 
nursing and doctors’ offices.  
 
Major recruitment issues such as patient confusion with, or mistrust of, random 
allocation is only going to be resolved by more effective education of potential 
participants. It is possible that the provision of patient information booklets about 
clinical trials, together with the patient information sheet, may alleviate patient 
confusion about clinical trials. Such publications are produced by a number of different 
cancer charities and are widely available. Such publications may also be trusted by the 
patient as they are produced by a source external to the hospital or research group. 
Another method which has been suggested to boost recruitment of patients into clinical 
trials is the use of remuneration for travel expenses or monetary compensation for the 
patient’s time. However, the use of such compensation is controversial, especially if the 
value of compensation is high, as it could be coercive (Gul and Ali, 2010). In addition, 
as the patients in the feasibility study were inpatients, and therefore did not have travel 
expenses, it is difficult to see how the use of compensation would have worked in the 
present study. The nature of the recruitment problems experienced during this trial 
support the use of feasibility studies to explore such issues before opening full studies 
of future interventions. 
 
In the feasibility study, nine patients were recruited over the 35 weeks in which the 
study was conducted, giving a patient per week calculation of 0.26 patients/week. This 
study aimed to recruit 66 patients. By extrapolating this recruitment rate it can be 
calculated that it would have taken an additional 219 weeks, or 3.84 years, to reach the 
previously specified number of patients. Seventy-nine of the 130 studies assessed for 
ROB contained enough information for the calculation of recruitment rate for these 
studies. These recruitment rates ranged from 0.153 patients a week in a study of 
glutamine in patients with solid tumours receiving chemotherapy (Alvarado et al., 2002) 
to 7.66 patients per week in a multi-site study of iseganan in patients with head and 
neck cancer (Trotti et al., 2004). The mean average rate of recruitment for all studies 
which provided enough information, was 1.13 patients per week, however, after the 
removal of multi-site studies, which could be reasonably expected to experience higher 
rates of recruitment, the mean average rate of recruitment fell to 0.79 patients per week 
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for the single site studies. In addition to patient refusal to participate, the recruitment 
rate for this trial was affected by other factors, such as a lack of access to patients, 
which limited the number of patients available for the researcher to recruit. It is likely 
that for future trials, the expected rate of recruitment would be much higher and similar 
to the average calculated for the single site studies assessed for ROB.   
 
9.5 Feasibility of informed consent 
After approaching patients to take part in the trial, the researcher returned at least 24 
hours later to ask the patient whether they would like to participate. The shortest 
duration between initial approach and the patient being asked for a decision was 26 
hours. This patient, who did not want to participate in the study, was approached to take 
part after he had already been admitted onto the ward. The longest duration between 
approach and patient decision was five weeks. This patient consented to take part in the 
study, and was the fifth patient to be randomized. Seven patients were admitted the day 
before starting chemotherapy. These patients were admitted from the day unit first thing 
in the morning, and then were sent to another area of the hospital for Hickman line 
placement. It was generally mid-afternoon before patients arrived on the transplant unit. 
After being allocated a room, patients were given a ward orientation and booked in by 
their nurse. They were also seen by a doctor who medically assessed them prior to 
initiation of treatment as per standard operating procedures. The researcher found it 
difficult to speak to the patient during this period due to the number of other people who 
also needed to access the patient; a problem which was compounded by the presence of 
the patient’s family and friends. The researcher therefore spent a large amount of time 
waiting around on the ward for the patient to be free. If the patient chose to consent to 
take part in the study the researcher asked them to complete the consent forms and got a 
doctor to sign the prescription securing the pharmacy release of the products. The 
method of informed consent employed in the feasibility study was feasible. However, 
ethical clearance to recruit patients from the day unit first thing in the morning, before 
they received their Hickman line would be a useful addition to the informed consent 
procedures planned for future studies. 
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9.6 Feasibility of randomisation 
Only 26 studies (19.8%) assessed for ROB were judged to have adequately described 
the randomisation process. Twelve of these studies employed computer generated 
sequence generation. This method of randomisation was also used in the feasibility 
study. The School of Nursing, Midwifery and Social Work Statistician used a computer 
program to create a randomisation schedule, which he then sent to Preston 
Pharmaceuticals. The intervention and placebo products were packaged by Preston 
Pharmaceuticals using this schedule, in sequentially numbered packages of identical 
appearance. Packaged trial products were then delivered by Preston Pharmaceuticals to 
the hospital pharmacy by courier and the researcher was provided with a list of numbers 
which was used to allocate each new patient the next number in sequence. Intervention 
and placebo products could not be dispatched out of sequence because the pharmacy 
were dispatching the products and were completing the trial paperwork, which 
prevented the products being released out of order. The method of randomisation 
employed in this study was feasible and could be employed in future studies.  
 
9.7 Feasibility of allocation concealment  
Seventeen studies (13%) of the trials assessed for ROB described adequate methods of 
allocation concealment. Seven (5%) of these studies employed pharmacy controlled 
randomisation, while two studies (1.5%) described the use of sequentially numbered 
drugs containers of identical appearance. Nuesch and colleagues (2009) conducted a 
review of 16 meta-analyses in a meta-epidemiologic study of trials of interventions for 
osteoarthritis, and used the ROB assessment instrument to compare the effect sizes of 
interventions assessed at low ROB to those assessed at high or unclear ROB for the 
allocation concealment and patient blinding domains. 46 trials (29%) were judged to be 
at low ROB of bias for allocation concealment in this review, with sequentially 
numbered drugs containers being the most frequently used method of allocation (26 
studies), followed by central allocation (15 studies) (Nuesch et al., 2009). The authors 
report a trend towards smaller effect sizes in studies with adequate allocation 
concealment being less beneficial than those assessed as unclear or at high risk of bias 
(Nuesch et al., 2009). Similarly, trials with large effect sizes were significantly 
associated with a judgement of unclear or high risk of bias for allocation concealment 
(Nuesch et al., 2009). The authors conclude that adequate allocation concealment should 
be ensured in future trials (Nuesch et al., 2009).  
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The feasibility study employed both central randomisation and sequentially numbered 
drugs containers of identical appearance as methods of allocation concealment. Early 
during the study one of the consultant Clinicians asked that a copy of the randomisation 
schedule be placed in the study file, to ensure that this information could be accessed 
quickly in an emergency, such as a SUSAR. This was rejected by the researcher and her 
supervisors on the grounds that this study file was freely available on the ward and 
could be accessed by any member of staff, including the researcher. A compromise was 
reached by one of the researcher’s supervisors emailing a copy of the schedule to the 
consultant. This was then stored on the consultant Clinician’s computer. When asked by 
the researcher, the consultant stated that he had not looked at the schedule as he wanted 
to be able to make decisions regarding adverse events without prior knowledge of 
allocations, but also wanted to be able to reach this information, if he needed it, quickly. 
Clearly, in future trials a balance needs to be reached between ensuring adequate 
allocation concealment and making sure emergency unblinding procedures can be 
conducted. In order that the treatment allocation for an individual patient be known, but 
that allocation concealment is maintained for all current and future patients, individual 
allocations could be concealed through a series of sealed envelopes. The methods of 
allocation concealment employed during this study proved to be feasible for use in 
future trials. Careful consideration needs to be given to unblinding procedures in the 
event of a SUSAR.  
 
9.8 Feasibility of pharmacy release 
Allowing time for pharmacy release was an area of concern, as there was only a window 
of approximately two hours between the patient arriving on the ward and the pharmacy 
closing for the day. The development of a good working relationship with the unit 
pharmacist, who knew which patients were eligible for the project and when they were 
being admitted onto the ward, helped the researcher meet the pharmacy deadlines. This 
pharmacist would check with the researcher whether or not a patient had consented to 
take part in the study before he went up to the pharmacy to deliver prescriptions for the 
unit, and if a patient had consented to take part, the pharmacist would personally fill the 
prescription and place it in the evening pharmacy delivery box, so that the researcher 
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was reassured that the patient would receive the intervention or placebo that evening, 
after the researcher had gone home for the evening.  
 
9.9 Feasibility of blinding   
Blinding was assessed in three criteria for the studies included in the ROB analysis 
shown in chapter four, these were patient blinding, carer blinding and outcome assessor 
blinding. Nineteen studies described carer blinding adequately. Seventy-five studies 
were assessed to adequately describe patient blinding and 77 studies were deemed to 
describe suitable methods of outcome assessor blinding. The term ‘double blind’ was 
used extensively in the mucositis literature. However, this term lacks a standard 
definition, as in addition to patients and outcome assessors it can also be used to 
describe the blinding of outcome assessors and clinical staff or patients and clinical staff 
(Viera and Bangdiwala, 2007). Therefore a sub-set analysis was conducted for studies 
which explicitly stated that the outcome assessor was blind, and revealed that only 19 
studies (14.5%) gave specific information that outcome assessors were blind, while all 
other studies in this category only described themselves as double blind. Blinding of 
patients was impossible for three interventions included in the Cochrane prevention 
review as there was no suitable control which would be used. These were: cryotherapy, 
dental stent and honey. The use of outcome assessor blinding in such trials is therefore 
of upmost importance. However, only one of these trials employed such blinding 
(Motallebnejad et al., 2008). Two of these studies were found to be beneficial for the 
prevention of mucositis at all three levels of interest in the Cochrane prevention review, 
however, the lack of outcome assessor blinding renders such results unreliable.  
 
The feasibility study went through the Ethics and MHRA approvals process as a single 
blind trial because the researcher and her supervisors were unsure how feasible it would 
be to conduct a double blind study with only one researcher. However, pharmacy 
release of sequentially numbered identical packages, which had been packaged by a 
third party, ensured adequate allocation concealment, and as the researcher did not have 
access to the randomisation sequence, blinding was successfully maintained throughout 
the study. In addition, the researcher did not actually see the intervention or placebo 
capsules until after the study had been completed as the ward pharmacist performed the 
capsule counts, which were performed to check compliance. The researcher was 
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therefore unaware of the allocation sequence until after the blinded AUC analysis was 
conducted by the statistician and the codes were broken by one of the researcher’s 
supervisors. Patient blinding was maintained by all patients being barrier nursed in 
isolation. Support staff on the unit were also blind to the treatment allocation, due to the 
use of pharmacy release. Conducting future trials with the lead researcher blind to the 
allocation concealment is therefore feasible, if care is taken in setting up the trial. There 
is no reason why future studies cannot be performed with adequate outcome assessor 
blinding. Specific information about which members of the research team were blind 
should be included in all future publications.  
 
9.10 Feasibility of stratification  
Stratification is a process whereby patients are grouped according to pre-specified 
criteria hypothesised to affect the outcome of interest. Each group is then separately 
randomised to receive a treatment. Stratification is important in studies which recruit 
fewer than 100 patients, due to the risk of imbalance (Kernan et al., 1999). Two patients 
recruited into the study had previously undergone stem cell transplantation. By chance 
these patients were randomly allocated to different interventions. However, it is 
apparent that in future studies in this population of patients should be stratified by 
whether or not they had received a previous transplant, as this may potentially affect the 
severity of mucositis experienced by the patient.  
 
Prior to conducting the conducting the feasibility study, stratification by type of 
transplantation had been planned. The non-recruitment of patients receiving allogeneic 
transplantation, or an allogeneic transplant together with TBI means the success of 
stratification during the feasibility study cannot be assessed. The use of stratification 
increased the administrative burden of the feasibility study as three separate labels had 
to be produced and for the intervention and placebo groups to be packaged three 
separate times by Preston Pharmaceuticals. It is likely that the extra time that these 
processes necessitated may explain some of the delay experienced by Preston 
Pharmaceutical in dispatching the products to the hospital pharmacy, and therefore 
some of the delay in starting the trial. Kernan and colleagues (1999) recommend the 
identification of potential stratification factors through the use of multivariate analyses, 
such as those discussed in chapter two. However, as discussed in this chapter, there is 
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little consistency in these trials and more research in this area is needed before 
recommendations can be made. Allogeneic and TBI patients were excluded from the 
feasibility trial as a result of Clinician opinion; there is no indication that this patient 
group should be excluded from future trials of interventions for the prevention of 
mucositis. Also, in the case of small studies, it seems advisable to include type of 
transplantation as a stratification factor, due to the lack of consistency in the literature 
concerning the potential for the use of TBI to worsen mucositis severity (Avritscher et 
al., 2004).  
 
9.11 Rates of withdrawal (attrition) 
Prior to starting the trial, the expected rate of withdrawal for patients in this study was 
estimated to be 30% of the study population. This estimate was not based on the 
literature assessed for ROB, but rather on the experiences of the independent statistician 
who advised on aspects of the trial. Three patients withdrew during the study, giving a 
withdrawal rate of 33%. However, two of these patients elected to discontinue with 
supplementation, but allow the researcher to continue to visit them to perform daily 
assessments, resulting in only one patient (11%) withdrawing from the trial all together. 
This patient was withdrawn from the study due to her emergency transfer to the CCU 
with a chest infection. 
 
Only 61 of 130 studies assessed for ROB gave information about drop-outs or 
withdrawals, with the remaining studies either stating that no patients withdrew or 
provided outcome data that matched the number of patients previously stated as 
randomised into the trial. There was also a large amount of variation in the number of 
withdrawals in these studies, with one study experiencing rates of withdrawal as high as 
42% (Pfeiffer et al., 1990). Such high levels of withdrawal can introduce sampling bias, 
and affect the internal and external validity of the trial (Gul and Ali, 2010, Marcellus, 
2004). Forty-three studies (33%) of the studies discussed in chapter four reported no 
withdrawals, which is a surprising result considering that these patients have cancer. 
However, similar results have been reported elsewhere in the literature: in a review of 
87 longitudinal studies of organisational behaviour, Goodman and Bulm (1996) report 
that 38 studies (44%) provided no information about withdrawals. In contrast rates of 
withdrawal from trials as high as 70% have also been reported (Marcellus, 2004). It is 
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possible therefore that at least some of the studies assessed for ROB did experience 
drop-outs but that the authors chose to only publish the results of a sub-group of patients 
who completed the trial. The CONSORT statement, which aims to improve RCT 
reporting, recommends that, in addition to 35 other criteria, the numbers of patients 
recruited to each arm, withdrawals, and the reasons for such withdrawals are stated 
when the study is published (Schulz et al., 2010). While 21 of these studies assessed in 
chapter four were published before the CONSORT statement in 2001 (Altman et al., 
2001), the remaining 22 studies are an area for concern. A 30% rate of withdrawal is a 
suitable expectation for a future study.  
 
9.12 Compatibility with standard care 
The feasibility trial was designed to be conducted over and above standard care. 
However, the unit did not have a mucositis prevention or treatment policy and patients 
were not given routine mouthcare advice. Only two patients enrolled in the study 
received any intervention for the prevention of mucositis: both performing oral cooling 
(cryotherapy) with ice during melphalan administration. However, only one of these 
patients received this intervention at the suggestion of a member of the clinical team, 
the other patient having read about the technique on the internet. Barker and colleagues 
(2005), identified substantial variation in standard care in a study which surveyed 
current oral care practices in 212 members of the Multinational Association of 
Supportive Care in Cancer (MASCC) or the International Society for Oral Oncology 
(ISOO) groups. Responses were received from 74 members (35%). The authors report a 
large amount of variation in the range and timing of oral hygiene measures and in the 
range of interventions prescribed for mucositis (Barker et al., 2005), and attribute the 
low response of this study to a lack of formalised oral care guidelines for patients 
undergoing cancer treatments at the non-responding institutions (Barker et al., 2005). 
However, this limited response rate, together with the fact that the authors do not 
provide information about which countries these responders came from, mean that the 
possibility that the results may be biased towards a practices in a particular country 
cannot be discounted. A lack of consensus in routine oral care strategies has also been 
identified in paediatric cancer centres (Glenny et al., 2004).  
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Benzydamine and Chlorhexidine were prescribed for the treatment of mucositis in the 
feasibility study on an ad-hoc basis. However, the use of neither drug is supported by 
either the Cochrane review for the treatment of mucositis (Clarkson et al., 2010), or the 
Multinational Association of Supportive Care in Cancer (MASCC) guidelines for the 
prevention and treatment of mucositis (Keefe et al., 2007). Patients in the feasibility 
study were also given a variety of other agents to “try out” including salt and soda 
mouthwash and Gelclair by the nursing staff. The only concession towards mouthcare 
witnessed by the researcher was that patients were occasionally given small pouches of 
saline to rinse out their mouths. However, this was often given with no instructions to 
the patient, or without the patient being informed of the importance of mouthcare.  
 
Few studies assessed for ROB provided information about what standard care a patient 
received. Jack and colleagues (2010) reported in their review of supportive care in lung 
cancer trials that less than 50% of studies provided information about what constituted 
standard care; and when such care was described, it was often accompanied by 
statements about care being provided at the discretion of the treating doctor. This is a 
notable result as best supportive care is often used as a comparator arm in clinical trials, 
and a failure to properly quantify what this care actually entails may have significant 
ethical implications in trials (Jack et al., 2010), especially those which utilise a 
‘standard care’ arm instead of a placebo or other  control arm. The issue of standard 
care needs careful consideration before any future OM trial is conducted on this unit as 
the wide variety of interventions available to patients introduces confounding variables 
to the study results and the potential for bias.  
 
9.13 Suitability of assessment instruments 
A recent systematic review identified 57 oral assessment instruments used in either 
research or clinical practice (Gibson et al., 2010). Four of these assessment instruments 
were used in the feasibility trial. The instruments used to grade the oral cavity were the 
WHO score and the DIM, and were chosen after an extensive review of the literature. 
Overt differences were noticed between these instruments in the oral assessment data 
generated during the trial and these differences continued to remain after the subjective 
elements of the DIM instrument were removed. In one instance, the WHO instrument 
only showed that the patient remained to be ulcerative, while the data generated by the 
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DIM assessment instrument showed that the condition of the oral cavity was in fact 
improving. Both instruments produced data that showed similar trends, however it is 
clear that the DIM instrument provided a greater level of detail. These differences 
support the use of two assessment instruments in future trials, in order to provide as 
much information as possible about the condition of the oral cavity.  
 
One patient, who ultimately did not consent to take part in the study, requested a 
demonstration of the oral assessment procedure during the initial approach by the 
researcher. When the researcher was talking the patient through the oral assessment 
process, and giving a physical demonstration, she noticed that the patient, who was 
Afro-Caribbean, had quite extensive racial pigmentation of the gingivae and mucosa, 
which would have made assessments of erythema (mucosal reddening) very difficult to 
conduct. Racial pigmentation is a common condition in people of Asian, African and 
Southern European descent with dark complexions (Webber, 2010). However, this issue 
does not currently appear to be reflected in the oral assessment literature. 
 
The OMDQ was chosen to provide daily information about the levels of pain and 
diarrhoea experienced by the patient. The first question on this instrument asks the 
patient about their overall health. When completing this instrument for the first time, all 
patients in the trial answered with some variation of the response “I’ve got cancer”. The 
researcher therefore asked the patient to interpret this question as “how well are you 
feeling today”. A rewording of this question should therefore be considered before its 
use in any future trial and if any such amendment is made, this instrument should be 
revalidated. One patient got confused when asked to mark his response on the VAS 
scale for some questions and circle his response on a list of numbers for other questions. 
This problem was resolved when the researcher took the patient through the 
questionnaire question by question. In future studies, it may therefore be advisable to 
either ask patients to complete a sample copy of the questionnaire when they enter the 
study, or alternatively take the patients through the baseline questionnaire question by 
question.  
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The PG-SGA instrument was used weekly to assess changes in the patients’ nutritional 
status. This instrument proved to be the most time-consuming, and arguably the least 
useful, instrument employed during the trial. As the PG-SGA is comprised of a large 
number of graded elements, changes in score can be due to a huge number of factors, 
resulting in results which are difficult to interpret. One of the variables scored in this 
instrument was patient weight loss; however, as patients received large amounts of 
fluids during the transplantation process, the weight losses experienced by patients were 
generally small. The last section of the instrument is an assessment of the amount of 
deficit in muscle and fat stores and whether a patient is experiencing fluid retention. 
Deficit was assessed over a number of different variables and the overall assessment 
then calculated, not by the addition of scores, but rather by the selection of an overall 
general score (no deficit, moderate or severe). This method of grading could therefore 
fail to reflect a large deficit in muscle or fat from one particular area of the body, 
because the rest of the patient is unaffected and the patient is therefore assessed as 
having an overall score of ‘no deficit’, resulting in the under-reporting of muscle or fat 
wastage. Furthermore, in order to complete the final section of this instrument, the 
researcher had to ask the patient to partially undress in order to make the assessments. 
In addition to the embarrassment for the patient, this process was time consuming, 
especially during the second week of treatment when the patient was very ill.  
Therefore, the PG-SGA instrument may be better utilised in trials which follow patients 
over long periods of time, instead of the three weeks it was employed in this study, and 
its use in any future study should be very carefully considered.  
 
9.14 Weekend cover 
The plan to conduct daily oral assessments in patients resulted in the researcher working 
seven days a week without a break for long periods of time. While this was feasible for 
a doctoral project, had more patients been recruited, or a second site opened, this 
situation would have become unworkable. Before starting the trial the researcher was 
promised that research nurses based on the ward would provide extra cover. However, 
the nursing staff in question were already managing extensive workloads from other 
trials and were either unwilling or unable to help. The most obvious option of dealing 
with this problem in any future trial would be to only conduct oral assessments on 
weekdays. However, this would result in a failure to capture the full picture of mucositis 
severity. Two of the patients recruited into the study became ulcerative towards the 
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second week of treatment, and remained ulcerative over the second weekend; but had 
experienced a resolution of their ulcerative symptoms by the time of their assessment on 
Monday. The use of weekday-only oral assessments for these patients would have 
precluded the accurate calculation of the days of ulcerative mucositis. In addition, the 
timing of conditioning chemotherapy commonly resulted in patients experiencing 
neutrophil and white blood cell count nadirs during the second weekend of treatment, 
occurrences which were associated with an increase in adverse events due to the risk of 
infections and febrile neutropenia. A lack of researcher cover during this period could 
result in adverse events being underreported and in the worst case scenario, a delay to 
the reporting of serious adverse events to the proper authorities.  
 
The provision of holiday cover was another issue that the researcher struggled to 
organise. Patients continued to be scheduled for transplantation over the Christmas 
holidays, and while both eligible patients admitted just prior to Christmas declined to 
take part in the trial, had they given consent, the researcher would have had to continue 
daily visits during the holidays. Clearly, for future studies it is not feasible for one 
researcher to conduct daily patient visits seven days a week, and a second researcher 
will have to provide some mid-week or weekend cover. In any future trial which 
necessitates daily assessments and therefore weekend and holiday cover, this cover 
should be formally organised before the commencement of the project, and inter-rater 
reliability testing should be conducted to ensure accurate reporting.  
 
9.15 Researcher support 
The seven day a week nature of the data collection process had a considerable impact on 
the researcher, who was a relative research novice. The patients recruited into this trial, 
like the rest of the patients on the ward, were very ill during the transplantation process, 
and the researcher found this quite difficult to deal with at times, especially during data 
collection periods in which she could foresee no chance for a day off. While the 
researcher had attempted to mentally prepare herself for severely ill and distressed 
patients, she found that she was unprepared for dealing with the distress of patients’ 
families. The rotational nature of nursing shift patterns resulted in the researcher often 
being the only person a patient was seeing consistently on a day-to-day basis, and 
therefore the families, and the patient themselves, often looked to the researcher to 
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provide support and reassurance about whether or not a particular symptom experienced 
was ‘normal’. This situation often caused the researcher to feel distressed.  
 
Research into physiological distress in cancer researchers is limited; however, some 
research has been in oncology nursing staff (Grulke et al., 2009). Grulke and colleagues 
(2009) conducted a prospective study using questionnaires to compare reports of 
emotional distress in allogeneic transplantation patients to that of their nurses. The 
authors reported a significant correlation between the patients and nurses in the level of 
distress experienced during transplantation (P<0.001) (Grulke et al., 2009). Other 
studies have reported that one-third of cancer nurses suffer from a clinically-relevant 
level of distress associated with their job (Catalan et al., 1996) and that caring for cancer 
patients negatively impacts the quality of life of oncology nurses (Ergun et al., 2005). It 
could be hypothesised that the levels of distress experienced by researchers working in 
oncology may be higher than those experienced by cancer nurses, as the researcher may 
experience additional stress by being unable to help the patient in any way.   
 
The researcher often found that during patient visits she was performing tasks that were 
outside her role as a researcher, such as helping a patient to perform mouthcare, or 
holding a sick bowl for a patient who was overcome with nausea. However, the 
researcher recognised that such practices are all part of the nature of research, and that 
after she had listened to the patient’s views about the program currently on television, 
the patient was often more amiable to the oral assessments or a discussion about their 
current levels of diarrhoea or vomiting, discussions some people might find quite 
personal. However, this additional time spent with the patients also increased the levels 
of distress felt by the researcher, especially when she could do nothing to help with the 
situation. The researcher found that speaking to the nursing staff, her friends, and her 
supervisors about these distressing episodes helped her to deal with them. However, 
future trials conducted in this area should aim to provide researcher support and an 
outlet for discussion of the issues that researchers find particularly distressing.  
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9.16 Initiation of study intervention 
Four patients missed their first dose of study medication. This delay in starting the trial 
was due to a lack of beds precluding hospital admission for two patients, and an 
oversight by nursing staff in one patient. The remaining patient missed his first dose due 
to a slight cough, which delayed a decision regarding his suitability for transplantation 
until ward rounds the next morning. As the researcher experienced many problems with 
consenting patients for the trial and organising pharmacy release on the day of patient 
admission to the ward, the possibility of patients first using the intervention or placebo 
on the day after admission to hospital should be considered in any future trial.  
 
There appears to be little consistency in when interventions were started in the studies 
assessed for ROB earlier in this thesis. Interventions can be roughly separated into those 
which are initiated at the start of treatment and administered at approximately the same 
time as therapy, such as cryotherapy or amifostine, and those which were not. However, 
this distinction becomes even more inexact when glutamine is considered, as there is 
substantial heterogeneity in terms of dose, scheduling and administration in the trials 
included in the prevention review for this intervention (Worthington et al., 2010), 
meaning that glutamine could therefore be classified in both groups. Among 
interventions not administered at the same time as therapy, there appears to be no 
rationale for the timing of starting intervention or placebo, with initiation at 24 hours 
before therapy (Jebb et al., 1994, Shieh et al., 1997), three days before therapy (Choi et 
al., 2007, Kaul et al., 1999), seven days before transplantation (Labar et al., 1993), 
seven days before therapy (Shieh et al., 1997) and two days after transplantation 
(day+2) (Oberbaum et al., 2001) all being reported. Therefore it makes practical sense 
to select a starting point which is realistic for the researcher to achieve, in this case 
starting the trial on the day after hospitalisation.  
 
9.17 Feasibility of stopping points 
Patients ceased supplementation when three consecutive days of grade one mucositis 
were recorded as assessed using the WHO instrument. A miscount of the number of 
days that patient 3 had a WHO score of below grade two led to an extra day of 
assessment in this patient, but not an extra day of supplementation as the patient had 
neglected to take the previous days dose. This miscalculation took place because it was 
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a weekend and the researcher did not have access to the previous week’s oral 
assessments, which had been filed and locked away in an office in a department that 
was not open over the weekend. Unable to check the notes, the researcher asked the 
patient if she could remember when she was last ulcerative. Unfortunately, the time 
point given proved not to be correct. The researcher learned from this experience and 
the mistake was not repeated. For all future patients that were close to finishing the trial 
and were seen on a weekend, a note was made in the researcher reflective diary 
detailing their previous two WHO scores.  
 
One patient did not develop ulcerative mucositis. The possibility that this may happen 
was not considered when the protocol was written due to the expected incidence of 
mucositis in this high-risk patient population. In this case, the researcher and her 
primary supervisor decided that the patient should receive supplementation for 15 days 
and then exit the study, as it was stated in the study protocol that patients would be 
expected to receive supplementation for approximately 15 days. Two patients withdrew 
from the study due to adverse events unconnected to the placebo or intervention 
employed in the trial. One patient withdrew due to nausea and vomiting. The other 
patient because of flu-like symptoms during chemotherapy which were suspected to be 
the result of a Hickman line infection. Both these patients gave verbal consent for the 
researcher to continue to follow them up and perform daily oral and pain assessments 
and weekly nutritional assessments. Due to the lack of a formal stopping rule for these 
patients, patients were followed up until they had reached the formal stopping rule for 
patients receiving the intervention or placebo, namely, three consecutive days of grade 
one mucositis.  
 
In future trials stopping rules need to be written for both patients who do not become 
ulcerative and those patients who stop the trial early but give consent for follow-up. For 
patients who do not become ulcerative, it is difficult to decide an appropriate cut-off 
based on the number of consecutive WHO scores, because of the possibility that a 
patient may experience delayed mucositis development. Therefore, the previously used 
cut-off of 15 days of supplementation seems appropriate. For patients who withdraw but 
give consent for follow-up, the cut-off of three consecutive days of grade one mucositis 
allows for direct comparison with other patients, and therefore seems suitable. The 
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possibility that patients may be discharged with ulcerative mucositis was also not 
considered when writing the protocol, and this should also be included as a stopping 
rule.  
 
The feasibility trial did not employ formal stopping rules for stopping the study. Early 
stopping due to an apparent benefit in clinical trials introduces bias into the results 
(Higgins and Altman, 2009), and was identified in one study assessed for ROB in 
chapter four (Loprinzi et al., 1990). Greater effect sizes have been identified in RCTs 
stopped early when the intervention of interest has shown an apparent benefit (Bassler 
et al., 2010). In addition, beneficial effects identified early on in a study have been 
shown to have vanished by the completion of the study (Abraham et al., 2003), 
suggesting that such an effect was down to chance (Heffner et al., 2007). If future 
studies employ formal trial stopping rules, such rules should only allow for the 
cessation of recruitment when the evidence is vast and a sufficient number of patients 
have been recruited into the study, in order to avoid a result caused by chance (Heffner 
et al., 2007).   
 
9.18 Dose and suitability of application method 
The dose chosen for this study was determined by what was available from Healthplus. 
However, as a variety of vitamin E doses have been used in patients receiving 
chemotherapy, it is possible that the dose used in any future trial may need to be 
reassessed depending on formulation and availability. The suitability of the method of 
applying the intervention or placebo was not measured quantitatively during this study, 
which may have been an oversight. However, patients did provide anecdotal feedback to 
the researcher during the daily assessments and this was recorded in the researcher 
reflective diary. Four patients reported that the gelatine capsules were difficult to break. 
However, this issue was resolved after discussion with the researcher, who 
recommended patients use their molars, rather than their incisors, to break the capsule. 
One patient (Patient 3) detested the taste of the capsule, and removed it from her mouth 
before swishing and expectorating the solution.  
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The mode of application was chosen because it had been used in a previous vitamin E 
trial (Ferreira et al., 2004), and the authors of that study did not comment on patient 
agreeability with the capsules. In the Sung and colleagues study, rather than using a 
gelatine capsule, the vitamin or placebo mixture was dissolved in an oil vehicle and then 
used as a mouthwash (Sung et al., 2007), which may be a more appropriate method of 
applying the intervention. In addition, to the mode of application, the texture of the 
intervention and placebo capsules was a problem for some patients, particularly those 
suffering from nausea and vomiting. Since completing the feasibility study, the 
researcher has become aware of another study which employed vitamin E for the 
prevention of mucositis in patients undergoing allogeneic transplantation. This study, 
which recruited 60 patients, was conducted in Iran, and was published in a journal 
which only recently became available on the Medline literature search engine. The 
authors reported that there was no difference between the groups in the incidence of 
mucositis experienced by patients, but that more trials were warranted (Ghoreishi et al., 
2007). Future trials should carefully consider both the suitability of the mode of 
application and the texture or consistency of the intervention. 
 
9.19 Adverse event reporting 
Doses of vitamin E of up to 3200iu have not been associated with consistent adverse 
events (Kappus and Diplock, 1992). Adverse events previously reported with high doses 
of vitamin E, which are mainly derived from case-reports or uncontrolled studies, 
include gastrointestinal (GI) distress, muscle weakness, mild creatinuria, elevated serum 
creatinine kinase, and elevated serum triglycerides. Of these events only gastrointestinal 
distress and elevated creatinine kinase were experienced by patients, and both these 
adverse events were also experienced by patients on the placebo control arm. No 
obvious difference between the arms was detected; however, statistical testing was not 
conducted due to the low numbers of patients recruited into the trial.  
 
Data were collected prospectively on all new side effects (adverse events) experienced 
by patients in the trial from the date of consent until 30 days after the last dose of 
intervention or placebo. All three sets of patient notes were viewed daily by the 
researcher, who was blind to the treatment allocations. In addition, patients were asked 
to report the number of episodes of diarrhoea and vomiting and nausea to the researcher 
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during their daily oral assessments. Adverse events were discussed with the consultant 
Clinician to determine whether an event was ‘normal’ during transplantation. Adverse 
events were graded using the common terminology criteria for adverse events version 3 
(Cancer Therapy Evaluation Program, 2003). Consequently, adverse event reporting 
took up a considerable amount of the researcher’s time. It is notable that the unit 
research nurses recorded adverse events retrospectively on a weekly basis in trials 
running concurrently with the researcher’s trial. Such a method of retrospective weekly 
adverse event reporting is an option for future trials, however, there is the possibility 
that events may be overlooked and therefore underreported. In addition the use of 
weekly reporting has the potential to take up a whole day of a researcher’s time and may 
result in a backlog of adverse event reporting if a researcher’s plans were changed at 
short notice.  
 
One serious adverse event (SAE) was recorded during this trial. This was a chest 
infection which was serious enough to necessitate the transferral of the patient to the 
critical care unit. This patient went on to make a full recovery. Patient 2 also 
experienced the greatest number of adverse events of any patient during the trial. Due to 
the low numbers of patients recruited during the trial, no statistical tests were used to 
analyse differences between the arms for the numbers or types or adverse event 
experienced by patients. While, it does not appear that patients in the vitamin E arm of 
the trial experienced adverse events of a greater number or severity than those in the 
placebo arm, the safety of vitamin E in this patient population remains unproven by this 
study. 
 
Only 62 studies assessed in chapter four reported adverse events, and there was no 
consistency in how such events were reported. Trotti and Bentzen (2004), reviewed 
event reporting in nine frequently cited head and neck studies and found that four 
different grading scales were used in these studies. The number of acute effects reported 
by these studies ranged from three to ten, with mucositis and neutropenia being the only 
two adverse events reported consistently by these studies (Trotti and Bentzen, 2004). 
Such a lack of consistency makes the comparison of treatments difficult, which in turn 
prevents patients being properly informed about the risks of a particular treatment. In 
addition, such a haphazard method of reporting events may result in late effects being 
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under-reported and introduces bias to the results (Trotti and Bentzen, 2004). When 
adverse events are reported, some studies do not report data for all randomised patients, 
instead reporting only those events which affect a certain number, or percentage, of 
patients, or reporting data as events rather than patients (Ioannidis et al., 2004). An 
extension to the CONSORT statement was published in 2004 which provides ten 
recommendations for adverse event reporting in clinical trials, these include: that events 
should be defined; that methods and timings of assessment should be explained and that 
any methods of analysis used should be described in the statistical methods; that 
withdrawals due to events should be stated and explained and that events should be 
described in terms of absolute risk; that sub-group analyses should be stated and 
described; and that the benefits and harms of a particular intervention should be 
discussed in detail (Ioannidis et al., 2004). It appears however, that such 
recommendations are yet to be adopted for the reporting of adverse events in mucositis 
clinical trials. In order for short term benefits, in terms of mucositis prevention, to be 
compared to longer term outcomes, such as event-free survival, better adverse event 
reporting in future mucositis prevention trials is crucial.  
 
In such future trials the time spent recording adverse events could be reduced by the 
inclusion of expected events relating to the transplantation process in the investigator 
brochure or protocol. This was not done for feasibility trial as the researcher was 
initially unsure what these events would be. These expected results are shown in Table 
26.  
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Table 26: Expected Adverse Events in a Future Trial in Stem Cell Transplant Patients 
Category Event 
Blood / bone marrow 
Reduction in white blood cell 
count (WBC) 
Reduction in platelet count 
Reduction in haemoglobin 
count 
Reduction in red cell count 
Reduction in neutrophil count 
Reduction in monocyte count 
Reduction in eosinophil count 
Reduction in lymphocyte count 
Reduction in basophil count 
Reduction in MCH and MCHC 
count 
Gastrointestinal 
Nausea 
Vomiting 
Diarrhoea 
Dermatology/ skin Alopecia 
Infection Febrile Neutropenia 
 
9.19.1 Suitability of 30 day after last dose AE reporting 
Adverse events were collected throughout the study from the first day of 
supplementation until 30 days after the patient had received their last dose. However, 
after a patient had been discharged from hospital the recording of adverse events proved 
problematic. When the patient attended outpatients appointments adverse blood values 
were recorded from the patient’s electronic notes. The patient was also asked by the 
researcher to verbally detail any problems they may currently be experiencing, or had 
experienced since leaving hospital. It is likely the method of adverse event reporting 
used after patient discharge in this trial resulted in the underreporting of adverse events. 
However, it is difficult to determine whether alternative methods of adverse event 
reporting would be more appropriate in any future study. These reporting problems 
were compounded by the referral of non-locally based patients to their local hospital for 
follow-up, in an attempt to reduce the amount of travelling they would have to 
undertake. All of the patients in question were seen in hospital by the researcher within 
30 days of their last dose of intervention or placebo, and adverse events were recorded 
at this visit. However, such referrals may delay expedient reporting in the event of a 
SAE.  
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One potential approach to recording adverse events in the discharged patients would be 
to ask patients to record events experienced after discharge in a patient diary. However, 
poor compliance with patient diaries has previously been reported (Stone et al., 2003). 
Stone and colleagues (2003), investigated patient compliance with paper diaries 
compared to electronic diaries in patients experiencing pain episodes. Patients were 
asked to complete these diaries at set times three times a day for 21 days. The ingenious 
inclusion of photosensors in the binder enclosing the paper diaries allowed the 
researchers to compare reported compliance (the number of pages of the diary 
completed) to actual compliance (the number of times the diary was opened) for diary 
completion and then calculate the amount of compliance faked by patients using this 
method of data collection. The reported compliance in the paper diary group was 90.5%. 
However, when data from the photosensors were included, actual compliance was only 
10.9%, indicating that 79.5% of all patient paper diary entries were faked (Stone et al., 
2003). In contrast, the rate of compliance for the group of patients using electronic 
diaries was 93.6%, and as the software for the electronic Palm computer only allowed a 
diary entry during a 30 minute window for each set data collection time point, this much 
higher rate of compliance with electronic methods of data collection appears to be 
genuine (Stone et al., 2003). The use of electronic methods to collection data after 
patients have been discharged from hospital, either through handheld computers or 
mobile phones has many potential benefits, namely that it would allow adverse events, 
self-reported oral mucositis scores and side effects such as taste changes to be tracked 
overtime, and reduce the likelihood that adverse events were underreported after 
discharge from hospital. The use of electronic methods of data collection is therefore a 
possibility for future trials. However, such a study would have to be supported by a 
large grant to cover the set-up and running costs of such a system.  
 
Another lower cost method of ensuring adequate adverse event reporting in discharged 
patients would be for the researcher to follow the patients up by phone on a weekly 
basis. However, this method may be problematic as the myeloma nurse also typically 
follows recently discharged transplanted patient up by phone between outpatient 
appointments, and therefore there is the potential for patients to under-report problems 
because they feel that they have already told someone about a particular symptom. 
Therefore reported symptoms would need to be cross-referenced between the researcher 
and the myeloma nurse. Alternatively, patients could be asked to retrospectively 
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complete a tick-sheet of adverse events when they attend an outpatient appointment. 
Adverse event reporting in the discharge patient is therefore problematic for any study. 
The method of reporting used in this trial for discharged patients was feasible and could 
be used in future trials, however, the use of alternative methods, such as phone calls, 
electronic devices or tick-sheets of symptoms, could be used in addition in an attempt to 
minimize under-reporting of events.  
 
9.20 Recommendations for future trials 
The results of this feasibility study have been used to make recommendations for future 
studies of pharmacological interventions for the prevention of OM. These are shown in 
Table 27. The low number of patients recruited into this study precludes any 
recommendation being made on the suitability of vitamin E used for the prevention of 
mucositis.  
 
Table 27: Recommendations for Future Trials of Pharmacological Interventions for the 
Prevention of Oral Mucositis in Patients Undergoing BMT 
Item Recommendation 
Approvals 
Regulatory 
approvals 
At least a year should be set-aside for gaining the necessary 
approvals prior to starting the study. 
Professional relationships 
Relationship with 
Clinicians 
Clinicians from the unit should be consulted early during the 
trial design process in order to work through any potential 
problems voiced.  
Relationship with 
support staff 
Good working relationships between research staff and support 
staff should be enthusiastically encouraged.  
Trial registration 
Registration of 
clinical trials 
Trials should be registered prior to starting recruitment. This 
will minimise publication bias and the selective reporting of 
significant findings in publications. In addition, this will avoid 
unnecessary duplication of trials, and ensure that healthcare 
decisions are made after consideration of all available evidence.  
Randomisation 
Randomisation Adequate descriptors of randomisation processes need to be 
included in future publications. 
Stratification 
Stratification Patients should be stratified by type of transplant (autologous/ 
allogeneic), type of conditioning (TBI/no TBI) and by history of 
previous transplant (yes/no).  
Allocation concealment 
Allocation Adequate allocation is essential and should be employed in 
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Item Recommendation 
concealment future mucositis studies. Appropriate methods of allocation 
concealment include sequentially numbered drugs containers of 
identical appearance and pharmacy controlled randomisation.  
Blinding and allocation concealment 
Blinding  Future trials should employ adequate blinding. In studies in 
which blinding of patients cannot be achieved, such as the 
cryotherapy or honey studies assessed for ROB, blinding of 
outcome assessors is essential. There is no reason why adequate 
outcome assessor blinding cannot be organised if the trial is set-
up carefully.  
Assessments 
Oral assessments Daily assessments of the oral cavity should be performed using 
an appropriate assessment instruments. Both a simple scale and 
a multi-component instrument should be employed to provide 
the greatest possible amount of information about the oral 
cavity, and facilitate inclusion of the results of the trial in meta-
analyses. Researchers should select an instrument that is 
validated, acceptable to patients, and suitable for their chosen 
population. Therefore no recommendation of specific 
instruments is made. If more than one researcher is to conduct 
the oral assessments then inter-observer reliability should be 
calculated before data collection commences.  
Timing of 
assessments 
Future studies need to have a clear rationale for the timing of 
oral assessments. Oral assessments should be conducted 
frequently enough to identify oral changes, but not frequently 
enough to burden the patient unduly. The use of daily oral 
assessments is recommended. 
Pain assessments If the OMDQ instrument is used in a future trial, the first 
question should be reworded and the instrument revalidated 
Staffing 
Weekend cover Cover should be organised to provide adequate breaks for 
researchers 
Researcher support Future studies should consider the psychological impact of 
working in oncology on the researcher and provide support 
accordingly 
Outcome reporting 
Outcome reporting Future studies should attempt to avoid reporting selective 
outcomes, such as the incidence of severe mucositis. Full 
reporting of pre-defined outcomes would ensure a large pool of 
eligible studies for inclusion in future editions of the Cochrane 
prevention review.  
Adverse event reporting 
Adverse event 
reporting 
Adverse event reporting should be performed prospectively. 
Appropriate methods of recording adverse events from patients 
who have been discharged from hospital should be considered 
and written into any future protocol.  
Standard care 
Standard care In studies conducted over and above standard care, attempts 
should be made to standardise care on the unit before starting 
the trial.  
Stopping points 
 241 
Item Recommendation 
Stopping points  Appropriate stopping points should be written into the protocol 
for patients who withdraw from the study early but continue to 
be assessed by the researcher, as well as for patients who do not 
become ulcerative. 
Rates of recruitment 
Expected rates of 
recruitment 
Single site studies should expect to recruit a mean of 0.78 
patients a week41. Recruitment should be planned accordingly.  
Rates of withdrawal 
Expected rates of 
withdrawal 
Rates of withdrawal in future studies can be expected to be 
approximately 30% of all patients randomised.  
Publication 
Publication Authors should follow the CONSORT guidelines when writing 
up their results for publication. 
 
9.21 Conclusion 
This chapter has discussed various issues identified in the previous chapters of this 
thesis. The feasibility trial was conducted as a full ‘dummy’ study using the same 
randomisation, allocation concealment, pharmacy release and data collection procedures 
as could be employed in a full study, and although the pre-stated number of patients 
were not recruited into the feasibility study, the results can still be used to inform future 
studies about a variety of important issues including expected recruitment rates, 
expected lengths of delays in obtaining regulatory approval and the potential issues that 
could be experienced when attempting to recruit patients into a study. Adequate 
blinding and allocation concealment were proved to be possible, through the use of 
sequentially numbered drugs containers of identical appearance, central allocation and 
the protection of the randomisation sequence from the outcome assessor. The use of 
outcome assessor blinding was proven to be possible even in small studies conducted by 
one member of staff. There is therefore no reason why outcome assessor blinding could 
not be employed in future studies trialling interventions, such as cryotherapy, in which 
blinding of patients is not possible. The results of the feasibility study also add to the 
literature on the lack of consistency in standard care for mucositis prevention. This issue 
needs to be addressed urgently to close the gap between research and clinical practice. 
 
                                                     
41
 Mean of the rates of recruitment in single site studies included in the Cochrane OM prevention review 
together with the rate of recruitment experienced in the vitamin E study.  
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Adverse event data collected during the feasibility study can be used to produce lists of 
expected adverse events in future trials, which should help reduce the amount of AE 
reporting in such trials. Omissions in adverse event reporting were identified as an issue 
in some of the studies included in the Cochrane prevention review. Such omissions are 
troublesome for researchers planning future studies, and may prevent the intervention in 
question being adopted into clinical practice. Conducting a feasibility trial before full 
data collection should be considered when designing future trials.  
 
9.22 Skills learned during the Doctoral programme 
• Significant insight into designing, setting up and conducting clinical trials 
• Knowledge of the regulatory approvals process 
• An insight into methodological issues in clinical trials 
• Knowledge of statistical testing, particularly the use of meta-analyses 
• Improved writing skills 
• Public speaking 
• Teaching experience 
• Good clinical practice training 
• Time management 
• Project management 
• Interpersonal skills  
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Chapter 10 Conclusion 
Oral mucositis is a painful and distressing side effect of therapy for cancer, which exerts 
a substantial economic and clinical impact, and negatively affects patient quality of life. 
Despite research into the pathogenesis of mucositis, the identification of treatment and 
patient related risk factors which may affect its development and a considerable amount 
of time and effort spent identifying and trialling interventions which may prevent or 
treat the condition, mucositis still represents a significant treatment-related toxicity.  
 
Various interventions have been trialled for the prevention of mucositis. Such 
interventions have varied in cost and complexity from the low cost ‘low tech’ use of ice 
chips during chemotherapy administration, at one end of the scale, to the use of growth 
factors in complex schedules at considerable cost, at the other. However, a consistent 
benefit of any particular intervention has yet to be demonstrated. The three interventions 
found to be beneficial in the 2010 update of the Cochrane prevention review at all three 
dichotomies of interest-keratinocyte GF, honey and cryotherapy-all have drawbacks 
either in terms of costs and adverse events, or the quality of the evidence, due to their 
lack of outcome assessor blinding. Fifty-seven oral assessment instruments were 
identified in the systematic review of orals assessment instruments shown in chapter 
five of this thesis. The multiplicity of oral assessment instruments available for the 
assessment of mucositis and the variation in what these tools actually measure has 
hampered the inclusion of studies, or entire interventions, into systematic reviews, 
including the Cochrane review of interventions for the prevention of mucositis. While 
this has been partially addressed by the inclusion of some studies in a ‘text only’ format 
in the recent update of the review (Worthington et al., 2010), a considerable number of 
studies were still excluded either because of an inappropriate method of assessment, or 
because data are presented in a format incompatible with the incidence by grade of 
mucositis measures used in the review. Vitamin E was identified in this thesis as one 
such intervention, with conflicting results reported by trials investigating the use of this 
supplement for mucositis prevention.  
 
A sensitivity analysis was conducted on the results of the Cochrane prevention review 
update, and showed that the results of the review were substantially changed if studies 
assessed to be at unclear or high risk of bias were excluded. The literature from the 
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prevention review was then assessed to determine how they could be used to inform 
future studies. A lack of consistency was identified in both the timing of oral 
assessments used in these studies, and the other outcomes reported by these studies. 
Adverse event reporting was also highlighted as an area of concern, as although was the 
most frequently reported of all outcomes, fewer than 50% of the trials included in the 
review update providing information about side effects.  
 
The issues surrounding conducting a trial of vitamin E for the prevention of mucositis 
were explored in a feasibility study. This feasibility study employed sequentially 
numbered drugs containers which were identical in appearance and pharmacy release, to 
protect the allocation schedule, and ensure adequate allocation concealment and 
outcome assessor blinding.  
 
This thesis has combined appraisal of the literature with empirical research and has used 
lessons learned from previous studies, together with the results of the feasibility study to 
identify best practice recommendations for future trials of interventions for the 
prevention of mucositis. Although low numbers of patients were recruited into the 
feasibility study, a problem which was mainly due to a lack of willingness of the 
Clinicians on the unit to allow their patients to participate in the project, and personnel 
dynamics between the Clinicians themselves, the results of this feasibility trial, allow 
for 19 recommendations for conducting future trials to be made. These include that 
future trials should allow at least a year to gain all the necessary regulatory approvals 
prior to starting the trial. Clinicians from the unit should be contacted early in the design 
of the study and asked for their input and any objections to the trial so that such issues 
can be resolved before regulatory approvals are made. Blinding of outcome assessors 
and adequate allocation concealment should be used in all future trials, and if such trials 
are to be conducted in a group of patients receiving a mix of different transplants, then 
stratification by type of transplant should be employed.  
 
The feasibility trial identified a difference between the oral assessment instruments 
employed during the trial, suggesting that authors of future trials need to think carefully 
about which instruments they employ, and the timing of these assessments. In addition 
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it was found that adverse event reporting, although crucial for patient safety, took up a 
significant amount of the researcher’s time. The data generated from the adverse event 
reporting has been used to suggest expected adverse events associated with BMT 
treatment, which could be written into the protocol for future trials, and would therefore 
reduce researcher burden in studies which stipulate that expected events do not have to 
be recorded. In future trials adverse event reporting should be conducted prospectively.  
 
The feasibility study identified a lack of consistency in the standard care employed on 
the unit, a problem which has been identified elsewhere in the literature. Attempts 
should be made to standardise care on units where this is a potential problem prior to 
starting recruitment. Finally attention should be given to the writing up of the results of 
the trial for publication. The manner of randomisation should be described in full and 
the authors should avoid the reporting of selective outcomes. Authors should follow the 
CONSORT guidelines when writing their report.  
 
The clinical and economic impact of mucositis, together with the devastating effect of 
mucositis on the patient, indicates that trials of new interventions, together with trials 
which confirm the results of existing interventions, are crucial. It is hoped that the 
experience and findings of this thesis can be used to guide researchers working on 
future trials of interventions for the prevention of mucositis. Such trials need to be 
conducted and reported as rigorously as possible in order to be beneficial for future 
patients.  
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Appendix 1 
 
Example ROB assessment. 
 
Study assessed to be at: 
 low overall ROB,  
 low ROB for allocation concealment  
 low ROB for outcome assessor blinding 
                                                     
42
 Dazzi et al, 2003, p560, 
Author (date) Intervention Adequate Sequence Generation? 
Allocation 
Concealment 
Blinding 
Incomplete Outcome 
Data Addressed? Free of Selective Bias? 
Free of other 
bias? Carer blinding Patient blinding 
Outcome 
assessor 
Blinding 
Dazzi et al, 
200342 
 
GM-CSF Unclear 
 
Quote: “…were 
randomly allocated to 
the GM-CSF or the 
placebo group” 
 
Comment: random 
component not 
described.  
Yes 
 
Quote: “Study 
suspensions were 
prepared by the 
pharmacy unit 
and provided to 
the bone marrow 
transplant 
patients.” 
 
Comment: 
Pharmacy 
controlled 
randomisation.  
Yes 
 
Comment: 
Intervention 
and control 
were 
dispatched 
from 
pharmacy, 
unlikely that 
carers would 
have 
knowledge of 
allocation.  
 
Yes 
 
Quote: 
“double blind” 
Yes 
 
Quote: 
“double blind” 
Yes 
 
90 patients randomised. 
ITT analysis used. No 
missing outcome data.   
Unclear 
 
Data presented for 
incidence of stomatitis, 
incidence and duration of 
severe stomatitis, and 
patients judged maximum 
mucositis score (table 3)  
Yes 
 
Study appears 
to be free of 
other sources 
of bias 
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Appendix 2 
 
Search strategy employed for systematic review of oral assessment instruments  
 
1. exp NEOPLASMS/ 
2. neoplasm$.mp. 
3. cancer$.mp. 
4. tumo?r.mp. 
5. malignan$.mp. 
6. exp RADIOTHERAPY/ 
7. radioth$.mp. 
8. exp CHEMOTHERAPY/ 
9. chemoth$.mp. 
10. BONE MARROW TRANSPLANTATION/ 
11. ("bone marrow" and transplant$).mp. 
12. or/1-11 
13. ORAL HYGIENE/ 
14. MOUTH DISEASES/ OR CANDIDIASIS, ORAL/ OR ORAL    
 MANIFESTATIONS/ OR ORAL ULCER/ OR STOMATITIS/ 
15. mouthcare.mp. 
16. 'mouth care'.mp. 
17. 'oral hygiene'.mp. 
18. SEVERITY OF ILLNESS INDEX/ 
19. OBSERVER VARIATION/ 
20. NURSING ASSESSMENT/ 
21. REPRODUCIBILITY OF RESULTS/ 
22. or/13-17 
23. or/18-21 
26. 12 and 22 and 23 
 
(UKCCLG-PONF, 2006) 
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Appendix 3 
Oral assessment instruments  
 
Daily Index of Mucositis (DIM) 
 
 
(Tardieu et al 1996, Permission Granted) 
 
 
World Health Organisation (WHO) instrument 
WHO 
Anon, 1979 
Grade 0 Grade 1 Grade 2 Grade 3 Grade 4 
“None” “Soreness and 
erythema” 
“Ulcers, 
erythema. 
Patient can 
swallow solid 
diet” 
“Ulcers, 
extensive 
erythema. 
Patient cannot 
swallow solid 
diet” 
“Mucositis to the 
extent that 
alimentation is 
not possible" 
(Anon, 1979) 
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Oral Mucositis Daily Questionnaire (OMDQ) 
 
 
(Stiff et al, 2006, Permission Granted) 
